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1GENERAl INTROduCTION
Parts of this chapter are published in J Neuroimmune Pharmacol 2010, 5: 220-230
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PREFACE
The current success rate of new drugs for central nervous system (CNS) disorders, 
including multiple sclerosis (MS), is very low, i.e. between 5 and 8%. The main cause of 
this low success rate is a lack of efficacy of new drugs in humans1. A widely recognized 
bottleneck in the selection of promising CNS drug candidates from the development 
pipeline is the lack of sufficiently predictive animal models. The choice of the animal 
model(s) to be used for the selection of the most promising agents from the development 
pipeline is a strategically important decision. 
While selecting an animal model for preclinical safety and efficacy evaluation of a 
new drug the following selection criteria should be considered:
1. The biodistribution and pharmacological properties of the target molecule should 
be comparable between humans and the chosen animal model.
2. The binding kinetics of the therapeutic agent to the target molecule should be 
comparable between humans and the chosen animal model. 
3. The model should preferably reveal unwanted side-effects of the treatment that 
could also occur in humans, such as cytokine release syndrome, complement 
activation, immune deficiency, and the exacerbation of latent infections. 
4. The animal model should be ethically acceptable.
5. The model should resemble the disease in the clinical manifestation, the pathology 
of the target organ, and the (immuno)pathogenesis.
When selecting an animal model for MS, the first three considerations plead for 
the development of relevant preclinical animal models that are pathogenetically more 
closely related to MS than the classical rodent models. Furthermore, new therapeutic 
agents, especially monoclonal antibodies (mAb), often have high species specificity 
and are therefore not cross-reactive with the target in rodents. A preclinical animal 
model that satisfies the first two criteria is experimental autoimmune encephalomyelitis 
(EAE) in the common marmoset. In principle, unwanted side-effects may occur in the 
marmoset EAE model, although these have not been seen in the therapies tested thus 
far2-5 (Chapter 4). The marmoset EAE model also satisfies the last two criteria, but 
these will be refined in this thesis, e.g. by replacing the adjuvant that is used to induce 
the disease.
The research strategy of this thesis integrates exploratory and applied research, 
which are closely linked. In the exploratory research, pathogenic mechanisms are 
investigated, which may lead to the identification of new therapy targets. Applied 
research focuses on the development of new therapies. This will validate known 
pathogenic mechanisms and reveal new pathogenic mechanisms if the intervention is 
successful (Figure 1). 
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MulTIPlE SClEROSIS
Clinical
MS is a chronic disease affecting the CNS with an average disease onset in the third 
or fourth decade of life. Clinical symptoms are caused by changes in the motor, sensory, 
visual, and autonomic systems. Most common symptoms include visual and balance 
disturbances, spasticity, bladder dysfunction, pain, and fatigue. At a later disease stage, 
paralysis may occur. Other symptoms are Lhermitte’s symptom, an electrical sensation 
running down the spine or limbs when the neck bends, and Uhthoff phenomenon, 
worsening of symptoms when the core body temperature increases6-9.
At least five clinical variants of MS are recognized, i.e. benign, relapsing-remitting 
(RRMS), secondary progressive (SPMS), primary progressive (PPMS), and progressive 
relapsing (PRMS) (Figure 2). In about 80% of the patients, the disease starts as RRMS. 
After 10-15 years, most of these patients develop SPMS, a stage with irreversible 
neurological decline. In about 20% of the patients the disease is progressive from onset, 
with (PRMS) or without relapses (PPMS)6-10. $SSOLHGUHVHDUFK1HZWKHUDS\GHYHORSPHQW,GHQWLILFDWLRQRIQHZWKHUDS\WDUJHWV6XFFHVVIXOLQWHUYHQWLRQKLJKOLJKWVLPSRUWDQWSDWKRJHQLFPHFKDQLVPV([SORUDWRU\UHVHDUFK3DWKRJHQHVLV
Figure 1. Research strategy.
Pathogenic mechanisms are investigated by exploratory research, which can lead to the identification 
of new therapy targets. Applied research focuses on the development of new therapies, which validates 
known pathogenic mechanisms and reveals new pathogenic mechanisms when the intervention is 
successful.
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Etiology 
The cause of MS is still unknown, but it is highly likely that MS is a complex disease 
involving the interaction of genetic and environmental factors. The concordance 
rate between monozygotic twins is about 6 times higher than among dizygotic twins 
(respectively 31% and 5%) suggesting contribution of genetic factors11. The risk for MS 
is increased by normally occurring polymorphisms in the human leukocyte antigen (HLA) 
gene complex, such as DQA1*0102, DQB2*0602, DRB1*1501, and DRB4*010112. In 
contrast, other HLA alleles may cause resistance, such as DRB1*14 and DRB1*1113. 
DRB1*1501 not only increases the risk for MS, but also increases disease severity 
compared to DRB1*1501-negative patients14. Genome-wide association studies 
and meta-analyses identified other risk genes, such as interleukin (IL)-2 receptor α 
chain, IL-7 receptor α chain, CLEC16A, CD6, CD58, tumor necrosis factor receptor 
superfamily member 1A, interferon response factor 8, and STAT315-17. Another genome 
wide association study revealed a polymorphism in the KIF1B locus18, although this 
could not be confirmed by others19. KIF1B encodes a kinesin that is important for axonal 
transport and which is the first genetic association without an apparent prominent role 
5506 630633063506
Figure 2. Clinical course of MS. 
About 80% of the MS patients start with relapsing-remitting MS (RRMS), which is characterized by 
relapses and remissions. Most RRMS patients develop secondary progressive MS (SPMS) after 10-15 
years. About 20% of the patients have progressive MS from onset, with (progressive relapsing, PRMS) 
or without relapses (primary progressive, PPMS). Based on10. 
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in the immune system. Integration of these genetic risk factors may lead to a predictive 
algorithm in the future20.
Environmental factors that may influence the risk for MS include sunlight exposure 
and infections. The risk for MS increases when moving away from the equator and is 
especially higher in the northern regions of the United States and Europe. This may 
be explained by a higher prevalence of HLA risk alleles in these regions, but also by 
the low UV-B exposure21,22, which may lead to low vitamin D levels8. High vitamin D 
levels in serum are associated with a lower risk for MS and a lower relapse rate23-25. In 
addition, vitamin D may change the T-cell activation and the cytokine profile25, but also 
HLA-DRB1*1501 expression26.
The risk of developing a relapse increases around the time of an infection, especially 
during upper respiratory tract infections. A relapse associated with an infection 
induces more sustained neurological deficit than a non-infectious relapse24,27. Human 
herpesviruses (HHV) are suggested to increase the risk for MS28. One of the most 
frequently studied HHV in MS is Epstein-Barr virus (EBV), albeit with contradictory 
results. Infection with EBV increases the risk for MS, which is even higher when the 
infection occurs after the age of 17 years29. All MS patients have serum immunoglobulin 
(Ig) G antibodies (Ab) against EBV, whereas anti-EBV IgG are detected in 80-90% of 
healthy individuals30. In contrast, anti-EBV IgG levels in cerebrospinal fluid (CSF) did not 
differ between MS patients and non-MS inflammatory CNS disease control patients31. 
Furthermore, EBV RNA could not be detected in CSF of MS patients31. It has been 
suggested that EBV-infected B-cells migrate to the target organ where they become a 
source of autoantibodies and provide co-stimulatory signals to T-cells32. Indeed, EBV-
positive B-cells were found in the meninges of MS brains33. However, others could not 
confirm this31,34.
How pathogens modulate the immune response in MS is currently unknown. It 
has been suggested that the gut flora is involved in the expansion of T-cells35. A 
change in the gut flora composition by a pathogen may alter the immune response. 
EBV modulates the immune response by infecting and activating B-cells32, which play 
an important role in MS36,37. To investigate the role of a human pathogen in MS it is 
essential that the animal, in which the disease is modeled, is susceptible to infection 
with that pathogen or closely related counterparts. As for HHV, higher non-human 
primate (NHP) species are naturally infected with viruses that are closely related to 
their human counterpart. Thus, in contrast to rodents, conventionally held colonies of 
NHP have experienced the immune shaping effect by similar environmental pathogens 
throughout their development and may therefore be a good representative for the 
situation in humans.
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Pathology
One of the criteria for the diagnosis of MS is the detection of white matter (WM) 
lesions in the brain with magnetic resonance imaging (MRI)38. WM lesions are the major 
pathological hallmark of MS and disseminate in time and space. They are characterized 
by inflammation, demyelination, axonal injury, edema, and blood-brain barrier (BBB) 
dysfunction7,9.
WM lesions develop through several stages, i.e. pre-active, active, chronic active, 
and chronic inactive. Pre-active, or early active, lesions are characterized by focal 
Figure 3. Pathology of MS.
A, A staining for proteolipid protein (PLP) shows the demyelinated hypocellular center of a chronic 
active lesion in the white matter of a MS brain (original magnification x50). B, At the rim of the lesion, 
where myelin is phagocytosed by macrophages, axonal transections are visualized by a staining for the 
amyloid precursor protein (original magnification x50). Axonal transections at the rim of the lesion in 
the square are enlarged in C (original magnification x100). D, A PLP staining of the grey matter shows 
a subpial lesion (original magnification x50). Photographs are kindly provided by E.-J. Kooi and Dr. J. 
Geurts (Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands).
See page 309 for a full-color representation of this figure.
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abnormalities in the WM, such as clusters of major histocompatibility complex (MHC) 
class II positive cells and perivascular infiltration. The MHC class II positive cells are 
mainly activated microglia or infiltrated macrophages. No demyelination is present in 
this lesion stage. In active lesions, MHC class II positive cells that have phagocytosed 
myelin are present in the center of the demyelinated area. Several other immune cells 
are also present, such as T-cells, B-cells, and plasma cells. In chronic active lesions 
the center of the lesion is hypocellular, whereas the rim is hypercellular with myelin 
positive phagocytic cells indicating ongoing demyelination (Figure 3). Chronic inactive 
lesions are hypocellular with astrogliosis and widened extracellular spaces39-41. Axonal 
transection is observed in active and chronic active lesions42,43 (Figure 3).
Four patterns of demyelination have been described, based on the target of 
injury and the mechanism of demyelination. Myelin is the target in patterns I and II, 
whereas the oligodendrocyte is the target in patterns III and IV. Patterns I and II are 
both characterized by the presence of T-cells, macrophages, and activated microglia. 
Deposition of Ig and complement occurs in pattern II lesions. Pattern III lesions also 
contain T-cells and activated microglia/macrophages, but these lesions are especially 
characterized by apoptotic oligodendrocytes and the specific loss of myelin associated 
glycoprotein (MAG). Pattern IV lesions were only detected in a subgroup of PPMS 
patients. Pattern IV lesions are characterized by infiltrated T-cells and macrophages and 
oligodendrocyte death. Deposition of Ig and complement, apoptosis, and specific loss 
of MAG are absent in this pattern44. Lucchinetti et al. described that the demyelination 
pattern was heterogeneous between patients, but homogeneous within a patient44. 
However, others could not detect lesion heterogeneity between patients45 or suggested 
that pattern III lesions may represent an early stage of lesion formation instead of a 
different pattern46,47. The different patterns may also represent different immunological 
effector mechanisms in response to a core process of T-cell mediated inflammation 
rather than disease heterogeneity9.
Brain WM lesions detected by MRI do not always correlate well with clinical signs 
and disease progression. This is known as the clinico-radiological paradox48,49. Factors 
that contribute to clinical deterioration include axonal injury and grey matter (GM) 
lesions. Axonal injury is present in active and chronic active lesions42,43,50. Progressive 
degeneration of axons, which is difficult to visualize with classical MRI techniques, 
contributes to brain atrophy, especially of the cortex, which may be a better correlate of 
clinical deterioration51,52. It has been proposed that when axonal injury reaches a certain 
threshold the disease transits from RRMS to SPMS50.
GM lesions can be observed in the neocortex, but also in other GM areas, such 
as in the hippocampus and the cerebellum. GM lesions are classified into four types. 
Leukocortical (type I) lesions extend in both the white and GM. Type II and type IV 
lesions are intracortical lesions with type IV lesions extending through the full width 
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of the cortex. Type III lesions are subpial lesions and are the most common cortical 
lesions, which can extend several gyri53-56 (Figure 3). The pathology of GM lesions 
differs from WM lesions in the low number of lymphocytes, low level of complement 
deposition, and the absence of BBB disruption54,57,58. However, profound activation of 
microglia is observed at the border of GM lesions53,54. It is suggested that changes in 
the GM correlate well with clinical disability in MS, probably more than WM lesions51,56,59. 
Therefore, a better understanding of GM lesions is needed as well as a therapy that 
reduces the GM lesion load.
Immunopathogenesis
The exact pathogenesis of MS is still unknown, but it is well accepted that once 
the disease has been initiated the immune system plays a major pathogenic role. The 
classical and general view on MS pathogenesis is that autoreactive T-cells are activated 
in the periphery by antigen presenting cells (APC) that present CNS or CNS cross-
reactive antigens (Ag). These activated T-cells may enter the CNS via the BBB or the 
choroid plexus60. Within the CNS, they encounter CNS Ag presented by local APC. This 
leads to T-cell reactivation and a cascade of events that induce demyelination, axonal 
injury, and gliosis. Autoantibodies directed against myelin or neuronal proteins enhance 
the immune response, for instance by activating the complement system. Infiltrated 
macrophages or resident microglia phagocytose myelin and produce inflammatory 
mediators6,9,61,62 (Figure 4). 
Demyelination is the pathological hallmark of MS and is caused by a combined 
cellular and humoral autoimmune attack on myelin. The myelin sheath is produced by 
oligodendrocytes and is wrapped around axons to increase the conductivity. Myelin 
is composed of 80% lipids and 20% proteins, such as myelin basic protein (MBP), 
proteolipid protein (PLP), MAG, and myelin oligodendrocyte glycoprotein (MOG) 
(Figure 5). MOG is a type I membrane glycoprotein and a member of the Ig superfamily 
produced by oligodendrocytes. MOG is located on the outer myelin sheath with the 
N-terminal amino acids 1 to 125 exposed to the extracellular environment where it is 
accessible for immune cells63,64 (Figure 5). MOG probably forms homodimers65 and is 
highly conserved among species, but has a still unknown function66,67. The MOG gene 
is located on chromosome 6 within the distal region of the MHC gene complex and 
therefore closely linked to gene loci associated with MS68. 
A significant increase of the number of MOG-specific T-cells was reported in 
peripheral blood mononuclear cells (PBMC) and CSF of MS patients69. Half of the 24 MS 
patients that were tested for proliferation against myelin epitopes showed proliferation 
against MOG, but only five MS patients showed proliferation against MBP and only two 
against PLP70. MOG-reactive T-cells are also present in the natural T-cell repertoire 
of healthy individuals71,72. The fact that these autoreactive T-cells are not depleted 
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Figure 4. Overview of the hypothetical pathogenesis of MS.
The triggers that cause MS are unknown, in contrast to the trigger in EAE, which is immunization with a 
myelin protein or peptide emulsified in an adjuvant. The classical and general view on MS pathogenesis 
is that autoreactive T-cells are activated in the periphery by antigen presenting cells (APC) that present 
CNS or CNS cross-reactive antigens (Ag). Both Th1 and Th17 cells may play a role in the pathogenesis. 
Also B-cells are activated via T-cell help leading to plasma cells and the production of autoantibodies. 
Activated lymphocytes, antibodies, and macrophages migrate via blood to the CNS, across the blood-
brain barrier, enter the Virchow-Robin space, and migrate into the parenchyma when the appropriate 
signals are provided. T-cells are then reactivated by local antigen presenting cells, such as activated 
microglia. This leads to a cascade of events that induce demyelination, axonal injury, and gliosis. 
Autoantibodies directed against myelin or neuronal proteins enhance the immune response, for instance 
by activating the complement system. Infiltrated macrophages or resident microglia phagocytose myelin 
and produce inflammatory mediators. Ag, antigen; BM, basement membrane; DC, dendritic cell; EC, 
endothelial cells; (Mϕ), macrophages; μglia, microglia. Based on6,9,61,62.
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Figure 5. Structure of myelin oligodendrocyte glycoprotein (MOG). 
A, MOG is present on the outer surface of myelin. B, Proposed models for the membrane topology 
of MOG. The N-terminus is localized on the extracellular side. The C-terminus is localized on the 
extracellular side (model A) or the C-terminal is associated with the lipid bilayer (model B). In both 
models, MOG34-56 is localized on the extracellular side. C, Schematic representation of the three-
dimensional structure of MOG that forms a dimer. MOG35-55 maps to the dark grey residues. D, Amino 
acid sequence of MOG of human, cynomolgus macaque, common marmoset, bovine, and mouse. 
MOG34-56 is indicated by the square. Based on63-65,67.
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during development of the immune system has been explained by the absence of MOG 
expression in the thymus73. It is suggested that these MOG-reactive T-cells are Th0 
cells in healthy individuals and Th1 cells in MS patients72,74. The T-cell response is 
mainly directed against three domains in the extracellular part of MOG, i.e. 1-22, 34-56, 
and 64-9674-76. The phenotype of these T-cells is CD4+CD8- and they use the αβ T-cell 
receptor (TCR) for Ag recognition. MOG-reactive T-cells can induce cytolysis of MOG-
pulsed PBMC72,74. It has long been thought that Th1 cells were the main pathogenic 
T-cells in MS, but more recent literature highlights an important pathogenic contribution 
of Th17 cells and CD8+ T-cells as well. Blood, CSF, and CNS lesions of MS patients 
contain IL-17A, Th17 cells77-82, and clonally expanded CD8+ T-cells33,83,84. However, the 
exact role of Th17 and CD8+ cells is still under investigation.
B-cells have long been thought to function in MS only as Ab-producing plasma cells. 
Indeed, intrathecal Ab production can be detected as oligoclonal bands in the CSF85. In 
addition, autoantibodies are present in serum and CNS lesions44,86. MS patients have 
increased IgG titers to native MOG87,88. There is some indirect evidence that B-cells 
also have other roles in MS, since treatment with the anti-CD20 Ab rituximab improved 
clinical symptoms and CNS pathology without changing total IgM and IgG levels. One 
suggested role for B-cells in MS, i.e. Ag presentation to T-cells36,37, is addressed in this 
thesis.
Therapy 
Acute MS relapses are often treated with high doses of corticosteroids, such as methyl 
prednisolone, which inhibit the pro-inflammatory immune response and decrease the 
extravasation of immune cells into the CNS89-91. Generally used drugs suppress some 
of the chronic symptoms, such as bladder dysfunction and spasticity9. However, to date 
there is no treatment that effectively prevents all symptoms and pathology of MS.
The availability of new therapeutic agents for RRMS has tremendously improved 
in the past decade92 (Table 1). Approved drugs include mitoxantrone, interferon (IFN) 
β, glatiramer acetate, and natalizumab. Mitoxantrone is a synthetic antineoplastic 
cytotoxic drug that inhibits DNA and RNA synthesis. Because of its toxic effects 
mitoxantrone has only been approved for short treatment periods of aggressive MS 
relapses93. Mitoxantrone enhances the production of Th2 cytokines, but does not alter 
the production of Th1 and Th17 cytokines94. IFN-β reduces clinical signs and MRI 
detectable lesions in RRMS, especially when the treatment is started in the early phase 
of the disease95-97. IFN-β promotes the production of Th2 cytokines and reduces IL-
17A production in vitro98,99. Furthermore, IFN-β may reduce the migration of immune 
cells into the CNS by altering the BBB or by increasing the expression of chemokines 
or chemokine receptors by leukocytes100,101. Unfortunately, treatment with IFN-β is not 
effective in all patients, which could be due to the development of neutralizing Ab102. 
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Another explanation, based on findings in the animal model for MS, may be that 
IFN-β inhibits Th1-mediated pathology, but exacerbates symptoms mediated by Th17 
cells103. This suggests that IFN-β is effective in patients with Th1-mediated disease, 
Table 1. A selection of therapies for MS.
Generic name drug name Main target Anticipated mechanism of action
Approved
Mitoxantrone Novantrone®
Ralenova®
T-cells, B-cells, 
and macrophages
• Inhibits DNA and RNA synthesis
•  Enhances production of Th2 
cytokines, but without changing 
IFN-γ and IL-17A levels
β Interferons Rebif® Avonex® 
Betaseron®
Leukocytes • Promotes Th2 cytokines
•  Inhibits Th1-mediated pathology, 
but exacerbates Th17-mediated 
pathology
• Inhibits leukocyte migration into CNS
Glatiramer acetate Copaxone® MHC class II 
molecules
•  Replacement of MBP in MHC II 
complex
• Promotes Th2 skewing
Natalizumaba Tysabri® α4β1/VLA-4 on 
lymphocytes and 
monocytes
• Inhibits leukocyte migration into CNS
under development
Statins • Lowers cholesterol
• Promotes Th2 skewing
•  Inhibits lymphocyte migration into 
CNS
•  Inhibits IFN-γ induced MHC class II 
expression
FTY720 Fingolimod® S1P receptor on 
e.g. lymphocytes 
and CNS cells 
•  Prevents egress of lymphocytes 
from lymph nodes
•  May promote CNS repair 
mechanisms
Alemtuzumaba Campath® CD52 on 
lymphocytes and 
monocytes
•  Depletes lymphocytes and 
monocytes
Daclizumaba Zenapax® CD25/IL-2Rα on 
activated T-cells
• Inhibits T-cell proliferation
Rituximaba Rituxan® CD20 on B-cells •  Reversible depletion of B-cells, but 
not plasma cells
a mAb monoclonal antibody
BBB, blood-brain barrier; S1P, sphingosine-1-phosphate; VLA-4, very late antigen-4
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but not in patients with a Th17 dominant phenotype. Glatiramer acetate is a synthetic 
mixture of polypeptides composed of four amino acids and is used as a therapy for 
RRMS104. The immunological effects of glatiramer acetate are widespread and include 
replacement of MBP epitopes on MHC class II complexes and Th2 skewing105,106. 
Natalizumab is a mAb that binds to α4β1 integrin (VLA-4), which is expressed by 
lymphocytes and monocytes. Natalizumab prevents the interaction of immune cells 
with vascular cell adhesion molecule 1 expressed by endothelial cells of the BBB and 
thereby reduces leukocyte infiltration into the CNS. Natalizumab profoundly reduces 
disease progression in RRMS patients107. Natalizumab was voluntary withdrawn from 
the market for a while, because a few patients developed progressive multifocal 
leukoencephalopathy (PML), which is caused by the JC polyomavirus108-110. The 
drug was reintroduced on the market with several restrictions111. It is currently under 
investigation whether monitoring JC virus reactivation can be used to diagnose the 
risk for PML development112,113.
Drugs that are currently in clinical trials include statins, FTY720, and mAb targeting 
CD52 (Alemtuzumab), CD20 (Rituximab), or the α chain of the IL-2 receptor/CD25 
(Daclizumab). Statins are cholesterol-lowering drugs that are extensively used for 
cardiovascular diseases. In addition, statins skew the T-cell response towards Th2 and 
inhibit lymphocyte migration across the BBB114-116. Statins have been tested in clinical trials 
for RRMS with promising results117. However, in vitro statins hamper myelin formation 
by oligodendrocytes indicating that they may inhibit remyelination in vivo118. FTY720, 
also known as fingolimod, is a small molecule that targets sphingosine-1-phosphate 
receptors expressed by many cell types including lymphocytes and CNS cells. FTY720 
prevents the egress of lymphocytes from lymph nodes and may promote repair in the 
CNS119. FTY720 reduces MRI detectable lesions and clinical symptoms of RRMS120,121. 
Alemtuzumab targets CD52 that is widely expressed by T-cells and B-cells as well as by 
a subpopulation of granulocytes122. Alemtuzumab reduces the relapse rate and lesion 
load123. Daclizumab prevents T-cell expansion by blocking the IL-2 receptor α chain 
expressed by activated T-cells124. However, daclizumab also reduces the frequency of 
systemic regulatory T-cells of which the effect is currently unknown125. RRMS patients 
with an incomplete response to IFN-β responded very well to daclizumab126. Rituximab 
targets CD20/B-1 antigen expressed by B-cells, but not by plasma cells. Rituximab 
profoundly reduces the relapse rate and lesion formation in RRMS36,37. B-cell depletion 
by rituximab resulted in PML in a few non-MS patients110. Second-generation B-cell 
depleting Ab directed against CD20, such as ofatumumab and ocrelizumab, are now 
also under development for clinical trials in MS127,128. 
The therapies described above are immunomodulatory treatments and most 
appropriate for RRMS. When these treatments were tested in PPMS they were less 
effective129,130. Inflammation may play a less dominant role in the progressive phase 
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of MS and in GM lesions. Therefore, therapies are required that interfere with axonal 
injury, that prevent GM lesions, or that stimulate remyelination131. Suggested targets 
are myelin-associated inhibitory factors, such as Nogo-A, which inhibit neurite 
outgrowth132.
ExPERIMENTAl AuTOIMMuNE ENCEPHAlOMYElITIS
For both exploratory and applied research into MS the use of a valid animal model 
is indispensable. The history of the animal model for MS starts in 1885 when humans 
were found to develop paralytic diseases after injection with rabies vaccine, which was 
isolated from the spinal cord of rabies infected rabbits133. Rivers started to investigate 
the cause of this paralysis by repeated intramuscular injection of rhesus macaques 
with rabbit brain homogenate. Only two of the eight monkeys developed symptoms 
and pathology after more than 50 injections134. However, when aqueous solutions and 
alcohol-ether extracts of rabbit brains were intramuscularly injected, six of the eight 
monkeys developed clinical signs and pathology135. Next, the procedure was refined to a 
single injection with brain homogenate in complete Freund’s adjuvant (CFA) or vaseline 
oil containing killed Mycobacterium bovis. This led to an acute neuroinflammatory 
disease with paralytic symptoms resembling acute disseminated encephalomyelitis 
rather than MS136,137.
Nowadays, there are several animal models for MS that spontaneously develop 
in transgenic mice138-142, or that are induced by viruses143-145, toxins146,147, adoptive 
transfer, or immunization148-160 (Table 2). The most widely used animal model is EAE, 
which is induced by active immunization with myelin derivates and an adjuvant. EAE 
can be induced in several species, such as rabbits, guinea pigs, rats, mice, and 
NHP. Most commonly used are inbred mouse and rat strains and outbred common 
marmosets in which different immunization protocols lead to different disease variants 
(Table 2).
The marmoset EAE model
The EAE model in the marmoset has first been developed fifteen years ago157. Since 
then, the model has been continuously refined. To induce EAE, marmosets were initially 
immunized with whole human myelin emulsified in CFA containing Mycobacterium 
tuberculosis in combination with two intravenous doses of heat-inactivated Bordetella 
pertussis organisms or particles157,161. This led to an experimental model with an acute 
onset of a relapsing-remitting disease course in which the animals were sacrificed with 
neurological symptoms as paresis and paralysis within 13 weeks. The CNS pathology 
was characterized by active lesions and disrupted axons. Furthermore, a destructive 
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inflammatory process was observed rather than selective demyelination as seen in MS. 
Cellular infiltrates consisted of lymphocytes, macrophages, and neutrophils161. 
To create a model with a milder clinical course and pathology, five marmosets were 
immunized with human myelin in CFA that contained a lower dose of M. tuberculosis. 
Bordetella pertussis was omitted from the EAE induction protocol. The average day 
of sacrifice was delayed to almost 37 weeks after immunization. Inactive lesions 
dominated over active lesions and the cellular infiltrates contained lymphocytes and 
macrophages161. 
The next step was to determine the contribution of specific immune reactions 
against the myelin proteins MBP and MOG to the development of EAE. Immunization 
with MBP in CFA, containing M. butyricum, without Bordetella pertussis induced only 
mild symptoms, such as loss of appetite and altered walking pattern, and small CNS 
lesions in two of the three marmosets. In contrast, immunization with recombinant 
human (rh) MOG, which represents the N-terminal domain of MOG from amino acid 
1 to 125 and is produced as non-glycosylated protein in E. coli, formulated with CFA, 
containing M. butyricum, induced neurological symptoms as paresis and paralysis. As 
in the previous models with human myelin, a single immunization with rhMOG in CFA 
led to a 100% disease incidence with a variable disease onset158. The heterogeneous 
disease onset is caused by the outbred nature of the marmosets. The analysis of the 
immune process underlying this heterogeneous disease course is one of the subjects 
of this thesis. 
The first lesions in the rhMOG/CFA model are detected by MRI between 5 and 
39 (mean 14) weeks after immunization. Lesions disseminate in time and space as 
is also seen in MS. The majority of the animals showed an increase in lesion load 
before neurological symptoms were detectable162. Active and inactive lesions were 
detected side-by-side, but most lesions were in the active phase and resembled the 
MS pattern II lesions with complement/Ab-mediated damage162-165. Histological signs 
of axonal injury, assessed by immunoreactivity for accumulated β-amyloid precursor 
protein and non-phosphorylated neurofilaments (SMI-32), was confined to inflammatory 
active lesions163. 
Three types of GM lesions are present in this EAE model, which are comparable 
with GM lesions observed in MS55,166,167. Leukocortical lesions were found in all six 
examined marmoset brains and accounted for 57% of the total number of cortical 
lesions. Intracortical lesions were found in two of the six marmoset brains, whereas 
subpial lesions were found in five of the six marmosets and accounted for 88% of the 
total demyelinated cortical area. Activated macrophages and microglia were found in 
leukocortical and intracortical lesions, but the density was lower than in WM lesions, 
as has also been described for MS. Subpial lesions expressed only little signs of 
inflammation166. Furthermore, the cortical thickness was reduced in marmosets with 
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EAE compared to controls, but no differences were observed between demyelinated 
and myelinated areas168. Intracortical, but not subpial, lesions displayed Ig leakage and 
complement deposition167. 
Myelin oligodendrocyte glycoprotein
The function of MOG in the CNS is unknown as MOG-deficient mice do not present 
clinical or histological abnormalities169. However, MOG is an important target of the 
autoimmune attack in EAE. Autoimmunity against MOG is crucial for the progression 
of EAE in Biozzi ABH mice170 and marmosets171. Immunization with rhMOG protein 
or MOG peptides induces Ab and T-cell responses172,173. Ab against MOG facilitate 
demyelination and phagocytosis in vitro174,175 and enhance demyelination in vivo in 
mice176, rats177,178, and marmosets156,179. T-cell responses against MOG are found in EAE 
models in mice148, rats180, marmosets158, and rhesus macaques155. Rearrangement of 
the TCR of MOG-specific T-cells is essential for the development of a relapse in mouse 
EAE models181. EAE can be induced by adoptive transfer of MOG-specific T-cells, 
demonstrating their pathogenic capacity182. Anti-MOG T-cells are present in the normal 
repertoire of marmosets, as was also observed in healthy human donors182. Both Th1 
and Th17 cells play a role in EAE, but the exact contribution of each cell type is still 
under debate183-190.
An interesting feature of MOG is that the sequence of MOG39-46 (WYRPPFSR) is 
almost identical to amino acid 986 to 993 (WLRSPFSR) from the major capsid protein 
UL86 of cytomegalovirus (CMV) and to amino acid 963 to 970 (WQRTPFSV) from the 
major capsid protein of HHV-6. MOG34-56-specific T-cell lines (TCL) obtained from 
MOG34-56/CFA-immunized rhesus macaques proliferated in vitro in response to the 
peptide from CMV, but not to the peptide from HHV-6. Immunization of rhesus macaques 
with UL86 peptide 981-1003, which includes the cross-reactive T-cell epitope 986-993, 
induced the activation of MOG34-56-specific T-cells in vivo, but neurological deficit was 
not observed191. This suggests that CMV-induced memory T-cells can be activated by 
APC that present MOG39-46.
Adjuvants 
The best-known and most widely used adjuvant for EAE induction is CFA, which is 
composed of paraffin oil containing the surfactant mannide mono-oleate (incomplete 
Freund’s adjuvant (IFA)) and heat-killed M. tuberculosis or M. butyricum. When IFA 
or CFA is mixed with the Ag in an aqueous solution, a viscous water-in-oil emulsion is 
formed. 
The exact mechanism of action of IFA and CFA is unknown, but several mechanisms 
are suggested. First, IFA and CFA form an Ag-depot prolonging the presence of the Ag 
at the injection site. Second, IFA and CFA enhance the uptake of Ag by local dendritic 
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cells (DC) that migrate to the draining lymphoid organs. Third, CFA, and to a lesser 
extent IFA, provide several signals to the (innate) immune system192. IFA and CFA can 
enhance the production of Ab. CFA skews the T-cell response towards Th1, but recently 
it was suggested that also Th17 cells can be activated by CFA192,193. IFA may favor Th2 
skewing194,195. Furthermore, CFA enhances the permeability of the BBB196. CFA and IFA 
do not activate the inflammasome via Nalp3197.
Both IFA and CFA cause inflammation and granuloma formation at the injection 
sites and in organs, such as lung and liver, although this is more severe with CFA192. 
Furthermore, CFA also induces enlargement of lymphoid organs, haematopoietic 
dysfunction, and disruption of lymph node architecture192. 
The addition of bacterial components, such as Toll-like receptor ligands or bacterial 
cell wall components, to IFA may also be sufficient to induce EAE198. Indeed, EAE in 
C57BL/6 mice can be induced by immunization with MOG35-55 in IFA with the addition 
of peptidoglycan derived from Staphylococcus aureus199. In contrast, EAE cannot be 
induced in SJL mice with PLP139-151 in IFA when CpG dinucleotides are added to 
activate TLR9193.
In addition to CFA, EAE induction in several mouse strains requires injection 
with inactivated Bordetella pertussis or pertussis toxin. Both adjuvants enhance 
the Th1 skewing effect of CFA and increase the expression of inducible nitric oxide 
synthase and TNF-α200,201. Moreover, they facilitate EAE development by inducing 
permeabilization of the BBB202. In addition, pertussis toxin induces clinical disease 
and peripheral proliferation of Th17 cells when co-injected with PLP and IFA in SJL 
mice203.
THE MARMOSET 
General features
The common marmoset, also called cotton-eared monkey or white-tufted ear monkey, 
is a New World monkey that belongs to the family of Callitrichidae, the genus Callithrix, 
and the species jacchus (Callithrix jacchus). The marmoset is a non-endangered species 
and has an evolutionary distance from humans of 35 million years204. The marmoset 
has its natural habitat in the Amazone forest in Brasil, has an average length of 20 cm 
with a 30 cm tail, an average weight of 300-350 gram, and an average life span of 10 
years. Marmosets reach sexual maturation between 10 and 15 months and have an 
average gestational period of 143 days. Once or twice a year, marmosets give birth to a 
twin or triplet205. Marmosets are social animals living in groups of about eight individuals 
usually comprising adults and their offspring206.
Marmosets are used in several disciplines of biomedical research, e.g. infectious 
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diseases, neuroscience, and drug development207,208. The use of marmosets in 
biomedical research has several advantages, but also limitations (Table 3). A particularly 
interesting aspect of marmosets is the stable bone marrow chimerism between twin 
siblings that is caused by the sharing of the placental blood stream. Consequently, 
the immune systems of twins are educated in the same thymic environment, making 
fraternal siblings immunologically more similar than siblings from different births209. 
This principle can be used in therapy trials where one twin sibling is treated with an 
experimental agent and the other sibling with placebo.
Immunogenetics and immunology
The Mhc is a dense genomic region, mainly comprising immune genes involved in 
Ag presentation. Two main regions are discerned within the Mhc, i.e. class I and II. Mhc 
class I contains the classical A, B, and C and the nonclassical E, F, G, H, and J genes. 
The classical class I molecules are heterodimers of a heavy α chain with β2-microglobin 
Table 3. Advantages and limitations of the marmoset.
Advantage
• (Neuro)anatomical, immunological, physiological and microbiological proximity to humans.
•  Outbred nature of the marmoset more closely reflects the genetic heterogeneity of the human 
population than inbred animal strains.
• EAE or other diseases are induced at adult age when the immune system is fully matured.
•  The conventional housing implies free exposure to immune shaping pathogens both from the ‘milieu 
exterieur’ (environment, gut flora) and the ‘milieu interieur’ (e.g. latent infection with herpesviruses 
such as CMV, EBV).
•  Biological therapeuticals developed for human diseases, such as monoclonal antibodies or cytokines, 
often cross-react with marmosets. These can thus be tested in marmosets as a preclinical evaluation 
of efficacy and safety.
• Easy housing and handling due to its small size.
• Therapeutic experiments require 10- to 20-fold less compound than in the larger macaques.
•  Twins are born as bone-marrow chimeras caused by the shared placental blood stream. Therefore, 
twins can be used as pairs in adoptive transfer studies or in the validation of new therapeutics.
limitation
•  Ethical: When the same information can be obtained in lower species, marmosets cannot be used. 
Also experimental manipulations are limited.
•  Outbred nature: the genetic heterogeneity creates clinical and pathological heterogeneity, which 
may affect the interpretation of data. This feature can be compensated in part by using twins, 
which due to the bone marrow chimerism are immunologically more comparable than unrelated 
monkeys.
• High costs not only of the monkeys themselves, but also of the housing and care.
•  Cross-reactivity of diagnostic reagents, such as FACS antibodies is more limited than for rhesus 
macaques.
• Blood volume that can be withdrawn is limited.
• Adoptive transfer studies are technically difficult.
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and are expressed by all nucleated cell types where they present intracellular Ag to 
cytotoxic (CD8+) T-cells. The nonclassical molecules have more diverse functions and 
are often cell type specific. Mhc class II is arranged in DP, DQ, and DR regions, each 
containing at least one pair of A and B genes encoding the α and β polypeptide chains 
of the MHC molecule. Class II molecules are only expressed by APC and present Ag to 
CD4+ T-cells. The Mhc region is characterized by genetic diversity as shown by the high 
number of genes and loci, which are acquired by duplication during evolution, and the 
presence of allelic polymorphisms. There is a lot of diversity between species through 
gain and loss of loci210.
In the marmoset, Mhc class I diversity is very limited. Caja-A, -B, and -C could 
not be identified and only 2 Caja-E and 5 Caja-G alleles have been described until 
now211,212 (Table 4). It has been suggested that Caja-E is orthologous to HLA-E, whereas 
a relationship between Caja-G and HLA-G is doubtful213. It is highly likely that Caja-G 
contains more alleles and that Caja-G functions as classical HLA molecule. 
Table 4. MHC alleles described for the marmoset.
Class Ib 
locus lineage
E *01
E *02
G *01 
G *02
G *03
G *04
G *05
Class IIc 
locus lineage Alleles
DQA1 *01 01
*27a 01
DQB1 *2201 01, 02
*23 01, 02
DQB2 *01 01, 02
DRB1 *03 01, 02, 03, 04, 05, 06, 07, 08, 09, 10, 11, 12, 14
DRB *W12 01, 02
DRB *W16 01, 04, 05, 06, 07, 08, 09, 10, 11, 12, 13, 14, 15, 16, 17, 
18, 20, 22, 23, 24
a previously described as *25
b Class I is based on 211,212
c Class II is based on 214-217
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The marmoset Mhc class II contains DQA1, DQB1, and DQB2, but Caja-DQA2 and 
Caja-DP could not be identified (Table 4). The Caja-DQA1*0101 allele clusters together 
with humans, apes, Old World monkeys, and New World monkeys. In contrast, Caja-
DQA1*2701 (previously called *2501) is restricted to New World monkeys. Although 
DQA2 and DQB2 are considered to be pseudogenes, Caja-DQB2 is highly similar to 
HLA-DQB2214. Marmosets contain one DRB region configuration, containing the three 
lineages DRB1*03, DRB*W12, and DRB*W16. Caja-DRB1*03 and -DRB*W16 are 
polymorphic with 13 and 20 alleles, respectively (Table 4). Caja-DRB*W12 appears 
to be monomorphic with two alleles, which differ only two codons from each other. 
All marmosets express Caja-DRB*W1201 or -DRB*W1202214-217. The expression of 
Caja-DRB1*03 is very low, if detectable at all. Exceptional alleles are DRB1*0307 
and DRB1*0312 that are highly expressed. Interestingly, exon 2 of DRB1*0307 and 
DRB1*0312 is similar to HLA-DRB1*03 and matches all features of the Caja-DRB1*03 
locus, whereas the other exons align with Caja-DRB*W16217. The exact nucleotide 
sequence of the alleles of the marmoset Mhc region has been published in an online 
database218. The low variability in MHC class II in marmosets may explain the increased 
susceptibility to fatal infections with certain bacteria, such as Klebsiella, Bordetella, 
Clostridium, and Shigella208,219. 
Despite the limited polymorphism of the Mhc, marmosets have a diverse and 
evolutionary stable TCR α- and β-chain repertoire. The constant region of the α-chain 
gene of marmosets has an 89% nucleotide and 80% amino acid similarity with humans. 
Furthermore, 46 joining genes and 35 genes for the variable region were identified. The 
similarity with humans at the nucleotide and amino acid level was higher than 80% and 
69%, respectively220. Analysis of the variable (V), diversity (D), and joining (J) genes 
of the β-chain identified 15 V, 2 D, and 13 J genes. These genes are highly similar to 
the human genes. For example, the 15 V genes of the marmoset TCR had an average 
similarity of 88.5% to human V genes. Two constant (C) genes were identified in the 
marmoset TCR, named CjCB1 and CjCB2, which were similar to two constant genes in 
humans, BC1 and BC2. In addition, the complementarity-determining region 3 (CDR3) 
of the TCR in marmosets has an average length of 10 amino acids, which is similar to 
the length in mice and humans221.
Six Ig heavy chain variable subgroups were detected, which show a high degree of 
sequence similarity to the heavy chain variable regions in humans. The major difference 
with humans is the absence of the second subgroup in the marmoset222. The IgE system 
is similar to humans, but IgE plasma levels were much lower in marmosets than in 
humans223. Further knowledge about the Ig genes in marmosets is still very limited, 
although this will likely improve in the near future since the marmoset genome has been 
sequenced recently.
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A large panel of mAb against human cluster of differentiation (CD) markers, which 
are developed to detect human leukocyte subsets, is cross-reactive with marmoset 
leukocytes224,225. This suggests a high level of conservation of CD markers in New World 
monkeys.
Neuroanatomy
The marmoset brain has an average weight of 7.9 gram, which represents about 
2.7% of its body weight. This is equivalent to the 2% brain mass in humans, whereas 
a rat brain only weights 0.5% of its total body weight207. The index of cranial capacity 
assesses the relationship between the observed cranial capacity and the expected 
cranial capacity. Marmosets have a cranial capacity index of 6.0, which is comparable 
to 8.2 of the rhesus macaque. Humans have a cranial capacity index of 23226. 
The neuroanatomy and the ratio between WM and GM in the marmoset brain are 
comparable to humans227. Several neurotransmitter receptors, such as the NMDA 
receptors, show a similar distribution pattern in the striate cortex of marmosets and 
humans228. The optic chiasm in marmosets has the same segregation hemispheric 
pathway as in humans, in contrast to rodents in which crossed and non-crossed fibers 
mix229.
To model MS in marmosets, it is important that the anatomy and function of the 
cortex is comparable between humans and marmosets as GM changes may play a 
role in the clinical deterioration of MS patients51,56,59. The marmoset cortex has indeed 
similarities with Old World monkeys and humans, but also several differences. The 
orbital and medial frontal cortices are highly conserved, whereas the granular frontal 
cortex has changed during evolution. For example, the histological subdivision of the 
granular frontal cortex is less obvious in marmosets than in humans230,231. 
Marmosets are extremely useful for application of imaging techniques in vivo and post 
mortem (Figure 6). The preferred imaging tool for the visualization and characterization 
of lesions in the brain is MRI, which can be performed in vivo or post mortem. In MRI 
the magnetic properties of protons, which occur at different concentrations in different 
regions of a tissue or organ, are used to generate contrast. The most frequently monitored 
MRI parameters in MS diagnosis are T2-weighted (T2W) and contrast-enhanced T1-
weighted (T1W) images (Table 5). GM lesions can be analysed by post mortem MRI 
using inversion images in which the GM signal is suppressed (Table 5, Figure 6) and 
small lesions may be visualized by fluid-attenuated inversion recovery imaging. 
Taken together, the multidisciplinary research conducted over the past decade has 
transformed the EAE model in marmosets into a preclinical model for translational 
research into the pathogenesis of MS and for the development of novel treatments, 
which are described in the following chapters.
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Figure 6. MRI sequences used for visualization of brain lesions. 
A, A marmoset monkey in which EAE was induced by immunization with rhMOG/CFA was subjected 
at 14 days interval to brain MRI at 4.7 Tesla. Scans of the same monkey before brain lesions were 
detected (pre-EAE) and during clinical EAE (EAE) are shown. The first picture is a high contrast T2-
weighted scan visualizing the spatial distribution and shape of lesions. The next three pictures are 
semi-quantitative scans in which the T1 and T2 relaxation times and the MTR ratios are plotted. The 
last picture shows a differential scan created by subtracting T1-weighted images recorded before and 
after intravenous injection of the paramagnetic contrast probe gadolinium-DTPA. B, High-contrast post 
mortem MRI shows white and grey matter lesions (arrows) on a T2-weighted scan, on a scan with the 
MTR ratios, and on a scan in which the grey matter (GM) signal was suppressed leading to a better 
visualization of GM lesions.
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Table 5. MRI parameters.
T1-weighted
Detects disappearance of tissue, e.g. due to demyelination or axonal injury.
T1W images are sensitized for the T1 relaxation time, a time constant that 
describes the rate in which the longitudinal component of the magnetization 
vector recovers. 
T1-weighted +  
contrast agent
Visualization of the permeability of the BBB.
Data is shown as percentage increase in signal intensity due to presence of 
the leaking MR contrast agent in the brain parenchyma.
T2-weighted Used to determine lesion volume (voxel or mm3).T2W images are sensitized for the T2 values. 
T2 relaxation time 
images
T2 values are sensitive to changes in water content (edema) and 
demyelination.
T2 image displays T2 relaxation time values, a time constant (~ milliseconds) 
describing the decay of the magnetization vector in the transversal plane.
Magnetization  
Transfer Ratio
The MTR is reduced by demyelination and edema.
Measures the ratio of protons of macromolecule-bound water and freely 
moving water. The macromolecule-bound protons of water are saturated by a 
magnetization transfer pulse and this saturation is transferred to the protons of 
freely moving water. The latter is, together with the T1 and T2 relaxation time, 
the main contributor to the MR signal. 
Data is shown as percentage decrease in signal intensity due to the saturation 
pulse.
Inversion recovery  
image
Images in which the signal arising from a specific fluid or tissue, such as CSF, 
white matter, or grey matter, is suppressed. Suppression of the grey matter 
signal facilitates the detection of grey matter lesions.
Diffusion tensor  
imaging
Diffusion MRI measures the diffusion of freely moving water molecules in 
tissue.  The presence of cell boundaries may restrict this diffusion. In diffusion 
tensor imaging (DTI) the preferred direction of the water diffusion is calculated. 
For an intact axon this will be mainly along the direction of the myelinated 
axons as the myelin sheaths will limit the diffusion of water perpendicular to 
this direction. In an injured axon water will also diffuse perpendicular to the 
direction of the axon.
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AIM ANd OuTlINE OF THIS THESIS
Despite many years of research, the (immuno)pathogenic mechanisms causing MS 
are still unknown and a therapy to arrest the disease is still lacking. For both exploratory 
and applied research (Figure 1) the marmoset EAE model can be used, because this 
model closely resembles MS in an immunological, clinical, and pathological manner. 
The aim of the research described in this thesis has been to investigate pathogenic 
mechanisms underlying EAE and MS and to identify new targets for MS therapy. 
To study immunopathogenic mechanisms in experimental models, flow cytometry 
and immunohistochemistry are indispensable techniques. A large panel of anti-human 
Ab that can be used for flow cytometry analysis of marmoset cells has already been 
described225. In chapter 2, we have investigated the cross-reactivity of a selection of 
anti-human Ab with lymphoid tissue from six NHP species, including the marmoset. 
Immunization of marmosets with rhMOG induces a 100% EAE incidence, but with a 
heterogeneous disease onset158. In chapter 3.1, we have investigated the autoimmune 
mechanisms underlying this heterogeneous disease course. In addition, we describe a 
new marmoset EAE model induced with MOG34-56 and the phenotype and function of 
T-cells associated with this disease.
In chapter 3.1, we demonstrate that MOG34-56 in IFA induces EAE in MOG74-
96/CFA sensitized animals. This led to the hypothesis that EAE in marmosets can be 
induced without CFA. Indeed, in chapter 3.2 we show that immunization with MOG34-
56 in IFA induced a disease with clinical symptoms and pathology similar to rhMOG/
CFA- and MOG34-56/CFA-induced marmoset EAE models.
The pathogenic role of IL-17A in rodent EAE models and in MS is still under 
debate. In marmosets, MOG34-56-specific T-cells produce IL-17A. Therefore, we have 
investigated the role of IL-17A in the marmoset EAE model. In chapter 4.1, EAE was 
induced by rhMOG in CFA and IL-17A was neutralized by two doses of a mAb. 
The B-cell depleting Ab rituximab is a promising treatment for MS, since clinical 
deterioration is prevented and the brain WM lesion load is reduced36,37. In chapters 
4.2 and 4.3, EAE was induced by rhMOG in CFA and B-cells were depleted by a mAb 
(HuMab 7D8) 21 days after immunization to avoid interference of the B-cell depletion 
with the induction of the immunopathogenic process. The pathogenic mechanisms 
underlying the effect of B-cell depletion in MS is unknown since total Ig levels were not 
changed. In chapter 4.2, we have investigated the effect of late B-cell depletion on the 
immune system. Here, evidence is shown that it is likely that B-cells act as APC in EAE. 
In chapter 4.3, we have investigated the effect of B-cell depletion on CNS pathology. 
The development of WM and GM lesions were analysed by in vivo and post mortem 
MRI. In addition, demyelination and inflammation were assessed in the WM and GM of 
the brain as well as in spinal cord and optic nerve by histology. 
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Instead of interfering with the immune response, promotion of (re)myelination and 
neuronal outgrowth may be a promising aim of therapy. To investigate this, MOG34-56/
CFA-immunized marmosets were treated with a mAb against the neurite outgrowth 
inhibitor Nogo-A in chapter 4.4. In addition, we demonstrate the role of Nogo-A in 
differentiation and myelination of oligodendrocyte precursor cells (OPC). 
MS relapse rate decreases during pregnancy, especially during the third trimester. 
In this phase, fragments derived from the β-subunit of the pregnancy hormone human 
chorionic gonadotropin (hCG) are present in serum and urine. Previous studies showed 
that synthetic β-hCG-related peptides have modulatory effects in acute immune 
responses. Therefore, we have investigated whether the β-hCG-related tetrapeptide 
LQGV can modulate EAE in chapter 4.5. 
In this thesis, EAE is induced in marmosets by three different induction protocols. 
In chapter 5, we discuss similarities and differences between these models. The 
experimental data presented in this thesis are discussed in relation to the pathogenic 
mechanisms of EAE and MS in the periphery and in the CNS. Furthermore, the 
mechanisms underlying the IFA model are discussed.
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ABSTRACT
Non-human primates (NHP) offer valuable animal models for basic research into 
human diseases and for the preclinical validation of new therapeutics. Detailed in situ 
examination of the involved cell types using immunohistochemistry is often hampered 
by the lack of cross-reactive antibodies (Ab). In the current study, we have tested a large 
panel of monoclonal Ab raised against human leukocyte differentiation and activation 
markers for cross-reactivity on cryosections of lymphoid tissue from six NHP species. 
In total, we have tested 130 Ab against 69 antigens expressed in tissues from one great 
ape species (chimpanzee/Pan troglodytes), two Old World species (rhesus macaque/
Macaca mulatta and cynomolgus macaque/Macaca fascicularis), and three New World 
species (common marmoset/Callithrix jacchus, cotton-top tamarin/Saguinus oedipus, 
and owl monkey/Aotus triviogatus). We have found a large panel of cross-reactive Ab: 
93 of 102 (91%) in chimpanzee, 97 of 125 (78%) in rhesus macaque, 70 of 109 (64%) 
in cynomolgus macaque, 69 of 116 (60%) in common marmoset, 40 of 81 (49%) in 
cotton-top tamarin, and 35 of 80 (44%) in owl monkey. Availability of a reliable panel of 
cross-reactive markers is important to gain further insight into immunological processes 
in disease-affected tissues from NHP species.
 
INTROduCTION
Non-human primates (NHP) provide important experimental models of immune-
mediated inflammatory disorders in biomedical research, because of the outbred nature 
and the phylogenetic proximity with humans. Recent milestones in biotechnology have 
resulted in the development of species-specific therapeutics, such as humanized 
antibodies (Ab) or fully human Ab1, which need to be evaluated in relevant disease 
models before they can be tested in patients. In cases in which rodent models are 
precluded by the lack of sufficient cross-reactivity, NHP models provide a useful 
alternative2.
A variety of NHP species is used in biomedicine. Although biomedical research in 
great apes has been banned from Europe for a few years, chimpanzees have been 
and still are productively used as models for human immunodeficiency virus (HIV) 
infection3,4 and for the development of certain vaccines, e.g. against hepatitis5. Old 
World monkeys, such as rhesus macaques and cynomolgus macaques, are frequently 
used as experimental models in transplantation6,7, tuberculosis8, malaria9, rheumatoid 
arthritis10, and HIV infection11. New World monkeys serve as important tools for e.g. 
Parkinson’s disease12, idiotypic colitis13, malaria vaccine research14, and for modeling 
multiple sclerosis (MS) in experimental autoimmune encephalomyelitis (EAE)15.
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Studies of immunopathogenic mechanisms in each of these experimental models 
rely on the availability of reagents and techniques for ex vivo immunodiagnosis, such as 
flow cytometry analysis or immunohistochemistry. Previously, the cross-reactivity in flow 
cytometry of anti-human monoclonal antibodies (mAb) with NHP has been reported16,17. 
However, little is known about the cross-reactivity of mAb on NHP tissue for usage in 
immunohistochemistry. In this study, we have investigated a set of 130 human-specific 
mAb against 69 molecules used in immunohistochemistry for cross-reactivity with 
lymphoid tissue of six NHP species. The mAb in this set were reactive against cluster 
of differentiation (CD) markers, cytokines, and other immunological markers, such as 
human leukocyte antigen (HLA) and immunoglobulins. The selection of CD markers 
included critical costimulatory molecules against which novel immunotherapeutics, 
such as CD4018,19, are under development. Furthermore, the selection included 
markers distinguishing leukocyte cell types as T-cells, B-cells, natural killer cells, and 
macrophages. The selected cytokines, such as interferon-gamma (IFN-γ), interleukin 
(IL)-12, and IL-17A, play a central role in inflammatory responses. The latter is produced 
by the newly identified Th17 functional T-cell subset, which is presumed to be critical 
in several autoimmune diseases, including rheumatoid arthritis and MS20. Furthermore, 
IL-17A may be involved in neutrophil recruitment21,22.
 
MATERIAlS ANd METHOdS
Tissues
For the detection of cross-reactivity, lymph node and/or spleen samples were 
used. Material from the African chimpanzee (Pan troglodytes), as a representative 
species of the great apes, was used. The selected Old World species were the rhesus 
macaque (Macaca mulatta) and the cynomolgus macaque (Macaca fascicularis). 
As representatives of New World species the common marmoset (Callithrix jacchus), 
the cotton-top tamarin (Saguinus oedipus), and the owl monkey (Aotus trigivatus) 
were chosen. All animals, except the cynomolgus macaques, were obtained from the 
outbred, genetically typed, breeding colonies at the Biomedical Primate Research 
Centre (BPRC), Rijswijk, The Netherlands. The breeding policy is aimed at prevention 
of inbreeding using genetic typing and the regular introduction of new animals. 
Cynomolgus macaques were obtained from licensed breeders. Tissue samples were 
collected at necropsy and were snap frozen in liquid nitrogen and stored at –80°C until 
use. Human tonsil served as positive control tissue.
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Monoclonal antibodies
All mAb described in this study are commercially available unless stated otherwise. 
Samples were kindly donated by the participating companies: Becton Dickinson (BD) 
bioscience (San Jose, CA), Dako (Glostrup, Denmark), Sanquin (Amsterdam, The 
Netherlands), Diaclone (Fleming, France), Serotec (Düsseldorf, Germany), Abcam 
(Cambridge, MA), Cymbus Biotech (Hampshire, UK), Beckman Coulter (Fullerton, CA), 
Bender MedSystems (Vienna, Austria), Genzyme (Framingham, MA), Sanbio (Uden, 
The Netherlands), Innogenetics (Gent, Belgium), Santa Cruz biotechnology (Santa Cruz, 
CA), U-Cytech (Utrecht, The Netherlands), Ebioscience (San Diego, CA), Nordic Labs 
(Tilburg, The Netherlands), Biosource (Nivelles, Belgium), and BMA Biomedicals (Augst, 
Switzerland). Other mAb were kindly provided by Dr. D. Boraschi (Centro Ricerche Sclavo, 
Sienna, Italy), Dr. R. Noelle (Dartmouth, Lebanon, NH), and Prof. Dr. G. Opdenakker 
(Rega Institute, Leuven, Belgium). BD bioscience and Cymbus biotech provided isotype-
matched Ab as controls. All specificities and clone names are listed in Table 1.
Immunohistochemistry
Immunohistochemistry was performed as described in detail previously23. Briefly, 
6 µm frozen spleen and lymph node sections were cut and thawed and mounted on 
glass slides. Slides were kept overnight at room temperature (RT), which is below the 
optimum temperature for most proteolytic enzymes, in a humidified atmosphere to allow 
controlled drying of the tissue. After the slides were air dried for 1 h, they were fixed 
either in fresh acetone or 4% paraformaldehyde in PBS (pH 7.4), both containing 0.02% 
(v/v) H2O2. Acetone-fixed slides were air dried for 10 min and subsequently washed in 
PBS, whereas paraformaldehyde-fixed slides were immediately washed in PBS. Tissue 
sections were incubated with primary Ab overnight at 4°C in a humidified atmosphere. Ab 
were tested in a dose titration that was based on the recommended dilution for human 
tissue and included a 10x dilution of the provided Ab. The same dose titration was used 
for all species. If the staining in a given case was doubtful, a higher concentration was 
tested if sufficient Ab was available. Incubations with secondary and tertiary reagents 
were performed for 1 h at RT. Between incubation steps the slides were washed twice 
with PBS. Detection of primary unlabeled mouse anti-human Ab was followed by 
incubation with rabbit anti-mouse-Ig-horseradish peroxidase (HRP) (Dako, Glostrup, 
Denmark), or in a three step staining with anti-mouse-Ig-biotin (Dako) and HRP-labeled 
avidin-biotin-complex (Dako). HRP activity was revealed by incubation for 10 min at 
RT with 3-amino-9-ethyl-carbozole (Sigma, Zwijndrecht, The Netherlands), leading to 
a bright-red precipitate. Some positive stainings, i.e. IL-17A, IFN-γ, and CD40, were 
enhanced with the tyramide signal amplification kit (Invitrogen, Carlsbad, CA). Human 
tonsil was used as positive control tissue. Incubation with isotype-matched primary Ab 
of irrelevant specificity and omission of the primary Ab served as negative controls.
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Table 1. Cross-reaction of anti-human antibodies on cryosections of non-human primate lym-
phoid tissue.
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Cd markers
CD2
CLB-T11/1 (6G4) 3 + + + - - -
RPA-2.10 1 + + + -/+ - -/+
S5.2 1 + + + + + -
B-E2 4 + + + + + -
LT2 5 + + + - - -
CD3
SK7 1 +
FN-18 6 + +
CLB-T3/2 (16A9) 3 + + - -/+ + -
SP34 1 + + -/+ - - -
CD4
SK3 1 - - -
MT477 1 - - -
CLB-T4/2 (6D10) 3 + - - - - +
SK3, SK4 1 + - - - - +
MT310 2 + - - - - +
CD5 UCHT2 7 + + + + -/+ +
CD7 B-F12 4 + + -/+ - + +
CD8
DK25 2 + +
SK1 1 - -
LT8 5 + + + -/+ - +
CLB-T8/4 (4H8) 3 + + + + - +
UCHT4 7 + + + - + -
CD10 ALB1 8 + - - + + +
CD11a
HI111 1 + + + + + +
G-25.2 1 + + + + + +
25.3 8 + + + + + +
B-B15 4 + -/+ + + + +
R7.1 9 + + + + + -
CD11b D12 1 + + + +
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CD13 B-F10 4 + + -/+ -/+ + +
CD14
322A-1 (MY4) 8 + + -/+ +
B-A8 4 + -/+ -/+ - -/+ -
CD16
NKP15 1 - + + - -/+ -
3G8 1 + + + + - +
B-E16 4 + + - - + -
CD18
L130 1 + + + + + -
CLB-LFA-1/1 (54) 3 + + + + + +
6.7 1 + + + + + +
CD19
SJ25C1 (FITC) 1 + - - - - -
4G7 1 + - - - + -
CD20
L26 2 + + + +
H299 (B1) 8 + + + + - -
B-H20 4 + -/+ - - + -
CD21
BL13 8 + + + + + +
B-LY4 1 + + + + + +
B-E5 4 + + + + + +
CD24 SN3 5 + -/+ -/+ - - -
CD25
B-B10 4 + + - - - -
Tu69 7 - - - - - -
CLB-IL2R/1 (TB30) 3 + + - - - -
2A3 1 +
CD26
BA5 2 -/+ + + - - +
L272 1 + - - - - -
CD27 L128 1 + - -/+ - - -
CLB-CD28/1 
(15E8)
3 + +
CD28 L293 1 + + + - - -
B-T3 4 + + + + + -/+
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CD29
TDM29 7 + + + + + +
B-D15 4 + + + + -/+ +
CD30L M81 10 +
CD31 5.6E 8 + + + - + -
CD33 D3HL60.251 8 +
CD34 QBEnd 10 3 + -
CD35 E-11 1 + + + + + +
CD38
T16 8 + - -/+ - + -
HB7 1 + - - - - -
CD40
5C3 1 + + - - -
CLB-14G7 3 + +
B-B20 7 + + + + + +
CD44
B-F24 4 + + - -/+ + +
NKI-P2 3 + + + + + +
F10-44-2 5 + - - + + +
CD45 B-A11 4 + + -/+ + + -
CD45RA B-C15 4 + + + + - +
CD45RO UCHL-1 1 + -
CD49d HP2/1 8 + + + - -/+ -
CD49e SAM1 8 + + + + - -
CD55 CLB-CD97L/1 3 - - +
CD56
123C3 11 + +
B-A19 4 + -/+ - - - -
N901 (NKH-1) 8 - - + + + -
MEM188 7 - + + - + -
NCAM16.2 1 + - + + - -
CD58
L306.4 1 -/+ - - - - -
1C3 1 + + + + + +
CD62L
FMC46 7 + - - - - -
DREG.55 9 + + + + - +
CD64 10.1 1 + +
CD68 KP1 2 + + + +
CD70 CLB-2F2 3 + + -/+ -/+
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CD80 M24 12 + + +
CD83 HB15A 8 + + + +
CD86
1G10 12 + + + +
B-T7 4 + + -/+ - + -
IT2.2 1 - + + + - -
CD95
UB2 8 + +
FAS6 3 + + +
APO1-1 9 -/+ -/+ + - - -
DX2 1 + + + - - -
BMS-140 9 + + + -/+ - -
CD97 CLB-CD97/1 3 + +
CD138
BB4 8 + + + - - -
CLB-1D4 3 + - - - - -
CD154/CD40L
TRAP1 1 + + +  +b
24-31 13 + + +
CD169 HSN1 (7D2) 5 + + +
Cytokines
IFN-α MC-16 14 + + +
IFN-γ
MD-1 14 +
MD-2 14 + + +
TNF-α 61E71 14 - + -/+ +
IL-1α Vmp18 15 + +
IL-1β Vmp20 15 + +
IL-2 80-3418-01 10   +b
IL-4
QS-4 14 + + +
1842-01 10 + -/+ +
IL-6 BE-8 15 + + +
IL-10 B-S10 16 + +  +  +
IL-12p40/p70 C8.6 1 + -/+ +
IL-17A eBio64CAP17 17 + +
Miscellaneous
HLA-ABC
G46-2.6 1 + + + - - -
W6/32 7 + + + + + +
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Immunohistochemistry analysis
Cross-reactivity is expressed as follows: - = no specific staining; -/+ = doubtful and 
needs more investigation; + = specific staining. 
Ethics
All NHP tissues that were used for this study were obtained from purpose-bred 
animals at the BPRC or purchased from licensed breeders. All tissues were from animals 
from other experimental studies; no monkeys were sacrificed solely for the purpose of 
this study. All study protocols were reviewed and approved according to Dutch law on 
animal experimentation.
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HLA-DP, DQ, DR CR3/43 2 + + +
HLA-DR
TAL-1B5 2 + +
B-F1 4 + + + + + +
CLB-HLA-DR (1E5) 3 + + + + + +
L243 1 + + + + + +
HLA-DQ SPV-L3 7 + + + + + +
IgM NI179 18 + +
IgG - 19 + + +
MMP-9 2D9 20 + +
MRP 14 27E10 (early) 21 + + +
a Providers: 1, Becton Dickinson Bioscience; 2, Dako; 3, Sanquin; 4, Diaclone; 5, Serotec; 6, Abcam; 
7, Cymbus biotech; 8, Beckman Coulter; 9, Bender MedSystems; 10, Genzyme; 11, Sanbio; 12, 
Innogenetics; 13, gift from Dr. R. Noelle; 14, U-Cytech; 15, gift from Dr. D. Boraschi; 16, Santa Cruz; 
17, Ebioscience; 18, Nordic Labs; 19, Bioscource; 20, gift from Prof. Dr. G. Opdenakker; 21, BMA 
Biomedicals. 
b Only cross-reactive when paraformaldehyde is used as fixative 
c +, cross-reactive; -, no specific staining; -/+, needs more investigation; blanc boxes, not tested. CD, 
cluster of differentiation; HLA, human leukocyte antigen; IFN-γ, interferon-gamma; IL, interleukin.
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Figure 1. Representative selec-
tion of cross-reactive monoclonal 
antibodies on spleen cryosections 
of rhesus macaque and common 
marmoset.
Spleen sections were stained for 
CD40, HLA-DR, IFN-γ, and IL-17A. 
Controls included isotype control 
and first antibody omission. 
Bar = 100 μm. See page 310 for a 
full-color representation of this figure.
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RESulTS 
Table 1 shows the Ab clustered according to their reactivity with CD markers, 
cytokines, and miscellaneous markers, such as HLA and immunoglobulins. For most 
markers, we have tested Ab clones obtained from several companies. Cross-reactivity 
was scored as: no specific staining (-), doubtful (-/+), or specific staining (+). Doubtful 
means that some staining is observed, but the specificity is unclear. To further investigate 
the cross-reactivity of these Ab, the titration of the mAb should be extended or another 
staining method will be necessary, but this was outside the scope of the current study. 
In total, we have tested 130 mAb against 69 markers: 105 clones against 50 CD 
Table 2. Number and percentage of cross-reactive monoclonal antibodies.
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Cd markers
Tested (n) 92 103 91 93 75 74
+ 84 75 55 47 35 30
+ (%) 91 73 60 51 47 41
Cytokines
Tested (n) 3 11 8 12
+ 2 11 5 12
+ (%) 67 100 63 100
Miscellaneous
Tested (n) 7 11 10 11 6 6
+ 7 11 10 10 5 5
+ (%) 100 100 100 91 83 83
Total
Tested (n) 102 125 109 116 81 80
+ 93 97 70 69 40 35
+ (%) 91 78 64 60 49 44
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markers, 13 clones against 11 cytokines, and 12 clones against 8 miscellaneous 
markers. The isotype controls and primary Ab omission were negative on all tissues 
tested (Figure 1). All Ab were directed against human antigens, and, as expected, were 
positive on human control tissue (data not shown). All mAb were first tested on acetone-
fixed tissue. In addition, mAb of particular interest that failed to stain cryosections were 
next tested on paraformaldehyde-fixed tissue. For example, a mAb against IL-2 that 
showed no cross-reactivity on acetone-fixed tissue did display cross-reactivity on 
paraformaldehyde-fixed common marmoset tissue. 
Table 2 summarizes the number and percentages of cross-reactive mAb tested 
per specificity per species. Predictably, the highest cross-reactivity was found in 
chimpanzees: 93 of 102 tested mAb showed cross-reactivity (91%). A somewhat lower 
percentage of cross-reactive mAb was found with the Old World species, i.e. 78% in 
rhesus macaques and 64% in cynomolgus macaques. An again lower, but still high, 
percentage of mAb were found to cross-react with New World species. In the common 
marmoset, cotton-top tamarin, and owl monkey the cross-reactivity was, respectively, 
60%, 49%, and 44%.
Figure 1 shows a selection of cross-reactive mAb on the spleen of a rhesus macaque 
and a common marmoset, i.e. mAb directed against CD40, HLA-DR, IFN-γ, and IL-
17A. 
 
dISCuSSION
NHP models are invaluable models for research in biomedicine. For the study 
of immunopathological mechanisms in these models, mAb for flow cytometry and 
immunohistochemistry are indispensable. A selection of mAb directed against human 
antigens for flow cytometry analysis of NHP cells has previously been reported16,17. 
The purpose of the current study was to compose a panel of cross-reactive mAb that 
could be used for immunohistochemical analysis of lymphoid tissues from six NHP 
species. Cross-reactive mAb can be used for immunopathological examination of NHP 
disease models, which subsequently will increase our knowledge about NHP models 
and human diseases. 
We have found a large panel of cross-reactive Ab for each species, with the highest 
level of cross-reactivity in chimpanzee, followed by monkeys of Old World origin and 
of New World origin. The decreasing level of cross-reactivity reflects the evolutionary 
distance, which has been estimated at 5 million years for chimpanzees, 25 million years 
for macaques, and 35 million years for marmosets24. We assessed the cross-reactivity 
in three categories, but not the intensity of the staining, although we did observe that 
some clones had more-intense staining than did other clones. We did not include this 
Proefschrift Yolanda Kap_compleet.indd   61 25-08-2010   21:24:45
Chapter 2.1
62
observation in the results, because a subjective scoring of intensity grades may be 
confusing. Furthermore, the intensity of a staining can be enhanced today by several 
techniques, and the intensity may vary between batches.
The markers shown in figure 1 were chosen because CD40, HLA-DR, IFN-γ and 
IL-17A are important in immune-mediated diseases. CD40 is a member of the tumor 
necrosis factor receptor family and is expressed on antigen presenting cells, such as 
B-cells, macrophages, and dendritic cells, and also on endothelial cells and fibroblasts. 
CD40 is a co-stimulatory molecule that binds to CD154 (CD40L) expressed on T-cells. 
Binding of CD40L to CD40 on B-cells induces B-cell proliferation and isotype switching. 
Interaction of CD40L with CD40 on monocytes induces the production of cytokines 
and nitric oxide. Furthermore, CD40 activation can prevent apoptosis of B-cells and 
monocytes. CD40 is involved in several immune-mediated diseases18,25,26. Blocking of 
CD40 prevents EAE in common marmosets19,27 and kidney allograft rejection in rhesus 
macaques28. HLA-DR is associated with several disease susceptibilities, such as 
rheumatoid arthritis and MS29. In the common marmoset, in which HLA-DR is called 
Caja-DR, Caja-DRB*W1201 is essential for the activation of Th1 cells that induce 
EAE30. IL-17A and IFN-γ are both pro-inflammatory cytokines produced by T-cells. 
IFN-γ is also produced by natural killer cells, and IL-17A may also be produced by non-
T-cells, such as microglia31 and lymphoid tissue inducer-like cells32. IL-17A is suggested 
to be involved in several immune-mediated inflammatory diseases, such as rheumatoid 
arthritis, psoriasis, and MS20. The IL-17-producing T-cells, called Th17, are now being 
recognized as a functional CD4+ T-cell subset in addition to Th1 and Th2, as critically 
reviewed recently33. In MS, IL-17A may play a role in blood-brain barrier transmigration 
of inflammatory cells34.
Some mAb clones cannot be used for immunohistochemistry, but can be used for 
flow cytometry analysis17 or vice versa. For example, the anti-CD4 clones MT310 and 
SK3, as well as the anti-CD3 clone SP34, can be used for flow cytometry analysis of 
common marmoset mononuclear cells, but cannot be used for immunohistochemistry 
on common marmoset tissue. Vice versa, clone B-B15 against CD11a can be used 
for immunohistochemistry of common marmoset tissue, but not for flow cytometry 
analysis of common marmoset cells. Representation and accessibility of Ab epitopes 
on live cells in cell suspensions can be quite different from that in frozen sections of 
solid tissue subjected to fixation, even with relatively mild fixatives such as acetone35. 
Another explanation is that the activation and differentiation status of leukocytes might 
differ between blood and lymphoid tissue.
Although rhesus macaques and cynomolgus macaques are closely related Old World 
species, differences in cross-reactivity can be found. For example, the anti-CD3 clone 
CLB-T3/2 showed cross-reactivity in rhesus macaque tissue, but not in cynomolgus 
macaque tissue. Differences between New World species were also observed. As an 
Proefschrift Yolanda Kap_compleet.indd   62 25-08-2010   21:24:46
Antibody selection for IHC in non-human primates
63
example, clone CLB-T8/4 against CD8 showed cross-reactivity in common marmoset 
and owl monkey tissue, but not in cotton-top tamarin tissue. In contrast, clone UCHT4 
directed against CD8 showed cross-reactivity in cotton-top tamarin tissue, but not in 
common marmoset and owl monkey tissue. This demonstrates that although species 
are closely related, differences in epitope conservation do occur.
Seven of the 69 markers seem to be highly conserved between human and NHP. Ab 
directed against CD11a, CD18, CD21, CD29, CD35, HLA-DR, and HLA-DQ were cross-
reactive with tissue of all six NHP. CD21 is the complement receptor 2 and CD35 is the 
complement receptor 1, suggesting a conservation of complement receptors between 
humans and NHP. CD21 is expressed on B-cells and is the receptor for Epstein-Barr 
virus (EBV). Conservation of CD21 suggests that these NHP are susceptible to infection 
with EBV-related herpesviruses, which is indeed compatible with the literature36. CD11a 
and CD18, which together form lymphocyte function-associated antigen-1, as well 
as the very late antigen-4 component, CD29, are expressed on leukocytes and are 
involved in adhesion. This may suggest conservation in the adhesion system between 
humans and NHP.
For some markers, no cross-reactive mAb were found for a species. For example, 
no cross-reactive anti-CD3 or anti-CD4 mAb could be found for the common marmoset. 
This was expected because in earlier studies it was observed that Ab against human 
CD3 did not cross-react with rhesus monkeys, necessitating the generation of a specific 
Ab, known as FN1837. A polyclonal Ab that recognizes multiple epitopes may overcome 
the problem of no cross-reactivity with mAb. For example, a polyclonal Ab against CD3 
(Dako) can be used to stain common marmoset tissue. To obtain Ab that recognize 
these species-specific epitopes, new Ab are being developed. For instance, Ito and 
colleagues recently generated mAb recognizing common marmoset lymphocytes38. 
In summary, we have identified a large panel of cross-reactive mAb for in situ 
analysis of NHP lymphoid tissues and organs affected by inflammation, infection, or 
tumors. These mAb will serve as important tools in future investigations of leukocyte 
differentiation and activation status in NHP and will aid in dissecting the mechanisms 
underlying the efficacy of novel vaccination and immunotherapeutic regimens.
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ABSTRACT
The recombinant human myelin oligodendrocyte glycoprotein (MOG)-induced 
experimental autoimmune encephalomyelitis (EAE) model in the common marmoset is 
characterized by 100% disease incidence, a chronic disease course, and a variable time 
interval between immunization and neurological impairment. We investigated whether 
monkeys with fast and slow disease progression display different anti-MOG T or B-cell 
responses and analyzed the underlying pathogenic mechanism(s). The results show 
that fast progressor monkeys display a significantly wider specificity diversification of 
anti-MOG T-cells at necropsy than slow progressors, especially against MOG34-56 and 
MOG74-96. MOG34-56 emerged as a critical encephalitogenic peptide, inducing severe 
neurological disease and multiple lesions with inflammation, demyelination, and axonal 
injury in the central nervous system (CNS). Although EAE was not observed in MOG74-
96-immunized monkeys, weak T-cell responses against MOG34-56 and low grade CNS 
pathology were detected. When these cases received a booster immunization with 
MOG34-56 in IFA, full-blown EAE developed. MOG34-56-reactive T-cells expressed 
CD3, CD4 or CD8, and CD56, but not CD16. Moreover, MOG34-56-specific T-cell lines 
displayed specific cytotoxic activity against peptide-pulsed B-cell lines. The phenotype 
and cytotoxic activity suggest that these cells are natural killer-cytotoxic T lymphocytes 
(NK-CTL). These results support the concept that cytotoxic cells may play a role in the 
pathogenesis of multiple sclerosis.
 
INTROduCTION
Multiple sclerosis (MS) is a chronic progressive inflammatory demyelinating disease 
of the human central nervous system (CNS). The pathological hallmark of MS is the 
lesion, being in the majority of cases a sharply demarcated demyelinated area in the 
CNS white matter (WM) that expresses a variable degree of inflammation, axonal injury, 
gliosis and remyelination1,2. Although the trigger of MS is not known, it is generally 
believed that lesion formation involves the synergistic action of cellular and humoral 
autoimmune reactions directed against components of the myelin sheath3. Anti-myelin 
autoimmune reactions may be induced by viruses that share cross-reactive T- and 
B-cell epitopes with myelin antigen (Ag), a phenomenon known as molecular mimicry4. 
In response to the requirement for a useful preclinical model for the efficacy 
evaluation of new biopharmaceutical agents for the treatment of MS, we have developed 
a chronic progressive experimental autoimmune encephalomyelitis (EAE) model 
in the New World primate species, the common marmoset (Callithrix jacchus). This 
EAE model has several intriguing aspects that makes it also a highly useful disease 
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model for basic research, including the 100% incidence despite the outbred nature, 
the chronic progressive course (reviewed in5,6), and the heterogeneous pathology 
present in WM and grey matter (GM) that ranges from early active to chronic inactive/
remyelinating lesions6-8. Moreover, using serially applied magnetic resonance imaging 
(MRI) sequences, brain lesions can be visualized and characterized in relation to the 
expression of an overt neurological deficit9-11. 
Several lines of evidence point to a critical role of autoimmune reactions directed 
against myelin oligodendrocyte glycoprotein (MOG) in the induction of chronic 
progressive EAE. Marmosets immunized with a chimeric protein combining myelin 
basic protein (MBP) and proteolipid protein (PLP) developed clinical EAE only after 
the spreading of the autoimmune reaction to MOG has taken place12. Moreover, the 
development of chronic progressive EAE in both Biozzi ABH mice13 and marmosets14 is 
impaired when the animals were immunized with MOG-deficient mouse myelin. 
The marmoset EAE model induced with recombinant human (rh) MOG1-125 (rhMOG) 
is characterized by a 100% disease incidence but variable clinical course. The high 
susceptibility of marmosets to this model maps to an invariant major histocompatibility 
complex (MHC) class II molecule, Caja-DRB*W1201, which emerged as a dominant 
restriction element for the activation of CD4+ T-cells specific for the epitope MOG24-3615. 
The monomorphic allele is present and expressed in each monkey16,17. Independently 
from us, Villoslada et al. showed by adoptive transfer that MOG24-36-reactive T-cells 
induce mild inflammatory CNS pathology18. 
The aim of the current study was to analyze autoimmune mechanisms underlying the 
variable clinical course. Hence, we investigated whether the rate of disease progression 
in the rhMOG-induced EAE model is associated with particular anti-MOG T- or B-cell 
response patterns. Furthermore, we examined the phenotype and function of T-cells 
involved in the induction of neurological impairment. We found that fast progressor 
monkeys displayed a broad T-cell repertoire with responses to epitopes encompassed 
within MOG34-56 and/or MOG74-96. Marmosets immunized with MOG34-56 in complete 
Freund’s adjuvant (CFA) developed CNS inflammation and widespread demyelination 
in the WM and GM, which may be caused by cytotoxic activity of infiltrated T-cells. In 
support of this, MOG34-56-specific T-cell lines (TCL) were found to express markers 
of natural killer-cytotoxic T lymphocytes (NK-CTL) (CD3+, CD4+ or CD8+, CD56+,and 
CD16-) and to lyse peptide-pulsed, autologous as well as allogeneic EBV-transformed 
B-cell lines. 
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MATERIAlS ANd METHOdS 
Animals
All monkeys included in the current study were purchased from two purpose-bred 
colonies, one being kept at the Biomedical Primate Research Centre (Rijswijk, The 
Netherlands) and the second at the German Primate Center (Göttingen, Germany). 
Individual data of all monkeys used in this study are listed in Table 1. Monkeys were 
included in the study only after a complete physical, hematological, and biochemical 
check-up had been performed. The reported experiments span a period of about 
six years. During the experiments, the monkeys were initially housed individually in 
spacious cages with padded shelter provided on the floor and were under intensive 
veterinary care. Since 2005, pair housing became the standard within the BPRC. The 
daily diet during the study consisted of commercial food pellets for New World monkeys 
(Special Diet Services, Witham, Essex, UK), supplemented with rice, raisins, peanuts, 
marshmallows, biscuits, fresh fruit, grasshoppers, and maggots. Drinking water was 
provided ad libitum. 
Ethics
In accordance with the Dutch law on animal experimentation, all study protocols 
and experimental procedures were reviewed and approved by the Institute’s Ethics 
Committee before the experiments could be started. 
RhMOG-induced EAE
 A recombinant protein encompassing the extracellular domain of human MOG 
(rhMOG) was produced in Escherichia coli and purified as previously described19. 
RhMOG-induced EAE was evoked in a total of 23 monkeys by injection into the dorsal 
skin of 600 µl stable emulsion containing 100 µg of rhMOG in 300 µl of buffered saline 
and 300 µl of CFA (Difco Laboratories, Detroit, MI) under ketamine anesthesia (40 mg/
kg; AST Pharma, Oudewater, The Netherlands) as described previously15. 
MOG peptide-induced EAE
 All MOG peptides for immunization and cell culture were purchased from prof. A. 
Ben Nun (Weizmann Institute of Sciences, Rehovot, Israel) or from ABC Biotechnology 
(London, UK). EAE was induced with synthetic peptides that represent amino acids 
34 to 56 (MOG34-56) and 74 to 96 (MOG74-96) of the human MOG extracellular 
domain. The monkeys were immunized with 100 µg of MOG peptide dissolved in 300 
µl of buffered saline and 300 µl of CFA as previously described15. Monkeys that did 
not develop overt neurological deficit (score ≥ 2.0) within 28 days received booster 
immunizations with the same amount of peptide in incomplete Freund’s adjuvant (IFA) 
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Table 1. Overview of monkeys included in this study.
Monkey Twin paira Sexb Agec Immunization Experiment
KK M 32 rhMOG
QI M 31 rhMOG
QK M 25 rhMOG
QR F 29 rhMOG
QQ M 28 rhMOG
Mi009 M 26 rhMOG
Mi010 M 26 rhMOG
Mi011 M 26 rhMOG
Mi020 M 28 rhMOG
Mi021 M 30 rhMOG
Mi022 M 48 rhMOG
Mi062 M 24 rhMOG
Mi065 M 23 rhMOG
Mi069 M 20 rhMOG
9501 M 35 rhMOG
9505 M 54 rhMOG
9601 M 25 rhMOG
9814 M 15 rhMOG
9819 M 15 rhMOG
9841 M 21 rhMOG
9853 F 22 rhMOG
9854 M 22 rhMOG
M9902 M 20 rhMOG
M0131 M 24 MOG34-56 1
M0167 M 20 MOG34-56 1
M0178 M 20 MOG34-56 1
M0182 M 19 MOG34-56 1
M02075 Twin M 22 MOG34-56 2
M02076 Twin M 22 MOG74-96 2,A
M02078 Twin M 23 MOG34-56 2
M02079 Twin M 23 MOG74-96 2,A
M02087 Twin M 22 MOG74-96 2,A
M02088 Twin M 22 MOG34-56 2
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at time points indicated in figure 2 and 6. Ag-adjuvant emulsion was prepared by gentle 
stirring of the PBS/oil mixture at 4°C for at least 1 h.
Clinical scoring
Clinical signs were scored twice daily by trained observers using a previously 
described semiquantitative scale20. Briefly, 0 = no clinical signs; 0.5 = apathy, loss of 
appetite, altered walking pattern without ataxia; 1 = lethargy, anorexia, tail paralysis, 
tremor; 2 = ataxia, optic disease; 2.5 = para- or monoparesis, sensory loss, brain 
stem syndrome; 3 = para- or hemiplegia; 4 = quadriplegia; and 5 = spontaneous death 
attributable to EAE. A score of 2 or higher reflects an overt neurological deficit. Monkeys 
were sacrificed for ethical reasons once complete paralysis of hind limbs (score ≥ 3.0) 
was observed or at the predetermined endpoint of the study. Moreover, monkeys were 
weighed three times per week. As in rodent EAE models, body weight serves as a 
reliable surrogate disease marker in the marmoset. Body weight data are depicted as a 
separate disease parameter above the clinical score graphs.
Ex vivo analysis of T-cell responses 
The maximum blood sample that can be collected in a month from primates at 
the BPRC should not exceed 1% of the body weight. For an average adult marmoset 
weighing 350 grams, this equals a maximum monthly blood sample of 3.5 ml. Hence, 
Monkey Twin paira Sexb Agec Immunization Experiment
M02120 Twin M 21 MOG34-56 2
M02121 Twin M 21 MOG74-96 2,A
M03017 Twin M 37 MOG34-56 3
M03018 Twin M 37 MOG74-96+ 
MOG34-56
3,B
M03026 Twin M 37 MOG34-56 3
M03027 Twin M 37 MOG74-96+ 
MOG34-56
3,B
M03032 Twin M 37 MOG34-56 3
M03033 Twin M 37 MOG74-96+ 
MOG34-56
3,B
a Twin pairs are indicated by ‘Twin’
b M, Male; F, Female.
c Age in months of the monkeys at the start of the experiment
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volumes of up to 1.5 ml at 2-weeks interval were collected into heparinized Vacutainer 
tubes (Greiner, Sölingen, Germany). Peripheral blood mononuclear cells (PBMC) were 
isolated from heparinized venous blood using lymphocyte separation medium (LSM®, 
ICN Biomedical Inc., Aurora, OH). Moreover, cell suspensions were prepared from 
aseptically removed axillary (ALN), inguinal (ILN), and cervical (CLN) lymph nodes and 
spleen. PBMC, lymph node, and spleen cells were cultured in triplicate for the detection 
of proliferative responses towards rhMOG and a panel of MOG peptides as previously 
described15. In some assays, PLP peptide 139-151 (PLP139-151), recombinant human 
MBP, and recombinant human αB-crystallin (both provided by Dr. J.M. van Noort, TNO-
Preventie en Gezondheid, Leiden, The Netherlands) were included. OVA served as 
control Ag in all studies. All Ag were tested at 5 µg/ml. After 48 h of culture, 0.5 µCi of 
tritiated thymidine ([3H]Thy) was added per well, and incorporation of the radiolabel 
was determined after 18 h using a matrix 9600 beta-counter (Packard 9600; Packard 
Instrument Company, Meriden, CT). Results are expressed as the mean stimulation 
index (SI). SI values above 2.0 were considered to be relevant.
Flow cytometry and CFSE labeling
To determine the phenotype of proliferating cells, 4 x 106 viable mononuclear 
cells (MNC) from ALN were suspended in 1 ml PBS and incubated for 7 min at 
room temperature with carboxyfluorescein diacetate succinimidyl ester (CFSE, final 
concentration 1.5 µM; Fluka, Deisenhofen, Germany). The labeled cells were cultured 
for 7 days with peptides under the standard conditions described above. For flow 
cytometric analysis we used the following commercially available, labeled monoclonal 
antibodies (mAb) directed against human CD markers: anti-CD3 with PerCP or Alexa 
Fluor 700 label (BD Biosciences), APC-labeled anti-CD4 (DAKO, Glostrup, Denmark), 
biotinylated anti-CD8 (Serotec, Düsseldorf, Germany), anti-CD56 with PE-Cy7 label, 
anti-CD16-PE, and streptavidin PE-Cy7 or streptavidin PerCP (BD Biosciences). Flow 
cytometric analysis was performed on a FACSort flow cytometer using FACSDiva 
software (BD Biosciences). First, viable cells were gated using the live/dead fixable 
violet viability stain (Invitrogen, Molecular Probes, Carlsbad, CA). Within the viable cell 
gate, lymphocytes/monocytes were selected using forward and side scatter. Within the 
lymphocyte/monocyte gate CD3+ cells were selected. The CD3+ population in the CFSE 
experiment consisted of CD4+ cells (48-70%) and CD8+ cells (12-18%). Within each 
gated subpopulation the percentage of cells with CFSE dilution was calculated.
Cytotoxicity assay
Autologous and allogeneic peptide-pulsed 51chromium-labeled, Epstein-Barr virus 
(EBV)-transformed B-cell lines were used as target cells to test the cytotoxic potential 
of MOG peptide-specific TCL. In brief, 106 B-cells were incubated for 60 min at 37°C 
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with 51chromium and pulsed with 100 µg MOG34-56 or MOG74-96 and subsequently 
washed thoroughly with PBS. Peptide pulsed B-cells were mixed with effector T-cells 
at 1:1, 1:4, and 1:16 ratio in U-well microtiter plates and cultured for 5 h at 37°C in 
culture medium, after which 100 µl of the supernatant was collected to determine the 
amount of radiolabel in a gamma-counter. Controls consisted of peptide-pulsed target 
cells without T-cells (spontaneous release) or peptide-pulsed target cells lysed with 1% 
Triton X-100 (maximum release). Results are expressed as % killing using the formula: 
(T-cell induced - spontaneous)/(maximal - spontaneous) x 100.
Generation of MOG peptide-reactive T-cell lines
At necropsy, cell suspensions were prepared from spleen, ALN, ILN, and CLN. 
MNC of rhMOG- or MOG peptide-immunized marmosets were stimulated ex vivo with 
rhMOG, MOG34-56, or MOG74-96 to establish specific TCL. Briefly, MNC (106/well) 
were seeded into 24-well plates (Greiner) and stimulated with 10 µg/ml rhMOG, MOG34-
56, or MOG74-96. Every 2 or 3 days, half of the culture supernatant was replaced with 
fresh medium containing 20 U/ml rh interleukin (IL)-2 (Proleukin, Chiron Corporation, 
Emeryville, CA) and split when needed. After 14 to 21 days of culture, part of the cells were 
transferred into 96-well flat-bottom plates (Greiner) and tested for reactivity with a panel 
of 23-mer MOG peptides15. Lethally irradiated (50 gray) EBV-transformed marmoset 
B-cells from stably growing lines maintained in 75-cm2 tissue culture flasks (Greiner) 
were used as antigen presenting cell (APC). Lines of interest were characterized by the 
expression of T-cell specific cell surface markers by flow cytometry using cross-reactive 
mAb raised against human CD markers21. Isotype controls were kindly provided by J. 
Miller (Chemicon International, South Hampton, UK). 
B-cell responses
Venous blood samples were centrifuged and the plasma supernatants were collected 
and stored frozen at -20°C until further analysis. Ab binding to myelin proteins (rhMOG, 
MBP, αB-crystallin, and HPLC-purified human PLP) or to a panel of overlapping 23-mer 
MOG peptide sequences was determined using ELISA22. Bound Ab was detected using 
polyclonal alkaline phosphatase-conjugated goat-anti-monkey IgM μ-chain (Rockland, 
Gilbertsville, PA) or rabbit-anti-human IgG (Abcam, Cambridge, UK). Ab specific for 
discontinuous MOG epitopes are considered particularly pathogenic23. To distinguish 
between Ab reactivity against discontinuous and linear epitopes, serum samples were 
preincubated with a mixture of all overlapping MOG peptides (10 µg/ml for each peptide) 
for 1 h at 37°C before probing them for reactivity with rhMOG coated onto ELISA plates. 
As an internal control, the MOG54-76 peptide was left out of the peptide mix used for 
preincubation because in previous studies this peptide was found to contain dominant 
B-cell epitopes. The results of the Ab assays are expressed as the fold increase of light 
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absorbance at 405 nm compared with the reactivity with OVA as an irrelevant antigen 
or compared to the reactivity in preimmune sera of the same monkeys. 
Post mortem examination
Monkeys selected for necropsy were first deeply sedated by intramuscular injection 
of ketamine (50 mg/kg), and subsequently euthanised by the infusion of pento-barbital 
sodium (Euthesate®; Apharmo, Duiven, The Netherlands). Brain, spinal cord, spleen, 
ILN, ALN, and CLN were removed. Representative parts of all organs were snap frozen 
in liquid nitrogen or fixed in 4% buffered formalin. Frozen tissues were stored at – 80°C. 
After at least 7 days of fixation in formalin, the tissues were transferred into buffered 
saline containing sodium azide for stabilization before MRI11.
To assess the total lesion load in the brain, MR images were made of formalin-fixed 
brains as described previously11,20. Both frozen and fixed tissues were examined with 
histological and immunohistochemical techniques as previously described20,24,25.
MRI procedures 
Brains of MOG34-56- and MOG74-96-immunized animals were analyzed by 
MRI. MRI experiments were performed post mortem on a 6.3 T horizontal bore MRI 
scanner (Varian, Palo Alto, USA). The formalin-fixed brains were submerged in a 
perfluoropolyether (Fomblin, Ausimont, NJ) for susceptibility matching. The following 
parameters were used in all experiments: field of view, 2.5×2.5 cm2; matrix, 128×128; 
slice thickness, 1 mm; number of slices, 20. T2-weighted (T2W) images were collected 
using a spin-echo sequence with the following parameters: repetition time, 4 s; echo 
time, 35 ms; number of signal averages, 8. T2-maps were recorded with a multiecho 
sequence using the following parameters: repetition time, 8 s; echo spacing, 20 ms; 
echo train length, 8; number of signal averages, 4. Diffusion tensor images were 
made using a pulsed field gradient spin echo sequence with the following parameters: 
repetition time, 4 s; echo time, 35 ms; number of signal averages, 8. Diffusion weighting 
was applied in 10 directions with the following pulsed field gradient parameters: Δ, 20 
ms; δ, 10 ms; diffusion gradient (Gdiff), 0; and 120 millitesla/meter (mT/m), resulting in 
b-value of 0 and 1717 s/mm2.
Image analysis
First, WM was segmented manually. In the WM, lesions were identified as regions 
with a T2 value 10% above the normal appearing white matter (NAWM). Average T2, 
apparent diffusion coefficient, and fractional anisotropy values were determined for 
lesions and NAWM. Image analysis was done using Mathematica (Wolfram Research 
Europe Ltd, Oxfordshire, UK).
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Statistics
The relation between a broad T-cell response and fast disease progression (see data 
in Table 2) was analyzed using Kaplan-Meier survival analysis. Statistical significance 
of differences between groups was calculated using the log rank test. Because four 
potential contrasts could be chosen for this analysis, p values were considered 
statistically significant when < 0.05/4 = 0.0125 (Bonferroni correction).
Results of T2 relaxation time, fractional anisotropy, and apparent diffusion coefficient 
were analyzed by a two population (independent) t test. 
 
RESulTS
disease course and autoimmune reactions in rhMOG-immunized monkeys
Table 2 gives a summary of data obtained from 23 rhMOG-immunized marmosets. 
Clinical scores are depicted in figure 1 showing that in 100% of the monkeys clinical EAE 
was induced but that the time interval between EAE induction and the expression of an 
overt neurological deficit varied considerably. Of the 23 examined monkeys, 20 were 
sacrificed after they had developed an EAE score ≥ 2. Three monkeys were withdrawn 
from their respective experiments without neurological impairment. One monkey (QK) 
had experienced serious body weight loss and was sacrificed pre-term to avoid a 
sudden deterioration of the clinical state, as has been observed in rhesus monkeys in 
which immunization with MOG34-56 induced acute onset EAE26. Two monkeys (Mi020 
and Mi021) were sacrificed with mild signs of EAE (score 0.5) as they reached the end 
of the experiment. The time interval between EAE induction and the development of 
hemiplegia/paraplegia (EAE score of 3) varied from 34 to 139 days (mean 73 days) 
(Table 2). Notably, serial MRI in selected monkeys reveals ample disease activity within 
the CNS WM during the asymptomatic interval, which apparently does not lead to an 
overt neurological deficit10,27. We have taken advantage of this unique outbred model to 
test whether monkeys with a fast or slow disease progression rate display different Ab 
and T-cell response patterns. 
Antibodies
Serum reactivity with rhMOG protein was detected in all monkeys (Table 2). The 
anti-MOG IgG Ab reactivity was directed against linear epitopes within three main 
regions, namely MOG4-26, MOG24-46, and MOG54-76. Analysis of immune sera that 
were collected at two week intervals during the entire disease course revealed that the 
first upcoming Ab reactivity was against MOG54-76. The anti-rhMOG Ab reactivity at 
necropsy was reduced by >95% when the immune sera were preincubated with a mix 
of the complete MOG peptide panel before the binding to rhMOG-coated ELISA plates 
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was tested. However, when MOG54-76 was left out of the peptide mix the reduction 
of serum reactivity with rhMOG was <10% (data not shown). These data indicate that 
the MOG54-76 peptide contains one or more important recognition sites for rhMOG-
induced Ab. Ab reactivities towards MBP and αB-crystallin were infrequently observed 
(data not shown). In summary, we observed no obvious association between disease 
progression and the number of MOG peptides recognized by IgG molecules present in 
necropsy sera (Table 2).
T-cell responses
RhMOG-induced TCL generated from ILN, ALN, or spleen of slow and fast disease 
progressors were tested for reactivity with a panel of MOG peptides. In accordance 
with previously published data15 a proliferative response against the peptide MOG24-
36 was found in all monkeys (Table 2). Besides this ubiquitous reactivity with MOG24-
36, individual monkeys displayed a variable reactivity with other MOG peptides. When 
the monkeys were ranked according to the total disease duration, it was evident that 
fast progressor monkeys displayed a broader T-cell reactivity with the MOG peptide 
panel than slow progressor monkeys (Table 2). The relation between a broader T-cell 
response with faster disease progression is highly significant (Figure 1; p < 0.0125).
Figure 1. Association of disease progression with T-cell reactivity diversification in rhMOG- 
induced EAE. 
A, The EAE course of 23 unrelated monkeys (Table 1) that received a single immunization with 100 µg 
rhMOG in CFA is shown. Note that the disease incidence is 100% but that the time interval between EAE 
induction and the expression of an overt neurological deficit varies clearly between individual monkeys. 
B, Kaplan-Meier plot shows survival curves of monkeys with a narrow (one or two peptides recognized) 
or broad (three or four peptides recognized) T-cell epitope diversification. The difference between both 
groups is highly significant (p < 0.001; log rank test). 
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Table 2. T-cell and antibody responses against rhMOG and MOG peptides in rhMOG- 
immunized marmosets.
Monkey Sexa Sacrificed 
(psd)
EAE 
score
T-cell reactivity
(MOG peptides)b
Abc reactivity
rhMOG pMOGd
QQ M 34 3 24-36 54-76 74-96 + 0
Mi022 M 36 5 24-36 64-86 + 0
KK M 38 3 24-36 34-50 94-110 + 7
QR F 42 3 24-36 34-50 64-86 + 5
M9902 M 44 3.5 24-36 94-110 + 6
QI M 50 2 24-36 + 6
9601 M 58 3 24-36 4-11 12-21 24-46 + 8
Mi011 M 62 3 24-36 4-11 34-50 + 1
9854 M 67 2.5 24-36 54-76 74-96 + 3
9853 F 67 3 24-36 + 3
Mi069 M 67 2.5 24-36 54-76 + 7
Mi065 M 67 2.5 24-36 + 7
9501 M 70 3 24-36 + 8
9814 M 78 2.5 24-36 + 1
9819 M 94 3 24-36 + 5
Mi010 M 106 3 24-36 NTe
Mi009 M 112 2.5 24-36 NTe
9841 M 112 2 24-36 + 1
9505 M 115 3 24-36 64-86 + 1
Mi062 M 139 3 24-36 + 7
Mean 
(n=23)
73
QKf M 50 0.5 24-36 + 6
Mi020f M 155 0 24-36 + 5
Mi021f M 163 0.5 24-36 74-96 + 8
a M, Male; F, Female
b MOG peptides of interest are indicated in bold
c Antibody reactivity was tested in necropsy serum
d For the serum reactivity with MOG peptides only the number of recognized peptides is given 
e NT, not tested
f Marmosets with positive MRI, no or mild clinical EAE
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Characterization of potentially encephalitogenic MOG peptides
To determine the contribution of individual MOG peptide-specific T-cell reactivities to 
the EAE pathogenesis in marmosets, we have taken advantage of a unique biological 
feature of this model. Marmoset twins develop in utero as stable bone marrow chimeras 
due to the shared placental blood stream28. This implies that the T-cells of both twins 
are educated in the same thymic environment and that similar mixed populations of 
bone marrow-derived elements are seeded into the peripheral tissues and organs of 
both siblings. Hence, despite the different genetic background, such nonidentical twin 
siblings can be regarded as immunologically similar. 
Of the three peptides that were most frequently recognized by T-cells from fast 
progressor monkeys, MOG34-56, MOG54-76, and MOG76-96 (Table 2), we chose 
MOG34-56 and MOG76-96 for the immunization of chimeric twins. Because we were 
mainly interested in T-cell responses, MOG54-76 was not included for further analyses 
as this peptide is also a B-cell epitope (see above).
Figure 2. Clinical course of MOG34-56 induced EAE. 
Eleven marmosets were immunized with 100 µg MOG34-56 in CFA. Monkeys without overt signs of EAE 
at the end of a pre-determined episode of ± 28 days received one, two, or three booster immunizations 
with 100 µg MOG34-56 in IFA (arrows). Clinical scores and changes in body weight (percentage 
compared with day 0) as a surrogate disease parameter of individual monkeys are shown. Ten of the 11 
monkeys were sacrificed with a clinical score of ≥ 2.5, whereas one monkey was sacrificed at the end 
of a 200-day observation period without neurological signs. Numbers in the figures represent the time 
point (psd) when overt neurological signs (score ≥ 2) were first observed.
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Figure 3. MRI reveals white 
matter pathology in MOG34-56- 
immunized monkeys. 
High contrast T2W images of 
formalin-fixed brains were recorded 
to assess the total lesion load. 
Corresponding slices from twins of 
which one sibling was immunized 
with MOG34-56 and the other 
with MOG74-96 are shown. The 
pictures clearly illustrate white 
matter pathology in MOG34-56-
immunized monkeys that displayed 
overt neurological signs. This 
was negligible in the MOG34-56-
immunized monkey (M02075) and 
in all four MOG74-96 monkeys in 
which overt neurological signs did 
not develop. Magnification of the 
lesions shown in the corner are 
indicated by boxes.
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Figure 4. diffusion tensor imaging of MOG34-56-induced brain lesions. 
The disruption of the normally restricted orientation (anisotropic) of water diffusion in white matter 
was used as an indirect MRI measure of tissue destruction in formalin-fixed brains. Brains from the 
four MOG34-56-immunized monkeys in experiment 1 (see Table 1) were used for this analysis. A 
tomographic section of the brain of monkey M0167 is depicted as a representative example. A, High 
contrast T2W images were made to visualize hyperintense structural abnormalities. B, The (disturbance 
of) fiber direction within the white matter is visualized with the standard color codes (red, left ==> 
right; blue, superior ==> inferior; green, anterior ==> posterior). C, The ellipsoid representation of fiber 
orientation within a lesion-rich area (white square) shows a round shape in the cortical (C) and lesion (L) 
area whereas these are more unidirectional in the compact white matter. D-F, Mean values of the total 
lesion (grey bars) and white matter (hatched bars) area of four monkeys (M0131, M0167, M0178, and 
M0182) are shown. The depicted quantitative parameters are as follows: 1) the mean of all voxels for T2 
relaxation times (D), which is higher in the lesions than in the NAWM due to increased water content; 2) 
the degree of fractional anisotropy (E), which is decreased due to destruction of compact myelin; and 
3) and the apparent diffusion coefficient (F), which is slightly higher in lesions than in NAWM. Data are 
mean ± SD. * P < 0.05, ** P < 0.001. See page 311 for a full-color representation of this figure.
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MOG34-56-induced EAE
A total of 11 monkeys were immunized in three separate experiments with MOG34-
56/CFA followed by booster immunizations on post sensitization days (psd) 28, 56, 
and ~125 with MOG34-56/IFA until overt clinical signs of EAE were detectable. The 
individual EAE scores depicted in figure 2 show a heterogeneous clinical picture. One 
monkey (M0167) developed EAE associated with marked weight loss within 30 days 
after EAE induction. In two monkeys (M0182 and M03017) EAE developed only after 
psd 145 and one monkey (M02075) was sacrificed at psd 200 with only mild symptoms 
(score 0.5). In the remaining 7 monkeys, overt neurological deficits were first observed 
around psd 75. Interestingly, in three monkeys (M0178, M03026, and M03032) we 
observed optic neuritis, which remitted spontaneously within two weeks.
T2W MR images were made of the formalin-fixed brains of all monkeys to visualize 
the spatial distribution and size of lesions. Contrast in T2W images is mainly based 
on differences in water content caused, for example, by inflammation. Hence, altered 
signal intensity in the in vivo T2W images of a tissue mainly reflects inflammation. 
However, T2W images of formalin-fixed tissues, can also be used to assess the extent 
of myelin destruction11. In figure 3 the post mortem brain MR images of four twins (Table 
1; Experiment 2) are depicted, illustrating that significant lesion formation has taken 
place in the MOG34-56-immunized monkeys. 
The loss of a highly organized compact myelin structure in a demyelinated lesion 
causes a reduction of the directional diffusivity of water, which can be visualized 
in diffusion tensor images (Figure 4A)10. To obtain an overall picture of the lesion 
pathology, MR images of the total fixed brain were recorded. More specific, the 
directional diffusivity (fractional anisotropy) of water in lesions and NAWM was 
determined. Figure 4B and 4C depict one slice as an illustrative example that shows 
the disturbed organization of WM in the T2 lesion, suggesting that compact myelin 
has disappeared. Figure 4E shows the mean fractional anisotropy values of all T2 
lesions throughout the brain of four MOG34-56-immunized marmosets; these were 
substantially lower in the lesions than of the perilesional NAWM, indicating the 
ubiquitous loss of compact WM. 
Pathological changes in the brain and spinal cord were also examined by histology. 
Figure 5 shows dramatic demyelination in the spinal cord WM area of a MOG34-
56-immunized monkey. At the time of necropsy demyelination was still taking place. 
The lesions were heavily infiltrated with T-cells and macrophages that contained 
phagocytosed myelin debris. Axonal pathology was clearly present. Significant 
demyelination was also observed in the spinal cord grey matter areas. Within these 
areas, activated microglia cells as well as infiltrating macrophages were detected. 
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Figure 5. MOG34-56 induces inflammation and demyelination in the CNS. 
A, Luxol fast blue staining (original magnification x23) reveals that in this cross-section of spinal cord 
> 50% of the white matter has been demyelinated (blue line, border with normal white matter) and is 
remyelinating. Magnified views of the rectangle are shown in B and C. B, CNPase staining (original 
magnification x160) confirms demyelination and remyelination. Arrowheads point at oligodendrocyte 
cell bodies in the lesion centre. C, CD3 staining (original magnification x160) shows the presence of T 
lymphocytes in this area. D, Luxol fast blue staining (original magnification x38) indicates the presence 
of demyelinating lesions in the corpus callosum. E, MRP-14 positive macrophages are present in these 
lesions (E, original magnification x99) together with CD3 positive T lymphocytes (F, original magnification 
x200). G, PLP staining (original magnification x310) reveals PLP degradation products in macrophages 
(arrowheads). H, IgM staining (original magnification x290) shows plasma cells and Ig deposition 
on myelin. I, Axonal injury (axonal spheroids) in these white matter lesions is visualized by amyloid 
precursor protein staining (original magnification x275). In addition to spinal cord and brain white matter 
lesions, prominent cortical demyelination is also present. J, PLP staining (original magnification x50) 
reveals subpial demyelination. The meningeal lining is at the upper part of the figure, the blue lining 
marks the border of the demyelinated cortex, and a magnified view of the area inside the rectangle is 
shown in K. K, The area inside the rectangle in J (original magnification x990) in which microglial cells 
with uptake of PLP-positive myelin degradation products can be found. L, These activated microglial 
cells (original magnification x185) also stain positively with MRP-14, being an early activation marker of 
macrophages. See page 312 for a full-color representation of this figure.
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MOG74-96-induced EAE
To test the encephalitogenic potential of the MOG74-96 peptide, the twin siblings 
of seven of the 11 MOG34-56-immunized monkeys were immunized with MOG74-96. 
Two separate experiments, denoted A and B, were done comprising four and three 
monkeys, respectively (Table 1).
Figure 6. Immunization with MOG34-56/IFA induces full blown EAE in MOG74-96 sensitized mar-
mosets. 
Seven marmosets, twin siblings of the monkeys in figure 2 (see Table 1) were immunized with 100 µg 
MOG74-96 in CFA. Monkeys without overt signs of EAE (score < 2) at the end of a pre-determined 
episodes of ± 28 days received three booster immunizations with 100 µg MOG74-96 in IFA (arrows). 
Clinical scores and changes in body weight (percentage compared with day 0) as surrogate disease 
parameter of individual monkeys are shown. Because none of the monkeys developed overt neurological 
deficit within the pre-determined observation period of 125 days, three (M03033, M03018, and M03027) 
received the third booster immunization of 100 µg MOG34-56 in IFA (arrow with an asterisk), resulting in 
full blown EAE in two monkeys (M03033 and M03018). Numbers in the figures represent the time point 
(psd) when overt neurological signs were first observed.
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Figure 7. Pathology of MOG34-56-boosted EAE in MOG74-96-immunized monkeys.
Pathology present in the spinal cord of monkey M03033 is shown in A-C; pathology in the optic tract 
is shown in D-J. A, Staining for luxol fast blue (original magnification x20) reveals demyelinated areas 
(bordered by blue dotted line) in the spinal cord white matter. B, Late active demyelination (original 
magnification x350) is shown by the presence of PLP-positive degradation products in macrophages. 
C, Besides demyelination, inflammation of the lesions is characterized by the presence of CD3+ 
lymphocytes (original magnification x150). D, Luxol fast blue staining (original magnification x45) shows 
large demyelinated lesions (borders indicated by dotted line) in the optic tract. Magnified views of the 
rectangular area are shown in E-J. E, Staining for PLP (original magnification x350) reveals the presence 
of PLP degradation products in macrophages (arrowheads). F, The optic tract lesions contained CD3+ 
lymphocytes (original magnification x150). G, Single macrophages are stained positively for MRP-14 
(original magnification x150). H, A bielschowsky stain for axons (original magnification x150) shows a 
reduced density of axonal fibers in the demyelinated area (D) compared to the surrounding NAWM (N). 
I, Staining for IgM (original magnification x300) and complement C9 (J, original magnification x300) 
shows deposition in the demyelinated areas. See page 313 for a full-color representation of this figure.
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Experiment A. In the first experiment (monkeys M02121, M02076, M02079, and 
M02087), overt neurological disease did not develop during the 200-day observation 
period. However, mild signs of EAE (score 0.5) were observed (Figure 6). 
To test whether monkeys immunized with MOG74-96 displayed pathological changes 
within the CNS WM, high definition T2W images were made of the formalin-fixed brains 
from all four monkeys. In three monkeys clear abnormalities, albeit of moderate severity, 
were detected in the brain WM, namely one large periventricular lesion in M02076, two 
large lesions in M02121, and several small lesions in M02087 (Figure 3). 
Histological examination confirmed the presence of mild demyelination in frontal 
regions in the brain of two monkeys that were scored positive with MRI, i.e. M02076 
and M02121. Interestingly, very little inflammatory activity was detected within these 
lesions (data not shown). In monkey M02087 no brain lesions were found, indicating 
that the abnormalities observed with MRI do not represent areas of inflammatory 
demyelination.
Experiment B. In the second experiment essentially the same results were obtained 
after the subsequent immunizations with MOG74-96, namely significant weight loss 
associated with only mild clinical signs. The mild CNS pathology observed in experiment 
A was associated with the appearance of low-level T-cell reactivity against MOG34-
56 (see next paragraph). To amplify this low-level response, all three MOG74-96-
immunized monkeys were given a single booster immunization with MOG34-56 in IFA. 
This induced overt neurological signs in two of the three monkeys within a few weeks 
(Figure 6). This observation contrasts with the situation in rhesus monkeys where 
booster immunization with MOG34-56 in IFA did not induce EAE, although this species 
is much more susceptible to EAE than marmosets26. In the third monkey (M03027), 
EAE scores fluctuating between 0.5 and 1.0 were recorded from psd 50 onwards. After 
the boost with MOG34-56, the disease stabilized at EAE score of 1. The monkey was 
finally sacrificed at psd 168 for histological analysis of the CNS.
The T2W post mortem images showed dramatic CNS pathology. Apart from large 
areas with increased T2W signal intensity, likely due to demyelination, the most 
remarkable feature was the presence of large “black holes” in the WM (data not shown). 
Histological analysis demonstrated comparable pathological changes as in MOG34-56-
immunized monkeys. Brain and spinal cord contained large demyelinated lesions with 
infiltrated T-cells and activated macrophages and microglia (Figure 7).
Autoantibodies in MOG peptide-induced EAE cases
Plasma samples prepared from venous blood collected at 7-day intervals from the first 
immunization and at necropsy were tested with ELISA for the presence of IgM and IgG 
Ab against rhMOG and MOG peptides. Only total IgG responses were tested, because 
IgG subclasses are not described for the marmoset. Figure 8 shows the results for IgG at 
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necropsy, which were representative for IgM and the data of the 7-day interval plasma.
The main Ab response in MOG34-56-immunized monkeys was against MOG24-46. 
In some monkeys we also found antibodies against MOG34-56 and rhMOG. In two 
MOG34-56-immunized monkeys a diversification of the Ab response to MOG54-76 was 
found (Figure 8A). Because this peptide, which is a dominant B-cell epitope in rhMOG-
induced EAE, has only two overlapping amino acids with the immunizing peptide, it may 
be that this reactivity is caused by epitope spreading.
The dominant response in MOG74-96-immunized monkeys was against the 
immunizing peptide; but in the monkeys from experiment B, which were boosted with 
MOG34-56 in IFA, low-level Ab reactivity against rhMOG and MOG24-46 was also 
detected (Figure 8B). 
T-cell reactivity in MOG peptide-induced EAE 
PBMC, isolated at 2-week intervals after immunization, and MNC from lymphoid 
organs were cultured with rhMOG and a MOG peptide panel to test proliferation. 
Moreover, cells of ALN from the twins of experiment 3 (Table 1) were CFSE labeled and 
Figure 8. Diversification of antibody reactivity in MOG34-56 and MOG74-96-immunized monkeys. 
Plasma of MOG34-56 (A) and MOG74-96 (B) immunized monkeys were collected at necropsy and tested 
with ELISA for IgG reactivity with rhMOG and the panel of 23-mer peptides that covers the extracellular 
domain of MOG (1-125). Results are expressed as fold increase of OD relative to pre-immune marmoset 
serum. Neg., <2; +, 2 to <4; ++, 4 to <8; +++, >8. NT, not tested due to lack of material.
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subsequently stimulated for 7 days with the immunizing peptides for the phenotyping of 
proliferating cells, visualized by the dilution of the fluorescent dye.
Proliferative responses in MOG34-56-immunized monkeys
In all monkeys, PBMC proliferation was found against MOG34-56 (Figure 9A). 
The proliferative response in PBMC remained low, rarely exceeding an SI of 5.0. As 
expected, much higher responses were found in the lymphoid organs collected at 
Figure 9. T-cell proliferation remains confined to the immunizing peptide MOG34-56.
Eleven marmosets were immunized with MOG34-56 in CFA (psd 0) followed by booster immunizations 
with MOG34-56 in IFA at psd 28, 56, and ~ 125. PBMC collected at different time points and MNC of 
secondary lymphoid organs collected at necropsy were probed for their proliferative response against the 
MOG peptide panel. Only responses above an SI of 2 (dotted line) are considered positive. Proliferative 
responses were found against MOG34-56. A, PBMC data from two representative monkeys. B, High 
responses were found in ALN and spleen at necropsy. C, Summary table of proliferative responses of 
ALN cells from all 11 monkeys against rhMOG and the MOG peptide panel. NT, not tested. 
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necropsy. The highest responses were mostly found in ALN and spleen (Figure 9B), 
while lower proliferation was found in ILN (data not shown). Only in monkey M02088 
proliferation could be detected in CLN (data not shown). Cells of ALN (Figure 9C), spleen 
and ILN (data not shown) also proliferated against rhMOG and peptides overlapping 
with MOG34-56.
Proliferative responses in MOG74-96-immunized monkeys
 In PBMC from MOG74-96-immunized monkeys proliferation against MOG74-96 was 
found (Figure 10A-B). In addition, from psd 104 proliferation against MOG34-56 was 
detectable (Figure 10A-B). The response to MOG34-56 could be amplified by a booster 
immunization with MOG34-56 in IFA (Figure 10B). At necropsy, MNC of MOG74-96-
immunized animals proliferated against MOG74-96, but not against MOG34-56 (Figure 
10C). The three monkeys challenged with MOG34-56 at the third booster displayed 
a reduced response against MOG74-96 and increased proliferation against MOG34-
56 (Figure 10C). Cells of ALN collected at necropsy also proliferated against rhMOG 
(Figure 10D).
Phenotype of MOG34-56- and MOG74-96-reactive T-cells
 MNC from ALN, which contained the highest proliferative response, were stained 
with the fluorescent dye CFSE and subsequently cultured with the respective peptides. 
After 7 days, cells were harvested and stained with fluorescein-labeled mAb used for 
the phenotyping of human MNC subsets that are known to cross-react with marmoset 
MNC21. Proliferating cells were identified by dilution of CFSE. MOG34-56 stimulation of 
MNC from MOG34-56-immunized monkeys induced CFSE dilution in both CD4+ and 
CD8+ T-cell subsets (Figure 11A). However, the percentage of divided CD4+ cells was 
about twice as high as that of divided CD8+ cells. Figure 11B shows the CFSE dilution 
in MNC cultures of monkeys immunized with MOG74-96 and boosted with MOG34-56 
(experiment B). Proliferation of cells stimulated with MOG34-56 or with MOG74-96 was 
found in both the CD4+ and the CD8+ T-cell subsets.
Cytotoxic activity of MOG34-56- and MOG74-96-specific T-cell lines
It was very difficult to generate stable TCL from the peptide-immunized monkeys from 
experiment 3 (Table 1), although we used the same method as successfully applied for 
the generation of stable TCL from rhMOG-immunized marmosets15. Most lines collapsed 
after two or three rounds of restimulation with peptide-pulsed B-cell lines. Stable TCL 
could only be obtained of three monkeys, i.e. the twins M03017 and M03018 and the 
monkey M03033. Cytolytic activity towards autologous MOG peptide-pulsed APC by 
MOG-reactive TCL from MS patients has been described29. Hence, we hypothesized 
that MOG peptide-specific T-cells from the marmoset might exert cytotoxic activity and 
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Figure 10. Amplification of anti-MOG34-56 T-cell responses in MOG74-96-immunized animals 
after a booster with MOG34-56 in IFA. 
Four marmosets were immunized with MOG74-96 in CFA (psd 0) followed by immunizations with MOG74-
96 in IFA at psd 28, 56, and 119 (experiment A). Three marmosets were immunized with MOG74-96 
in CFA (psd 0) followed by two booster immunizations with MOG74-96 in IFA at psd 28 and 56. At psd 
130 the monkeys received a booster with MOG34-56 in IFA (arrowhead) (experiment B). PBMC were 
collected at different time points and probed for their proliferative response against MOG74-96 and 
MOG34-56. Only responses above an SI of 2 (dotted line) are considered positive. A, Proliferation of 
PBMC of two representative monkeys of experiment A. Proliferative responses were mainly directed 
against MOG74-96, although after psd 100 also responses above an SI of 2.0 against MOG34-56 were 
detected. B, Proliferation of PBMC of the monkeys of experiment B. Proliferative responses were mainly 
directed against MOG74-96, although after the booster immunization with MOG34-56 in IFA proliferative 
responses against this peptide increased. C, Proliferation of MNC collected at necropsy. The monkey 
codes are given on the x-axis. The monkeys of experiment A show high responses to MOG74-96, 
whereas the monkeys of experiment B show increased responses to MOG34-56. D, Summary table of 
proliferative responses of ALN MNC from all 7 monkeys against rhMOG and the MOG peptide panel. 
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kill the peptide-pulsed B-cell lines that were used as APC. To test this hypothesis, the 
phenotype and cytolytic activity of MOG peptide-specific TCL were determined. 
MOG34-56- and MOG74-96-specific TCL contained a CD3+ cell population that 
consisted of a mixture of CD4+CD8-, CD4-CD8+, and CD4+CD8+ cells (data not shown). 
A significant fraction of the TCL, ranging from 14.8 to 78.9%, expressed the NK-CTL 
marker CD56 (Figure 11C). 
Figure 11. MOG34-56- and MOG74-96-reactive T-cells show an NK-CTl like phenotype and activity. 
A-B, Freshly isolated MNC of ALN from EAE-affected marmosets were labeled with the fluorescent 
probe CFSE and subsequently cultured for 7 days with MOG34-56 or MOG74-96. Harvested cells 
were stained for CD3, CD4, and CD8 and analyzed by flow cytometry. The percentages of proliferated 
CD3+CD4+ (light shading) and CD3+CD8+ (dark shading) living cells under 3 stimulatory conditions 
are shown: without stimulant, with MOG34-56, or with MOG74-96. Data are shown for MOG34-56-
immunized monkeys (M03017 and M03032) (A) and monkeys sensitized against MOG74-96 and finally 
boostered with MOG34-56 (M03018 and M03027) (B). C-D, Short-term T-cell lines (TCL) (effector cells) 
from 3 monkeys (M03017, M03018, and M03033) against MOG34-56 and MOG74-96 were established 
from MNC of spleen, ALN, and CLN. Shown are the data of M03018. C, Viable CD3+ cells of MOG34-
56- or MOG74-96-specific TCL derived from ALN of M03018 were stained for CD4 and CD56. D, The 
specific cytotoxicity was tested against 51Cr labeled autologous EBV-transformed B-cell lines (target 
cells), which were untreated or pulsed with MOG34-56 or MOG74-96. Shown is the % killing by MOG34-
56-specific TCL (top) and MOG74-96-specific TCL (bottom). TCL were cultured with MOG34-56-pulsed 
autologous B-cell lines (closed symbols) or MOG74-96-pulsed autologous B-cell lines (open symbols).
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Cytolytic activity of the three stable lines was tested with peptide-pulsed EBV-
transformed autologous and allogeneic B-cell lines as target cells. The results in figure 
11D show the peptide-specific cytotoxicity of MOG34-56 or MOG74-96 induced TCL 
from M03018 against autologous B-cell lines. MOG34-56-specific TCL were cytotoxic 
for MOG34-56-pulsed B-cells and MOG74-96-specific TCL killed MOG74-96-pulsed 
B-cells. MOG34-56 and MOG74-96-specific TCL of M03018 could also kill, respectively, 
MOG34-56 and MOG74-96-pulsed B-cell lines of M03033 (data not shown). No 
cytotoxicity of the MOG34-56- and MOG74-96-specific TCL against nonpulsed B-cells 
was observed (data not shown).
To collect phenotypical data from more monkeys, TCL that were stored frozen after 
three rounds of peptide stimulation and expansion on IL-2 were thawed. Reactivation 
was performed by a single round of peptide-specific stimulation using EBV-transformed 
B-cells as APC, followed by 8 days expansion on IL-2. This yielded seven MOG34-
56-specific TCL derived from five monkeys (M03017, M03018, M03026, M03027, and 
M03033) and two MOG74-96-specific TCL derived from two monkeys (M03017 and 
M03027). The CD3+ population of MOG34-56-specific TCL consisted of 30.9% (range 
11-58%) CD4+ cells, 11.4% (range 3-19%) CD8+ cells, and 54.2% (range 37-80%) 
Figure 12. Phenotype of MOG34-56-specific T-cell lines.
Seven T-cell lines (TCL), which were frozen after three rounds of antigenic stimulation and expansion on 
IL-2, were thawed and restimulated with MOG34-56 presented by autologous EBV-transformed B-cells. 
After 8 days expansion on IL-2, the phenotype of these lines was determined by FACS analysis. Vital 
CD3+ lymphocytes were analyzed for CD4 and CD8 expression. This resulted in CD4+, CD8+ and CD4/
CD8 double positive populations. CD16 and CD56 expression was determined in these populations. 
The percentages of T-cell subpopulations in all 7 lines is given in table A. The dot plots in B depict a 
representative example, being the MOG34-56-specific TCL derived from the ALN of M03017. Numbers 
in the quadrants represent percentages of the subpopulation described above each dot plot.
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CD4+CD8+ double positive cells. The high proportions of CD4/CD8 double positive 
cells is not an artifact of the freeze/thawing procedure, as this subpopulation is also 
found in peptide-stimulated cultures of freshly isolated lymph node and spleen cells. 
CD56 expression was most pronounced on single CD8+ T cells (62%; range 33-91%), 
followed by 45% (range 18-69%) of the double positive cells and 32% (range 9-58%) 
of the single CD4+ cells. In none of the subpopulations was CD16 expression observed 
(Figure 12). The CD3+ population of two additional MOG74-96-specific TCL consisted 
of 10.6% (1.8/19.4) CD4+ cells, 38.7% (63.4/13.9) CD8+ cells, and 48.3% (32.3/64.2) 
double positive cells. All three subpopulations expressed significant CD56 levels, 
respectively 50.4% (79.5/21.2) of the CD4+, 82.1% (96.9/76.3) of the CD8+, and 72.1% 
(93.4/50.8) of the CD4+CD8+ populations (data not shown). 
 
dISCuSSION
Several aspects of EAE in common marmosets make it a unique experimental 
model of MS, in particular the outbred nature, the genetic and immunological proximity 
to humans, and the remarkable neuropathological similarity with the disease in humans 
[for review6]. The disease typically follows a progressive course that can last from 
several weeks to more than a year20. Of the many components of CNS myelin with 
proven encephalitogenic capacity in mice, MOG appeared to be the most critical for 
the induction of chronic progressive disease in Biozzi ABH mice and marmosets13,30. 
This prompted us to investigate the MOG-induced autoimmune mechanisms that drive 
progression of the disease using a rhMOG-induced EAE model. 
We have previously shown in a relatively small group of monkeys that the 100% EAE 
prevalence maps to the invariant MHC class II molecule Caja-DRB*W1201, which is 
involved in the activation of MOG24-36 specific encephalitogenic T-cells15. Although the 
presence of Caja-DRB*W1201 in the MHC repertoire of each individual monkey at the 
genomic level was already known for several years16, it was only recently reported that 
mRNA transcripts of this allele are indeed expressed in APC of all tested monkeys17. 
With regard to MOG-induced autoimmune mechanisms involved in the progression 
of rhMOG-induced EAE, we report here several novel findings that in part contrast with 
published data. The current results show that monkeys displaying a relatively broad 
reactivity of their lymph node T-cells with a MOG peptide panel developed neurological 
deficit significantly earlier than monkeys with a more restricted reactivity profile. By 
contrast, we observed no association between the reactivity profile of immune sera with 
the MOG peptide panel and the rate of EAE progression. Hence, we conclude that the 
different time spans between EAE induction and the expression of neurological signs is 
associated with a diversification of proliferative T-cell responses against MOG epitopes 
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beyond MOG24-36. Our interpretation of this finding is that fast progressor monkeys 
may be (genetically predisposed) high responders to peptides processed from rhMOG 
and presented to encephalitogenic T-cells present in the normal repertoire. We have 
chosen MOG34-56 and MOG74-96 for further examination since these peptides were 
detected in most fast progressor monkeys. Moreover, strong T-cell reactivity to these 
peptides is found in rhMOG-induced EAE models15,31. 
Ten of 11 monkeys immunized with MOG34-56/CFA developed overt clinical EAE, 
although the susceptibility of individual monkeys varied, as reflected by the number of 
booster immunizations needed for EAE induction. In our previous study we reported 
that in monkeys immunized with peptide MOG14-36, only CD4+ Th1-cells were induced 
together with mild inflammatory CNS pathology15. Our current data show that in MOG34-
56-immunized monkeys, CD4+ as well as CD8+ T-cells are activated and that many 
inflammatory/demyelinating lesions are formed in the WM and, in some monkeys, also 
in the GM. Moreover, MOG34-56 induced TCL phenotypically resembled NK-CTL and 
displayed specific cytotoxic activity towards peptide-pulsed B-cell lines. The observation 
that essentially the complete clinical and pathological picture of rhMOG-induced EAE 
was reproduced in monkeys immunized with a single 23-mer peptide contrasts with data 
from Genain and colleagues showing that the development of full blown EAE depends 
on anti-MOG Ab recognizing discontinuous epitopes, and that full-blown EAE cannot be 
induced with MOG peptides32. 
Monkeys sensitized against the peptide MOG74-96 did not show overt neurological 
signs, although we observed clinical EAE scores up to 1 as well as low-level CNS 
inflammation and demyelination by both MRI and histology. Furthermore, we detected 
low-level T-cell proliferation against MOG34-56. These data indicate that mild EAE may 
have been induced by in vivo activation of MOG34-56-reactive T-cells. This assumption 
is supported by the observation that a single booster immunization of the monkeys with 
MOG34-56 in IFA induced overt neurological signs within a few weeks in two out of 
three monkeys. This observation cannot be explained by cross-reactivity between the 
two peptides, as neither TCL nor immune sera from MOG34-56-immunized monkeys 
cross-reacted with MOG74-96 and vice versa. Hence, we conclude that in the MOG74-
96-immunized monkeys MOG34-56-reactive T-cells had been recruited from the resting 
state, indicating that limited epitope spreading had taken place. 
We like to propose as the underlying mechanism that MOG34-56-reactive (memory) 
T-cells present in the naive repertoire are activated by APC carrying myelin Ag from 
the lesions to draining lymph nodes. This concept is supported by previously reported 
findings. First, the ubiquitous autoreactivity against MOG14-36 induces CNS infiltration 
of T-cells and macrophages, which may trigger initial CNS WM damage15,18. Second, 
myelin-loaded APC can be found localized in the CLN and spleen of EAE-affected 
monkeys33. We have not (yet) been able to directly demonstrate induction of autoreactive 
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T-cells by myelin-loaded APC present within the CLN. However, the localization in 
T-cell areas of the lymph nodes creates the conditions needed for such a functional 
interaction. Third, data from the rhesus monkey EAE model show that MOG34-56-
reactive T-cells present in the naive repertoire can be activated by immunization with a 
23-mer peptide derived from the major capsid protein (UL86) of human cytomegalovirus 
(CMV; CMV UL86981-1003)26. The CMV of common marmosets has not been isolated 
and characterized yet. However, assuming that CMV-induced memory T-cells do occur 
in the natural repertoire of common marmosets, as is the case in humans as well as 
rhesus monkeys, it is tempting to speculate that T-cells present in lymph nodes and 
spleen may be activated by myelin-loaded APC draining from the EAE-affected CNS33. 
The mechanisms underlying the dramatic CNS pathology upon immunization with 
MOG34-56 remain to be fully elucidated. Our data demonstrate that the induction of 
NK-T-cell like cytotoxic activity represents at least one of the pathogenic mechanisms. 
The cytotoxicity assay shown in figure 11 was performed with a mixture of CD56+ cells, 
namely CD4+, CD8+, and CD4+CD8+. The phenotype of the cells (CD3+CD4+ and/or 
CD8+CD56+CD16-) as well as the capacity to lyse peptide-pulsed, autologous and 
allogeneic, B-cell lines are suggestive of an NK-T-cell like activity. Interestingly, a similar 
activity has been observed for anti-MOG T-cell-lines from MS patients29. The possible 
involvement of such cells in the pathogenesis of MS has been reported by several 
groups34,35. We are currently exploring further the different cell subsets involved and the 
cytotoxic effector mechanisms, both ex vivo and in situ. 
In conclusion, we report an association between disease progression in the 
rhMOG- induced EAE model in marmosets with the diversification of the anti-MOG 
T-cell response. In addition to a T-cell response against MOG24-36, which is present 
in all monkeys and is the presumed trigger of the disease, T-cell responses against 
MOG34-56 and MOG74-96 are detectable in monkeys with a rapid disease progression. 
MOG34-56 displays potent encephalitogenic activity leading to inflammation and tissue 
destruction in the CNS, most likely via the activation of cytotoxic T-cells with a NK-CTL-
like phenotype. In our view the marmoset EAE model offers a unique experimental 
setting to further unravel the pathogenic mechanisms and to develop novel therapeutic 
approaches targeting these mechanisms, including the cytotoxic activity. 
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ABSTRACT
Experimental autoimmune encephalomyelitis (EAE) in the Neotropical primate 
common marmoset (Callithrix jacchus) is a relevant autoimmune animal model 
of multiple sclerosis. T-cells specific for peptide 34 to 56 of myelin oligodendrocyte 
glycoprotein (MOG34-56) have a central pathogenic role in this model. The aim of this 
study was to assess the requirement for innate immune stimulation for activation of this 
core pathogenic autoimmune mechanism. Marmoset monkeys were sensitized against 
synthetic MOG34-56 peptide alone or in combination with the nonencephalitogenic 
peptide MOG74-96 formulated in incomplete Freund’s adjuvant (IFA), which lacks 
microbial compounds. EAE development was recorded by monitoring neurological signs, 
brain magnetic resonance imaging, and longitudinal profiling of cellular and humoral 
immune parameters. All monkeys developed autoimmune inflammatory/demyelinating 
central nervous system disease characterized by massive brain and spinal cord 
demyelinating white matter lesions with activated macrophages and CD3+ T-cells. 
Immune profiling ex vivo demonstrated the activation of mainly CD3+CD4+/8+CD56+ 
T-cells against MOG34-56. Upon ex vivo stimulation, these T-cells produced more 
interleukin 17A compared with Th1 cytokines (e.g. interferon-γ) and displayed peptide-
specific cytolytic activity. These results indicate that the full spectrum of marmoset EAE 
can be induced by sensitization against a single MOG peptide in IFA lacking microbial 
compounds for innate immune activation and by eliciting antigen-specific T-cell cytolytic 
activity. 
 
INTROduCTION
Multiple sclerosis (MS) is a chronic neurological disease affecting the central 
nervous system (CNS) of 1 per 1,000 young adults in the moderate climate areas 
of the United States and Europe1. During the past decades, understanding of the 
immunopathogenic mechanisms that drive the disease has advanced considerably, 
resulting in the development of several effective disease-modifying agents2. However, 
the few successes are in contrast to a long list of treatments that failed to reproduce 
the beneficial effects in animal models of MS when tested in MS patients. The poor 
translation of scientific data to the clinic is in part attributed to the wide gaps between 
human patients and animal models3,4. 
Limitations of the current MS models in inbred and specific pathogen free laboratory 
rodent strains include the lack of genetic diversity and exposure to environmental 
pathogens, both of which have a strong influence on the developing immune system5. 
Moreover, persistent latent infections with herpesviruses that have a strong impact on the 
Proefschrift Yolanda Kap_compleet.indd   103 25-08-2010   21:24:54
Chapter 3.2
104
aging of the human immune system do not occur in rodents6. Finally, rodents are most 
often used at young adult ages (8-12 weeks). Non-human primates do not have these 
limitations because they are long-lived and are housed under conventional conditions in 
social groups where a high genetic and microbiological diversity is maintained.
The common marmoset (Callithrix jacchus) is a small Neotropical primate that 
provides a valid preclinical MS model. The model reproduces the progressive clinical 
course and approximates the neuropathological complexity of human MS7,8. The parallel 
clinicopathological features of this model and the close genetic, immunological, and 
microbiological similarities of humans and marmosets create an attractive experimental 
system for the dissection of critical pathogenic mechanisms that are promising candidate 
targets for MS therapy9. 
We previously demonstrated that autoimmunity against the extracellular domain 
of myelin oligodendrocyte glycoprotein (MOG), a quantitatively minor component 
of CNS myelin, is critical for the activation of the pathogenic mechanisms that drive 
experimental autoimmune encephalomyelitis (EAE) progression in Biozzi ABH mice10 
and marmosets11. The immunopathogenic mechanisms elicited by human MOG 
were unraveled in marmosets immunized with recombinant human MOG (rhMOG), 
a recombinant protein representing the extracellular domain (residues 1-125) of 
human MOG12. Whereas the 100% incidence of EAE induction could be mapped to 
the activation of T helper 1 cells specific for the peptide MOG24-3613, T-cells directed 
against epitopes encompassed within peptide MOG34-56 were found to play a critical 
role in the progression of rhMOG-induced EAE12.
Having identified the activation of MOG34-56 T-cells as a core pathogenic 
autoimmune mechanism in the marmoset EAE model, we set out to investigate the 
minimum activation requirements. We report that marmosets sensitized against 
MOG34-56 peptide in incomplete Freund’s adjuvant (IFA), a formulation that lacks 
microbial antigens (Ag) for innate immune activation, all developed severe clinical 
EAE, which is characterized by marked inflammation and primary demyelination in the 
CNS. Immune profiling supports a key pathogenic role for CD3+CD4+/8+CD56+ T-cells, 
with pro-inflammatory and cytolytic capacities. Although antibodies (Ab) against the 
immunizing peptides were formed, these failed to bind intact rhMOG, arguing against 
a direct pathogenic role. Our present results challenge the concept that innate immune 
mechanisms triggered by microbial compounds in the Ag inoculum are a necessary 
prerequisite to break T-cell tolerance leading to EAE. The possibility of inducing EAE 
without the need for complete Freund’s adjuvant (CFA), which induces necrotizing skin 
lesions that cause serious discomfort to the animals, also implies a major refinement 
of the model.  
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MATERIAlS ANd METHOdS
Animals
The monkeys included in this study originated from purpose-bred colonies of the 
Biomedical Primate Research Centre (BPRC), Rijswijk, The Netherlands, and the 
German Primate Centre (DPZ), Göttingen, Germany. Monkeys purchased from DPZ 
had been housed for at least 6 months in the BPRC before use. Individual data for 
all monkeys are listed in Table 1. Before inclusion in the study, the monkeys received 
complete physical, haematological, and biochemical examination, and during the study, 
they remained under veterinary care. Monkeys were housed in pairs in spacious cages 
enriched with branches and toys and with padded shelter provided on the floor. The daily 
diet consisted of commercial food pellets for New World monkeys (Special Diet Services, 
Witham, Essex, UK), supplemented with rice, raisins, peanuts, marshmallows, biscuits, 
fresh fruit, grasshoppers, and maggots. Drinking water was provided ad libitum. 
Table 1. Overview of marmosets used in this study and their response to EAE.
Experiment Monkey Sexa Ageb Immunization
MOG peptide
Clinical 
EAE signs
lesions 
on MRI
1 M03138 F 36 34-56 + 74-96 Yes Yes
M03139 F 36 34-56 + 74-96 Yes Yes
M04033 F 31 34-56 + 74-96 Yes Yes
M04034 F 31 34-56 + 74-96 Yes Yes
2A M03162 M 47 34-56 + 74-96 Yes Yes
M05056 M 27 34-56 + 74-96 Yes Yes
M05082 M 25 34-56 + 74-96 Yes Yes
M06012 M 20 34-56 + 74-96 Yes Yes
M06017 M 21 34-56 + 74-96 Yes Yes
2B 9847 M 105 34-56 Yes Yes
M05047 M 30 34-56 Yes Yes
M06006 M 29 34-56 Yes Yes
M06018 M 21 34-56 Yes Yes
M06020 M 21 34-56 Yes Yes
a F, female; M, male
b Age in months at the start of the experiment 
EAE, experimental autoimmune encephalomyelitis; MOG, myelin oligodendrocyte glycoprotein; MRI, 
magnetic resonance imaging
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Ethics
In accordance with the Dutch law on animal experimentation, all study protocols 
and experimental procedures were reviewed and approved by the Institute’s Ethics 
Committee before the start of experiments. 
Antigens 
The human MOG extracellular domain (rhMOG) was expressed as an unglycosylated 
recombinant protein in Escherichia coli and purified, as previously described14. 
Synthetic MOG peptides based on the human MOG sequence used for immunization 
and cell culture were purchased from ABC Biotechnology (London, UK) and Cambridge 
Research Biochemicals (Cleveland, UK).  
Induction of EAE
EAE was induced with 100 µg MOG34-56 or with the mixture of 100 µg MOG34-56 and 
100 µg MOG74-96. For each immunization, the monkeys were injected into the dorsal 
skin with the MOG peptide dissolved in 300 µl PBS (Invitrogen, Gibco BRL, Glasgow, 
UK) and emulsified with 300 µl IFA (Difco Laboratories, Detroit, MI). The inoculum was 
injected into the inguinal and axillary regions of the dorsal skin divided over 4 spots 
of 150 µl each. Ag-adjuvant emulsions were prepared by gentle stirring the peptide/
oil mixture at 4ºC for at least 1 h. Monkeys that failed to develop serious neurological 
deficits (score ≥ 2.0; see next paragraph) within 28 days received re-challenges at 
4-weeks interval with the same dose of peptide(s) in IFA until EAE developed. 
Clinical scoring
Clinical signs were scored daily by two trained independent observers, as described7. 
Briefly: 0 = no clinical signs; 0.5 = apathy, loss of appetite, altered walking pattern without 
ataxia; 1 = lethargy, anorexia, loss of tail tonus, tremor; 2 = ataxia, optic disease; 2.5 
= para- or monoparesis, sensory loss, brain stem syndrome; 3 = para- or hemiplegia; 
4 = quadriplegia; 5 = spontaneous death attributable to EAE. Monkeys were sacrificed 
for ethical reasons once complete paralysis of one or both hindlimbs (score ≥ 3.0) was 
observed or at a predetermined endpoint. 
To obtain an objective surrogate disease marker, the monkeys were weighed three 
times per week. This was performed without sedation using the Perspex cylinder with 
which adequately trained monkeys were captured from the home cage. 
Post mortem examination
At the time of necropsy, the monkeys were first deeply sedated with ketamine 
(50 mg/ml PBS) (Produlab Pharma, Raamsdonkveer, The Netherlands) injected 
intramuscularly at a dose of 100 µl/kg body weight; they were subsequently euthanised 
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by infusion of pentobarbital sodium (Euthesate; Apharmo, Duiven, The Netherlands). 
Brain, spinal cord, spleen, cervical lymph nodes (CLN), inguinal lymph nodes (ILN), and 
axillary lymph nodes (ALN) were aseptically removed. Small parts of all organs were 
snap-frozen in liquid nitrogen and stored at -80ºC for immunohistochemistry. One brain 
hemisphere was fixed for at least 7 days in 4% buffered formalin and subsequently 
transferred into buffered saline with sodium azide (Sigma-Aldrich, Gillingham, UK) to 
allow stabilization before magnetic resonance imaging (MRI). To assess the total brain 
lesion load, MR images were made of formalin-fixed brains as described15. After MRI, 
the tissues were examined with histological and immunohistochemical techniques as 
described7,12.
Magnetic resonance imaging
MR brain images were acquired from live animals and post mortem formalin-fixed 
brains. In vivo MRI experiments were performed on the two animals that had no clear 
overt clinical scores and were still alive at the end of the protocol (i.e. M06006 and 
M06012). Experiments were performed on a 4.7-T horizontal bore MRI scanner (Varian, 
Palo Alto, CA). T2-weighted (T2W) images (field of view, 40 x 40 mm; matrix, 128x 128; 
zero-filled, 256 x 256; slice thickness, 1 mm; number of experiments, 2) were collected 
using a spin-echo sequence with a repetition time of 2.75 s and an echo time of 30 
ms. Post mortem images were obtained on a 9.4-T MRI scanner (Varian). Formalin-
fixed brains were submerged in a perfluoropolyether (Fomblin, Fluortek AB, Knivsta, 
Sweden) for susceptibility matching. T2W images (field of view, 25 x 25 mm; matrix, 
256 x 256; zero-filled, 512 x 512; slice thickness, 0.75 mm; number of experiments, 2) 
were collected using a spin-echo sequence with a repetition time of 2.6 s and an echo 
time of 20 ms.
Assays for innate immune stimulatory activity
The immunizing peptides MOG34-56 and MOG74-96 and IFA were screened for 
contamination with ligands of Toll-like receptors (TLR) using human endothelial kidney 
(HEK293) cells transfected with human TLR2, TLR3, TLR4, or TLR5 and HEK293XL 
cells transfected with TLR7, TLR8, TLR9, or TLR10 (all from InvivoGen, San Diego, 
CA). The cell lines were cotransfected using Polyfect (Qiagen Benelux, Venlo, The 
Netherlands) with a reporter vector expressing luciferase under the control of an NF-κB-
responsive promoter (pNifty2-luc; InvivoGen). Stably transfected clones were selected 
and used in bioassays. Cells were plated in flat-bottom 96-wells plates (Greiner Bio-
one, Frickenhausen, Germany) at a density of 1 x 105 cells/well and were stimulated 
with individual MOG peptides, IFA, or a mix of MOG peptide and IFA. After 16 h 
incubation at 37ºC, the cells were lysed in 50 µl Steady Glo luciferase buffer (Promega 
Benelux, Leiden, The Netherlands) for 10 min, and bioluminescence was measured 
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using a Packard 9600 Topcount Microplate Scintillation & Luminescence Counter 
(Packard Instrument Company, Meriden, CT). As a positive control for NF-κB-mediated 
activation (i.e. the presence of the pNifty2-luc vector), 25 ng/ml tumor necrosis factor 
(TNF)-α (Peprotech, London, UK) was used. Positive controls for TLR2 and TLR4 
activation were lipopolysaccharide (100 ng/ml); TLR3, polyriboinosinic polyribocytidylic 
acid (Poly(I:C)) (20 µg/ml); TLR5, flagellin (1 µg/ml); TLR7, an adenine derivate (CL-
087) (1 µg/ml); TLR8, a thiozoloquinolone derivate (CL-075) (1 µg/ml); TLR9, synthetic 
oligonucleotides that contain unmethylated CpG (ODN2006) (2 µmol/ml). No ligands 
are known for TLR10, but TLR10 expression in the transfected HEK293 cell lines was 
confirmed with Western blot (data not shown). The TLR-specific ligands were obtained 
from InvivoGen.
For cytokine production assays, CD14+ cells isolated from buffy coats of healthy 
human donors with MACS beads (Miltenyi Biotech, Auburn, CA) were cultured for 7 
days with 20 ng/ml macrophage colony-stimulating factor (PeproTech) to differentiate 
them into macrophages. Culture supernatants of macrophages and peripheral 
blood mononuclear cells (PBMC) also isolated from buffy coats were collected after 
24 h stimulation with both immunizing MOG peptides and IFA to measure cytokine 
production. 
Mononuclear cell and T-cell line preparation
The maximum monthly blood volume that can be collected from marmosets is 1% 
of the body weight, which is 3.5 ml for an average adult monkey of 350 g. Longitudinal 
immune monitoring was performed using 1 ml of venous blood collected at 2-weeks 
interval from the femoral vein into heparinized vacutainers (Greiner, Sölingen, Germany). 
At necropsy mononuclear cell (MNC) suspensions were also prepared from aseptically 
removed ALN, ILN, and spleen. MNC and PBMC were isolated using lymphocyte 
separation medium (LSM, ICN Biomedical Inc, Aurora, OH). 
T-cell lines (TCL) were generated from MNC isolated from spleen and ALN by 
alternate stimulation with MOG34-56 or MOG74-96 and recombinant human IL-2 
(Proleukin, Emeryville, CA), as described previously13. Lethally irradiated (70 Gy) 
Epstein-Barr virus (EBV)-transformed autologous marmoset B-lymphoblastoid cells 
(B-LCL)16 from stably growing lines maintained in 75-cm2 tissue culture flasks (Greiner 
Bio-one, Frickenhausen, Germany) were used as antigen presenting cells (APC). TCL 
displaying Ag specificity were characterized with cross-reactive monoclonal Ab raised 
against human CD markers17. 
Ex vivo analysis of T-cell responses
The PBMC and MNC suspensions were assayed in triplicate for proliferation against 
rhMOG (10 µg/ml) and a panel of MOG peptides (each 10 µg/ml)12,13. Proliferation was 
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assessed by the incorporation of [3H]-thymidine (0.5 µCi/well) (PerkinElmer, Boston, 
MA) during the final 18 h of a 64 h culture using a matrix 9600 β-counter (Packard 
Instrument Company). Results are expressed as stimulation index (SI), that is, the ratio 
of radiolabel incorporation in stimulated versus unstimulated cultures. SI values greater 
than 2.0 were considered positive.
Flow cytometry and carboxyfluorescein succinimidyl ester (CFSE) assay phenotyping 
of proliferating cells were performed as described12. In brief, PBMC and MNC from ALN 
and spleen were suspended in 1 ml PBS and incubated for 7 min at room temperature 
with the fluorescent vital dye CFSE (final concentration 1.5 µM; Fluka, Deisenhofen, 
Germany), followed by culturing for 7 days at 37ºC with or without Ag. Harvested 
cells were stained with labeled monoclonal Ab raised against the following human CD 
markers17: anti-CD3 (BD Biosciences, San Diego, CA), anti-CD4 (DAKO, Glostrup, 
Denmark), anti-CD8-biotin (Serotec, Düsseldorf, Germany), anti-CD56, anti-CD16, and 
streptavidin PE-Cy7 or streptavidin PerCP (BD Biosciences). Viable cells were gated 
using violet viability stain (Invitrogen, Molecular Probes, Carlsbad, CA). Within each 
gated subpopulation the percentage of cells with CFSE dilution was calculated. Flow 
cytometric analysis was performed on a FACS LSRII flow cytometer using FACSDiva 
software 5.0 (BD Biosciences). 
For cytokine analyses, supernatants of PBMC, ALN, and spleen cells were collected 
after a 48 h stimulation with rhMOG or a panel of overlapping MOG peptides. Supernatants 
were assayed according to manufacturers’ instructions with commercial ELISA kits for 
monkey TNF-α, monkey interferon-γ (IFN-γ) (U-Cytech, Utrecht, The Netherlands) and 
human cross-reactive IL-17A (eBioscience, San Diego, CA). Culture supernatants of 
human macrophages and PBMC stimulated with MOG34-56 and MOG74-96 peptides 
and IFA were assayed with human IL-6, IL-12p40+p70, TNF-α, and IL-1β (U-Cytech, 
Utrecht, The Netherlands) ELISA kit. 
For cytotoxicity assays, autologous B-LCL labelled with 51Chromium (PerkinElmer) 
were pulsed with peptides of interest and used as target cells to test cytolytic activity 
of MOG peptide-specific TCL, as described previously12. Controls consisted of peptide-
pulsed 51Chromium-labeled target cells without T-cells (i.e. spontaneous release) or 
peptide-pulsed 51Chromium-labeled target cells lysed with 1% Triton X-100 (Sigma-
Aldrich, Steinheim, Germany) (maximum release). To test whether the cytolytic activity 
was perforin mediated, T-cells were pre-incubated with 28 nmol/l concanamycin A 
(Sigma-Aldrich) for 2 h at 37ºC. After extensive washing, the cells were mixed with 
peptide-pulsed 51Chromium-labeled target cells. Results are expressed as percentage 
killing: (T-cell induced release – spontaneous release)/(maximal release – spontaneous 
release) x 100%.
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Autoantibody detection 
Venous blood samples were centrifuged and plasma supernatants were collected 
and stored at -20ºC until further analysis. Ab binding to rhMOG (or to a panel of 
overlapping 23-mer pMOG (residues 1-125) sequences was determined using ELISA, 
as described18. Bound IgG Ab was detected using polyclonal alkaline phosphatase-
conjugated rabbit-anti-human IgG (Abcam, Cambridge, UK). The results of the Ab 
assays are expressed as fold increase of light absorbance at 405 nm compared with 
the reactivity present in preimmune sera of the same monkeys.
Statistical analysis
A high variation in the disease course and associated immune parameters between 
individual animals is inherent to the outbred nature of this model. Statistical evaluation 
of data was performed using unpaired t-test when this was possible and relevant; values 
of p < 0.05 were considered significant. For the immune assays, values above the mean 
background ± 2 SD for T-cell proliferation (SI ≥ 2) and Ab production (fold increase ≥ 
2.0) were considered positive.
 
RESulTS
lack of innate immune activation by peptide/IFA constituents
The TLR and Nodlike receptor families of pathogen recognition receptors comprise 
important mediators for the activation of innate immune mechanisms, which have been 
considered essential for EAE induction in most rodent models and are engaged by 
microbial compounds in CFA19,20. To determine the presence of possible innate immune 
stimulatory activity, the synthetic MOG peptides and IFA used for immunization were 
probed for stimulation of human macrophages and PBMC and TLR-transfected HEK293 
cells. 
Macrophages and PBMC were incubated with IFA, MOG34-56, and MOG74-96 
in PBS, or MOG34-56/IFA emulsion. Culture supernatants were assayed for IL-6, 
IL-12p40+p70, and TNF-α. No significant levels of these cytokines were detected 
(Figure 1A). No IL-1β was detected in the supernatants, indicating that this signature 
cytokine of the inflammasome pathway was also not activated under the conditions 
tested. The IFA and MOG peptides were also tested for the activation of the NF-κB-
driven luciferase reporter gene in HEK293 cells transfected with human TLR2, TLR3, 
TLR4, TLR5, TLR7, TLR8, TLR9, or TLR10; no cell stimulation was detected in any of 
these assays (Figure 1B).
Because tissue injury from skin injection of peptide/IFA emulsion may elicit danger 
signals that can activate APC and because skin flora microbes might infect the inoculum 
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site despite appropriate cleaning, we also compared CFA and IFA immunization for 
EAE in EAE-susceptible Biozzi ABH and C57BL/6 mice. The mice were first immunized 
with human MOG34-56 in CFA or in IFA with additional intraperitoneal pertussis toxin. 
Figure 1. MOG34-56 and MOG74-96 are not contaminated with known pattern recognition recep-
tor ligands.
A, Human CD14+ cells were isolated and differentiated to macrophages. The macrophages (left panel) 
and human peripheral blood mononuclear cells (PBMC) (right panel) were incubated with MOG34-
56, MOG74-96, incomplete Freund’s adjuvant (IFA), or lipopolysaccharide (LPS) (500 ng/ml). The 
supernatants were tested for the presence of IL-6, IL-12p40/p70, TNF-α and IL-1β by ELISA. Data are 
shown from 1 of 2 experiments performed. B, Toll like receptor (TLR) activity of the MOG peptides was 
assessed in human endothelial kidney 293 (HEK293) cell lines stably transfected with human TLR2, 
TLR3, TLR4, TLR5, TLR7, TLR8, TLR9, and TLR10 and the NF-κB luciferase reporter gene. The TLR 
expressing cell lines were incubated with the MOG peptides, IFA, or MOG plus IFA. Responses are 
expressed as fold increase of luciferase activity (mean ± SD). Peptide-stimulated HEK293 cells are 
compared with unstimulated cells. Fold increases greater than 2 were considered positive. In both 
assays, the peptides and IFA did not reveal significant stimulatory activity. Data from 2 of 6 experiments 
are pooled.
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Booster immunizations were with MOG34-56 in IFA plus intraperitoneal pertussis 
toxin. Only sensitization against MOG34-56 was observed in CFA-induced (mild) EAE, 
whereas this was not observed in MOG34-56/IFA-immunized mice (data not shown).
Together, these data confirm that the peptides used for EAE induction are not 
contaminated with ligands for innate antigen receptors 
Clinical disease
The intracutaneous injection of the peptide/IFA emulsion elicited only moderate 
redness at the injection sites attributable to a moderate inflammatory reaction to local 
injury of the injected skin. In the first experiment, 4 female marmoset monkeys were 
immunized with a mixture of equal amounts of MOG34-56 and MOG74-96 in IFA. 
In a second experiment, the same immunization protocol was repeated in 5 males 
(Experiment 2A). In parallel, another 5 males were immunized with only 100 µg MOG34-
56 in IFA (Experiment 2B). Figure 2 shows that the 4 monkeys in experiment 1 had 
onset of clinical signs almost simultaneously around psd 85, i.e. shortly after the third 
rechallenge immunization. Disease development in the 5 animals in experiment 2A was 
more heterogeneous: One monkey (M06017) developed EAE after one rechallenge; two 
monkeys (M05056 and M05082) needed two rechallenges; and one monkey (M03162) 
needed three rechallenges before clinical disease (score ≥ 2.0) developed. One monkey 
(M06012) recovered within a few days after a short episode of neurological signs after 
the second rechallenge and maintained a mild EAE score of 0.5 for the reminder of the 
160-day observation period. 
The 5 animals immunized only with MOG34-56 in IFA (experiment 2B) also 
developed heterogeneous EAE courses consisting of hindlimb paralysis and ataxia 
along with body weight loss. Because omission of MOG74-96 did not markedly alter 
the courses, this is consistent with our previous observation that MOG34-56 (given 
in CFA) was a more relevant Ag for EAE induction and progression. One monkey in 
this group (M05047) developed EAE after a single immunization. M06018 and 9847 
needed two immunizations, and M06020 required three immunizations for development 
of overt neurological disease. M06006 recovered within a few days after a short episode 
of neurological signs after the second immunization. Thus, EAE can be induced in 
marmosets with a single MOG peptide in an adjuvant formulation that does not contain 
microbial compounds that stimulate innate antigen immune receptors. 
Brain MRI
Increased signal intensity in T2W images of an EAE-affected marmoset brain 
recorded in vivo usually reflects edema caused by inflammation, whereas a hyperintense 
region in post mortem T2W images usually represents a demyelinated lesion7,15. In vivo 
T2W brain images confirmed the presence of brain lesions in the two monkeys (M06012 
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Figure 2. Monkeys immunized with MOG peptide in IFA all developed clinical EAE. 
In 2 experiments, 4 female (Experiment 1) and 5 male (Experiment 2A) marmosets were immunized with 
MOG34-56 and MOG74-96 emulsified in IFA (post sensitization day 0). A third group of 5 male monkeys 
was immunized with only MOG34-56 in IFA (Experiment 2B). At the indicated time points (arrows) 
challenges were given with the same antigen preparations. The graphs depict the clinical scores (right 
y-axis, solid line) and the percentage body weight loss compared with day 0 (left y-axis, dotted line).
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and M06006) from experiment 2 that had exhibited relapsing/remitting disease but had 
scores of 0.5 at the time of necropsy (Figure 3A). At the MRI level, the lesions induced 
with MOG34-56 in IFA do not display marked differences from those induced using 
CFA12.
High-definition T2W post mortem brain images of all 5 EAE monkeys induced 
with MOG34-56 in IFA displayed variable lesion loads (Figure 3B). In particular, there 
were numerous large and confluent lesions in monkey M05047 and M06006. The T2 
hyperintensity was not confined to the white matter because it also affected leukocortical 
regions. 
Histology and immunohistochemistry
Representative histological and immunohistochemical findings are shown in figure 
4. The brain and spinal cord sections showed many demyelinated lesions containing 
infiltrating CD3+ T-cells and activated macrophages. Proteolipid protein (PLP) and 
MRP14 staining in lesions showed macrophages containing degraded PLP products. 
Spinal cord sections also showed that staining for immunoglobulin overlapped with that 
of complement C9neo staining, a marker of complement-mediated tissue injury. Thus, 
the lesions induced in monkeys immunized with MOG34-56 in IFA are highly similar to 
those induced by immunization with MOG34-56 in CFA12.
 
T-cell reactivities and cytokine production 
Immune parameter profiles varied among individual animals reflecting the genetic 
variation of this outbred model. Spleen and CLN drain the brain21, whereas ALN and 
ILN drain the peptide/IFA inoculation sites. The MNC isolated from blood and lymphoid 
organs from the 4 animals in experiment 1 were tested for proliferation against MOG34-
56, MOG74-96, and rhMOG (Figure 5A). In PBMC from 3 of 4 monkeys (except 
M03138), proliferation was detected against both MOG34-56 and MOG74-96; T-cell 
proliferation in PBMC against rhMOG was observed only in M04034. Spleen MNC from 
monkey M03139 showed reactivity against the tested MOG peptides, and proliferation 
against rhMOG was detected only in M03139 and M04033. Proliferation responses in 
MNC from the pooled lymph nodes paralleled those in PBMC. In 9 of the 10 monkeys 
from experiment 2, proliferation against the immunizing peptide(s) was detected in at 
least one of the analyzed compartments, but no T-cell proliferation was detected in 
monkey M05056 (Figure 5A). 
We next analyzed the T-cell phenotypes of the cells that displayed specific proliferation 
against MOG34-56. In the model induced with MOG34-56/CFA, the main proliferation 
response against MOG34-56 mapped to a subset of CD3+ T-cells expressing CD4 and/
or CD8 in combination with CD5612. Specific proliferation of T-cells in PBMC, spleen, and 
ALN against MOG34-56 was mainly observed in the CD4/CD8 double-positive fraction 
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Figure 3. T2-weighted magnetic resonance brain images confirm inflammation despite clinical 
remission in 2 animals and show lesion load distribution in post mortem brains.
Lesions framed in white lines are sharply demarcated areas of increased signal intensity. A, Brain 
imaging of the 2 monkeys that were in remission at the time of death (see Figure 2) demonstrated 
CNS white matter lesions before death. B, High-resolution T2-weighted images were made of complete 
formalin-fixed brains to assess the total lesion load.
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Figure 4. MOG34-56 in IFA induces demyelination and inflammation in brain and spinal cord. 
Hyperintense white matter areas that were detected in T2-weighted images were analyzed with 
histology and immunohistochemistry. Brain of M05047 (A, D-G) and spinal cord of 9847 (B,C, H-K) 
are shown as representatives. A, Luxol fast blue-Periodic acid-Schiff (LFB-PAS) staining (original 
magnification x4) shows multiple large demyelinating lesions (arrowheads). The lesion in the corpus 
callosum (arrow) is enlarged in figures D-G. B, Subpial demyelination in spinal cord demonstrated with 
LFB-PAS (original magnification x25). The arrow indicates the area enlarged in H-K. C, Multiple large 
focal lesions are also seen in the spinal cord (arrowheads; original magnification x25). D, Enlargement 
of the area indicated with arrow in panel A. LFB-PAS (original magnification x125) staining shows late 
active demyelination and the presence of PAS-positive macrophages. E, Macrophage immunostaining 
using the macrophage marker MRP14 (original magnification x400). F, Immunostaining for myelin PLP 
(original magnification x500) shows macrophages containing phagocytosed PLP positive fragments 
(arrowheads). G, Immunostaining for CD3 (original magnification x200) shows that the lesions contain 
few T -cells. H-K, (original magnification x200) H, Subpial spinal cord area immunostained for MRP14 
shows the presence of macrophages. I, CD3 immunostaining shows some meningeal T lymphocytes. J, 
K, Staining for immunoglobulin (J) reveals deposition in a pattern that overlaps with that of complement 
factor C9neo (K). See page 314 for a full-color representation of this figure.
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with or without CD56 expression (Figure 5B). However, ALN also showed increased 
proliferation of CD3+CD4+ and CD3+CD4+CD56+ cells. The highest T-cell proliferation 
was observed in the spleen and ALN compared with the PBMC.
Freshly isolated PBMC, spleen, and ALN cells were stimulated for 48 h with rhMOG 
and overlapping MOG peptides, after which culture supernatants were collected for 
detection of IL-17A, IFN-γ, and TNF-α cytokine levels (Figure 6). In experiment 2A, a 
high level of the Th17 signature cytokine IL-17A was measured in spleen cell cultures 
of all animals after stimulation with rhMOG or MOG34-56 and in 3 of 5 monkeys after 
MOG74-96 stimulation. IL-17A was produced only in PBMC cultures of M06012; in 3 
monkeys, we observed production by ALN cells. In experiment 2B, there was marked IL-
17A production from rhMOG-stimulated PBMC of 2 monkeys (9847, M06006), in spleen 
cell cultures of 3 monkeys (9847, M06018, and M06020) upon stimulation with rhMOG 
and MOG34-56, and in ALN cells of 2 monkeys (9847 and M06020) after stimulation 
Figure 5. Ex vivo MOG34-56 stimulation induces proliferation in the Cd3+Cd4/Cd8+Cd56+ fraction. 
Mononuclear cells (MNC) from blood, spleen, axillary lymph nodes (ALN), and inguinal lymph nodes (ILN) 
were collected at necropsy and tested for ex vivo reactivity with recombinant human MOG and the panel 
of 23-mer overlapping MOG peptides. A, Proliferation was determined by [3H]-thymidine incorporation 
and expressed as stimulation index (SI) relative to unstimulated cultures. Data are presented in graded 
grey scale. B, CFSE labelled MNC of animals in experiment 2 were cultured for 7 days with MOG34-56. 
Harvested cells were analyzed by flow cytometry to determine phenotype of MOG34-56-reactive cells. 
Data were pooled from monkeys that displayed clinical signs at the time of sacrifice (n=8). Mean ± SEM 
is given for each subset. SI greater than or equal to 2 is considered significant. NT, not tested. 
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with MOG34-56 and/or rhMOG. Variable profiles of IFN-γ and TNF-α production were 
detected in all 3 groups, i.e. they were absent in ALN cells cultures and present in 
PBMC and in spleen cell cultures of only some monkeys. 
T-cell lines
TCL were generated from spleen and ALN against MOG34-56 and MOG74-96. 
There were high expansion rates of TCL specific for MOG74-96, whereas those against 
MOG34-56 collapsed after a few (range 4-6) restimulations. One possible explanation 
for this may be that MOG34-56 T-cells killed the peptide-presenting B-LCL APC; this is 
similar to MOG-specific T-cells from MS patients22.
The specific cytolytic activity of MOG34-56 and MOG74-96 TCL was tested using 
autologous 51Chromium-labeled B-LCL presenting either peptide. The MOG34-56-
induced TCL lysed target cells pulsed with MOG34-56 more effectively than they 
lysed target cells pulsed with MOG74-96 (Figure 7A). Conversely, MOG74-96-induced 
TCL lysed target cells pulsed with MOG74-96 more effectively than those pulsed with 
MOG34-56. Cytolysis was completely abrogated when the T-cells were preincubated 
with concanamycin A (Figure 7B), indicating that the cytolytic activity is largely dependent 
on granule exocytosis23. 
These data show that immunization with MOG34-56 activates CD4+ and CD8+ T-cells, 
Figure 6. Ex vivo production of IL-17A, TNF-α, and IFN-γ by rhMOG and MOG peptide-stimulated 
mononuclear cells (MNC). 
MNC from blood, spleen, and axillary lymph nodes (ALN) from experiment 2A and 2B monkeys were 
cultured for 48 h with rhMOG and a panel of MOG peptides. Culture supernatants were tested for the 
presence of the cytokines. 
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including CD3+CD56+ cells expressing both CD4 and CD8. Bulk cultures stimulated with 
MOG34-56 display specific cytolytic activity toward peptide-pulsed B-LCL and produce 
a higher level of the Th17 signature cytokine IL-17A than of the Th1 signature cytokine 
IFN-γ. Whether these activities are all exerted by the same subset of T-cells remains to 
be determined.
Figure 7. MOG-peptide reactive T-cell lines have cytolytic activity that can be blocked by con-
canamycin A.
Short-term T-cell lines against MOG34-56 and MOG74-96 were obtained from spleen, axillary lymph 
nodes (ALN), and pooled lymph nodes (LN) by stimulation with peptide-pulsed autologous Epstein-Barr 
virus (EBV)-transformed B-cells. A, Cytolytic activity of specific T-cell lines (effector cells [E]) was tested 
using 51Chromium-labeled EBV-transformed B-cells as target cells (T) that were pulsed with MOG34-56 
or MOG74-96 or without antigen. Specific lysis of target cells is expressed in percentage killing. Dotted 
lines indicate background killing with irrelevant peptide. The cytolytic activity of MOG34-56-induced lines 
is peptide-specific. B, Before cytotoxicity testing, the effector cells were incubated with concanamycin A 
(CMA) to inhibit cytolytic activity based on granule exocytosis23. 
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Figure 8. Plasma IgG antibody binding to MOG peptides and rhMOG. 
IgG antibody levels in plasma samples collected from monkeys immunized with MOG34-56 and MOG74-
96 (experiment 1 and 2A) or with only MOG34-56 (experiment 2B). Antibody responses were measured 
by ELISA to rhMOG and a panel of overlapping MOG peptides in plasma samples collected every 4 
weeks during the entire study (A) and at necropsy (B). IgG responses are expressed in fold increase; 
plasma levels are compared with preimmune plasma. Fold increase greater than 2 is considered 
positive.
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Autoantibody response
Plasma samples were tested for the presence of IgG binding to plate-bound rhMOG 
or overlapping sets of MOG peptides (Figure 8A). Figure 8B shows anti-MOG IgG levels 
in necropsy plasma. All monkeys in experiment 1 and 2A, immunized with MOG34-56 
and MOG74-96, showed IgG reactivity with MOG24-46, MOG34-56, and MOG64-86. 
In all 4 female monkeys in experiment 1, serum IgG reactivity was directed against 
rhMOG, but not to MOG74-96. Remarkably, sera from monkeys in experiment 2A also 
contained IgG against MOG74-96, but IgG binding with rhMOG was only observed 
in M03162 and M06012, albeit at a low levels. Interestingly, necropsy plasma of 2 
monkeys from experiment 2A contained IgG against MOG54-76, a dominant B-cell 
epitope in the rhMOG-induced EAE model (Figure 8B)13. Because the overlap of 
this peptide with MOG34-56 is only marginal (i.e. 2 amino acids), this Ab specificity 
was likely generated in response to demyelination. Sera from marmosets sensitized 
against MOG34-56 alone (Experiment 2B) only showed reactivity to the immunizing 
peptide and the overlapping peptide MOG24-46. There were no detectable IgG Ab 
levels against rhMOG, demonstrating that in monkeys immunized with MOG34-56/
IFA, production of autoantibodies binding to MOG protein was not a requirement for 
mediating demyelination24. 
 
dISCuSSION
We report here that 14 of 14 marmosets from an outbred colony develop overt 
clinical EAE associated with CNS inflammation, demyelination, and axonal damage 
upon sensitization against MOG34-56 in IFA or MOG34-56 combined with the 
nonencephalitogenic peptide MOG74-96 in IFA. 
Although CFA is a powerful tool for EAE induction, there are also several major 
disadvantages. It is notorious for the induction of granulomas at inoculation sites and in 
body organs (liver, lung), causing serious discomfort to immunized animals. The potent 
systemic stimulatory effect of CFA also causes a strong enlargement of lymphoid organs, 
haemopoietic dysfunction, and disruption of lymph node architecture25,26. CFA also has 
a strong systemic immune-stimulatory effect mediated by its component mycobacteria 
that may overwhelm more subtle immune regulatory mechanisms, such as causing Th1 
skewing of cellular autoimmune reactions25. Collectively, these arguments warrant the 
determination of whether use of CFA is mandatory for induction of EAE in marmosets or 
if it can be replaced with the less noxious Ag formulation with IFA. 
Immune profiling of the marmosets that were immunized with MOG peptides in IFA 
revealed induction of cellular and humoral autoreactivity against the sensitizing peptide 
as well as rhMOG protein in several cases. These results imply that EAE induction in 
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this new EAE model relies on the activation of adaptive immune mechanisms without 
the need for simultaneously activating innate immune mechanisms by microbial 
compounds in the inoculum, as is required in rodent models. These findings suggest 
that the activation requirements for MOG34-56-reactive T-cells present in the mature 
immune repertoire of adult (2 – 5 years) marmosets living under conventional conditions 
differ profoundly from those for the activation of MOG34-56-reactive T-cells present in 
the immature repertoire of young-adult (8 – 12 weeks) specific pathogen free laboratory 
mice. 
Our in vitro experiments confirm that the components of the peptide/IFA inoculum 
lack innate immune stimulatory activity via receptors for pathogen-associated molecular 
patterns, such as TLR and Nodlike receptors, which relay danger signals to engage 
innate immune activation of APC. However, we cannot conclude that EAE induction in 
this model occurs entirely without involvement of innate immune mechanisms. Quite 
obviously, APC present at the injection site of the peptide/IFA emulsion can be activated 
by danger signals released from the injured skin and from the IFA action. Unlike the 
EAE model induced with CFA, however, the autoreactive T-cells would have to migrate 
from the lymph nodes where they are activated to the CNS in the absence of the strong 
systemic innate immune activation signals elicited by CFA. This might be explained by a 
recent report that IL-17A producing CCR6+ T-cells have the capacity to enter the resting 
noninflamed CNS via the choroid plexus and the cerebrospinal fluid27. Interestingly, IL-
17A producing T-cells are prominent in the MOG34-56/IFA induced EAE model but seem 
less prominent in the Th1-dominated models induced with CFA13,28. Our serial brain 
MRI studies demonstrate that the first signs of cerebral inflammation in MOG34-56/IFA 
immunized monkeys are often detected around the lateral ventricles is noteworthy in 
this context (data not shown). 
The observation that autoantibodies against intact MOG are not directly involved in 
the generation of demyelination in monkeys immunized with only MOG34-56 in IFA is 
another discrepancy between the CFA-independent and CFA-dependent EAE model in 
marmosets and rodents. Although Ab against the immunizing peptides were consistently 
found in the current study, we detected Ab binding to non-glycosylated recombinant 
MOG1-125, a prerequisite for demyelination, only in some animals28. This was clearly 
demonstrated by von Büdingen et al28,29 who reported that immunization with (pooled) 
MOG peptides in CFA, supported by intravenous Bordetella pertussis particles, incited 
only mild inflammatory EAE in marmosets. Induction of robust EAE associated with 
demyelination required supplementary infusion of Ab against conformational MOG 
epitopes28. 
The close immunologic similarities between humans and marmosets suggest 
parallels between T-cell mediated immunopathogenic processes between MS and 
the MOG34-56/IFA induced EAE model. The phenotype (CD3+CD4/8+CD56+) and 
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cytolytic activity of the MOG34-56-reactive marmoset T-cells are reminiscent of the 
finding of CD4+CD56+ cytolytic T-cells in MS patients, although they may use a different 
cytotoxic mechanism. Cytolysis of human oligodendrocytes was found to be major 
histocompatibility complex (MHC)-independent30,31 and to involve interaction of NKG2D 
on CD4 cells with NKG2D ligands (MICA/B) on the target cells32. By contrast, the 
peptide-specific and concanamycin A-sensitive cytolytic activity of the marmoset T-cells 
suggests that the cytolytic mechanism resembles that of classical MHC class I-restricted 
cytotoxic T-cells. Interestingly, another group reported that MOG-reactive T-cells cloned 
from blood of MS patients, but not those from the blood of healthy controls, display 
cytolytic activity towards autologous target cells pulsed with MOG peptides 1-22, 34-
56, and 74-9622. Although oligodendrocytes normally lack detectable MHC expression, 
MHC class I molecules are induced under inflammatory conditions rendering them as 
potential targets for killing by CD3+CD8+ cytotoxic T-lymphocytes in EAE and MS33. 
In conclusion, we present a new EAE model in which MS-like clinical disease and 
pathological alterations are induced by immunization with a single peptide formulated 
with IFA. This novel model represents a major improvement for ethical, practical, and 
mechanistic reasons. First, the model definitively proves that the presence of microbial 
ligands for innate antigen receptors in the inoculum is not essential for induction of 
autoimmune disease in a species closely related to man. Second, replacement of CFA 
with IFA substantially reduces the discomfort to the animals, a central aim of biomedical 
research in non-human primates34. Third, the model is more useful for the study of 
the subtle regulatory networks that keep autoreactive T- and B-cells in check and 
maintain homeostasis within the CNS because these are often overwhelmed by the 
strong systemic Th1-skewed immune stimulation by the bacterial Ag in CFA. Fourth, 
refinement of the model by use of IFA may reduce the attrition rate of experimental 
therapies by reducing the occurrence of both false-positive and false-negative studies. 
As an example, the disappointing effect of anti-IL-12p40 Ab (ustekinumab) therapy 
in MS35 contrasts sharply with the impressive results obtained in two marmoset EAE 
models36,37. In retrospect, it seems possible that these remarkably discrepant effects 
might be explained by the Th1-skewing effect of CFA (which is absent in MS) on the 
immunopathogenic process. Finally, preclinical immunotherapy studies with novel 
biologicals targeting immunity in EAE models induced are often hampered by the strong 
stimulation of neutralizing Ab formation by CFA. This complication is removed in our 
new model. Based on the latter two arguments, we believe that the new model is highly 
useful for immunotherapy development. 
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ABSTRACT 
We report on the effect of antibody-mediated neutralization of IL-17A in a non-
human primate experimental autoimmune encephalomyelitis (EAE) model induced with 
recombinant human myelin oligodendrocyte glycoprotein (rhMOG). We tested a human-
anti-human IL-17A-antibody in two doses (3 and 30 mg/kg) against placebo (PBS). 
The treatment was started one day before EAE induction and continued throughout 
the experiment. Although all monkeys developed clinically evident EAE, the onset of 
neurological signs was delayed in some monkeys from both treatment groups. Total 
CNS lesion volumes, demyelination, or inflammation did not differ between the different 
groups. Immune profiling revealed an altered distribution of IL-17A-producing cells in the 
lymphoid organs of mAb treated monkeys. Comparable numbers of IL-17A-producing 
cells were observed in the brain. RhMOG-induced T-cell proliferation in the lymph nodes 
was slightly reduced after anti-IL-17A antibody treatment. To summarize, we found that 
anti-IL-17A antibody as a single treatment from disease induction leads to a modestly, 
albeit not significantly, delayed neurological disease progression in the marmoset EAE 
model. This suggests a role of IL-17A in late stage disease in the marmoset EAE model, 
but IL-17A may not be the dominant pathogenic cytokine. 
 
INTROduCTION
Multiple sclerosis (MS) is a progressive neurological disease of unknown origin 
characterized by the progressive accumulation of inflammation and degeneration in 
the grey and white matter of the central nervous system (CNS). The accumulation of 
injury involves a combined cellular and humoral autoimmune attack on the protective 
myelin sheaths around axons leading to disturbed saltatory pulse conduction1,2. This 
immunopathogenic process is modeled in experimental autoimmune encephalomyelitis 
(EAE), an experimental disease induced in genetically susceptible laboratory animals 
including mice, rats, guinea pigs, and monkeys. The EAE model in common marmosets, 
a small-sized Neotropical primate, combines a remarkable clinical and neuropathological 
similarity with MS and a high genetic and immunological proximity to humans3. The 
model is therefore exquisitely suitable for translational research into immunopathogenic 
mechanisms and the efficacy evaluation of therapeutic antibodies (Ab), which because 
of their high target specificity do not cross-react with lower species. The marmoset EAE 
model forms a bridge narrowing the gap between EAE models and MS4,5.
Research conducted in the past years has shown that the 100% disease incidence 
and variable progression rate of neurological deficit is associated with the mobilization 
of highly reactive T-cells present in the normal repertoire with variable specificities for 
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myelin oligodendrocyte glycoprotein (MOG)6,7. Whereas disease induction could be 
mapped to the Caja-DRB1*W1201 restricted activation of T helper (Th) 1 cells specific for 
MOG24-368, the rate of disease progression appeared to be regulated by natural-killer 
like T-cells specific for MOG34-566,7. Further research confirmed that this T-cell subset 
is able to induce clinical signs and pathology in the CNS white and grey matter without 
the support of innate antigen receptor ligands in the inoculum or autoantibodies against 
rhMOG or the inducing peptides7. These data led to the hypothesis that MOG34-56-
specific T-cells have a central pathogenic role in the regulation of disease progression 
in the marmoset EAE model. 
The most obvious immunological characteristics of MOG34-56-specific T-cell lines 
generated from EAE-affected monkeys were specific cytolytic activity towards MOG34-
56-pulsed target cells and production of IL-17A6,7. However, typical Th1 cell-derived 
cytokines, such as IFN-γ or TNF-α, that are abundantly produced by MOG24-36-
specific Th1 cells involved in EAE initiation8 were not produced by MOG34-56-specific 
T-cells7. This may well be due to the fact that for the activation of encephalitogenic 
Th1 cells in mice as well as in marmosets strong bacterial adjuvants are needed, i.e. 
complete Freund’s adjuvant (CFA)9. By contrast, our data in the marmoset EAE model 
demonstrates that encephalitogenic T-cells specific for MOG34-56 can also be activated 
by immunization with MOG34-56 in incomplete Freund’s adjuvant (IFA)7.
These observations prompted us to test whether Ab-mediated neutralization of 
IL-17A modulates disease progression in the EAE model in marmosets, elicited by a 
single immunization with recombinant protein of the extracellular domain of human 
MOG (MOG1-125) in CFA. The most prevalent disease course in this model is clinically 
characterized by the appearance of progressively accumulating motor defects after 
an episode of variable length, during which MRI-detectable lesions do not lead to 
evident neurological symptoms6,8. A typical relapsing-remitting disease course is only 
occasionally observed. Our previous studies have revealed that intervention with an 
Ab against the shared p40 subunit of IL-12 and IL-23 has a clear beneficial effect in 
the rhMOG-induced EAE model10,11. This supports an important pathogenic role of IL-
12 and IL-23, which may be exerted via the inhibition of IL-17A production, as IL-23 
promotes IL-17A production12. 
Here, we report that prophylactic treatment with anti-IL-17A monoclonal antibody 
(mAb) at doses achieving plasma through levels above 1 µg/ml induced a moderate 
delay of EAE onset. These data indicate that IL-17A is only one of several cytokines 
driving progression of the marmoset EAE model to clinically evident neuroinflammatory 
disease; absence of IL-17A being possibly compensated by Th1 cytokines that are 
abundantly produced in the rhMOG/CFA model.
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MATERIAlS ANd METHOdS 
Animals
The common marmoset monkeys used in this study were randomly selected from 
the outbred colony kept at the Biomedical Primate Research Centre (Rijswijk, The 
Netherlands) under conventional and not specific pathogen free conditions. Animals 
were only included after a complete physical, hematological, and biochemical check-up 
had been performed. During the study, monkeys were pair-housed in spacious cages 
and remained under intensive veterinary care. The daily diet consisted of commercial 
food pellets for New World monkeys (Special Diet Services, Witham, Essex, UK), 
supplemented with rice, raisins, peanuts, marshmallows, biscuits, fresh fruit, 
grasshoppers, and maggots. Drinking water was provided ad libitum. In accordance 
with the Dutch law on animal experimentation, all study protocols and experimental 
procedures have been reviewed and approved by the Institute’s Ethics Committee. 
The study comprised 22 male and 2 female monkeys (M05011 and M04049). The 
average age of the monkeys was 33 ± 16 months, which is adult age for marmosets. 
The average body weight was 377 ± 35 gram. 
RhMOG-induced EAE
EAE was induced by immunization with a recombinant protein encompassing the 
extracellular domain of human MOG residues 1-125 (rhMOG), which was produced 
in Escherichia coli and purified as previously described13. The inoculum, containing 
100 µg rhMOG in 300 µl phosphate buffered saline (PBS) emulsified with 300 µl CFA 
containing mycobacterium butyricum (Difco Laboratories, Detroit, MI), was injected at 
four locations into the dorsal skin under ketamin anesthesia (40 mg/kg; AST Pharma, 
Oudewater, The Netherlands). 
Clinical signs were scored daily by two independent observers using a previously 
documented semi-quantitative scale14: 0 = no evident clinical signs; 0.5 = apathy, loss 
of appetite, altered walking pattern without ataxia; 1 = lethargy, anorexia, tail paralysis, 
tremor; 2 = ataxia, optic disease; 2.25 = monoparesis; 2.5 = paraparesis, sensory loss; 
3 = para- or hemiplegia. For ethical reasons monkeys were sacrificed before or once 
complete paralysis of hind limbs (score ≥ 3.0) was observed, or at the pre-determined 
endpoint of the study (post sensitization day (psd) 113). Body weight measurements of 
conscious monkeys, which is used a surrogate disease marker, were performed three 
times per week.
Monkeys selected for necropsy were first deeply sedated by intramuscular injection 
of ketamin (50 mg/kg) and subsequently euthanised by infusion of pento-barbital sodium 
(Euthesate®; Apharmo, Duiven, The Netherlands).
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Reactivity and dosing regimen of anti-Il-17A mAb
The test substance was produced by UCB Celltech (UK) as a humanized IgG4κ 
mAb specific for human IL-17A, coded as 497.g2. The mAb has been extensively 
characterized in vitro in terms of bioassay, affinity for IL-17A, and cross reactivity against 
marmoset IL-17A. The affinity of the mAb with marmoset IL-17A is two fold lower than 
with human IL-17A when assessed by Biacore and four fold less potent in a bioassay 
compared to humans.
The animals were subcutaneously injected once a week starting one day before 
immunization until the predetermined end of the study at day 113. Animals were randomly 
assigned to three experimental groups. Eight animals received 3 mg/ml/kg anti-IL-17A 
mAb diluted in PBS, eight animals were injected with 30 mg/ml/kg anti-IL-17A mAb diluted 
in PBS, and eight control animals received sterile PBS (1 ml/kg) as placebo treatment. 
All animals received the same volume per kg body weight. One monkey (M04063) in 
the 30 mg/kg anti-IL-17A mAb dose group succumbed at psd 69 unexpectedly without 
prior signs of EAE and was therefore excluded from further analyses. Autopsy revealed 
that the cause of death was not related to the test substance or EAE, but to perforation 
of the gastro-intestinal tract by plant material, possibly originating from the branches 
used for cage enrichment. 
Blood sampling and plasma levels of anti-Il-17A mAb
Venous blood was collected into heparinized vacutainers (Greiner, Sölingen, 
Germany) under ketamin anesthesia (40 mg/kg) at psd 0, 6, 34, 62, and at necropsy.
After centrifugation plasma was collected and stored frozen at -20°C until analysis of 
test substance levels was performed. Test substance plasma levels were determined by 
ELISA. Microtitre plates were coated with human IL-17A (R&D Systems, Minneapolis, 
MN) at 0.5 μg/mL in PBS overnight, blocked with PBS/1% BSA, glazed with PBS/5% 
lactose/0.1% BSA, dried, sealed in foil pouches, and stored at 2-8°C. The standard curve 
was prepared by making serial doubling dilutions of the 497.g2 top standard (starting 
at 200 ng/mL) in PBS/1% BSA/1% BGG/1% human plasma. 50 μL of each standard, 
interassay control, and sample (diluted at least 1/100) were added to the appropriate 
wells containing 50 μL PBS/1% BSA/1% BGG. The interassay control concentrations 
were nominally 80, 20, and 8 ng/mL. Standards, interassay control, and samples were 
tested in duplicate. The plate was covered and incubated with agitation at RT for two 
hours. The plate was washed with PBS/0.1% Tween-20 four times and incubated with 
goat anti-human Kappa-HRP conjugate (1/10000) in PBS/1% BSA/1% BGG at RT for 
30 min. The plate was washed again with PBS/0.1% Tween-20 four times and incubated 
with 100 μL tetramethyl benzidine substrate for 10 min. The reaction was stopped with 
50 μL/well of 2.5 M H2SO4 and measured at 450 nm (and 630 nm as a reference).
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MRI
Post mortem magnetic resonance images (MRI) of one brain hemisphere were 
recorded to assess differences in the CNS lesion load between treated and control 
monkeys15. Half of the brain collected at necropsy was fixed in 4% buffered formalin and 
transferred into buffered saline containing sodium azide after two weeks. 
MRI experiments were performed on a 9.4 T horizontal bore MRI scanner (Varian, 
Palo Alto, CA). The formalin-fixed brains were submerged in a non-magnetic oil 
(Fomblin; perfluorinated polyether, Solvay Solexis, Weesp, The Netherlands) to prevent 
unwanted susceptibility artifacts. 
The following quantitative images were obtained (field of view, 2.5×2.5 cm2; matrix, 
256×256; slice thickness, 0.75 mm; number of slices, 41; number of experiments, 2):
- T2-maps, which were calculated from the images obtained of a multi echo sequence 
using the following parameters: repetition time, 4000 ms; echo spacing, 14.75 ms; 
echo train length, 4. T2-maps were the result of a mono-exponential fit of the MRI 
signal intensities as a function of TE. The T2-weighted images with TE of 14.75 ms 
were used for region of interest (ROI) analyses. 
- Magnetization transfer ratio (MTR) maps were calculated from two T1-weighted 
spin echo images with and without a magnetization transfer-saturation pulse, with 
MTR=100*[(Munsaturated-Msaturated)/Munsaturated]. Repetition time, 1675 ms; 
echo time, 23 ms; MT-pulse, 8.19 ms gaussian shaped pulse, nominal flip angle 
1000, offset - 9.4 kHz.
ROI were defined using the free available Medical Image Processing, Analysis 
and Visualization (MIPAV version 4.3.0, National Institutes of Health, Bethesda, MD) 
package. ROI of lesions, defined as areas with abnormal increased signal intensities, 
were automatically outlined in all T2-weighted images containing white matter structures 
using the level-set method of MIPAV. Volumes, T2, and MTR values were calculated 
from these ROI.
Histology and immunohistochemistry
Frozen and fixed tissues were processed for histological and immunohistochemical 
techniques as previously described16,17.
Demyelination was visualized by staining myelin and myelin degradation products 
with Klüver Barrera method (Luxol Fast Blue with Periodic Acid-Schiff). Inflammation 
was visualized by staining infiltrating cells with hematoxylin and eosin. Of each animal 
8 sections, approximately 6 cm2 in total, were analysed.
Snap-frozen sections of the brain, spleen, and axillary (ALN), inguinal (ILN), and 
cervical lymph nodes (CLN) were used to determine the number of IL-17A-producing 
cells. Sections of 6 µm were thaw mounted on gelatin/chrome alum coated glass slides 
and stored overnight in humidified atmosphere. Next day, sections were air-dried for 
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1 h at RT. Within 2 weeks sections were fixed at RT in fresh acetone containing 
0.02% H2O2. After air-drying, sections were washed with PBS containing 0.05% 
Tween-20 (Sigma-Aldrich Chemie, Zwijndrecht, The Netherlands) and incubated with 
1% blocking reagent (TSA HRP kit, Invitrogen, Molecular Probes, Carlsbad, CA) at 
RT for 1 h. After blocking, sections were incubated for 1 h with a primary Ab against 
IL-17A (eBio64Cap17, eBiosciences, San Diego, CA). All incubations were performed 
at RT and between incubations sections were washed with 1% blocking reagent. 
Primary Ab was detected by incubation for 1 h with biotinylated rabbit anti-mouse 
IgG (DAKO, Glostrup, Denmark) and streptavidin-HRP (TSA HRP kit, Invitrogen) for 
30 min, both diluted in 1% blocking reagent. Sections were incubated for 10 min with 
tyramide-biotin dissolved in amplification buffer (TSA HRP kit, Invitrogen) containing 
0.15% H2O2. Next, sections were again incubated for 30 min with streptavidin-
HRP. To reveal peroxidase activity, sections were incubated with AEC (3-amino-
9-ethylcarbazole, Sigma) substrate for 10 min resulting in a bright red precipitate. 
Sections were counterstained with hematoxylin and embedded with glycerol-gelatin. 
In control stainings in which the first Ab was omitted or using an isotype control, 
no immunopositive cells could be detected. For the lymph nodes, the number of IL-
17A-producing cells is the mean of the number of IL-17A positive cells of three non-
adjacent sections. 
Analysis of T-cell reactivities
T-cell responses against different antigens were analysed ex vivo as described 
previously8. Briefly, PBMC were isolated by density gradient centrifugation over 
lymphocyte separation medium (Axis-Shield PoC AS, Oslo, Norway). Mononuclear cell 
(MNC) suspensions were prepared from aseptically removed spleen and ALN. Cells 
were cultured in triplicate for detection of proliferative responses towards rhMOG and 
a panel of MOG peptides. All antigens were tested at 5 µg/ml. After 48 h of culture, 0.5 
µCi/well of tritiated thymidine ([3H]Thy) was added and incorporation of radiolabel was 
determined after 18 h using a matrix 9600 β-counter (Packard 9600; Packard Instrument 
Company, Meriden, CT). Results are expressed as the mean stimulation index (SI), 
which is defined as the counts per minute (cpm) of stimulated cells divided by the cpm 
of unstimulated cells. SI values above 2.0 were considered to be relevant.
The phenotype of proliferating cells was determined as described previously6. Briefly, 
4x106 viable MNC from ALN or spleen were suspended in 1 ml PBS and incubated for 
7 min at RT with CFSE (final concentration 1.5 µM; Fluka, Deisenhofen, Germany). 
Labeled MNC were cultured for 7 days with rhMOG or MOG peptides. For flow 
cytometric analysis we used the following commercially available labeled mAb directed 
against human CD markers: Alexa Fluor 700-labeled anti-CD3 (BD Biosciences), APC-
labeled anti-CD4 (DAKO), biotinylated anti-CD8 (Serotec, Düsseldorf, Germany), and 
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streptavidin PerCP (BD Biosciences). Flow cytometric analysis was performed on a 
FACSort using FACSDiva software (BD Biosciences). 
Statistics
Log Rank test, One-way Anova, and Student’s t-test were performed to statistically 
analyse the results. Results were considered statistically different at p<0.05.
 
RESulTS
Plasma levels of anti-Il-17A mAb in rhMOG-immunized monkeys
The marmosets included in the study were randomly assigned to three treatment 
groups. The control group (n=8) received 1 ml/kg PBS and the two treatment groups 
received anti-IL-17A mAb at 3 mg/ml/kg (n=8) or 30 mg/ml/kg (n=7). The test substances 
were subcutaneously administered once per week starting one day before immunization. 
Plasma levels of the anti-IL-17A mAb were determined 7 days after each administration 
(Figure 1). As expected, plasma concentrations of the mAb in the 3 mg/kg mAb dose 
group were about 10-fold lower compared to the 30 mg/kg mAb dose group. In two 
animals (M04099 and M03144) of the 3 mg/kg mAb dose group plasma mAb trough 
levels, measured one week after administration, were remarkably low, i.e. below 1 µg/
ml at psd 34, while these were above 1 µg/ml in all the other monkeys of this group. 
In the 30 mg/kg mAb dose animals the plasma levels of the test substance were above 
10 µg/ml from psd 6 throughout the experiment. 
Figure 1. Plasma levels of anti-human Il-17A mAb were sustained during the study. 
Once a week, animals received a subcutaneous injection with 1 ml/kg PBS (not shown), 3 mg/kg anti-IL-
17A mAb (left graph), or 30 mg/kg anti-IL-17A mAb (right graph) starting one day before immunization. 
Plasma was collected from venous blood at several time points during the study and anti-IL-17A mAb 
evels in plasma were determined by ELISA. The y-axes have log scales. M04099 and M03144 of the low 
antibody dose group were not able to sustain a trough level of the antibody above 1 μg/ml. 
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Clinical signs after anti-Il-17A mAb treatment
EAE was induced by a single immunization with rhMOG emulsified in CFA. The 
course of clinical signs in individual animals is depicted in figure 2. Solid lines represent 
clinical scores and dotted lines represent percentage body weight loss, serving as a 
surrogate disease marker in this model. The figure shows a similar disease course in the 
monkeys that developed full-blown clinical EAE. Three monkeys from the 3 mg/kg mAb 
dose group and one monkey in the 30 mg/kg mAb dose group did not reach the stage of 
hind-limb paralysis (score 3) within the pre-determined observation period of 113 days. 
In the 3 mg/kg mAb dose group one monkey (M05020) did not develop any signs of 
EAE within the pre-defined observation period. A second monkey of this group (M9913) 
reached EAE score 2 around psd 85, remitted, and developed a second episode of EAE 
score 2 (psd 106), which remained present until the end of the observation period. Two 
monkeys (M04008 and M05004) had to be sacrificed for ethical reasons with EAE score 
2 due to serious body weight loss. It is noteworthy that the two monkeys with the lowest 
anti-IL17A mAb plasma levels at day 34 (M03144 and M04099) were amongst the first 
monkeys to be sacrificed.
The EAE progression-rate to overt neurological deficit was defined as the time 
interval between the day of rhMOG/CFA immunization (psd 0) and the first day that 
clinical score 2 was observed. At the level of this parameter we observed a delayed EAE 
progression in the 3 mg/kg mAb dose group (mean psd 69.3; range 48–113) compared 
to the placebo group (mean psd 57.1; range 39-91) and the 30 mg/kg mAb dose group 
(mean psd 60.0; range 51–69). It is noteworthy that the variation between animals of 
this parameter was much lower in the 30 mg/kg mAb dose group (18 days) than in the 
placebo group (52 days) and the 3 mg/kg mAb dose group (> 65 days). 
The disease progression from EAE score 2 (=ataxia) to the ethical end-point at score 
3.0 (=paraplegia) or excessive body weight loss (> 20%) was more rapid in placebo 
group monkeys (mean 10.8 days, range 3-20) than in monkeys from the 3 mg/kg mAb 
(mean 12.9, range 5-28) and 30 mg/kg mAb (mean 13.7, range 6-31) dose group. 
Statistical evaluation of both disease phases (score 0 to 2 and score 2 to > 2) was done 
by survival analysis, but no significant differences were found (Figure 3).
In summary, these data show a moderate inhibitory effect of the Ab treatment on 
the EAE course, although differences between the groups did not reach statistical 
significance. 
Figure 2. Clinical score and body weight loss of rhMOG-immunized marmosets. 
Shown are the clinical score (solid line, right y-axis) and the body weight change in percentages 
compared to day 0 (dotted line, left y-axis) of the placebo group (left graphs), the low dose group (middle 
graphs), and the high dose group (right graphs). Numbers in the figure represent the time points (psd) 
when neurological signs (score ≥ 2) were first observed and the day of sacrifice.
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Effect of anti-Il-17A mAb on white matter lesion load
Prior to sectioning for histological examination, post mortem T2-weighted MR images 
were made of the formalin-fixed cerebral hemispheres to visualize and quantitate the 
total lesion load. The analysed parameters were lesion volume, T2, and MTR values of 
white matter lesions. In fixed brains an increased T2 signal reflects demyelination, while a 
reduction of MTR values correlates well with the intensity of macrophage infiltration15. 
Significant differences were not observed between the three groups (Table 1). In the 
analysed hemispheres of two animals of the control group cerebral white matter lesions 
were absent. White matter lesion volumes were slightly increased in the 30 mg/kg mAb 
dose group compared to the placebo group. Monkey M05004 had clinical score 2 for a 
long time, which might explain the high lesion load. The lesions in the 3 and 30 mg/kg mAb 
dose group had a slightly higher T2 and lower MTR value compared to placebo (Table 1). 
These results were confirmed by the quantitative histology data (Table 1). Both 
inflammation and demyelination were moderately increased, although not significant, in 
the two mAb treated groups compared with the placebo group.
For the correct interpretation of these data it is pertinent to emphasize that lesion 
formation in this model starts well before neurological deficits can be observed. 
Moreover, most animals were sacrificed at the stage of clinically evident EAE, which 
occurred at different time intervals after immunization. It may therefore not be surprising 
that major effects of the mAb treatment on the CNS pathology were not observed, 
neither in positive nor in negative direction.
Figure 3. Survival curves. 
Survival time to score 2 (A) and survival time to day of sacrifice (B) are shown. P-values indicated in the 
graph are the results of comparing three groups. Comparing the survival to the day of sacrifice of the 
control group versus only the 3 mg/kg group resulted in a p-value of 0.1610. When two animals of the 3 
mg/kg group with low anti-IL-17A mAb plasma levels (M04099 and M03144) are included in the control 
group instead of the 3 mg/kg group, the p-value is 0.0428. According to the Bonferroni correction this is 
not significant, but it is highly suggestive for a delay in disease progression. 
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Table 1. white matter lesion parameters.
wM lesions assessed by MRI Histology
Animal Volume 
(mm3)
T2 (ms) MTR # Inflammatory 
lesions/cm2
# demyelinating 
lesions/cm2
demyelination 
% 
Control
M0176 87 28.0 31.3 16 4.7 1.5
M03115 597 24.0 32.0 20 9.2 1.5
M04009 150 29.7 30.3 15 3.7 0.8
M04098 0 - - 1 0.2 0
M04109 163 26.0 32.1 19 5.3 1.6
M05011 2 23.2 35.9 3 1.0 0.1
M05014 0 - - 0 0.0 0
M05023 449 27.9 31.2 60 6.2 1.3
Mean 181 26.5 32.1 17 3.8 0.9
SEM 79 1.0 0.8 7.9 1.3 0.3
3 mg/kg
M03144 483 29.9 29.9 32 7.7 1.6
M04008 135 27.6 29.2 25 9.8 1.6
M04099 113 26.6 33.9 11 1.7 0.3
M04122 354 27.6 31.2 45 12.0 2.4
M05020 178 26.1 33.3 19 3.3 0.4
M05021 30 29.3 30.9 5 2.0 0.2
M05024 642 27.5 31.2 52 11.0 2
M9913 321 25.9 29.7 13 4.3 3.3
Mean 282 27.5 31.2 25 6.5 1.5
SEM 73 0.5 0.6 5.9 1.5 0.4
30 mg/kg
M03116 39 27.0 32.8 6 2.5 0.3
M03149 304 31.9 28.7 5 1.0 0.2
M03160 50 32.8 28.6 45 8.7 1.1
M04049 212 25.9 32.3 68 4.7 1.1
M04112 354 27.6 31.2 34 8.7 3
M05004 1261 25.8 29.7 52 8.8 3.4
M05039 715 27.1 31.5 18 3.2 0.7
Mean 419 28.3 30.7 33 5.4 1.4
SEM 165 1.1 0.6 9.1 1.3 0.5
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Il-17A expression in the brain and lymphoid organs
To assess the effect of anti-IL-17A mAb treatment on in situ expression of IL-17A, 
cryosectioned brains and lymphoid organs were examined with immunohistochemistry. 
In the brains of control and anti-IL-17A mAb treated animals IL-17A-positive cells 
were found in the perivascular space or in the vicinity of blood vessels (Figure 4A). No 
differences were observed between placebo and anti-IL-17A mAb treated animals. 
IL-17A-producing cells in secondary lymphoid organs were mainly found in the 
red pulp of the spleen and in the medulla of the lymph nodes. We observed a trend 
towards higher numbers of IL-17A-producing cells in the spleen of animals dosed with 
3 mg/kg anti-IL-17A mAb compared to animals that had received placebo or 30 mg/
kg mAb, although the differences were not significant (Figure 4A-B). By contrast, we 
detected lower numbers of IL-17A-producing cells in the ALN, ILN, and CLN in both 
treatment groups compared to the placebo group (Figure 4A-B). Taken together, these 
data suggest that the anti-IL-17A mAb treatment caused altered distribution of IL-17A-
producing cells over the different lymphoid compartments.
Effect of anti-Il-17 mAb on T-cell proliferation
Cellular immune parameters of the three groups were examined to underpin the 
observed in vivo effects of the IL-17A mAb. To this end, PBMC and MNC of spleen and 
ALN were tested for proliferation against rhMOG and a panel of 23-mer overlapping 
MOG peptides.
Similar to previous studies6, proliferation of PBMC during the disease course and at 
necropsy was low and remained confined to the immunizing rhMOG protein and a few 
peptides, i.e. MOG14-36, MOG24-46, and MOG34-56 (Figure 5). No clear differences 
were observed between the three groups. 
More robust proliferative responses were observed in the lymphoid organs, 
especially in the ALN and spleen. Figure 5 shows that in most animals the highest 
proliferative response was against rhMOG followed by peptides MOG14-36 and 
MOG24-46. MNC from the ALN of the anti-IL-17A mAb treated groups displayed 
a lower proliferative response against rhMOG and MOG peptides than MNC from 
Figure 4. differential expression of Il-17A in the brain and lymphoid organs. 
IL-17A expression was detected by immunohistochemistry. Panel A (original magnification x200) 
shows representative examples of each group for brain, spleen, and axillary (ALN), inguinal (ILN), 
and cervical (CLN) lymph nodes. Panel B shows the number of IL-17A-positive cells per mm2 (mean 
± sem). Only one CLN of the control group was analyzed. No IL-17A-producing cells were detected 
in the ILN of the 30 mg/kg treated group. Statistical differences between the numbers of IL-17A-
positive cells were analysed by One-Way Anova. Results were considered statistically different at 
p<0.05. No statistical differences were found between the three groups. See page 315 for a full-color 
representation of this figure.
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ALN of the placebo group (Figure 5). No differences between the three groups were 
observed in the spleen (Figure 5).
Next, we analysed the phenotype of the rhMOG responsive cells using the CFSE 
fluorescent dye dilution technique in combination with cell phenotyping for surface 
markers. RhMOG responsive CD3+CD4+ and CD3+CD8+ cells with CFSE dye dilution 
were visualized by flow cytometry. The percentages of CD3+CD4+ and CD3+CD8+ 
cells determined by fluorescent dye dilution did not differ significantly between 
placebo and anti-IL-17A mAb treated groups (data not shown), suggesting that the 
treatment with anti-IL-17A mAb did not cause a skewing of the CD4/CD8 ratio of 
rhMOG-specific T cells.
In conclusion, treatment with the anti-IL-17A mAb did not exert an obvious effect 
on the quality or quantity of the cellular autoimmune reactions. However, we like to 
emphasize again that the analysed lymphoid organs were collected at different time 
intervals after the EAE induction, creating a possible bias in the data.
Figure 5. T-cell responses after anti-Il-17A mAb treatment. 
PBMC and mononuclear cells isolated from the axillary lymph node (ALN) and spleen at necropsy were 
tested for proliferation against rhMOG and MOG peptides. The stimulation index (SI) was calculated by 
dividing the counts per minute (cpm) of stimulated wells by cpm of unstimulated wells. The stimulation 
index is divided into groups with different shading as indicated in the figure. 
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dISCuSSION
Key pathogenic elements for EAE development in rhMOG-immunized marmosets 
comprise CD40, IL-12, and IL-2310,18-20. We have shown that a mAb against the shared 
p40 subunit of IL-12 and IL-23 caused profound suppression of disease symptoms when 
dosed from disease induction. One possible mechanism of action could have been a 
reduction in IL-17A that is one of the downstream cytokines from IL-23. However, the 
modest effect of an anti-IL-17A mAb in the current study indicates that a reduction in IL-
17A does not account for the activity of IL-12p40 mAb and that other cytokines, perhaps 
IL-12 directly or other cytokines downstream of IL-12 and/or IL-23, are more important 
in the induction phase of this non-relapsing model.
The results of the current study demonstrate that prophylactic treatment with an 
anti-IL-17A mAb induced only a moderate extension of the disease-free time interval 
after EAE induction. Furthermore, immune parameters of the disease, such as T-cell 
proliferation against rhMOG or MOG peptides was only somewhat reduced, whereas 
also a marginal aggravation of CNS pathology was observed. However, the variations 
were all within the normal range of variation in this outbred model and may also be 
attributable to the longer survival. Using immunohistochemistry only a few IL-17A-
positive cells could be detected in the brains of placebo and treated-monkeys, but no 
significant differences between groups were observed. The number of IL-17A-positive 
cells was increased in the spleen in the 3 mg/kg group and decreased in the axillary and 
inguinal lymph nodes of both groups compared to placebo animals. The higher number 
of IL-17A-producing cells in the spleen of monkeys that have been treated with anti-IL-
17A mAb compared to placebo monkeys may be explained by feedback regulation. The 
observation that IL-17A receptor deficient mice produce more IL-17A21 indicates that 
IL-17A production may be regulated by a negative feedback loop. In conclusion, the 
current results fail to show a robust effect of the anti-IL-17A mAb treatment on the EAE 
course in rhMOG/CFA-immunized marmosets. 
The moderate protection against EAE induction is in agreement with data reported 
by some groups in mouse EAE models. Also in IL-17A-/- mice22, in mice treated with 
anti-IL-17A mAb12,23,24, and in mice vaccinated against IL-17A25 only moderately delayed 
onset of clinical signs has been observed. However, other groups have demonstrated 
more robust effects of IL-17A on the EAE course in mice. Examples are by vaccination 
with IL-17A-OVA complexes that induce IL-17A blocking Ab26 or adoptive transfer of IL-
17+ and IL-17- T-cells12,22,27. Furthermore, in the chronic-relapsing EAE model in Biozzi 
ABH mice, prophylactic dosing with an anti-IL-17A mAb produced a small delay in onset 
of the acute phase of disease, whereas treatment with the mAb started after the acute 
phase or during the secondary-progressive phase was very efficacious, and could even 
reverse the chronic motor disability (Smith, unpublished observations). Other groups 
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suggested that Th17 cells are not pathogenic at all28 or that besides Th17 cells, Th1 
cells are also essential in EAE29-31.
How can it be explained that IL-17A neutralization does not fully protect against 
EAE in the rhMOG-induced marmoset model? One possible explanation is the high 
complexity of the model. Unraveling of the pathogenic mechanisms showed that the 
disease is initiated by Th1 cells specific for MOG24-36, which induce small inflammatory 
lesions8. The moderate inflammatory injury caused by Th1 cells can be dramatically 
amplified by Ab against conformational epitopes of MOG32, which are clearly produced 
in the rhMOG model. Another subset of highly reactive T-cells with natural killer-
cytotoxic T-lymphocyte characteristics and specific for MOG34-56 becomes involved 
at a later stage in the disease6. Our previously reported studies in marmoset EAE 
models induced with MOG34-56 in CFA6 or IFA7 demonstrated that the same clinical 
and pathological end-points can be reached via different immunopathogenic routes. 
It can thus be envisaged that after neutralization of IL-17A in the complex rhMOG/
CFA-induced model other pathogenic mechanisms, such as Th1 cells, may come into 
play. It could also be possible that Th1 and Th17 cells act in different phases of the 
disease. In the previously reported study in the rhMOG-induced marmoset EAE model 
it was observed that Th1 cells specific for MOG24-36 are engaged in EAE induction, 
whereas MOG34-56 specific T-cells, which produce mainly IL-17A, mediate disease 
progression6,7. This suggests that, consistent with the results in the Biozzi ABH mouse 
model, neutralizing IL-17A in a later phase of the disease is more effective.
Yet, another possible explanation is that IL-17A, although being the signature 
cytokine of Th17 cells, is not the dominant pathogenic factor produced by Th17 cells. 
This explanation is supported by data in mice. IL-12/IL-23p40-/- mice are completely 
resistant to EAE, whereas only clinical scores and not the disease incidence is reduced 
in IL-17-/- mice22,33-35. Moreover, treatment of mice with anti-IL-23 mAb prevented either 
EAE induction or relapse, in contrast to the anti-IL-17A mAb treatment that blocked 
relapse, but had a smaller effect on the induction phase24. This may suggest that 
other Th17 cytokines induced by IL-23 may be pathogenetically more relevant than 
IL-17A in the induction phase, such as IL-21 or IL-22 (reviewed in:36). In addition, 
Chen et al. suggested that IL-23 may also directly activate macrophages to produce 
inflammatory cytokines, such as IL-6, IL-1, and TNF-α, which may cause inflammation 
and demyelination even when IL-17A is neutralized24. 
Is there a place for an IL-17A neutralizing antibody in the treatment of MS? Axtell 
et al. reported that on the basis of clinical response to IFN-β two groups may be 
distinguished in the MS patient population. Responsiveness to IFN-β treatment requires 
a Th1 cytokine profile, whereas cases with a Th17 dominated cytokine profile are non-
responders to IFN-β treatment37. It is tempting to speculate on the basis of these and 
our data that non-responder cases to IFN-β treatment in the MS population may benefit 
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from treatment with IL-17A antibody. The ideal study design to obtain proof-of-principle 
may be a parallel effectivity analysis in the marmoset EAE model, where in one sibling of 
a chimeric twin EAE is induced with MOG34-56 in CFA, which is a Th1 prone model, and 
in the other twin sibling with MOG34-56 in IFA, which is a more Th17 prone disease6,7.
In summary, we found that treatment with anti-IL-17A mAb induces a moderate delay 
of clinical EAE in marmosets, but that EAE is not completely abrogated. This suggests 
a pathogenic role for IL-17A in the marmoset EAE model and maybe in MS, but IL-17A 
may not be the only key pathogenic cytokine. 
 
ACKNOwlEdGEMENTS
The authors like to thank Fred Batenburg for excellent biotechnical assistance 
and daily care of the monkeys, Jaco Bakker DVM, Gerco Braskamp DVM and Merei 
Keehnen DVM for expert veterinary care, Tom Haaksma and Dr. Ivanela Kondova for 
autopsy of the monkeys. The authors thank Henk van Westbroek for the artwork. 
 
REFERENCES
1. Sospedra M et al. Immunology of multiple sclerosis. Annu Rev Immunol 23:683-747 (2005)
2. Compston A et al. Multiple sclerosis. Lancet 372:1502-1517 (2008)
3. ‘t Hart BA et al. Clinical, pathological, and immunologic aspects of the multiple sclerosis 
model in common marmosets (Callithrix jacchus). J Neuropathol Exp Neurol 68:341-355 
(2009)
4. ‘t Hart BA et al. Modelling of multiple sclerosis: lessons learned in a non-human primate. Lancet 
Neurol 3:588-597 (2004)
5. Kap YS et al. Experimental Autoimmune Encephalomyelitis in the Common Marmoset, a Bridge 
Between Rodent EAE and Multiple Sclerosis for Immunotherapy Development. J Neuroimmune 
Pharmacol 5:220-230 (2010)
6. Kap YS et al. Fast progression of recombinant human myelin/oligodendrocyte glycoprotein (MOG)-
induced experimental autoimmune encephalomyelitis in marmosets is associated with the activation 
of MOG34-56-specific cytotoxic T cells. J Immunol 180:1326-1337 (2008)
7. Jagessar SA et al. Induction of progressive demyelinating autoimmune encephalomyelitis in common 
marmoset monkeys using MOG34-56 peptide in incomplete Freund adjuvant. J Neuropathol Exp 
Neurol 69:372-385 (2010)
8. Brok HP et al. Myelin/oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis in 
common marmosets: the encephalitogenic T cell epitope pMOG24-36 is presented by a monomorphic 
MHC class II molecule. J Immunol 165:1093-1101 (2000)
9. Billiau A et al. Modes of action of Freund’s adjuvants in experimental models of autoimmune 
diseases. J Leukoc Biol 70:849-860 (2001)
10. Brok HP et al. Prevention of experimental autoimmune encephalomyelitis in common marmosets 
using an anti-IL-12p40 monoclonal antibody. J Immunol 169:6554-6563 (2002)
11. ‘t Hart BA et al. Suppression of ongoing disease in a nonhuman primate model of multiple sclerosis 
by a human-anti-human IL-12p40 antibody. J Immunol 175:4761-4768 (2005)
Proefschrift Yolanda Kap_compleet.indd   147 25-08-2010   21:25:02
Chapter 4.1
148
12. Langrish CL et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. 
J Exp Med 201:233-240 (2005)
13. Kerlero de Rosbo N et al. Predominance of the autoimmune response to myelin oligodendrocyte 
glycoprotein (MOG) in multiple sclerosis: reactivity to the extracellular domain of MOG is directed 
against three main regions. Eur J Immunol 27:3059-3069 (1997)
14. ‘t Hart BA et al. Preclinical assessment of therapeutic antibodies against human CD40 and human interleukin-
12/23p40 in a nonhuman primate model of multiple sclerosis. Neurodegener Dis 5:38-52 (2008)
15. Blezer EL et al. Quantitative MRI-pathology correlations of brain white matter lesions developing in 
a non-human primate model of multiple sclerosis. NMR Biomed 20:90-103 (2007)
16. ‘t Hart BA et al. Histopathological characterization of magnetic resonance imaging-detectable brain 
white matter lesions in a primate model of multiple sclerosis: a correlative study in the experimental 
autoimmune encephalomyelitis model in common marmosets (Callithrix jacchus). Am J Pathol 
153:649-663 (1998)
17. Laman JD et al. Expression of accessory molecules and cytokines in acute EAE in marmoset 
monkeys (Callithrix jacchus). J Neuroimmunol 86:30-45 (1998)
18. Boon L et al. Prevention of experimental autoimmune encephalomyelitis in the common marmoset 
(Callithrix jacchus) using a chimeric antagonist monoclonal antibody against human CD40 is 
associated with altered B cell responses. J Immunol 167:2942-2949 (2001)
19. Laman JD et al. Protection of marmoset monkeys against EAE by treatment with a murine antibody 
blocking CD40 (mu5D12). Eur J Immunol 32:2218-2228 (2002)
20. ‘t Hart BA et al. Treatment with chimeric anti-human CD40 antibody suppresses MRI-detectable 
inflammation and enlargement of pre-existing brain lesions in common marmosets affected by 
MOG-induced EAE. J Neuroimmunol 163:31-39 (2005)
21. Smith E et al. IL-17A inhibits the expansion of IL-17A-producing T cells in mice through “short-loop” 
inhibition via IL-17 receptor. J Immunol 181:1357-1364 (2008)
22. Komiyama Y et al. IL-17 plays an important role in the development of experimental autoimmune 
encephalomyelitis. J Immunol 177:566-573 (2006)
23. Hofstetter HH et al. Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune 
encephalomyelitis. Cell Immunol 237:123-130 (2005)
24. Chen Y et al. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune 
encephalomyelitis. J Clin Invest 116:1317-1326 (2006)
25. Rohn TA et al. Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis. 
Eur J Immunol 36:2857-2867 (2006)
26. Uyttenhove C et al. Development of an anti-IL-17A auto-vaccine that prevents experimental auto-
immune encephalomyelitis. Eur J Immunol 36:2868-2874 (2006)
27. Jager A et al. Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis 
with different pathological phenotypes. J Immunol 183:7169-7177 (2009)
28. Haak S et al. IL-17A and IL-17F do not contribute vitally to autoimmune neuro-inflammation in mice. 
J Clin Invest 119:61-69 (2009)
29. O’Connor RA et al. Cutting edge: Th1 cells facilitate the entry of Th17 cells to the central nervous 
system during experimental autoimmune encephalomyelitis. J Immunol 181:3750-3754 (2008)
30. Lees JR et al. Host T Cells Are the Main Producers of IL-17 within the Central Nervous System 
during Initiation of Experimental Autoimmune Encephalomyelitis Induced by Adoptive Transfer of 
Th1 Cell Lines. J Immunol 180:8066-8072 (2008)
31. Kroenke MA et al. IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, 
CNS chemokine profile, and response to cytokine inhibition. J Exp Med 205:1535-1541 (2008)
32. Genain CP et al. Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate. J Clin 
Invest 96:2966-2974 (1995)
Proefschrift Yolanda Kap_compleet.indd   148 25-08-2010   21:25:03
Anti-IL-17A mAb treatment of EAE in a primate
149
33. Becher B et al. Experimental autoimmune encephalitis and inflammation in the absence of 
interleukin-12. J Clin Invest 110:493-497 (2002)
34. Gran B et al. IL-12p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis: 
evidence for redundancy in the IL-12 system in the induction of central nervous system autoimmune 
demyelination. J Immunol 169:7104-7110 (2002)
35. Cua DJ et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune 
inflammation of the brain. Nature 421:744-748 (2003)
36. Fouser LA et al. Th17 cytokines and their emerging roles in inflammation and autoimmunity. Immunol 
Rev 226:87-102 (2008)
37. Axtell RC et al. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis 
and experimental encephalomyelitis. Nat Med 16:406-412 (2010)
Proefschrift Yolanda Kap_compleet.indd   149 25-08-2010   21:25:03
Proefschrift Yolanda Kap_compleet.indd   150 25-08-2010   21:25:03
J Immunol (in press)
1Department of Immunobiology, Biomedical Primate Research Centre, Rijswijk, 
The Netherlands; 2Department of Immunology, Erasmus Medical Centre, 
Rotterdam, The Netherlands; 3MS Centre ErasMS, Rotterdam, The Netherlands; 
4Image Sciences Institute, University Medical Center Utrecht, Utrecht,  
The Netherlands; 5Genmab, Utrecht, The Netherlands; 6GlaxoSmithKline 
Discovery, BioPharm R&D, Stevenage, United Kingdom
Yolanda S. Kap1,2,3, Nikki van Driel1, Erwin Blezer4, Paul W.H.I. Parren5, 
Wim K. Bleeker5, Jon D. Laman2,3, Jenny L. Craigen6, and Bert A. ’t Hart1,2,3
late B-cell depletion with a human anti-human Cd20 
IgG1κ mAb halts the development of experimental 
autoimmune encephalomyelitis in marmosets 
4.2
Proefschrift Yolanda Kap_compleet.indd   151 25-08-2010   21:25:03
Proefschrift Yolanda Kap_compleet.indd   152 25-08-2010   21:25:03
  Late B-cell depletion prevents marmoset EAE
153
ABSTRACT  
Depletion of CD20+ B-cells has been related to reduced clinical activity in relapsing-
remitting multiple sclerosis. The underlying mechanism is not understood as serum IgG 
levels were unaltered by the treatment. We report the effect of late B-cell depletion on 
cellular and humoral immune mechanisms in a preclinical MS model, i.e. experimental 
autoimmune encephalomyelitis (EAE) in the common marmoset. We used a novel 
human-anti-human CD20 IgG1κ monoclonal antibody (HuMab 7D8) that cross-reacts 
with marmoset CD20. EAE was induced in fourteen marmosets by immunization with 
recombinant human myelin oligodendrocyte glycoprotein (rhMOG) in CFA. After 21 days, 
B-cells were depleted in seven monkeys by HuMab 7D8 and seven control monkeys 
received PBS. Humab 7D8 induced profound and long-lasting B-cell depletion from 
PBMC and lymphoid organs throughout the observation period of 106 days. Whereas 
all control monkeys developed clinically evident EAE, overt neurological deficits were 
substantially reduced in three HuMab 7D8 treated monkeys and four HuMab 7D8 treated 
monkeys remained completely asymptomatic. The effect of HuMab 7D8 was confirmed 
on magnetic resonance images, detecting only small lesions in HuMab 7D8 treated 
monkeys. The infusion of HuMab 7D8 arrested the progressive increase of anti-MOG 
IgG antibodies. Although CD3+ T-cell numbers in lymphoid organs were increased, their 
proliferation and cytokine production were significantly impaired. Most notable were 
the substantially reduced mRNA levels of IL-7 and pro-inflammatory cytokines (IL-6, IL-
17A, IFN-γ, TNF-α). In conclusion, B-cell depletion prevents the development of clinical 
and pathological signs of EAE, which is associated with impaired activation of MOG-
reactive T-cells in lymphoid organs.
 
INTROduCTION
Recent clinical trials in multiple sclerosis (MS) with the chimeric CD20 monoclonal 
antibody (mAb) rituximab (Rituxan) have triggered renewed interest in the pathogenic 
relevance of B-cells. Treatment of relapsing-remitting MS (RRMS) with rituximab led to 
sustained peripheral B-cell depletion, reduced relapse rate, and reduced numbers of 
brain white matter (WM) lesions1-3. B-cell depletion by rituximab also reduced the lesion 
volume enlargement in primary progressive MS but had only a modest effect on disease 
progression4. Rituximab not only depletes B-cells from peripheral blood, but also from 
cerebrospinal fluid and cerebral perivascular spaces5-7.
Traditionally, B-cells were thought to contribute to MS mainly via the production 
of autoantibodies, which upon binding to myelin sheaths initiate Ab-dependent cell-
mediated cytotoxicity and complement-dependent cytotoxicity8. Autoantibodies directed 
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against myelin proteins, such as myelin oligodendrocyte glycoprotein (MOG), have 
been isolated from MS patients9,10 and healthy controls11. Autoantibodies were found 
to amplify demyelination in mouse12, rat13, and non-human primate14 experimental 
autoimmune encephalomyelitis (EAE) models. Furthermore, evidence for antibody- 
and complement-mediated demyelination has been described in type II MS lesions15. 
Recently, B-cells were detected in ectopic lymphoid structures in the meninges of MS 
brains, although their putative pathogenic role in these structures is still unknown16,17. 
The fact that plasma cells do not express CD20 and were therefore not depleted 
by anti-CD20 mAb, likely explains the lack of reduction in total IgG serum2,3. It has 
therefore been suggested that the clinical effect of depleting B-cells in RRMS may be 
due to interference with other B-cell functions, such as antigen presentation and cytokine 
production, leading to impaired activation of T-cells and macrophages2,3. Reduced 
numbers of T-cells have been reported in the cerebrospinal fluid after B-cell depletion, 
but not in blood4,6. Because access to body fluids or organs other than blood for immune 
profiling is limited in MS patients and healthy controls, we chose to investigate the effect 
of B-cell depletion on T-cell activation in lymphoid organs in a relevant animal model of 
MS, EAE in the common marmoset18,19.
The recombinant human MOG (rhMOG)-induced EAE model in the common 
marmoset is a relevant model for the purpose of this study, because both autoantibodies 
and anti-MOG T-cells are induced. Autoantibodies contribute significantly to the 
pathogenic process in this marmoset EAE model14,20. However, full development of 
evident neurological disease does not strictly depend on the presence of autoantibodies, 
because T-cells specific for the MOG34-56 epitope can induce demyelination21,22. 
These highly pathogenic T-cells, which are activated in the rhMOG-induced EAE model, 
express CD56, are cytotoxic, and produce IL-17A21,22. Cytotoxic CD56+ MOG-specific 
T-cells are also present in MS23,24. In marmosets, these T-cells can be activated by a 
very mild immunization protocol that only includes MOG34 56 emulsified in incomplete 
Freund’s adjuvant (IFA), suggesting that anti-MOG T-cells are highly pathogenic and 
important in the pathogenic process22. 
In recent years, a panel of fully human CD20 Ab was generated in Ig transgenic 
mice25. This panel included ofatumumab and HuMab 7D8, which both bind to a unique 
membrane-proximal CD20 epitope, comprising the small and large extracellular 
loops. Ofatumumab and HuMab 7D8 display superior CD20 binding and complement 
dependent cytotoxicity compared to rituximab25-28.
In the current study, we have induced profound B-cell depletion by weekly infusion 
of the human-anti-human CD20 mAb HuMab 7D8 starting three weeks after the EAE 
induction by a single immunization with rhMOG formulated in complete Freund’s adjuvant 
(CFA). The treatment was started simultaneously in all animals well after immunization 
(i.e. at week three) to avoid interference with induction of the immunopathogenic 
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process but before the onset of overt clinical EAE. Neurological signs in the used 
model appear between four and 16 weeks after immunization with rhMOG/CFA21. The 
earliest responders display clinical signs already within four weeks, suggesting that the 
autoimmune mechanisms needed for the induction of lesions and neurological deficit 
can be induced within four weeks after immunization. 
We report that this semi-therapeutic treatment schedule with HuMab 7D8, when 
autoantibody production is already ongoing, impaired the development of neurological 
deficit. The immunological correlates of this remarkable therapeutic effect were arrest of 
already initiated autoantibody production and impaired activation of autoreactive T-cells 
in lymphoid organs, read-out by reduced proliferation and pro-inflammatory cytokine 
production in lymphoid organs. These data obtained in a valid preclinical model of MS 
contribute to a better understanding of the elusive mechanism underlying the clinical 
effect of B-cell depletion in RRMS. 
 
MATERIAlS ANd METHOdS
Animals
The common marmoset monkeys used in this study were purchased from two 
outbred colonies, respectively kept at the Biomedical Primate Research Centre (Rijswijk, 
The Netherlands) or the German Primate Centre DPZ (Göttingen, Germany). Only 
animals that were declared healthy after the veterinarian’s physical, hematological, and 
biochemical check-up were included. Monkeys were pair-housed in spacious cages 
and under intensive veterinary care throughout the study. The daily diet consisted 
of commercial food pellets for New World monkeys (Special Diet Services, Witham, 
Essex, UK), supplemented with rice, raisins, peanuts, marshmallows, biscuits, fresh 
fruit, and grasshoppers. Drinking water was provided ad libitum. According to the Dutch 
law on animal experimentation, all study protocols and experimental procedures have 
been reviewed and approved by the Institute’s Ethics Committee. 
Twelve marmosets were used to find an effective dose (pharmacokinetics/-dynamics 
(PK/PD)) and fourteen marmosets were used for efficacy assessment in the EAE model 
(Table 1). The average body weight distribution of monkeys selected for the EAE experiment 
was the same for the control (367 ± 30 gram) and treatment group (332 ± 41 gram).
RhMOG-induced EAE
EAE was induced with a recombinant protein encompassing the extracellular 
domain of human MOG residues 1-125 (rhMOG), which was produced in Escherichia 
coli and purified as previously described29. The inoculum contained 100 µg rhMOG in 
300 µl phosphate buffered saline (PBS) and was emulsified in 300 µl CFA containing 
Proefschrift Yolanda Kap_compleet.indd   155 25-08-2010   21:25:03
Chapter 4.2
156
Table 1. Overview of monkeys included in the pharmacokinetic/pharmacodynamic (PK/Pd) 
study and the EAE study.
PK study
Nr Monkey Sexa Ageb Treatment Concentration 
(mg/kg)
day of 
sacrifice
1 M05051 F 34
Placebo
7
2 M06050 F 22 62
3 Mi013024 M 40 7
4 Mi013212 M 34 62
5 M06028 F 26
HuMab 7D8
10 (one dose) 7
6 M06067 F 22 62
7 Mi012698 M 49 7
8 Mi013067 M 26 62
9 M06047 F 23
HuMab 7D8 20 (one dose)
7
10 Mi012964 M 53 62
11 Mi013294 M 34 7
12 Mi013362 F 30 62
EAE
Monkey Sexa Ageb Treatment Concentration (mg/kg)
M02052 M 84
Placebo
M06061 M 31
M06081c M 28
M07021 M 24
M07029 M 24
M07048 M 21
M07080 M 20
M04096 M 56
HuMab 7D8 Single dose of 20 mg/kg followed by a weekly dose of 5 mg/kg
M05073 M 43
M06055 M 31
M07012 M 26
M07075 M 21
M07085 M 20
M07095 M 19
a F, Female; M, Male
b Age in months at the start of the experiment
c M06081 died on psd 33 without EAE
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mycobacterium butyricum (Difco Laboratories, Detroit, MI) by gentle stirring for at 
least 1 h at 4ºC. The emulsion was injected at four locations into the dorsal skin under 
alfaxalone anesthesia (10 mg/kg; alfaxan; Vetoquinol, Den Bosch, The Netherlands). 
Clinical signs were scored daily by two independent observers using a previously 
described semi-quantitative scale30. Briefly, 0 = no clinical signs; 0.5 = apathy, altered 
walking pattern without ataxia; 1 = lethargy, tail paralysis, tremor; 2 = ataxia, optic 
disease; 2.25 = monoparesis; 2.5 = paraparesis, sensory loss; 3 = para- or hemiplegia. 
Overt neurological deficit starts at score 2. For ethical reasons monkeys were sacrificed 
once complete paralysis of limbs (score ≥ 3.0) was observed, or at the pre-determined 
endpoint of the study, i.e. post sensitization day (psd) 106. Body weight measurements 
of conscious monkeys, which is used a surrogate disease marker, were performed 
three times per week.
Cd20 treatment 
HuMab 7D8 is a human IgG1κ mAb25 (Genmab, Utrecht, The Netherlands) directed 
against human CD20 and cross-reactive with marmoset CD20 (data not shown).
The PK/PD study comprised 12 marmosets. Four monkeys received a single i.v dose 
of 10 mg/kg HuMab 7D8 from a 2.86 mg/ml stock solution. Four marmosets received a 
single i.v dose of 20 mg/kg HuMab 7D8 from a 12.18 mg/ml stock solution. Four control 
animals received 1 ml/kg sterile PBS. 
The EAE study comprised 14 marmosets. Seven monkeys received a single i.v. 
dose of 20 mg/kg HuMab 7D8 21 days after immunization. To maintain plasma levels 
above 5-10 µg/ml of HuMab 7D8, 5 mg/kg was administered i.v. every week for the 
duration of the study. Seven control animals received 1 ml/kg sterile PBS.
Blood sampling, cell numbers, and plasma levels 
For the initial PK/PD study, 50 µl blood was collected in 450 µl citrated PBS at 5, 
15, 30, 60, 120, and 240 min. After 1, 3, 7, and 34 days 500 µl blood was collected in 
heparinized vacutainers (Greiner, Sölingen, Germany) under alfaxalone anesthesia (10 
mg/kg). After centrifugation, plasmas were collected and stored frozen at -20°C until 
analysis of test substance levels was performed. 
Every two weeks during the EAE study, 1.5 ml venous blood was collected into EDTA 
vacutainers (Greiner) under alfaxalone anesthesia (10 mg/kg). The alternating weeks, 50 
µl blood was collected in 450 µl PBS/EDTA without sedation. The number of red and white 
blood cells was measured on a Sysmex XT-2000iV (Sysmex, Norderstedt, Germany). 
Plasma levels of HuMab 7D8 were determined by ELISA, in which an idiotype specific 
mouse mAb (Genmab MS3001-009) was used for capture and a mouse anti-human 
IgG (Fc-specific) HRP conjugated mAb (MH16-1, CLB, Amsterdam, The Netherlands) 
for detection. The quantification limit was 1 µg/ml in plasma.
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Necropsy
Monkeys selected for necropsy were first deeply sedated by intramuscular injection 
of alfaxalone (10 mg/kg). Maximum volume of blood was collected into EDTA or 
heparanized vacutainers and subsequently the marmoset was euthanised by infusion 
of pento-barbital sodium (Euthesate®; Apharmo, Duiven, The Netherlands). 
Spleen and lymph nodes from several anatomical locations were collected aseptically 
and cut into four pieces, which were processed for cell culture, fixed in buffered formalin, 
snap-frozen in liquid nitrogen, or processed for RNA extraction with RNAlater (Sigma, 
St. Louis, MO). Half of the brain and spinal cord was stored in formalin and the other 
half was snap-frozen in liquid nitrogen. Femur was collected in PBS for isolation of 
bone-marrow cells.
Magnetic resonance imaging (MRI)
One cerebral hemisphere collected at necropsy was fixed in 4% buffered formalin 
and two weeks later transferred into buffered saline containing sodium azide to allow 
stabilization of MR relaxation time characteristics31. High-contrast post mortem MR 
images were recorded on a 9.4 T horizontal bore NMR spectrometer (Varian, Palo Alto, 
CA), equipped with a quadrature coil (RAPID, Biomedical, Rimpar, Germany). Brains 
were submerged in non-magnetic oil (Fomblin; perfluorinated polyether, Solvay Solexis, 
Weesp, The Netherlands) to prevent unwanted susceptibility artifacts.
On a sagittal scout image, 41 contiguous coronal slices of 0.75 mm were defined 
covering the complete brain, with the following characteristics: field of view, 25x25 mm; 
matrix, 256x256; zero-filled, 512x512; voxel volume, 7.15x10-3 mm3, two transitions. 
The following MRI data sets were collected:
- T2 maps were calculated by a mono-exponential fitting of six spin echo images with 
increasing TE. TR, 2650 ms; TE, 10+5x10 ms. The second image of this series, i.e. 
TE, 20 ms, was used for Region of Interest (ROI) determination. 
- MTR maps were calculated from two T1W spin echo images with and without a 
Magnetization Transfer saturation pulse. Magnetization transfer ratio (MTR) values 
represent the percentage decrease in MR signal intensity as a result of this pulse. 
TR, 1675 ms; TE, 23 ms; MT-pulse: 8.19 ms gaussian shaped pulse, nominal flip 
angle 1000, offset –9.4kHz.
Calculations of T2 and MTR were done with a homemade software package 
developed in MATLAB (v. 7.2 The Mathworks Inc., Natick, MA). ROI were defined 
using the free available Medical Image Processing, Analysis and Visualization package 
(MIPAV version 4.3.0., National Institutes of Health, Bethesda, MD). WM lesions were 
defined as areas with abnormal high signal intensities in the WM. The total volume of 
WM lesions was determined for the complete hemisphere.
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Anti-MOG Ab detection
Ab binding to rhMOG and MOG54-76 was determined using ELISA as described21. 
Bound IgM Ab was detected using alkaline phosphatase-conjugated goat-anti-monkey 
IgM (Rockland Immunochemicals, Gilbertsville, PA) and bound IgG Ab was detected 
using polyclonal alkaline phosphatase-conjugated rabbit-anti-human IgG (Abcam, 
Cambridge, UK). The results of the Ab assays are expressed relative to a standard 
curve of pooled necropsy plasma from three rhMOG/CFA-immunized control marmosets 
of this study. The Ab concentration in pooled plasma was arbitrarily defined as 350 
when OD = 1 and ELISA data of 10- and 100-fold diluted test samples were fitted 
to a four-parameter hyperbolic function, using home-made software ADAMSEL (dr. E. 
Remarque, BPRC, The Netherlands).
Procedures and assays for quantification of cellular immune response
• MNC isolation: Mononuclear cell (MNC) suspensions from PBMC, spleen, and 
bone marrow were isolated by density gradient centrifugation over lymphocyte 
separation medium (Axis-Shield PoC AS, Oslo, Norway). Cell suspensions from 
axillary (ALN), inguinal (ILN), lumbar (LLN), and cervical (CLN) lymph nodes were 
isolated by gently pressing the organ through a nylon mesh and washed with 
RPMI medium.
• Phenotyping with flow cytometry: To enable visualization of residual CD20 expressing 
cells in the circulation or lymphoid organs of monkeys treated with HuMab 7D8, 
MNC were subjected to an Ab stripping protocol aimed at removal of HuMab 7D8. 
Cells (2 x106) were incubated with 5 ml acidic buffer (50 mM glycin-HCl, 5 mM KCl, 
130 mM NaCl, pH 3) for 4 min at RT and subsequently washed and used for flow 
cytometry. The flow cytometry protocol used to phenotype MNC involved staining of 
dead cells using violet viability stain (Invitrogen, Molecular Probes, Carlsbad, CA) 
for 25 min at RT. Subsequently, cells were incubated with CD3-AF700 (SP34-2, BD 
Biosciences, San Diego, CA), CD20-PE (H299, Beckman coulter, Fullerton, CA), 
CD40-FITC (B-B20, Abcam, Cambridge, MA), CD4-APC (MT310, Zebra bioscience, 
Enschede, The Netherlands), and CD8-biotin (LT-8, Serotec, Düsseldorf, Germany) 
for 30 min at 4°C. CD8-positive cells were visualized by incubation with streptavidin-
PerCP (BD Biosciences) for 30 min at 4°C. Finally, cells were fixed in 1% cytofix 
(BD Biosciences). Flow cytometric analysis was performed on a FACS LSRII using 
FACSDiva software (BD Biosciences). 
• Proliferation: Proliferation of MNC was assayed as previously described32. Briefly, 
cells were cultured in triplicate at a cell density of 2 x105 per well in 96-wells U-bottom 
plates with rhMOG, MOG peptides, OVA, and ConA. All antigens were tested at 5 
µg/ml. After 48 h culture, 50 µl supernatant was harvested for cytokine ELISA and 
0.5 µCi/well of tritiated thymidine (3[H]Thy) was added to the cells. Incorporation of 
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radiolabel was determined after 18 h using a matrix 9600 β-counter (Packard 9600; 
Packard Instrument Company, Meriden, CT). 
• Phenotyping of proliferating cells: This was performed by CFSE vital dye dilution 
assay as described elsewhere21.
• Cytokine detection with ELISA: Due to limitation of sample volume and availability of 
cross-reactive ELISA reagents we chose to assay for three cytokines. The production 
of IL-17A, IFN-γ, and IL-12p40/p70 was measured in culture supernatants with 
commercial ELISA according to manufacturers instructions (U-Cytech, Utrecht, The 
Netherlands).
• Cytokine detection with quantitative PCR (qPCR): RNA was isolated using RNeasy 
minikit (Qiagen, Hilden, Germany) and cDNA was synthesized using RevertAid 
First Strand cDNA Synthesis Kit (Fermentas, St. Leon-Rot, Germany) according 
to the manufacturers instructions. Random hexamer primers were used for cDNA 
synthesis. Expression levels of mRNA were determined by quantitative PCR 
using iTaq supermix with ROX and CFX96 Real-Time System (both from Bio-Rad, 
Hercules, CA). Primer and probes used are listed in table 2. Probes were obtained 
from the Universal Probe Library set for human (Roche, Indianapolis, In). Transcript 
levels were normalized against the reference gene abelson (ABL)33.
Immunohistochemistry
Spleen and lymph nodes obtained at necropsy were snap-frozen in liquid nitrogen 
and stored in -80°C. Frozen spleen and lymph node sections of 6 µm were cut and thaw 
mounted on gelatin/chrome alum coated glass slides. Slides were kept overnight at RT 
Table 2. Primer and probe combinations for qPCR.
Gene Forward primer Reverse primer Probe
ABL CAGAGAAGGTCTATGAACTCATGC GGTGGATTTCAGCAAAGGAG GCAGTGGA
CD3 AGGCAAGAGTGTGTGAGAACTG GATGCAGATGTCCACTATGACAA GGAGGTGG
CD19 CAGCCCCGTCTTATAGAAACC CACTGTCCGGCTCCTCATAG AGAAGAGGA
IL-17A CCTCATTGGTGTCACTGCTG TGCAATTCCTGCCTTCACTA GCTGCTGA
IFN-γ GGAGAGAGGAGGGTGACAGA TTGGATGCTCTGGTTGTCTTTA CAGAGCCA
TNF-α GGACGAGCTCTCCAAGGACT GTCACTCGGGATTCGAGAAG GGCCCTGG
IL-7 TGCACCAGCAAGGTTAAAGA CCAAACTCTTTGTCGGTTGG TGCCCTGG
IL-4 CTAAAACGGCTGGACAGGAA CCTTCACAGGACAGGAGTTCA CAGCCTGG
IL-6 CCAATCTGGATTCAATGAGGA AACTCCAAAAGACCAGTGGTGA GCCTGCTG
IL-10 GTTGCCTTCAGCAGAGTGAA GCAACCCAGGTAACCCTTAAA TGCTGGAG
IL-1β TGGTCCTAAACAGATGAAGTGC GTAGTGCTGGCGGGAGAGT GACCTGGA
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in a humidified atmosphere. After air-drying the slides for 1 h, they were fixed in fresh 
acetone containing 0.02% (v/v) H2O2. Acetone fixed slides were air-dried for 10 min and 
subsequently washed in PBS. Tissue sections were incubated with primary Ab overnight 
at 4°C in a humidified atmosphere. Primary Ab were mouse-anti-human CD20 (clone 
L26, Dako, Glostrup, Denmark), mouse-anti-human CD40 (clone B-B20, Chemicon, 
Billerica, MA), and rabbit anti-human CD3 (Dako). Incubations with secondary and 
tertiary reagents were performed for 1 h at RT. Between incubation steps the slides 
were washed twice with PBS. Detection of primary unlabelled Ab was followed by 
incubation with donkey-anti-mouse or goat-anti-rabbit, both biotin labeled. This was 
followed by incubation with HRP-labelled avidin-biotin-complex (Vectastain ABC, Vector 
laboratories, Burlingame, CA). HRP activity was revealed by incubation for 10 min at RT 
with 3-amino-9-ethyl-carbozole (AEC; Sigma, Zwijndrecht, The Netherlands), leading 
to a bright red precipitate. CD40 expression was enhanced with the tyramide signal 
amplification kit (Invitrogen, Carlsbad, CA). Incubation with isotype-matched primary Ab 
of irrelevant specificity and omission of the primary Ab served as negative controls.
Statistics
Data are presented as mean ± sem of 6 control and 7 treated marmosets. Statistical 
analysis was performed using Prism 5.0b for Mac OS X. Survival was analysed using 
Log-Rank test. Other data was analysed using the Mann-Whitney U test. p < 0.05 was 
considered statistically significant.
 
RESulTS
Dose-finding and PK/PD of HuMab 7D8
The effective Ab dose for maximum B-cell depletion from blood and lymph nodes 
was determined in twelve marmosets. Groups of 4 monkeys each received a single i.v. 
injection with placebo (PBS) or HuMab 7D8 at a dose of 10 mg/kg or 20 mg/kg (Table 
1). At the indicated time points during the first (Figure 1A) and subsequent days (Figure 
1B), small venous blood volumes were withdrawn for plasma isolation in which HuMab 
7D8 levels were determined, respectively. As expected, all placebo-treated monkeys 
scored negative in the assay (data not shown). The average HuMab 7D8 levels in 
the 10 mg/kg and 20 mg/kg dose group measured in the 5 min blood sample were 56 
and 181 µg/ml, respectively. The plasma concentration was maintained at trough level 
above 10 µg/ml during the following seven days. 
Predictably, the CD20 molecule on B-cells in the treated group may be bound by 
HuMab 7D8 and therefore could not bind the anti-CD20 Ab conjugate used in flow 
cytometry. Because anti-CD19 mAb cross-reacted only poorly with marmosets, we have 
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Figure 1. A single dose of the human anti-human Cd20 antibody HuMab 7d8 induces profound 
and long-lasting B-cell depletion in naive marmosets. 
A-B, Circulating plasma levels of HuMab 7D8 were determined at 5, 15, 30, 60, 120, and 240 min 
(A) and 1, 3, 7, and 34 days (B) after administration of HuMab 7D8. Animals received a single dose 
of 10 mg/kg (closed symbols, Table 1) or 20 mg/kg (open symbols, Table 1). Plasma levels of the 
antibody (y-axis) are shown in log-scale. Plasma levels of the 20 mg/kg group were higher until day 34. 
C-D, Seven or 62 days after administration of HuMab 7D8, two animals of each group (Table 1) were 
sacrificed and CD20 expression was determined in lymphoid organs by flow cytometry. White bars, 
control; grey bars 10 mg/kg HuMab 7D8; black bars, 20 mg/kg HuMab 7D8. Cells underwent a stripping 
procedure to remove the in vivo administered HuMab 7D8 from cells. Shown are the animal numbers 
on the y-axis (corresponding to Table 1) and the percentage living CD20+ or CD40+ cells on the x-axis. 
At day 7, the percentage of CD20+ B-cells was lower in both treatment groups (C). At day 62, animal 8 
(Mi013067) and animal 12 (Mi013362) showed higher percentages of CD20+ and CD40+ B-cells than 
the other treated animals (D).
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also determined CD40-expressing cells as surrogate marker for B-cell depletion. CD20 
is a pan-B-cell marker expressed throughout the B-cell lineage with the exception of 
plasma cells. CD40 is expressed besides on activated antigen presenting cells (DC and 
macrophages) also on resting and activated mature B-cells, but not on plasma cells.
Seven days after the single administration of HuMab 7D8, two animals of each 
group were sacrificed (Table 1) and the extent of B-cell depletion from spleen and ALN 
was assessed by flow cytometry. The profound depletion of CD20+ cells by both doses 
of HuMab 7D8 is depicted in Figure 1C. The remaining six animals were sacrificed 62 
days after HuMab 7D8 administration (Table 1). Figure 1D shows that even two months 
after the administration of a single HuMab 7D8 dose reduced percentages of CD20+ 
and CD40+ cells were found in all lymphoid organs. However, the figure also shows that 
in one monkey of each group (nr 8/Mi013067 and nr 12/Mi013362) insufficient B-cell 
depletion or partial repletion of B-cells had occurred in the spleen and ALN at that time 
(Figure 1D). 
Anti-Cd20 mAb effectively depletes B-cells throughout the EAE experiment
Fourteen unrelated marmosets were immunized with rhMOG in CFA. Seven animals 
were randomly selected for treatment with HuMab 7D8 from psd 21 and seven animals 
for placebo treatment with PBS (Table 1). Based on the PK/PD data we chose to induce 
complete B-cell depletion with a single loading dose of 20 mg HuMab 7D8 per kg body 
weight followed by a weekly intravenous maintenance dose of 5 mg/kg. This dosing 
regimen aimed at a plasma trough level of 5-10 µg/ml, which was previously described 
to be sufficient for sustained biological activity in vivo34. 
Plasma levels of HuMab 7D8 were measured every week at seven days after 
intravenous administration of HuMab 7D8 or PBS. The plasma level of HuMab 7D8 
remained above 5 µg/ml, with the exception of one time point (day 42) in one monkey 
(M07075) (Figure 2A). Every two weeks, percentages of CD20- and CD40-expressing 
cells in PBMC were determined by flow cytometry to confirm B-cell depletion by HuMab 
7D8. Seven days after the first dose of HuMab 7D8, i.e. 28 days after immunization, 
CD20+ and CD40+ cells were almost completely depleted compared to the control group 
(Figure 2B, Supplemental Figure 1). Throughout the study, the percentage of CD20 
remained at very low level in the treatment group, except at psd 84. At this time point, 
six of the seven animals, M07095 being the only exception, contained elevated numbers 
of CD20+ cells in PBMC. However, as CD40 expression remained low at this time point 
we assume that these might be immature B-cells repleting the peripheral compartment 
(Figure 2B, Supplemental Figure 1).
At necropsy, the percentage of CD20+ and CD40+ cells present in PBMC, spleen, 
bone marrow, and lymph nodes were determined by flow cytometry. In the HuMab 7D8 
treatment group, CD20- and CD40-expressing cells were detected, but the levels were 
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still significantly lower than in the control group (Figure 2C, Supplemental Figure 2). 
Also, the expression of CD19, assessed in spleen and ALN by qPCR, was significantly 
lower in the treatment group (Figure 2D).
In conclusion, the chosen HuMab 7D8 dosing regimen induced profound and 
persistent B-cell depletion from blood and lymphoid organs.
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Figure 2. B-cells are depleted significantly from blood and lymphoid organs in the marmoset 
EAE model. 
A, Treatment with HuMab 7D8 was started 21 days after immunization with rhMOG in CFA. Plasma 
levels of circulating HuMab 7D8 were determined at the indicated time points during the study and are 
shown in log-scale (y-axis). B, CD20 and CD40 expression in PBMC was determined by flow cytometry 
throughout the study. Shown are the percentages of living CD20+ or CD40+ cells of total measured cells. 
The treatment period is indicated as grey-shaded box. Open symbols represent the control animals 
and closed symbols the treated animals. CD20 was not removed with the stripping procedure, because 
the number of available PBMC was too small. CD40 was used to confirm B-cell depletion. At post 
sensitization day (psd) 28, 42, 56, and 70 a significant lower percentage of B-cells was observed in 
treated animals compared to control animals. It is of note that the number of animals decreased during 
the study: the number of control animals was 6 until day 42; at psd 56, 70, 84, 98, CD20 and CD40 
expression were analysed in 5, 4, 2, and 1 control animals, respectively; the number of HuMab 7D8 
treated animals remained seven during the study. C, At necropsy, CD20 and CD40 expression was 
determined in PBMC and lymphoid organs by flow cytometry. White bars are control animals and black 
bars are treated animals. Cells underwent a stripping procedure to remove anti-CD20 Ab from cells. 
Shown are the percentages viable CD20+ cells and CD40+ cells that were gated from the total analysed 
cell number using the live/dead marker (mean ± sem). B-cells were depleted significantly from PBMC 
and lymphoid organs. D, CD19 mRNA expression was determined by quantitative PCR and normalized 
to expression levels of abelson (ABL) gene. Shown are mean ± sem. y-axis is in log-scale. CD19 
mRNA expression was significantly decreased in treated animals, confirming B-cell depletion. * p < 0.05 
compared to the control group using Mann-Whitney U test.
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B-cell depletion prevents the development of clinical signs
Six of the seven control animals developed clinically evident EAE characterized 
by overt neurological signs above EAE score 2 from psd 55 onward (Figure 3A). One 
control animal died unexpectedly at psd 33 without any detectable neurological signs 
(M06081). The most likely cause of death deduced from pathology examination was 
cardiac failure. Therefore, this monkey was excluded from further analysis. Four of the 
six control animals were sacrificed with at least one paralyzed limb (hemi- /paraplegia; 
score = 3). M02052 was sacrificed with clinical score 2.25, because of persistent optic 
neuritis, which started at psd 48, and excessive weight loss. M07048 was sacrificed 
at the predetermined end-point psd 106 after three short-lasting episodes of ataxia 
(Figure 3A).
In contrast, four of the seven animals treated with HuMab 7D8 failed to develop 
detectable neurological signs (Figure 3A). The remaining three treated animals 
developed neurological signs only for one day (M07075 and M07095) or two separate 
days (M04096). Paralysis was observed in none of the treated animals and all animals 
were sacrificed with clinical score 0 or 0.5 at the predetermined end-point psd 106 
(Figure 3A). The curves for disease-free survival (i.e. time to EAE score 2.0) and overall 
survival (time to end-point) show that the clinical differences between the two groups 
are highly significant (Figure 3B). In conclusion, late B-cell depletion abrogated the 
development of neurological signs.
B-cell depletion prevents (MRI-detectable) CNS pathology
MRI sequences of fixed hemispheres were recorded to confirm that B-cell depletion 
not only prevented the development of neurological signs, but also of brain lesions. 
Figure 4A and B show representative examples of T2-weighted (T2W) images and MTR 
images of two control and two HuMab 7D8 treated marmosets. Figure 4C shows that 
the lesion load is significantly lower in the HuMab 7D8 treated group than in the control 
group. No lesions could be observed in three of the seven treated monkeys and only 
very small lesions in four of the seven treated monkeys. A lower T2 and a higher MTR 
of lesions in the treatment group suggest that the tissue damage was less in the HuMab 
7D8 treated animals compared to the control animals (Figure 4C). 
In conclusion, these data show that B-cell depletion significantly reduced EAE-
associated brain pathology. 
B-cell depletion results in reduction of plasma autoantibodies 
The immunological hallmark and most widely accepted biomarker of B-cell 
contribution in the EAE model is the production of autoantibodies. To obtain evidence 
whether B-cell functionality is eliminated completely in HuMab 7D8 treated monkeys, 
we measured plasma levels of IgM and IgG against rhMOG and MOG54-76 every 
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two weeks and at the start of the treatment. Antibodies against MOG54-76 were 
measured, because this peptide comprises a dominant B-cell epitope of anti-MOG 
Ab generated in the rhMOG-induced EAE model21. IgM levels peaked in both groups 
at psd 28 and declined after that (data not shown). The levels of rhMOG- or MOG54-
76-specific IgG were clearly higher in the control group than in the HuMab 7D8 
treated group (Figure 5A). Until psd 28, i.e. 7 days after the start of the treatment, 
IgG levels were comparable between both groups. After psd 28, IgG levels did not 
increase further in the treatment group, whereas more than a 10-fold increase was 
detected in the control group (Figure 5A). The area under the curves was calculated 
for each individual animal and group means were calculated. Figure 5B shows that 
IgG autoantibodies against rhMOG and MOG54-76 were significantly lower in the 
treatment group compared to the control group. Also at necropsy, significant reduction 
of autoantibodies was observed (Figure 5C). 
Effect of B-cell depletion on cell numbers, T-cell phenotype, and proliferation  
To test the systemic effect of B-cell depletion on the cellular immune compartment in 
the marmoset EAE model, we first analysed the distribution of leukocyte and lymphocyte 
subsets. Figure 6A shows the variation of white blood cell, lymphocyte, neutrophil, and 
monocyte numbers in PBMC in both groups. Increased numbers of monocytes were 
observed in the treatment group (Figure 6A). At necropsy, we also observed increased 
absolute numbers of white blood cells, lymphocytes, neutrophils, and monocytes in the 
treatment group, although not significant (Figure 6B). It is of note, that the cell numbers 
at necropsy are determined at different/individual time points, i.e. the day each animal 
is sacrificed with full-blown EAE in the control group and the end of the study for treated 
animals.
Figure 3. late B-cell depletion prevents the development of neurological signs. 
A, the clinical scores of control (left column) and treated (right column) animals are depicted. Post 
sensitization day (psd) is indicated on the x-axis. Dotted lines indicate the percentage of body weight 
loss compared to the day of immunization (left y-axis). Solid lines indicate clinical score (right y-axis). 
The treatment period is indicated with a grey-shaded box. The day of sacrifice of individual monkeys 
is indicated in the figure with cyphers. Monkey M06081 succumbed without neurological deficit from 
cardiac failure. Of the six remaining control animals five developed sustained neurological signs (clinical 
score ≥ 2). Control animal M07048 developed neurological signs for three independent days, but post 
mortem MRI analysis confirmed the presence of substantial brain white matter demyelination (Figure 4). 
Four of the seven HuMab 7D8 treated animals developed no neurological signs and three of the seven 
developed neurological signs for only one or two days. B, shows the survival curves. The upper panel 
shows the disease free survival, meaning the time until the animals developed EAE score 2. The lower 
panel is the survival time until the day of sacrifice, which was the humane or pre-determined end-point. 
B-cell depletion significantly increased both types of survival (p < 0.05 Log Rank).
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During the study and at necropsy, the phenotype of lymphocytes was analysed by 
flow cytometry to assess the effect of B-cell depletion on the T-cell compartment. We 
observed no effect on the CD3 percentage or the CD4/CD8 ratio in PBMC throughout 
the observation period (Figure 6C). At necropsy, however, higher percentages of CD3+ 
cells were observed in PBMC, spleen, and lymph nodes (Figure 6D). Although we like to 
emphasize that this is a percentage and not an absolute number and may be caused by 
depletion of the B-cell population, CD3 mRNA levels were also significantly increased in 
the ALN (Figure 6E). The CD4/CD8 ratio was not changed in PBMC or lymphoid organs 
at necropsy (data not shown). 
Figure 4. Reduced cerebral white matter lesion load in B-cell depleted EAE marmosets. 
Formalin-fixed hemispheres were analysed with MRI for volume (mm3), T2 signal intensity (ms), and 
MTR (% reduction in signal intensity) of white matter lesions. T2W images were used to calculate 
the volume (mm3). Representative examples of T2W images (A) and MTR images (B) of two control 
and two HuMab 7D8 treated animals are shown. White lines encircle the lesions. C, B-cell depletion 
significantly reduced the volume of white matter lesions. Lower T2 and higher MTR within the lesions of 
the HuMab 7D8 treated animals suggest less damage within the lesions of treated animals. * p < 0.05 
compared to the control group using Mann-Whitney U test.
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Next, we analysed the effect of B-cell depletion on proliferation and cytokine 
production. At necropsy, we observed a higher level of proliferation in PBMC from the 
treatment group stimulated with rhMOG, MOG peptides 24-46 and 34-56, or ConA 
(Figure 7A). By contrast, the proliferative responses of MNC from monkeys in the 
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Figure 5. Reduced plasma levels of IgG after B-cell depletion. 
Plasma IgG levels against rhMOG and MOG54-76, being the dominant binding site of anti-MOG IgG 
Ab, were determined by ELISA. Recorded OD values were transformed into arbitrary units (A.U., y-axis, 
log-scale) using home-made software. A, The upper panel shows the control animals and the lower 
panel shows the HuMab 7D8 treated animals with the treatment period indicated as grey-shaded box. 
Post sensitization day is shown on the x-axis. Shown are the IgG levels of individual animals. B, Area 
under the curve was calculated for each individual animal and is depicted as mean ± sem. Plasma IgG 
levels against rhMOG and MOG54-76 were significantly reduced after B-cell depletion. Shown is mean 
± sem. C, Reduced IgG levels were also observed in treated animals at necropsy, which reflects peak of 
the disease in control animals. Results are depicted as mean ± sem. * p < 0.05 compared to the control 
group using Mann-Whitney U test.
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treatment group to these antigens were lower in spleen, ALN, and LLN. It is of note that 
also the background proliferation and the response to OVA and ConA were reduced 
in these organs (Figure 7A). No differences were observed in ILN or CLN (data not 
shown). 
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Figure 6. Hematological effects of B-cell depletion. 
A-B, The absolute number of white blood cells, lymphocytes, neutrophils, and monocytes was determined 
during the study (A) and at necropsy (B). The grey-shaded box indicates the treatment period. Shown 
are mean ± sem. The results of day 56 are the mean of five instead of six control animals. At psd 
42, a significantly higher number of monocytes was recorded in the treatment group compared to the 
control group. At necropsy, higher numbers of all analysed cell types were observed in the treatment 
group, although differences were not significant. The higher number of lymphocytes at necropsy may be 
compensatory for the loss of B-cells. C, During the study the percentages of CD3+ cells were analysed 
by flow cytometry. Shown is the change in CD3+ cell frequencies relative to the day of immunization. No 
difference in CD3+ cells or CD4/CD8 ratio was observed throughout the study. Shown are the mean ± 
sem until day 56, since after psd 56 we started to take control animals out of the study. The grey-shaded 
area indicates the treatment period. D, At necropsy, significant increase of CD3+ cell percentage was 
observed by flow cytometry in PBMC and secondary lymphoid organs, but not in bone marrow. E, At 
necropsy, CD3 mRNA expression in spleen (left y-axis) and ALN (right y-axis) was analysed by qPCR 
and normalized to the expression levels of abelson (ABL) gene. Shown is the mRNA expression of CD3 
relative to ABL (mean ± sem). CD3 mRNA was significantly increased in ALN, but not in spleen. * p < 
0.05 compared to the control group.
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The phenotype of the cells in spleen and ALN that proliferated against rhMOG was 
assessed with the CFSE dilution assay. We observed that depletion of CD20+ cells led 
to reduced proliferation of both CD4+ and CD8+ T-cells from ALN and, albeit to a lesser 
extent, from spleen (Figure 7B and data not shown). 
In conclusion, the late depletion of B-cells has profound effects on the T-cell 
compartment. The most obvious effect observed in blood at necropsy was increment 
of monocyte numbers. CD3+ T-cells were also increased in blood and all analysed 
secondary lymphoid organs. The activity assessment showed that proliferation was 
increased in blood but decreased in the secondary lymphoid organs. 
Reduced cytokine production after B-cell depletion
The rhMOG-induced protein levels of interleukin (IL)-12 (p40/p70), IL-17A, and 
IFN-γ were analysed in supernatant of rhMOG-stimulated MNC cultures. We observed 
IL-17A production by splenocytes in four of the six control animals, and by MNC from 
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Figure 7. Increased T-cell proliferation in blood versus reduced T-cell proliferation in lymphoid 
organs after B-cell depletion. 
A, Proliferation at necropsy was assessed using the incorporation of 3[H]-thymidin. Shown are the 
mean ± sem in counts per minute (y-axis). Proliferation in the spleen was assessed in six of the seven 
HuMab 7D8 treated animals, since the spleen of M05073 could not be analysed due to small cell 
numbers. Proliferation in the LLN was analysed in 4 animals of each group. Increased proliferation 
against rhMOG and MOG peptides was observed in PBMC of treated animals. In contrast, reduced 
general (no stimulation, OVA, ConA) and MOG-specific proliferation was observed in lymphoid organs 
of treated animals. B, Shows the percentage of dividing CD3+CD4+ or CD3+CD8+ cells in the ALN. 
Percentages of total measured events are shown in mean ± sem. Reduced proliferation against rhMOG 
and OVA was observed in both T-cell compartments. * p < 0.05 compared to the control group using 
Mann-Whitney U test.
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Figure 8. Cytokine profiles in B-cell depleted and control EAE marmosets. 
A, The production of cytokine protein was determined with ELISA in supernatants of cells stimulated 
for 48 h with rhMOG or OVA. Shown are the cytokine concentrations (pg/ml) produced in response to 
rhMOG from which the OVA-induced cytokine production was subtracted. Cytokine levels in unstimulated 
cells were below 25 pg/ml. IL-17A was detected in four of the six control animals, but only in one of the 
seven treated animals. B-C, Cytokine gene transcript levels in tissue was also determined by qPCR and 
normalized to expression levels of abelson (ABL) gene. In the case of two y-axes, the left y-axis refers 
to the spleen and the right y-axis to the ALN. B, Shows the mRNA expression levels of the cytokines 
relative to ABL (mean ± sem). No differences in mRNA levels of T-cell specific cytokines were observed, 
but IL-10 and IL-1β were increased in ALN of treated animals compared to controls. IL-7 mRNA levels 
were substantially reduced in spleen and ALN of treated animals compared to control animals. Since 
CD3 mRNA expression levels were significantly increased in the ALN of treated animals (Figure 6E), 
the levels of T-cell specific cytokines of Figure 8B were also expressed relative the CD3 mRNA levels of 
Figure 6E. This shows the cytokine mRNA levels per CD3 mRNA (mean ± sem). The normalized values 
show in the ALN, but not in the spleen, significantly lower levels of IL-17A, IFN-γ, TNF-α, and IL-6 (C). * 
p < 0.05 compared to the control group using Mann-Whitney U test.
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ALN and LLN from 2 of the 6 control animals in response to stimulation with rhMOG. 
By contrast, we observed rhMOG-stimulated IL-17A production only in splenocytes of 
one of the seven B-cell depleted animals (Figure 8A). No such obvious differences 
between control and treated animals were observed for the production of IFN-γ and 
IL-12 (Figure 8A).
Cytokine production in spleen and ALN was also analysed at the mRNA level. In 
treated animals, mRNA levels of IL-10 and IL-1β were increased in the ALN and IL-7 
mRNA was reduced in both spleen and ALN compared to the control animals. This 
indicates that B-cells are an important source of IL-7 in the rhMOG-induced EAE model. 
No differences between treated and non-treated animals were observed for IL-17A, 
IFN-γ, TNF-α, IL-6, and IL-4 (Figure 8B). 
The data in the previous paragraph demonstrated that CD3+ T-cell numbers are 
increased in the lymphoid organs of B-cell depleted monkeys, as was also reflected 
by increased CD3 mRNA levels in the ALN (Figure 6E). For this reason we chose to 
normalize the T-cell cytokine mRNA levels (IL-17A, IFN-γ, TNF-α, IL-6, and IL-4) against 
CD3 instead of ABL. Indeed, the corrected data show reduced IL-17A, IFN-γ, TNF-α, 
and IL-6 levels in the ALN of treated animals, suggesting less cytokine production per 
T-cell (Figure 8C).
In conclusion, the reduction of T-cell proliferation together with the reduced cytokine 
production in lymphoid organs indicates that the depletion of CD20+ B-cells impairs the 
activity and/or pathogenic function of cellular autoimmune mechanisms.
B-cell depletion alters the composition of T-cell and B-cell areas in spleen and 
lymph nodes
We have investigated in more detail the effect of B-cell depletion on the organization 
of spleen and ALN using haematoxylin/eosin (HE) staining and immunostaining of 
cryosections. The anti-CD20 Ab (clone L26) used for immunostaining recognizes an 
intracellular epitope of CD2035. Therefore, this Ab does not compete with the anti-CD20 
Ab administered in vivo.
The HE staining of the spleen shows a similar structural organization in control and 
HuMab 7D8 treated animals. The spleen of all animals, except M04096, is composed 
of similar areas of white pulp (WP) and red pulp (RP) (Figure 9). In the control animals 
the WP consisted of T-cell and B-cell areas. In the HuMab 7D8 treated animals the 
WP consisted only of T-cells, even in the areas where B-cells were expected (Figure 
9). M07095 showed a small area of CD20+ and CD40+ cells (data not shown), but 
in none of the other HuMab 7D8 treated animals CD20 or CD40 expressing B-cells 
were observed in the WP. A few CD40+ cells were detected in the WP of HuMab 7D8 
treated animals, but the morphology suggests that these were follicular dendritic cells 
or macrophages (Figure 9 insert). 
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The structure of the medulla and the cortex in the ALN was also similar in both groups 
as assessed by the HE staining (Figure 9). CD3 staining shows the normal structural 
organization in control animals. However, in the HuMab 7D8 treated animals the number 
Figure 9. Histological analysis of T-cell and B-cell areas in the spleen and AlN of B-cell depleted 
and control monkeys. 
Shown are representative examples of HE (original magnification x40), CD20 (original magnification 
x100), CD40 (original magnification x100), and CD3 (original magnification x100) staining on spleen (two 
left columns) and ALN (two right columns). The HE staining shows that the overall histology of the spleen 
and ALN was not changed by B-cell depletion. Spleen: The CD20 staining of the control animal shows 
a clearly demarcated B-cell area in the white pulp, which is also CD40+. CD40+ cells are also present 
in the red pulp. The CD3 staining of the white pulp shows the CD3+ T-cell area. In the B-cell depleted 
spleen no CD20+ cells are present. A few CD40+ cells are present, but these morphologically resemble 
follicular dendritic cells or macrophages (insert). The white pulp of the B-cell depleted animal seems to 
consist completely of T-cells. ALN: The ALN of the control animal contains a clearly demarcated CD20+ 
area, which stains also CD40+. CD40+ cells are also observed in the medulla. CD3+ cells are confined to 
the T-cell areas of the cortex. In the ALN of B-cell depleted animals, the B-cell area is hypocellular with a 
few CD20+ and CD40+ cells, but the latter do not have the morphology of B-cells. The number of T-cells 
seems to be increased in the cortex of the ALN of B-cell depleted animals. See page 316 for a full-color 
representation of this figure.
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of CD3+ cells appeared to be increased in the cortex (Figure 9), which is in line with 
the increased CD3 mRNA expression (Figure 6E). A few CD20+ cells were observed 
in M07075 and M07095, but in the other five HuMab 7D8 treated animals no CD20 
staining was found. CD40 was detected in B-cell areas of the ALN of both control and 
HuMab 7D8 treated animals. However, in the HuMab 7D8 treated animals we observed 
that the B-cell areas were hypocellular compared to control animals. Furthermore, flow 
cytometry showed a reduced number of B-cells and also the morphology of the CD40+ 
cells suggested that these cells were not B-cells. 
These data demonstrate that the general structure of secondary lymphoid organs 
is not changed by B-cell depletion. In the spleen, the B-cell areas appeared to be filled 
with T-cells. In the ALN, T-cell numbers seemed to be increased in the T-cell areas and 
the B-cell areas were hypocellular and only contained CD40+ non-B-cells.
 
dISCuSSION
Clinical trials with a chimeric CD20 mAb have shown that depletion of B-cells has 
beneficial effects in RRMS, while autoantibody levels were unaffected2,3. This observation 
has raised questions on the exact immunopathogenic role of B-cells in MS. We have 
investigated in a non-human primate model of MS, i.e. EAE in the common marmoset, 
which immunopathogenic mechanisms are altered by B-cell depletion. As the chimeric 
anti-CD20 mAb (rituximab) does not cross-react with marmoset CD20 we used the 
fully human CD20 mAb HuMab 7D825,26. In the first part of the current study, we have 
analysed the extent and duration of B-cell depletion after a single i.v. dose of HuMab 
7D8 at 10 or 20 mg/kg. The results demonstrate the high potency of HuMab 7D8 in the 
marmoset as it induced profound and long-lasting depletion of B-cells from peripheral 
blood as well as lymphoid organs. In the second part of the study we have chosen a 
dosing regimen with a high loading dose of 20 mg/kg HuMab 7D8 for obtaining a robust 
B-cell depletion and thereby lowering the risk of inducing neutralizing Ab, followed by 
a 4-fold lower weekly maintenance dose at 5 mg/kg for maintaining maximum efficacy. 
The data show that the applied dosing schedule completely abrogated the typical MS-
like clinical and pathological signs of this EAE model. This demonstrates the high in vivo 
efficacy of the Ab in this model and emphasizes the important role of B-cells in MS. 
We observed substantially lower levels of rhMOG-specific IgG in marmosets treated 
with HuMab 7D8 compared to control animals, although the early stage production 
of IgM autoantibodies was unaffected. It is important to note that at the time that the 
HuMab 7D8 treatment was started, i.e. 21 days after immunization, the production of 
anti-MOG IgG production had already been initiated but had not reached peak levels. 
Peak levels of IgG autoantibody in the control group were reached about three weeks 
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later. The reported data suggest that the HuMab 7D8 treatment did not completely 
suppress anti-MOG IgG production but rather arrested the further increased production 
of anti-MOG IgG. The effect of B-cell depletion on autoantibody production in MS is 
unknown. Interestingly, in systemic lupus erythematosus (SLE) patients treatment with 
rituximab led to suppression of IgG autoantibody production, whereas no effect was 
observed on total IgG serum levels36.
The question is warranted whether the dramatic effect of HuMab 7D8 treatment on 
clinical scores and lesion formation in the marmoset EAE model can be completely 
attributed to the observed reduction of autoantibody levels. Previous research has 
shown that the EAE development in marmosets immunized with rhMOG in CFA involves 
the activation of cellular and humoral autoimmune mechanisms32. However, we would 
like to emphasize that autoantibodies do not have an essential influence on the EAE 
course, as lesions and neurological signs develop also in the absence of anti-MOG 
antibodies20-22. This is compatible with the finding that axonal injury in lesions is more 
linked to the presence of inflammation than of demyelination37. We like to postulate here 
that although the capacity of anti-MOG antibodies to amplify demyelination and mild 
clinical signs in the marmoset EAE model has been clearly demonstrated14,38, they are 
not an indispensable factor in the immunopathogenic process. 
The current study shows that depletion of CD20+ B-cells induced a few changes 
in peripheral blood, i.e. increased number of monocytes and increased proliferation 
of MNC against rhMOG and MOG peptides. A more profound effect was found in the 
lymphoid organs. The histological analysis of spleen and lymph nodes demonstrated 
that B-cell depletion dramatically altered the relative proportions of B-cells and T-cells. 
Where the complete depletion was expected, we had not anticipated the increase of 
T-cells. It can be assumed safely that the altered T/B ratio changes the environmental 
conditions under which the activation of the MOG34-56-reactive T-cells, which 
mediate the expression of neurological deficit, occurs21,22. The immune profiling 
of spleen and lymph nodes indeed confirmed that although these organs contain 
higher percentages of CD3+ T-cells, proliferation of MOG (peptide)-reactive T-cells 
is impaired and cytokine production is skewed towards a more anti-inflammatory 
profile characterized by reduced IL-17A and IFN-γ and increased IL-10. The strong 
reduction of IL-7 production in the B-cell depleted monkeys may be of particular 
interest as this is a crucial cytokine for the survival of IL- 17A producing T-cells, which 
are thought to have a central pathogenic role in MS and EAE models39, including the 
EAE model in marmosets22. Impairment of T-cell activation has been put forward as 
a possible explanation for the clinical effect of B-cell depletion in RRMS2,3. Reduced 
T-cell activity after B-cell depletion has been observed in various experimental 
systems including naive mice, NOD mice, two mouse models for arthritis, and mice 
infected with Listeria monocytogenes40,41. Taken together, these data suggests that 
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the beneficial effect of systemic B-cell depletion may be mediated by mitigated T-cell 
activation in lymphoid organs.
In view of recent data on the pathogenic function of intra-CNS localized EBV-infected 
B-cells in MS42, although not confirmed by others43,44, it is tempting to speculate whether 
the clinical effect of the anti-CD20 Ab can be explained by the depletion of B-cells from 
the CNS. Several lines of evidence indicate that MOG34-56-specific T-cells, which have 
a key role in the clinical expression of EAE in marmosets, can be activated ex vivo 
by EBV-transformed B-cells21,22(Haanstra et al., manuscript in prep). Indeed, we have 
observed that the CD20+ cells that are clearly present in the CNS of EAE-affected control 
marmosets cannot be detected in the anti-CD20 Ab-treated monkeys (not shown). We 
cannot exclude, however, that this is due to masking of CD20 by the therapeutic Ab. 
CD40 expression cannot be used as control, as this marker is strongly upregulated in 
the EAE-affected CNS and Ab for human CD19 do not cross-react with the marmoset 
counterpart45.  
In conclusion, we have shown that B-cell depletion in the marmoset EAE model 
mitigated the activation of autoreactive T-cells. We like to postulate that this reduction 
in T-cell activation contributes to the remarkable clinical effect of B-cell depletion and 
we hypothesize that a similar T-cell change occurs in MS. It is difficult to prove this 
directly in MS patients since the T-cell activity in lymphoid organs cannot be examined. 
Current clinical trials support the idea that B-cell depletion is a major step in therapy 
development for RRMS patients. Future studies are warranted to elucidate further the 
antigen presenting function of B-cells, especially in the CNS, and to further investigate 
the organization of lymphoid organs after B-cell depletion.
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SuPPlEMENTAl FIGuRES
Supplemental figure 1. B-cells are depleted from PBMC after treatment with HuMab 7D8. 
CD20 and CD40 expression in PBMC was determined by flow cytometry every two weeks. Shown are 
the percentages of living CD20+ (open symbols) and CD40+ (closed symbols) cells of total measured 
cells. The left column are control animals, the right column are animals treated with HuMab 7D8, which 
was started 21 days after immunization. The treatment period is indicated as grey-shaded box. CD20 
was not removed with the stripping procedure, because the number of available PBMC was too small. 
CD40 was used to confirm B-cell depletion.
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Supplemental figure 2. B-cells are depleted from PBMC and lymphoid organs after treatment 
with HuMab 7d8. 
CD20 and CD40 expression in PBMC and lymphoid organs was determined by flow cytometry at necropsy. 
Shown are the percentages of living CD20+ and CD40+ cells of total measured cells. HuMab 7D8 was 
removed by a stripping procedure before flow cytometry staining. The upper row are control animals, the 
lower row are animals treated with HuMab 7D8, which was started 21 days after immunization. Note that 
the scale of the y-axis differs between the control and HuMab 7D8-treated animals. ALN, axillary lymph 
node (LN); ILN, inguinal LN; CLN, cervical LN; LLN, lumbar LN; BM, bone marrow.
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ABSTRACT
This study aimed at investigating the effect of CD20+ B-cell depletion on central 
nervous system grey and white matter demyelination in a relevant preclinical model of 
multiple sclerosis, i.e. experimental autoimmune encephalomyelitis (EAE) in common 
marmosets. EAE was induced in thirteen marmosets by immunization with myelin 
oligodendrocyte glycoprotein formulated in CFA. At 21 days post-immunization, B-cell 
depletion was induced by weekly treatment with HuMab 7D8, a human-anti-human 
CD20 antibody cross-reacting with marmoset CD20. In vivo MRI showed widespread 
brain white matter demyelination in control animals, which was absent in HuMab 7D8 
treated animals. High-contrast post mortem MRI showed white matter lesions in four 
of seven HuMab 7D8 treated animals, but these were significantly smaller than in 
controls. The same technique revealed grey matter lesions in five of six control animals, 
while these were absent in HuMab 7D8 treated animals. Histology confirmed that 
inflammation and demyelination were substantially reduced in brain, spinal cord, and 
optic nerve of HuMab 7D8 treated monkeys. In conclusion, CD20+ B-cell depletion by 
HuMab 7D8 profoundly reduced the development of grey and white matter pathology in 
the marmoset CNS. These data underline the central pathogenic role of B-cells in the 
induction of CNS pathology in the model.
 
INTROduCTION
Multiple sclerosis (MS) is a chronic autoimmune neurological disease characterized 
by inflammation and demyelination in the white matter (WM) and grey matter (GM) 
of the central nervous system (CNS)1,2. It is widely accepted that CNS pathology is 
caused by an autoimmune attack mediated by CD4+ and CD8+ T-cells, macrophages, 
and autoantibodies3. Recent studies have highlighted a prominent pathogenic role of 
B-cells in MS, which could not be explained by removal of the source of autoantibody 
production, suggesting other pathogenic mechanisms mediated by B-cells4,5. Depletion 
of B-cells with the chimeric CD20 monoclonal antibody rituximab reduced the relapse 
rate in patients with relapsing-remitting MS (RRMS)4-6. The remarkable clinical effect of 
B-cell depletion in RRMS was supported by the demonstration with magnetic resonance 
imaging (MRI) that the total number and volume of T2 lesions and the number of new 
gadolinium-enhancing brain WM lesions were reduced4,5.
The current study was undertaken to obtain proof-of-principle that B-cells are 
a valid target for antibody-mediated therapy aiming at the prevention of injury in the 
CNS WM as well as GM. We have investigated this in a valid preclinical MS model, 
i.e. experimental autoimmune encephalomyelitis (EAE) in common marmosets7,8. 
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This model is characterized by MS-like pathology affecting both WM and GM9,10. The 
experiment comprised two groups of monkeys in which progressive EAE was induced 
by a single immunization with rhMOG in CFA. In one group depletion of CD20+ B-cells 
was induced at 21 days post-immunization using a human-anti-human CD20 antibody 
(HuMab 7D8)11,12. This induced profound and long-lasting depletion of CD20+ B-cells 
from the circulation and lymphoid organs of marmosets (Kap et al., J Immunol, in press). 
The second group received placebo-treatment with an equivalent volume of phosphate 
buffered saline (PBS). Treatment was started late to model intervention in an ongoing 
immunopathogenic process, while achieving complete B-cell depletion before disease 
onset in early EAE responders13.
The immunological changes caused by CD20+ B-cell depletion are reported 
separately (Kap et al., J Immunol, in press). Here, we report the dramatic effect on CNS 
pathology, i.e. that antibody-mediated depletion of CD20+ B-cells profoundly reduced 
lesion development in the WM as well as the GM of the brain as assessed with MRI and 
histology. Also in the spinal cord and in the optic nerve of HuMab 7D8 treated monkeys 
we observed a significantly reduced intensity of inflammation and demyelination. These 
data support the central pathogenic role of B-cells in a valid preclinical model of MS 
and contribute to a better understanding of the therapeutic action of B-cell depleting 
monoclonal antibodies.
 
MATERIAlS ANd METHOdS
Animals
Fourteen healthy adult common marmoset monkeys used in this study were 
randomly selected from the outbred colony kept at the Biomedical Primate Research 
Centre (Rijswijk, The Netherlands) (for individual data see Table 1). Only animals that 
were declared healthy after the veterinarian’s physical, hematological, and biochemical 
check-up were included. The average body weights of the monkeys did not differ 
between the control and treatment group and was 367±30 gram and 332±41 gram, 
respectively. The monkeys were pair-housed under conventional conditions in spacious 
cages and were under intensive veterinary care throughout the study. The daily diet 
consisted of commercial food pellets for New World monkeys (Special Diet Services, 
Witham, Essex, UK), supplemented with raisins, marshmallows, biscuits, and fresh 
fruit. Drinking water was provided ad libitum. According to the Dutch law on animal 
experimentation, all study protocols and experimental procedures have been reviewed 
and approved by the Institute’s Ethics Committee. 
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RhMOG-induced EAE
EAE was induced with a recombinant protein encompassing the extracellular domain 
of human MOG produced in Escherichia coli (residues 1-125; rhMOG) and purified as 
previously described14. The inoculum contained 100 µg rhMOG in 300 µl PBS emulsified 
with 300 µl complete Freund’s adjuvant (CFA, containing Mycobacterium butyricum; 
Difco Laboratories, Detroit, MI). The emulsion was injected at four locations into the 
dorsal skin under alfaxalone anesthesia (10 mg/kg; alfaxan; Vetoquinol, Den Bosch, 
The Netherlands). 
Clinical signs were scored daily by two independent observers using a previously 
described semi-quantitative scale15. Briefly, 0 = no clinical signs; 0.5 = apathy, altered 
walking pattern without ataxia; 1 = lethargy, tail paralysis, tremor; 2 = ataxia, optic 
Table 1. Overview of monkeys and their clinical score.
Body Post sensitization day
Monkey Pair Sexa Ageb weightc Score 2 Score 3 End
Control
M02052 1 M 84 307 46 - 59
M06061 2 M 31 306 41 54 55
M06081d M 28 283 - - 33
M07021 3 M 24 339 66 83 83
M07029 4 M 24 377 78 91 91
M07048 5 M 21 316 71e, 84e, 88e - 105
M07080 6 M 20 322 66 73 73
CD20 Ab
M04096 1 M 56 308 41e, 43e - 104
M05073 2 M 43 430 - - 106
M06055d 2 M 31 333 - - 106
M07012 3 M 26 330 - - 105
M07075 4 M 21 374 103e - 106
M07085 5 M 20 273 - - 104
M07095 6 M 19 347 46e - 105
a F, Female; M, Male
b Age in months at the start of the experiment
c Body weight (gram) at start experiment
d M06081 died on psd 33 without EAE. M06055 was added to pair 2 for MRI analysis
e Score 2 for 1 day
Survival time to score 2: p=0.0291; survival time to sacrifice with clinical signs: p=0.0021
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disease; 2.25 = monoparesis; 2.5 = paraparesis, sensory loss; 3 = para- or hemiplegia. 
For ethical reasons monkeys were sacrificed once complete paralysis of hind-limbs 
(score ≥ 3.0) was observed, or at the pre-determined endpoint of the study, which was 
arbitrarily set at post sensitization day (psd) 106. 
Cd20 treatment
HuMab 7D8 is a human IgG1κ monoclonal antibody (mAb) directed against human 
CD2011,12 that cross-reacts with marmoset CD20 (data not shown). Seven marmosets 
received a single i.v. dose of 20 mg/kg HuMab 7D8 at psd 21 to induce robust B-cell 
depletion from blood and lymph nodes. To maintain plasma trough levels of HuMab 
7D8 above 5-10 μg/ml16, 5 mg/kg was administered i.v. every week. The seven control 
animals received 1 ml/kg sterile PBS (Table 1).
In vivo MRI
T2 images are highly sensitive to the increased water content in lesions caused by 
vasogenic edema. The MTR value of a tissue is calculated from the ration of free and 
lattice-bound protons, Hence, reduction of MTR value of a tissue occurs when the tissue 
water content increases (inflammation) and when the density of tissue macromolecules 
decreases, such as by demyelination. T1-weighted (T1W) images were recorded to 
visualize active lesions with a more permeable blood-brain barrier. Increase of the T1W 
signal intensity by intravenously administered Gadolinium containing contrast agent 
(Gadovist), occurs when the paramagnetic probe leaks through the blood-brain barrier, 
which is more permeable by local production of inflammatory mediators.
Experiments were performed using a 4.7 T horizontal bore NMR spectrometer 
(Varian, Palo Alto, CA). After sedation with alfaxalone anesthesia (10 mg/kg; alfaxan; 
Vetoquinol, Den Bosch, The Netherlands) the animals were prepared for mechanical 
ventilation by an endotracheal intubation. A tail vein was cannulated for administration 
of a bolus of Gadovist (gadobutrol, Gd-BT-DO3A, Bayer Schering Pharma AG, 
Leverkusen, Germany).  
Animals were immobilized in a specially designed stereotactic holder and placed 
in an animal cradle, which was inserted into the NMR spectrometer. During MR-
experiments the animals were ventilated with isoflurane (1-2%) in N2O/O2 (70/30). 
Expiratory CO2 was monitored, and the body temperature was maintained at 37°C with 
a heated water pad. An infrared sensor (Nonin Medical Inc, Plymouth, Minnesota, USA) 
was attached to the animal hind paw for monitoring of heart rate and blood oxygen 
saturation. A homebuilt Helmholtz volume coil (∅ 85 mm) and a self-made inductively 
coupled surface coil (∅ 35 mm) were used for radio frequency (RF) transmission and 
signal reception, respectively. 
On a sagittal scout image, 35 contiguous coronal slices of 1 mm were defined 
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covering the complete brain with the following characteristics: field of view, 40x40 mm; 
matrix, 128 x 128; zero-filled, 256 x 256; voxel volume, 97x10-3 mm3, two transitions. 
From these slices the following MRI data sets were collected (total duration of the 
experiments ~1.5 hrs):
- T2 maps [ms]. Maps were obtained by a mono-exponential fit of five multi-echo 
images. TR, 2850 ms; TE, 15 + 4x15 ms. The second image in this series, i.e. TE, 
30 ms, was used for Regions of Interest (ROI) determination. 
- Magnetization Transfer Ratio (MTR) maps [% decrease in signal intensity]. Maps 
were calculated from two T1W gradient echo images with and without a MT-
saturation pulse, with MTR=100*((Munsaturated-Msaturated)/Munsaturated). TR, 
680 ms; TE, 3.17 ms; MT-pulse: 12 ms gaussian shaped pulse, nominal flip angle 
500°, offset – 4.7 kHz. Pixel-intensities display the percentage decrease in the MR 
signal intensity due to saturation pulse.
- Gadovist leakage images [% increase of signal intensity] were calculated from two 
T1W gradient echo images (TR=200 ms, TE=2.75 ms, alpha=45°) before and after 
a bolus of 0.5 mmol/kg Gadovist (i.v. 10 min in circulation) with Gadovist leakage 
= 100*((T1Wpost Gadovist- T1Wpre-Gadovist)/T1Wpre-Gadovist). Pixel-intensities 
display the percentage increase in the MR signal intensity due to Gadovist 
leakage.
Post mortem MRI
One cerebral hemisphere collected at necropsy was fixed in 4% buffered formalin and 
transferred into buffered saline containing sodium azide after two weeks to stabilize MR 
relaxation time characteristics17. High contrast post mortem MR images were recorded 
on a 9.4 T horizontal bore NMR spectrometer (Varian), equipped with a quadrature 
coil (RAPID, Biomedical, Rimpar, Germany). Formalin-fixed brains were submerged 
in a non-magnetic oil (Fomblin; perfluorinated polyether, Solvay Solexis, Weesp, The 
Netherlands) to prevent unwanted susceptibility artifacts.
T2 and MTR images were collected. An inversion recovery experiment was performed 
in which the signal from the GM was suppressed facilitating the detection of GM lesions. 
Image resolution was more than ten times higher than the resolution obtained with in 
vivo MRI. Next to the areas described above, GM Lesions, and normal appearing GM 
(NAGM) areas were also outlined.
On a sagittal scout image, 41 contiguous coronal slices of 0.75 mm were defined 
covering the complete brain, with the following characteristics: field of view, 25x25 mm; 
matrix, 256x256; zero-filled, 512x512; voxel volume, 7.15x10-3 mm3, two transitions. 
The following MRI data sets were collected:
- T2 maps. These maps were calculated by a mono-exponential fitting of six spin echo 
images with increasing TE. TR, 2650 ms; TE, 10+5x10 ms. The second image of 
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this series, i.e. TE, 20 ms, was used for ROI determination. 
- MTR maps. Maps were calculated from two T1W spin echo images with and without 
a MT-saturation pulse. TR, 1675 ms; TE, 23 ms; MT-pulse, 8.19 ms gaussian shaped 
pulse, nominal flip angle 1000, offset –9.4 kHz.
- Inversion recovery experiment in which the signal of the GM was suppressed. Fast 
spin echo sequence, TR, 4050 ms; echo train length, 9; echo spacing, 8.93 ms; 
effective TE, 17.86 ms; Inversion Time, 425 ms for GM suppression. 
data evaluation MRI  
Calculations of T2, MTR, and Gadovist leakage were done with a homemade software 
package developed in MATLAB (v. 7.2 The Mathworks Inc., Natick, USA). ROI were 
defined using the free available Medical Image Processing, Analysis and Visualization 
(MIPAV version 4.3.0., National Institutes of Health, Bethesda, USA) package. 
The following ROI were defined on T2W images for both in vivo (TE, 30 ms) and 
post mortem (TE, 20 ms) images:
- WM lesions: defined as areas with abnormal high signal intensities in the WM. WM 
lesions were outlined in the total brain. 
- WM: the WM area was outlined in a predefined slice, i.e. the first caudal to rostral 
slice which showed a complete corpus callosum connection.
- GM: GM areas were outlined in the predefined slice as described for WM.
- Normal Appearing WM (NAWM): the NAWM area was calculated for the predefined 
slice with NAWM = WM – WM Lesions. 
For the post mortem images the following areas were also included:
- GM lesions were defined as areas with abnormal signal intensities on a combined 
T2W image and the inversion recovery experiment with suppression of the MR 
signal arising from GM. The latter experiment facilitates the detection of grey matter 
lesions. The total hemisphere was examined.
- Normal Appearing GM (NAGM). The NAGM area was calculated on the same 
predefined slice describe above with NAGM = GM – GM Lesions.  
Histology and Immunohistochemistry 
Frozen and fixed tissues were processed for histological and immunohistochemical 
techniques as previously described18,19. 
Statistics
Data are presented as mean ± s.e.m. of 6 control and 7 treated marmosets. Statistical 
analysis was performed using Prism 5.0b for Mac OS X. Survival was analysed using 
Log-Rank test. Differences between control and treated marmosets were analysed 
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using the Mann-Whitney U test. Differences between WM lesions and WM or NAWM 
within the control group were analysed by the paired Student’s t test. p < 0.05 was 
considered statistically significant.
 
RESulTS
Clinical course and in vivo brain MRI recording
One monkey from the control (PBS-treated) group succumbed unexpectedly at psd 
33 of cardiac failure and was therefore excluded from further analyses. The analysis of 
clinical EAE development in the remaining 6 control monkeys and 7 antibody-treated 
monkeys shows that depletion of CD20+ B-cells significantly prevented the development 
of clinical signs (Table 1, survival time to score 2: p=0.0291; survival time to sacrifice 
with clinical signs: p=0.0021). 
Before the start of the experiment, the animals were paired two-by-two based on 
age and body weight. Of each pair one monkey received control substance and one 
monkey the therapeutic antibody (for pairing see Table 1). The first MRI was planned 
before the start of the treatment, i.e. at psd 18. When at least one monkey of a pair 
had experienced evident neurological signs (clinical score ≥ 2) a second MRI was 
made of both paired monkeys to assess whether the two monkeys had a different 
brain lesion load.
At psd 18, none of the animals showed MRI detectable brain lesions, although 
the presence of small non-focal pathological alterations invisible with the applied MRI 
techniques could not be excluded (Figure 1A). In four pairs evident neurological signs 
(score 2 or higher) were first observed in the control monkey, whereas at that time the 
four paired HuMab 7D8 treated monkeys had no neurological signs (pair 2, 3, 4, 5). 
The MRI of the other two pairs were made because the treated animal (pair 6) or both 
animals (pair 1) displayed clinical score 2. In four of the six control animals, WM lesions 
were detected at the second MRI (Table 2, Figure 1A). Two control animals, i.e. M07021 
and the asymptomatic monkey M07080, had no detectable brain WM lesions. In none 
of the HuMab 7D8 treated animals brain lesions were detected with MRI, although two 
animals (M04096 and M07095) had experienced a short episode of clinical score 2 (one 
day) only a few days before the MRI was made (Table 2).
In vivo MRI analysis
Several clinically relevant MRI parameters were quantitated in WM, NAWM, GM, 
and WM lesion in the second MRI. The normal MRI characteristics of WM lesions in 
this model were found only in control animals, i.e. increased T2, decreased MTR, and 
increased Gadovist leakage compared to WM or NAWM (Table 3, Supplementary table 1). 
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Figure 1. Overview of MR images of one control EAE marmoset. 
The figure shows a typical example of a control animal (M06061) that developed severe EAE (Table 1). 
A, during the first MRI experiment, i.e. psd 18, no abnormalities were detected on the in vivo images 
(upper row). The second MRI (second row; see for psd Table 2) showed typical MRI abnormalities 
associated with the presence of white matter lesions, i.e. increase T2, decreased MTR and increased 
DOTA leakage values. The white arrow points to a typical white matter lesion. B, this lesion (white 
arrowhead) can be even better appreciated on the post mortem images that are obtained with a more 
then ten times higher resolution. Grey matter lesions (black arrow) are also visible on the post mortem 
image, specifically on the image on which the signal arising from the grey matter is suppressed. T2W, 
T2-weighted; MTR, Magnetization Transfer Ratio.
ROI were defined as follows: WM or GM area was outlined in a predefined slice, i.e. the first caudal to 
rostral slice which showed a complete corpus callosum connection; WM or GM lesions were defined as 
areas with abnormal signal intensities in the WM or GM. WM or GM lesions were outlined in the total 
brain; NAWM or NAGM area was calculated for the predefined slice with NAWM = WM-WM Lesions and 
NAGM = GM - GM lesion.
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In controls, MTR is significantly lower in WM lesions compared to NAWM. Differences 
between NAWM of control and treated animals were not observed. The increment of T1 
signal intensity by intravenous Gadovist was substantially lower in the WM of HuMab 
7D8 treated animals than WM and NAWM of control animals, suggesting that in the 
control animals there is a higher overall increment of BBB permeability throughout the 
complete WM. This observation suggests that the WM of control animals is certainly not 
normal. Differences between both groups were not observed for the GM with respect to 
volume, T2, MTR, and Gadovist leakage. 
Whereas the total volume of WM lesions was high in the control group, the fact 
that no lesions could be detected in the HuMab 7D8 treated monkeys precluded more 
detailed analysis (Table 3, Supplementary table 1). 
In conclusion, these data demonstrate that late stage depletion of CD20+ B-cells 
prevents the development of WM lesions that can be detected by in vivo MRI.
Post mortem MRI of the brain
Animals were sacrificed at the peak of the disease or after a pre-determined time 
interval of 106 days in cases where the disease was less severe or absent (Table 1). 
To maximize the detection of EAE-associated pathology, we examined formalin-fixed 
hemispheres with high resolution MRI at 9.4 T field strength. On these post mortem 
images also GM lesions are detectable, especially when the MR signal of GM was 
suppressed (Figure 1). 
The MRI scans revealed the presence of WM lesions in all six control animals with 
the normally observed characteristics, i.e. significantly increased T2 and significantly 
decreased MTR in WM lesions compared to WM or NAWM (Figure 1B). Interestingly, 
Table 2. Brain wM lesion volume and day of recording of the second in vivo MRI.
Pair psd MRI psd 
score 2
Control Volume 
(mm3)
Volume 
(mm3)
Cd20 Ab psd 
score 2
1 48 46 M02052 22.4 0 M04096 41a , 43a
2 48 41 M06061 590.6 0 M05073  
  0 M06055  
3 73 66 M07021 0 0 M07012  
4 85 78 M07029 8.4 0 M07075 103a
5 85 71a, 84a,88a M07048 2.3 0 M07085  
6 50 66 M07080 0 0 M07095 46a
a score 2 for 1 day
psd, post sensitization day
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small WM lesions were observed in four of the seven treated animals, but the average 
WM lesion volume of the treatment group was significantly lower than the control group 
(Table 4, Supplementary table 2). Note that the voxel volume of the post mortem images 
is more than ten times higher than for the in vivo images (7.2x10-3 versus 97.6x10-3 mm3) 
facilitating the detection of small lesions. Although four HuMab 7D8 treated animals 
contained WM lesions, their T2 values were significantly lower and the MTR values 
were higher compared to the lesions in control animals. Furthermore, T2 and MTR 
Table 3. Volume, T2, MTR, and Gadovist leakage during the second in vivo brain MRI.
Control Cd20 Ab
Volume (mm3)
WM 51.0 ± 2.8 45.7 ± 2.8
GM 96.1 ± 3.3 97.2 ± 1.4
NAWM 43.6 ± 9.4 -b
WM lesiona 104.0 ± 97.4 0.00 ± 0.00 *
T2 (ms)
WM 58.04 ± 2.62 55.53 ± 0.68
GM 59.76 ± 0.63 60.86 ± 0.84
NAWM 55.47 ± 0.68 -b
WM lesion 63.95 ± 3.06 -b
MTR (% decrease signal intensity)
WM 42.33 ± 1.15 43.81 ± 0.51
GM 32.18 ± 0.17 32.01 ± 0.41
NAWM 42.97 ± 0.77 -b
WM lesion 36.48 ± 1.04 ρ -b
Gadovist leakage (% increase signal intensity)
WM 7.30 ± 1.03 6.02 ± 0.27
GM 7.98 ± 0.33 7.65 ± 0.25
NAWM 7.26 ± 1.01 -b
WM lesion 13.31 ± 2.91 -b
a Note that lesion volumes were determined in the total brain, whereas WM, GM, and NAWM values 
were only determined for a single pre-defined slice, i.e. the first caudal to rostral slice which showed the 
complete corpus callosum connection. Consequently WM lesion volumes can be larger than the WM/
NAWM volume. 
b Could not be determined, because of the absence of WM lesions
Shown are mean ± sem, * P<0.05 compared to the control group with the Mann-Whitney U test. ρ 
P<0.05, Paired Student’s t test was used to compare MTR values of WM lesions versus NAWM of the 
four control animals with WM lesions (Supplementary table 1).
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values of WM lesions of treated animals did not significantly differ from WM or NAWM 
in these treated animals, which is the case in control animals. These data suggest that 
the lesions of treated animals contain less myelin damage. 
Importantly, we detected considerable GM lesion formation in five of the six 
Figure 2. Reduced demyelination and inflammation in the white matter after B-cell depletion. 
A, Luxol fast blue staining for myelin shows demyelination in the brain (original magnification x50), 
spinal cord (original magnification x25), and optic nerve (original magnification x25) of a representative 
control animal (upper panel). The lower panel shows the intact myelin pattern in brain, spinal cord, 
and optic nerve of treated animals. B, T-cells (upper panel) and B-cells (lower panel) were observed in 
brain and spinal cord lesions of control animals, but not in treated animals (original magnification x200). 
See page 317 for a full-color representation of this figure.
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control animals, but in none of the HuMab 7D8 treated animals (Figure 1B, Table 4, 
Supplementary table 2). Relatively, differences in MR characteristics between GM 
lesions and surrounding unaffected tissue (GM/NAGM) was much lower than the 
differences observed for WM lesions versus WM/NAWM. In conclusion, the depletion 
of CD20+ B-cells not only reduced the development of WM lesions, but also prevented 
the development of GM lesions.
 Table 4. Post mortem MRI of one brain hemisphere.
Control Cd20 Ab
Volume (mm3)
WM 23.0 ± 1.9 18.8 ± 1.2
GM 36.4 ± 2.9 40.8 ± 1.5
NAWM 15.4 ± 2.4 17.1 ± 1.3
NAGM 35.1 ± 3.4 -b
WM lesiona 103.6 ± 56.1 0.2 ± 0.1 * 
GM lesiona 9.7 ± 9.0 0.0 ± 0.0 *
T2 (ms)
WM 29.56 ± 0.93 28.03 ± 0.96
GM 33.66 ± 1.11 34.81 ± 1.49
NAWM 28.45 ± 0.70 28.03 ± 0.96
NAGM 34.18 ± 1.20 -b
WM lesion 34.93 ± 0.78 ρ 30.19 ± 0.70 *
GM lesion 35.33 ± 1.27 -b
MTR (% decrease signal intensity)
WM 33.98 ± 1.52 36.69 ± 0.34
GM 22.46 ± 0.22 22.25 ± 0.37
NAWM 35.40 ± 0.90 36.79 ± 0.58
NAGM 22.49 ± 0.27 -b
WM lesion 28.83 ± 0.91 ρ 32.18 ± 1.79
GM lesion 24.33 ± 0.78 -b
a Note that lesion volumes were determined in the total brain whereas WM, GM and NAWM values were 
only determined for a single pre-defined slice. See also table 3. 
b could not be determined, because of the absence of GM lesions
Shown are mean ± sem, * P< 0.05 compared to the control group with the Mann-Whitney U test. ρ 
P<0.05, Paired Student’s t test was used to compare MTR values of WM lesions versus NAWM of the 
six control animals with WM lesions.
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Figure 3. B-cell depletion prevents the development of grey matter lesions. 
A, stainings for proteolipid protein and MRP14+ macrophages show a large demyelinated lesion in 
cortical grey matter of a control animal (upper panel). No grey matter demyelination was observed 
in CD20+ B-cell depleted animals (lower panel) (original magnification x500). B, Left hemisphere of 
a control animal is immunostained for PLP. The arrow points to a group of lesions that are depicted 
in the five smaller photographs. The first two photographs show the grey matter lesions in a PLP 
staining (original magnification x25 and x50). MRP14+ staining shows an active lesion (upper lesion) 
with many (recently infiltrated) macrophages and an inactive lesion with macrophages only at the rim 
of the lesion (lower lesion). T-cells and B-cells were present in these lesions (original magnification 
x400). C shows a lesion in the hippocampus (arrow). Demyelination is shown by PLP staining. 
MRP14+ macrophages, T-cells and B-cells were present in this lesion. See page 318 for a full-color 
representation of this figure.
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Histology of CNS 
Figure 2 depicts the characteristic pathological aspects in WM of brain, spinal 
cord, and optic nerve that can be observed in the marmoset EAE model. Also the 
immunohistochemical detection of T- and B-cells is shown. To quantitate the beneficial 
effect of HuMab 7D8 we have determined the extent of WM demyelination in all three 
parts of the marmoset CNS. Histological analysis revealed actively demyelinating brain 
lesions in all control animals, even in the animals that had only small MRI detectable 
lesions on the post mortem images (M07029 and M07080). By contrast the small WM 
lesions that were detected with high contrast post mortem MRI in four HuMab 7D8 
treated animals, showed limited or no histological signs of active demyelination (Table 
5, Supplementary table 2). The extent of demyelination was significantly lower in the 
brain and spinal cord of treated animals compared to control animals. Demyelination 
in the optic nerve was observed in three of the six control animals, but in none of the 
treated animals (Figure 2A, Table 5). 
Five of the six control animals contained prominent inflammation in the spinal cord. 
Spinal cord lesions were undetectable in the control animal that was sacrificed without 
clinical signs at the end of the study (M07048). Spinal cord lesions were also absent 
in four of the seven antibody-treated animals and very small-sized in three antibody-
treated animals. Overall the severity of inflammation in spinal cord was significantly 
higher in control animals than in the HuMab 7D8 treated animals. Inflammation in the 
optic nerve was detected in four of the six control animals, but in none of the treated 
animals (Table 5). No T-cells and B-cells could be observed in the CNS of HuMab 7D8 
treated animals, in contrast to control animals (Figure 2B). 
A very important aspect of the marmoset EAE model, that distinguish it from the 
majority of rodent EAE models, is the demyelination in the cortical GM. Figure 3 shows 
that demyelination in the GM can be substantially more extensive than the usually focal 
demyelination in WM. Note that lesions in the depicted control animal were not only 
observed in the cortical GM (Figure 3B) but also in the hippocampus (Figure 3C). We 
have analysed the GM lesions that were detected with post mortem MRI in several 
control brain specimens, also with histology. In five control animals GM lesions were 
detected by MRI and in three of these animals this was confirmed by histology. Our 
histology analysis confirmed the observation with MRI, that no GM lesions had been 
formed in the HuMab 7D8 treated animals (Figure 3, Table 5, Supplementary table 2). 
In conclusion, these data demonstrate that depletion of CD20+ B-cells dramatically 
attenuated the development of MS-like pathology affecting WM and GM in different 
parts of the marmoset CNS, i.e. brain, spinal cord, and optic nerve.
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Table 5. Histology of brain, spinal cord, and optic nerve. 
Brain Spinal cord Optic nerve
Demyelinationa Inflam-
mationb
Demyelina-
tion (%)
Inflam-
mationb
Demyelina-
tiona
WM (%) GM (%)
Control
M02052 27 1 1 13 + +
M06061 42 5 3.2 36 + +
M07021 2 0 2.3 44 - -/+
M07029 3 0 1.7 64 - -
M07048 9 0.5 0 0 -/+ -/+
M07080 5.5 0 1.3 37 - -
Mean 14.75 1.08 1.583 32.33
SEM 6.613 0.800 0.450 9.298
Cd20 Ab
M04096 0 0 0 0 - -
M05073 0 0 0 0 - -
M06055 0 0 0 0 - -
M07012 0 0 0 0 - -
M07075 0 0 0.5 4 - -
M07085 0 0 0.3 0 - -
M07095 0 0 0.2 2 - -
Mean   0 * 0  0.143 *  0.86 *
SEM 0 0 0.075 0.595
a Demyelination was visualized by staining myelin and myelin degradation products with Klüver Barrera 
(Luxol fast blue with periodic acid-Schiff) or proteolipid protein (PLP). Demyelination in the brain was 
determined as follows: brain sections stained for PLP were photographed at 2.5x magnification. Images 
were then imported in the Scion Image program (freeware downloaded from www.scioncorp.com), an 
image processing and analysis program based on NIH Image, developed at the National Institutes of 
Health, USA. In density slice mode, first the total area of the section was measured. After this, total WM 
(about 40 mm2) was measured and subtracted from the total area, resulting in the GM area (about 100 
mm2). Lesions in WM and GM were selected by freehand mode and their size was measured. Finally 
the demyelination in WM or GM was calculated as percentage of total WM or GM. Eight sections of the 
spinal cord of each animal was analysed, which was approximately 6 cm2 in total. Demyelination in optic 
nerve is quantified as: + = demyelination, -/+ = some demyelination, - = no demyelination.
b Inflammation was visualized by staining infiltrating cells with hematoxylin and eosin, CD3, CD20, 
or MRP14. The inflammatory index of the spinal cord is given as the average number of inflamed 
bloodvessels/spinal cord cross section. Inflammation in optic nerve is assessed by staining macrophages 
with MRP14, + = macrophages present, -/+ some macrophages present, - = no macrophages
* P< 0.05 compared to the control group
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dISCuSSION
Clinical trials in RRMS patients have shown a marked clinical effect of CD20+ B-cell 
depletion, namely marked reduction of relapse frequency associated with a decrease 
of contrast enhancing lesions in the cerebral WM4,5. The mechanism of action of the 
CD20+ B-cell antibody was unexpected, as plasma IgG-levels were not depleted. 
As a first step towards better understanding the presumed multifaceted pathogenic 
role of B-cells in CNS demyelinating disease, we have investigated the systemic effect 
of CD20+ B-cell depletion in the rhMOG-induced EAE model in marmosets. The model 
is characterized by MS-like lesions developing in CNS WM and GM, which are induced 
by the synergistic action of autoreactive T-cells and autoantibodies8,9,13,20. We have used 
the antibody HuMab 7D8, a human CD20 specific monoclonal antibody with potent 
cytolytic activity that cross-reacts with marmosets11,12. 
We report that the depletion of CD20+ B-cells initiated well after EAE induction 
(psd 21) led to protection against evident clinical EAE and reduced volume of brain 
WM lesions. In addition, we observed suppression of demyelination in the optic nerve 
and in spinal cord, similar to the situation in a mouse EAE model21. Probably the most 
important finding in the current study is the complete abrogation of GM demyelination, 
which is a relatively recently recognized aspect of the complex MS pathology and which 
is thought to be clinically more relevant than lesions in the WM2,22. To our knowledge, 
this is the first documented evidence that demyelination of GM can be prevented with a 
CD20+ B-cell depleting antibody. Finally, the depletion of CD20+ B-cells also had a small 
but detectable effect on MRI parameters of the peri-lesional NAWM and NAGM.
The mechanisms underlying the dramatic effect of rituximab on the extent of 
demyelination in MS are unknown. We show here in the marmoset EAE model that 
demyelination of the CNS is profoundly reduced after depletion of CD20+ B-cells. 
According to a widely supported concept, autoimmune demyelination in MS can take 
place in the absence (pattern 1 lesion) or presence (pattern 2 lesion) of IgG antibody 
binding to myelin23. This view is strongly supported by findings in the marmoset EAE 
model13,24-26. We have observed that animals treated with HuMab 7D8 had lower anti-
rhMOG IgG levels in their circulation compared to the control animals (Kap et al., J 
Immunol, in press). This may partly explain the reduced demyelination observed in 
this study. In the rituximab trials in RRMS, no significant reduction of total serum IgG 
levels was found, although the specific effect on anti-myelin antibodies had not been 
determined4,5. The authors speculate that serum IgG levels were not affected by rituximab 
because plasma cells do not express CD20 and are therefore not depleted following 
short-term treatment by an anti-CD20 mAb27. The question is therefore warranted 
whether the clinical effect is mediated by another mechanism via which B-cells can 
induce demyelination. One possibility is that only long-lived plasma cells remain, 
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whereas short-lived (CD20+) plasma cells are depleted by the treatment. Indeed, this 
has been shown in a mouse arthritis model after anti-CD20 treatment28. 
On the basis of our research in the marmoset EAE model we would like to coin an 
alternative mechanism, namely abrogation of antigen presentation by CD20+ B-cells to 
pathogenic T-cells. We have previously reported that the expression of clinical signs of 
EAE is associated with the activation of a unique subset of cytotoxic IL-17A producing 
T-cells, which mediate widespread CNS demyelination in the absence of anti-MOG 
antibodies13,26. Separately, we have reported the observation in rhMOG-induced EAE in 
marmosets (the same animals as published in this paper) that late B-cell depletion by 
HuMab 7D8 significantly reduced T-cell proliferation and cytokine production in spleen 
and lymph nodes (Kap et al., J Immunol, in press). Importantly, we found no T-cells 
in the CNS of HuMab 7D8 treated animals (this report). Since demyelination in EAE 
affected marmosets can occur in the absence of autoantibodies, we propose that the 
abrogation of CNS pathology after B-cell depletion is mainly caused by the prevention 
of T-cell recruitment into the CNS.
In conclusion, B-cell depletion prevents the development of inflammation and 
demyelination in the WM and GM of the brain as well as in spinal cord and optic 
nerve. We show that CD20+ B-cells have a central pathogenic role in inflammation and 
demyelination and are important in lesion development in all areas of the CNS. B-cell 
depletion reduced inflammation in WM of MS patients and thereby reduced the relapse 
rate. That B-cell depletion also reduced demyelination of GM may suggest that B-cell 
depletion will slow down the disease progression and have beneficial effects on long-
term disease disability. These data underline the prominent pathogenic role of B-cells in 
the induction of widespread CNS pathology.
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Supplementary table 1. Individual data of in vivo MRI of the second MRI experiment.
Volume (mm3)
wM GM NAwM wM lesiona
Control
M02052 49.93 84.45 47.63 22.39
M06061 56.93 91.89 15.99 590.58
M07021 40.89 92.19 -b 0.00
M07029 55.03 99.24 53.22 8.42
M07048 57.59 105.59 57.59 2.34
M07080 45.65 103.15 - 0.00
Mean 51.01 96.09 43.61 103.96
SEM 2.75 3.26 9.43 97.39
Cd20
M04096 50.71 92.26 - 0
M05073 56.25 99.19 - 0
M06055 42.11 95.02 - 0
M07012 52.56 101.29 - 0
M07075 38.77 95.95 - 0
M07085 36.89 95.04 - 0
M07095 42.26 101.81 - 0
Mean 45.65 97.22 - 0.0
SEM 2.82 1.36 - 0.0
T2 (ms)
wM GM NAwM wM lesion
Control
M02052 55.09 57.68 54.51 68.28
M06061 71.07 58.35 57.30 69.67
M07021 55.45 60.24 - -
M07029 54.56 60.91 54.35 61.24
M07048 55.71 59.64 55.71 56.62
M07080 56.35 61.71 - -
Mean 58.04 59.76 55.47 63.95
SEM 2.62 0.63 0.68 3.06
Cd20
M04096 55.66 58.79 - -
M05073 53.27 60.34 - -
M06055 55.51 60.28 - -
M07012 56.82 59.70 - -
M07075 58.70 65.68 - -
M07085 54.55 60.19 - -
M07095 54.21 61.00 - -
Mean 55.53 60.86 - -
SEM 0.68 0.84 - -
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 (Supplementary table 1 continued)
MTR (% decrease signal intensity)
wM GM NAwM wM lesion
Control
M02052 43.26 32.87 43.49 38.17
M06061 36.61 32.10 40.76 35.46
M07021 43.56 32.13 - -
M07029 43.97 32.39 44.28 34.04
M07048 43.36 31.90 43.36 38.25
M07080 43.25 31.66 - -
Mean 42.33 32.18 42.97 36.48
SEM 1.15 0.17 0.77 1.04
Cd20
M04096 43.95 32.57 - -
M05073 44.83 32.60 - -
M06055 45.17 32.68 - -
M07012 43.65 32.30 - -
M07075 40.96 29.59 - -
M07085 43.91 32.35 - -
M07095 44.15 31.97 - -
Mean 43.81 32.01 - -
SEM 0.51 0.41 - -
Gadovist leakage (% increase signal intensity)
wM GM NAwM wM lesion
Control
M02052 7.76 6.97 6.88 19.76
M06061 12.23 9.36 10.17 16.20
M07021 5.85 7.95 - -
M07029 5.62 7.87 5.50 10.70
M07048 6.49 8.28 6.49 6.60
M07080 5.87 7.43 - -
Mean 7.30 7.98 7.26 13.31
SEM 1.03 0.33 1.01 2.91
Cd20
M04096 5.72 7.43 - -
M05073 7.22 8.18 - -
M06055 5.39 6.53 - -
M07012 5.87 8.08 - -
M07075 5.66 7.08 - -
M07085 6.83 8.27 - -
M07095 5.47 7.95 - -
Mean 6.02 7.65 - -
SEM 0.27 0.25 - -
a Note that lesion volumes were determined in the total brain whereas WM, GM, and NAWM values were only 
determined for a single pre-defined slice, i.e. the first caudal to rostral slice which showed the complete corpus 
callosum connection. Consequently WM Lesion volumes can be larger than the WM/NAWM volume. 
b This parameter could not be determined, because of the absence of WM lesions
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Supplementary table 2. Post mortem MRI of individual animals.
Volume (mm3)
wM GM NAwM NAGM wM lesiona GM lesiona
Control
M02052 27.36 22.57 7.14 22.57 228.64 0.91
M06061 28.79 38.27 8.83 36.22 322.28 54.55
M07021 17.10 34.90 16.82 34.90 21.76 0.66
M07029 21.11 39.39 20.69 39.33 0.58 0.09
M07048 23.94 42.60 19.57 42.60 45.73 1.83
M07080 19.73 40.49 19.29 -b 2.33 0.00
Mean 23.00 36.37 15.39 35.12 103.55 9.67
SEM 1.85 2.95 2.41 3.41 56.09 8.98
Cd20
M04096 21.25 38.94 - - 0.00 0.00
M05073 22.88 44.40 - - 0.00 0.00
M06055 20.83 39.95 20.83 - 0.21 0.00
M07012 18.90 39.56 - - 0.00 0.00
M07075 15.68 37.21 15.64 - 0.50 0.00
M07085 14.76 37.19 14.76 - 0.13 0.00
M07095 17.21 48.00 17.21 - 0.23 0.00
Mean 18.79 40.75 17.11 - 0.15 0.00
SEM 1.15 1.51 1.34 - 0.07 0.00
T2 (ms)
wM GM NAwM NAGM wM lesion GM lesion
Control
M02052 31.14 31.15 27.91 31.15 33.87 35.41
M06061 31.33 32.52 29.41 32.48 34.14 35.45
M07021 27.37 33.27 27.27 33.27 38.33 30.65
M07029 30.01 37.12 29.90 37.12 35.97 37.99
M07048 31.42 36.85 30.33 36.85 34.14 37.15
M07080 26.10 31.03 25.90 31.03 33.12 -
Mean 29.56 33.66 28.45 34.18 34.93 35.33
SEM 0.93 1.11 0.70 1.20 0.78 1.27
Cd20
M04096 26.75 32.97 - - - -
M05073 25.47 30.75 - - - -
M06055 25.18 30.81 25.18 - 31.03 -
M07012 29.96 32.60 - - - -
M07075 29.97 38.13 29.97 - 31.38 -
M07085 31.53 40.46 31.53 - 28.24 -
M07095 30.37 37.97 30.37 - 30.09 -
Mean 28.03 34.81 28.03 - 30.19 -
SEM 0.96 1.49 0.96 - 0.7 -
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(Supplementary table 2 continued)
MTR (% decrease signal intensity)
wM GM NAwM NAGM wM lesion GM lesion
Control
M02052 29.12 22.84 33.40 22.84 28.69 23.70
M06061 29.59 22.97 32.12 22.98 28.45 24.00
M07021 36.09 21.45 36.23 21.45 24.79 22.98
M07029 37.85 22.71 37.98 22.70 31.27 27.38
M07048 34.60 22.46 35.83 22.46 29.80 23.61
M07080 36.64 22.34 36.83 - 29.97 -
Mean 33.98 22.46 35.40 22.49 28.83 24.34
SEM 1.52 0.22 0.90 0.27 0.91 0.78
Cd20
M04096 36.70 22.27 - - - -
M05073 37.04 22.63 - - - -
M06055 35.56 20.86 35.56 - 30.09 -
M07012 35.94 21.54 - - - -
M07075 37.89 23.47 37.90 - 31.67 -
M07085 37.67 23.33 37.67 - 37.40 -
M07095 36.04 21.65 36.04 - 29.58 -
Mean 36.69 22.25 36.79 - 32.18 -
SEM 0.34 0.37 0.58 - 1.79 -
a Note that lesion volumes were determined in the total brain whereas WM, GM and NAWM values were only 
determined for a single pre-defined slice, i.e. the first caudal to rostral slice which showed the complete corpus 
callosum connection. Consequently WM lesion or GM lesion volumes can be larger than the WM/NAWM or 
GM/NAGM volume. 
b This parameter could not be determined, because of the absence of GM lesions
Proefschrift Yolanda Kap_compleet.indd   207 25-08-2010   21:25:13
Proefschrift Yolanda Kap_compleet.indd   208 25-08-2010   21:25:13
Role of amino-Nogo-A antagonism in oligodendrocyte 
differentiation and myelination in experimental 
demyelinating diseases
Yi-Yang Yvonne Li1, Ryan Wang1, Yolanda S. Kap2,3,4, Yahui Zhang1, Ailian Liu1, 
Yonggang Zhao1, Maggie Song1, Lei Zhang1, Zailian Lu1, Rab K. Prinjha5, 
Yuchen Xu1, Jianfeng Xu1, Nikki van Driel2, Erwin Blezer6, Jan Bauer7, 
Matthew Cleveland8, Jens U. Wurthner8, Jim D. Faulkner8, Daniel Lee9, 
Hongtao Lu1, Bert A. ’t Hart2,3,4, Jingwu Zhang1
1Department of Neuroimmunology, GlaxoSmithKline R&D Centre, Shanghai, 
China; 2Department of Immunobiology, Biomedical Primate Research Centre, 
Rijswijk, The Netherlands; 3Department of Immunology, Erasmus Medical Centre, 
Rotterdam, The Netherlands; 4MS Centre ErasMS, Rotterdam, The Netherlands; 
5Epinova DPU, Immuno-Inflammation Centre of Excellence for Drug Discovery, 
GlaxoSmithKline; 6Imaging Sciences Institute, University Medical Centre Utrecht, 
Utrecht, The Netherlands; 7Brain Research Institute, University of Vienna, Austria; 
8GlaxoSmithKline, Biopharm R&D, Stevenage, UK; 9Department of Translational 
Medicine, GlaxoSmithKline R&D Centre, Shanghai, China
YYL, RW, and YSK contributed equally to this work
Submitted for publication
4.4
Proefschrift Yolanda Kap_compleet.indd   209 25-08-2010   21:25:14
Proefschrift Yolanda Kap_compleet.indd   210 25-08-2010   21:25:14
 Amino-Nogo-A inhibits OPC differentiation
211
ABSTRACT
Nogo-A is a central nervous system myelin protein with two distinct domains, 
amino-Nogo-A and carboxyl Nogo66, which inhibits axonal outgrowth and promotes 
growth cone collapse. Here we show that antagonism of amino-Nogo-A ameliorated 
experimental autoimmune encephalomyelitis in marmosets. The treatment efficacy 
strongly correlated with markedly reduced levels of CNS demyelination. Axonal and 
myelin repair was further demonstrated with amino-Nogo-A antibody treatment in a 
lysophosphatidylcholine-induced demyelination model. The role of amino-Nogo-A was 
further validated in vitro as amino-Nogo-A, but not Nogo66, inhibited oligodendrocyte 
precursor cell differentiation and myelination in co-culture with dorsal root ganglion 
neurons and in organotypic cerebellar slices. Molecular analyses revealed that the 
underlying mechanism for the role of amino-Nogo-A on oligodendrocyte precursor cell 
differentiation and maturation involved the inhibition of Akt signaling pathway. The study 
provides new evidence supporting amino-Nogo-A antagonism as a potential therapeutic 
approach for multiple sclerosis and other demyelinating diseases through axon and 
myelin repair.
INTROduCTION
Multiple sclerosis (MS) is a chronic inflammatory and demyelinating disease affecting 
the central nervous system (CNS) characterized by focal white matter inflammation 
and the loss of the myelin sheath. It involves both cellular and humoral autoimmune 
attacks primarily targeting the myelin in the CNS resulting in demyelination, gliosis, 
and axonal injury as typically seen in MS lesions1. Substantial evidence supports that 
autoimmune inflammation in MS is associated with marked reduction in differentiation 
of oligodendrocyte precursor cells (OPC) and impairment in myelin tissue repair. It has 
been increasingly recognized that the reduced rate of remyelination in the MS brain 
is one of the major attributes to persistent demyelination and axon degeneration. The 
underlying mechanism is unclear and suggested to involve a potential blockade of OPC 
differentiation to mature and myelinating oligodendrocytes2,3. Key signaling molecules 
identified in the signaling pathways include, but not limited to, Akt, Fyn, αv or β1 integrins, 
neuregulin, and Wnt4-8.
Nogo-A is a high molecular weight transmembrane protein expressed mainly in 
oligodendrocytes at all stages and is initially identified as a potent inhibitor for neurite 
outgrowth9-11. It is believed that the inhibitory effects of Nogo-A are mediated through 
both the C-terminal 66-residue extracellular domain (Nogo66) and the amino-terminal 
region12. Studies accumulated so far have indicated that Nogo66 plays a critical role 
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in the induction of growth cone collapse through interaction with Nogo-A receptor 
(NgR) while amino-Nogo-A appears to have a predominant inhibitory effect on neurite 
outgrowth via β1 integrins, thus preventing cell adhesion and spreading13,14. However, 
a specific receptor for amino-Nogo-A has not been identified. In rodent and marmoset 
spinal cord injury models, amino-Nogo-A antagonism was found to enhance axonal 
regeneration10,15-17, which was attributed to removal of the inhibitory role of amino-Nogo-A 
in neurite outgrowth. However, the role of amino-Nogo-A in oligodendrocyte biology and 
myelination is unknown. Notably, elevated Nogo-A expression was reported in chronic 
active demyelinating lesions of secondary progressive MS patients and elevated levels 
of the soluble form of Nogo-A in cerebrospinal fluid of MS patients18,19. A study by 
Karnezis et al. suggested that Nogo-A antagonism or its gene deficiency in rodents may 
confer protection in experimental autoimmune encephalomyelitis (EAE) as indicated by 
delayed disease onset and reduced disease severity20. However, the role and underlying 
mechanism of Nogo-A and its antagonism in demyelinating diseases is unknown. It is 
unclear whether the treatment efficacy observed in EAE with Nogo-A antagonism was 
mediated through axonal mechanism or potential remyelination mechanism. 
In this study, we investigated our hypothesis that amino-Nogo-A plays a detrimental 
role in CNS myelination under pathological conditions where amino-Nogo-A is aberrantly 
expressed in injured myelin tissue. We first studied the antagonism of amino-Nogo-A 
in an EAE model in the common marmoset, as this non-human primate model closely 
resembles the essential clinical and pathological features of MS21,22. The effect of amino-
Nogo-A antagonism was further evaluated in a non-inflammatory demyelinating model 
induced by lysophosphatidylcholine (LPC). An important aspect of this study was to 
delineate the mechanisms underlying the role of amino-Nogo-A and its antagonism in 
myelination and OPC differentiation at both cellular and molecular levels. These novel 
findings have important implications in the development of new treatment modality for 
MS by targeting the myelin repair mechanism. 
 
MATERIAlS ANd METHOdS 
Antibodies
Amino-Nogo-A specific monoclonal antibodies (mAb) were generated by immunizing 
mice with a GST-amino-Nogo-A fusion protein. One of the resulting Ab (2A10) was 
characterized for its specificity by binding to an epitope encompassing amino acid 
residues 610-621 (VLPDIVMEAPLN) of human and rat amino-Nogo-A. The Ab binds 
to GST-amino-Nogo-A protein with high affinity (Kd = 0.8 – 1.0 nM) and was effective 
in blocking amino-Nogo-A-mediated inhibition of neurite outgrowth. Amino-Nogo-A Ab 
was humanized using the best-fit CDR-grafting technique23. The resulting Ab retained 
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the same binding affinity to human amino-Nogo-A (Kd = 0.66 nM). The Ab was tested 
in neurite outgrowth functional assay where it was shown to neutralize the inhibition 
induced by amino-Nogo-A. The parental mouse Ab against the same epitope was 
used in all experiments described here with the exception of marmoset EAE where the 
humanized version was used. 
Ab used for immunoblot and immunohistochemistry experiments are as follows: 
rabbit anti-MBP, mouse anti-CNPase, mouse anti-NG2, mouse anti-GFAP, mouse anti-
NeuN, rabbit anti-Olig2 and mouse anti-neurofilament H. They were all purchased from 
Millipore Chemicon (Billerica, MA). 
Induction of EAE in marmosets
The induction of marmoset EAE was performed as described22. Briefly, the animals 
of comparable age and body weight were immunized with a peptide corresponding to 
residues 34-56 of human myelin oligodendrocyte glycoprotein (MOG34-56), which was 
obtained from ABC Biotechnology (London, UK) or Cambridge Research Biochemicals 
(Cleveland, UK). The peptide was emulsified in phosphate buffered saline (PBS) and 
complete Freund’s adjuvant (Difco Laboratories, Detroit, MI) as described previously22. 
Clinical signs were scored daily by two independent observers using a previously 
described semi-quantitative scale24. Briefly, 0 = no clinical signs; 0.5 = apathy, loss of 
appetite, altered walking pattern without ataxia; 1 = lethargy, anorexia, tail paralysis, 
tremor; 2 = ataxia, optic disease; 2.25 = monoparesis; 2.5 = paraparesis, sensory loss; 
3 = para- or hemiplegia. Monkeys were sacrificed for ethical reasons once complete 
paralysis of hind limbs (score ≥ 3.0) was observed. Body weight measurements 
of conscious monkeys were performed three times per week. Monkeys selected for 
necropsy were first deeply sedated by intramuscular injection of ketamine (50 mg/kg, 
AST Pharma, Oudewater, The Netherlands) and subsequently euthanized by infusion of 
pentobarbital sodium (Euthesate, Apharmo, Duiven, The Netherlands). The marmoset 
EAE protocol was approved by the Institute’s Ethics Committee.
Treatment of marmoset EAE with humanized amino-Nogo-A Ab
Animals were intravenously (i.v.) injected with 30 mg/kg of humanized amino-Nogo-A 
Ab or PBS solvent under ketamine anesthesia (40 mg/kg). Treatment was given once a 
week starting one day before immunization until day 120 or day 168. Formalin fixed brains 
(8-10 slices) and spinal cords (8-10 cross sections) were embedded in paraffin and 5 µm 
sections were cut. For basic classification of inflammation, demyelination, and axonal 
pathology, sections were stained with haematoxylin and eosin (H&E), Luxol fast blue 
(LFB) myelin stain, and Bielschowsky silver impregnation, respectively. Demyelination 
was measured by using a morphometric grid. In spinal cord, the demyelination was 
given as percentage of white matter of the spinal cord.
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lysophosphatidylcholine (lPC)-induced corpus callosum demyelination mouse 
model
LPC-induced focal demyelination was performed as described25. All experimental 
and surgical procedures were performed according to protocols approved by IACUC 
of GSK R&D China. C57BL/6 mice were anesthetized with pentobarbital sodium (60 
mg/kg) diluted in 0.9% sterile saline and positioned in a stereotaxic frame (RWD Life 
Science Co., Ltd, China). Two µl of 1% LPC (Sigma) was injected unilaterally into the 
corpus callosum using appropriate stereotaxic coordinates (1.42 mm anterior to bregma, 
1.00 mm lateral to bregma, 2.25 mm deep from the skull surface) for 20 min, with a 10 
µl Hamilton syringe containing (Sigma, Gillingham, UK). The needle was kept in place 
for 10 min to reduce reflux up the needle track. Amino-Nogo-A Ab was then delivered 
locally at the indicated concentrations on day 3 post LPC injection. Three days after Ab 
injection, brains were collected and samples were prepared for histological analyses to 
assess demyelination. 
Electron microscopy
Brain tissues were immersed in 2.5% glutaraldehyde in 0.1 mol/L phosphate buffer (pH 
7.4), post-fixed in 1% osmium tetroxide, dehydrated in ascending alcohols, and infiltrated 
and embedded in Epon 618 (Sigma), with each corpus callosum oriented for transverse 
axonal analysis. Sections were prepared at 1 µm thickness from each block and stained 
with Toluidine blue. After examination under light microscopy, selected areas were trimmed 
for electron microscopy (EM). Ultra-thin sections (50-60 nm) were collected and stained 
with 3% uranyl acetate and lead citrate and then examined under a transmission electron 
microscope (Philips CM-120, Eindhoven, The Netherlands) at 100 kV.
Cerebellar slice culture
The cerebellar slice culture was established as described26. Briefly, parasagittal 
slices of postnatal day 10 (P10) rat cerebellum were cut at 350 µm using Leica VT1200 
tissue Slicer (Leica Instruments, Wetzlar, Germany) and cultured on collagen-coated 
transwells (Costar, Lowell, MA) containing 50% basal medium with Earle’s salts, 25% 
Hanks’ buffered salt solution, 25% horse serum, and 5 mg/ml glucose (Invitrogen, 
Glasgow, UK). Demyelination was induced by LPC treatment at 0.5 mg/ml for 15-17 h 
followed by several washes. Amino-Nogo-A Ab or control Ab were added to the culture 
at indicated concentrations for 4 days. For whole-mount immunostaining, the slices 
were first blocked for 2-4 h with PBS containing 10% goat serum, 1% BSA, and 0.2% 
Triton X-100 at RT followed by primary and secondary Ab incubation overnight at 4°C. 
Images were captured using an Olympus BX60 microscope and Zeiss LSM confocal 
microscope.
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OPC differentiation assay
Cell suspension enriched for OPC were obtained from forebrain of 2-day old rat pups 
as described27. After repeated trituration, cells were pelleted, resuspended, and plated 
on poly-D-lysine (PDL)-coated T75 flasks. The resulting cultures were supplemented 
with the medium twice per week and subjected to a serial shake-off procedure after 
two weeks to obtain pure OPC. Specifically, the mixed glial cells were shaken initially 
for 1 h at 100 rpm to remove microglia and continuously shaken for 20–22 h at 37°C at 
200 rpm to enrich OPC. OPC were collected by centrifugation at 1200 rpm for 5 min, 
resuspended in chemically defined basal medium (BDM). BDM consisted of DMEM 
supplemented with N2 medium (Invitrogen), glutamine (4 mM, Invitrogen), BSA (0.1 
mg/ml, Sigma), hydrocortisone (20 nM, Sigma), selenium (30 nM, Sigma) and biotin (10 
nM, Sigma). OPC were seeded in poly-ornithine-coated culture dishes and maintained 
in BDM supplemented with bFGF (10 ng/ml, Invitrogen) and PDGF (10 ng/ml, R&D 
systems, Minneapolis, MN) before experimental manipulation. Purity of OPC was >95% 
as quantified by A2B5+ staining. To initiate OPC differentiation, OPC were cultured in 
BDM supplemented with triiodothyronine (30 nM, Sigma) and N-acetyl-L-cysteine (30 
µM, Sigma) to differentiate into MBP+ mature oligodendrocytes for 3-5 days. 
Construction of Nogo-A RNAi 
Cloning and lentiviral vector packaging of small hairpin RNA (shRNA) was done using 
the Lenti-X shRNA Expression System (Clontech, Mountain view, CA). Synthesized 
shRNA oligonucleotides with designed BamHI and EcoRI sticky ends were annealed 
and cloned to the pLVX-shRNA2 plasmid. Sequences of rat Nogo-A shRNA are 
GATCCGCACCACAGCAAACACTTTCCTTCAAGAGAGGAAAGTGTTTGCTGTGGTG
CTTTTTG (sense) and AATTCAAAAAGCACCACAGCAAACACTTTCCTCTCTTGAAG
GAAAGTGTTTGCTGTGGTGCG (antisense). Sequences of non-targeting control shRNA 
are GATCCTCGCTTACCGATTCAGAATGGTTCAAGAGACCATTCTGAATCGGTAAGC
GATTTTTG (sense) and AATTCAAAAATCGCTTACCGATTCAGAATGGTCTCTTGAAC
CATTCTGAATCGGTAAGCGAG (antisense). To package the lentiviral vectors 
containing the shRNA, pLVX-shRNA2 carrying Nogo-A or control shRNA and the Lenti-
XHT Packaging Mix were cotransfected into HEK293T cells. Packaging cell supernatant 
was collected 48 h later and concentrated by centrifugation as previously described28. 
RNAi lentiviruses carrying green fluorescent protein (GFP) were generated to determine 
the transfection efficiency. Oligodendrocytes were infected with lentivirus at 3 m.o.i. per 
cell and approximately 50% of transfected oligodendrocytes were GFP positive. Cell 
viability was not altered by shRNA transfection.
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Immunocytochemistry
Cells were fixed in 4% paraformaldehyde and then incubated with indicated primary 
Ab overnight at 4°C29. After several washes, samples were incubated with appropriate 
Alexa-labeled secondary Ab (Molecular Probes, Carlsbad, CA) for 2 h. They were then 
mounted in VectaMount (Victor, Burlingame, CA) and visualized by Olympus BX60 
fluorescence microscopy.
Co-culture of oligodendrocytes with dRG
The co-culture system was established using a protocol as described30. Briefly, 
dorsal root ganglions (DRG) were dissected from rat embryos E14-16. After papain 
(30 U/ml, Sigma) and collagenase (200 µg/ml, Sigma) digestion for 15 min, the 
dissociated cells were plated onto 96-well plates coated with poly-D-lysine and 
laminin (Invitrogen) at a density of 5 x 104 cells/well. The resulting neurons were 
cultured for 2 weeks in Neurobasal medium (Invitrogen) supplemented with 5% 
fetal bovine serum, in the presence of nerve growth factor (25 ng/ml, Invitrogen). 
To remove contaminating fibroblasts and glial cells, the cultures were pulsed 
every 3 days for a total of three times with 30 µM 5-fluorodeoxyuridine (Sigma). 
Enriched populations of OPC were obtained from P0 rats as described above. The 
enriched OPC (>95% pure) were added to DRG culture for 4-5 h followed by amino-
Nogo-A treatment in the presence or absence of amino-Nogo-A Ab. Co-culture was 
maintained for another 3 days before the cells were fixed and immunostained for 
Cellomics analysis.
western blot analysis
Protein extraction from either cerebellar slice culture or OPC culture was carried out 
using RIPA lysis buffer (50 mM Tris-HCl, pH 7.5; 1 mM EDTA; 1 mM EGTA; 1 mM sodium 
orthovanadate; 50 mM sodium fluoride; 0.1% 2-mercaptoethanol; 1% Triton X-100, and 
1% protease inhibitor cocktail (Roche, Indianapolis, IN)). Protein concentration was 
determined by BCA method (Pierce) and 10-15 µg of protein were separated on SDS-
PAGE, transferred to PVDF membranes, and blotted with Ab specific for MBP, Tuj-
1, Akt/pAkt and Nogo-A, using actin as a loading control. Signals were detected by 
enhanced chemiluminescence (Millipore). 
CNPase activity assay 
CNPase activity was measured by a fluorometric assay as previously described31. 
Nicotinamide adenine dinucleotide 2’, 3’-cyclic monophosphate (2’, 3’-cNADP) was 
used as a substrate. Briefly, 5 µl of protein homogenate from cerebellar slice culture 
were added to 100 µl of a reaction mixture composed of 0.2 M MES buffer, pH 6.0; 1.0 
mM 2’,3’-cyclic NADP (Sigma); 30 mM MgCl2; 1.0 mM disodium EDTA; 1.5 mM glucose-
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6-phosphate; 0.3% BSA and 23 µg/ml glucose-6-phosphate dehydrogenase (140 U/
rag, Sigma). The fluorescence of the NADPH formed in the reaction was measured at 
an emission wavelength of 460 nm after excitation at 360 nm (Molecular Device).
Neurite outgrowth assay
Cerebellar granule neurons (CGN) were isolated from day 7 postnatal mice as 
described10. PDL-coated 96-well plates were cultured for 7 days. Soluble amino-Nogo-A 
was added (5 µg/ml) to the indicated wells while myelin was coated onto the plate (0.5 
µg/well) and unbound myelin was washed off by PBS before seeding CGN. Amino-
Nogo-A Ab or its isotype control Ab was added at concentrations of 1, 5, and 20 µg/ml 
to the wells and incubated for 72 h. The number of neurons and the neurite length was 
measured by Cellomics.
Statistical analysis
A two-tailed Student’s t-test was performed in all experiments. All data are expressed 
as mean ± S.D. A P value of < 0.05 was considered statistically significant. 
RESulTS
Amelioration of marmoset EAE by treatment with amino-Nogo-A Ab
The effect of an amino-Nogo-A Ab in CNS myelination was first examined in a 
marmoset EAE model induced by immunization with MOG34-56 in CFA21. The treatment 
group was administered intravenously with a humanized monoclonal amino-Nogo-A 
Ab at 30 mg/kg, starting one day prior to immunization and once a week thereafter, 
and monitored until post immunization days (p.i.d) 112 and 168. The clinical score 
and histopathology were compared in parallel with those of a control group where five 
marmosets received PBS under the same experimental conditions. As shown in Figure 
1A, there was a marked reduction in EAE clinical score in the treatment group when 
compared to those of control marmosets (PBS or IgG1 isotype control, data not shown) 
(p <0.01), which correlated with Kaplan-Meier analysis of survival (Figure 1B). Consistent 
with the improvement in the clinical score was a significant reduction in demyelination 
(Luxol Fast Blue (LFB) staining) and axon degeneration (Bielschowsky staining) in the 
spinal cord of amino-Nogo-A Ab treated marmosets indicating a correlation between 
CNS pathology and clinical signs (Figure 1C-D).
Although the observed beneficial effects described above were accompanied with 
decreased infiltrating mononuclear cells by H&E staining in Ab treated group (Figure 
1C), there was no evidence to suggest that amino-Nogo-A antagonism had a direct 
anti-inflammatory effect as shown by the lack of surface amino-Nogo-A expression in 
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Figure 1. Amelioration of EAE in marmosets by amino-Nogo-A antibody treatment.
A, Individual clinical scores of EAE marmoset treated with amino-Nogo-A antibody (aNogoA mAb) 
and control. Animals (n=5/group) were administered intravenously with a humanized aNogoA mAb or 
control at 30 mg/kg, starting one day before immunization and every week thereafter and monitored 
until post immunization days (p.i.d) 112 and 168. B, Survival analysis in aNogoA mAb treatment and 
control groups. C, Representative spinal cord sections obtained from EAE marmosets analyzed for the 
degree of demyelination by LFB staining and axon integrity by Bielschowsky staining and infiltrating 
mononuclear cells by H&E staining. Scale bar, 600 µm (LFB, upper), 200 µm (LFB, lower), 200 µm 
(H&E) and 50 µm (Bielschowsky). (D) Percentage of demyelination areas in the white matter of spinal 
cord and the brain. See page 319 for a full-color representation of this figure.
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mononuclear cells derived from EAE marmosets, including CD4+ T-cells, B-cells, and 
macrophages (data not shown), and the lack of effect by amino-Nogo-A Ab treatment on 
T-cell reactivity to MOG, a causal activity of encephalitogenic T-cells (data not shown). 
Reduction in non-inflammatory demyelination in vivo and ex vivo by amino-
Nogo-A Ab 
To demonstrate the effect of amino-Nogo-A antagonism in myelination, we employed 
a non-inflammatory rodent CNS demyelination model induced by direct injection of LPC 
into the rat corpus callosum. As shown in Figure 2A, treatment with amino-Nogo-A Ab 
led to significantly reduced demyelination in corpus callosum compared to controls. 
Consistently, Toluidine blue staining of the lesion areas revealed a significantly decreased 
number of demyelinating axons (Figure 2B), which correlated with EM analysis of 
demyelinated axons in the affected corpus callosum (Figure 2B and 2C). At the border 
of the lesions, there was a significant increase in the number of preserved axons in the 
amino-Nogo-A Ab treated group while the number of demyelinated axons was markedly 
reduced (Figure 2B). EM analysis indicated that there was no difference in the total 
number of preserved axons between the two groups while the number of demyelinated 
axons in amino-Nogo-A Ab treated group was significantly reduced (Figure 2C). 
In both Toluidine and EM analyses, there was an increased number of small diameter 
axons in the treated group reminiscent perhaps of axon sprouting, which was confirmed 
by peripherin staining, a specific marker for axon sprouts16,17 (Figure 2D). 
To evaluate the role of amino-Nogo-A in myelination at the cellular level, we 
examined the effect of amino-Nogo-A Ab in an organotypic cerebellar slice culture 
system. This system has the advantage of maintaining the local CNS microenvironment 
and the interactions among the different neural cell types involved in demyelination and 
remyelination processes32. In this model, LPC treatment led to marked demyelination 
and, to a lesser extent, axonal injury, as shown by myelin basic protein (MBP) and 
neurofilament staining (Figure 3A). Addition of amino-Nogo-A Ab in the system restored 
the levels of MBP expression in oligodendrocytes and NF expression in axons as 
compared to those of isotype control (Figure 3A). The increase in areas positively co-
stained for MBP and NF indicated enhanced myelination and/or remyelination upon 
amino-Nogo-A Ab treatment (Figure 3A). Consistent with this observation was the 
increased expression of both MBP and Tuj-1 (a neuronal marker) in cerebellar slice 
homogenates as detected by Western blot analysis (Figure 3B). Furthermore, the 
enzymatic activity of CNPase (2, 3-cyclic nucleotide 3-phosphodiesterase) in immature 
or mature oligodendrocytes was significantly enhanced by the Ab treatment (Figure 3C). 
Increased MBP production and remyelination by amino-Nogo-A Ab was demonstrated 
in LPC-induced demyelination in cerebellar slice culture where amino-Nogo-A was 
released as a result of myelin breakdown. This was confirmed by the detection of 
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Figure 2. Reduction of demyelination and protection of axons by the treatment of amino-Nogo-A 
antibody in an lPC-induced demyelination model.
A, Area of demyelination by aNogoA mAb treatment in LPC-induced corpus callosum demyelination 
model. Brain samples were collected from mice 3 days after aNogoA mAb treatment or PBS control 
and analyzed for the degree of demyelination by LFB staining. Arrows point to the injection sites or 
needle tracts. Arrowheads indicate the demyelination areas. Scale bar, 500 µm (upper panels) and 200 
µm (bottom panels). Bar graph represents the quantification of the area of demyelination in the corpus 
callosum in relation to the indicated doses of aNogoA mAb. B, Toluidine blue staining of 1 μm corpus 
callosum sections (left) and magnified images of the boxed border areas (right). Scale bars, 2 µm. The 
bar graphs represent the total number of axons and % averages of demyelinated axons from the border 
areas. C, Representative electromicrographs of corpus callosum sections from normal and LPC-injected 
mice treated with aNogoA mAb (2 µg/mouse) or control. Red asterisks denote macrophages. Boxed 
areas are enlarged (bottom). D, Axon sprouting in the lesion area (white asterisks) as demonstrated by 
peripherin staining (green) or neurofilament H (red). *p < 0.05; **p < 0.01. See page 320 for a full-color 
representation of this figure.
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amino-Nogo-A in cerebellar slice homogenates by Western blot (Figure 3B) and by 
IHC staining (Supplemental Figure 2) and the direct inhibitory effect of soluble amino-
Nogo-A on MBP production in cerebellar slices (Figure 3D).
Furthermore, the potential inhibitory effect of amino-Nogo-A on neurite outgrowth 
was assessed in an in vitro neurite outgrowth assay where cerebellar granule neurons 
(CGN) were seeded on either amino-Nogo-A or Nogo66 recombinant protein coated 
plate, respectively. Amino-Nogo-A Ab specifically reversed the inhibition of neurite 
outgrowth induced by amino-Nogo-A, but not Nogo66 (Supplemental Figure 1A and 
B), and partially the inhibitory effect of myelin on neurite outgrowth (Supplemental 
Figure 1C). 
Figure 3. Restoration of axon integrity and myelination by amino-Nogo-A antagonism in lPC-
treated cerebellar slice culture.
A, Representative confocal images of LPC-treated cerebellar slice cultured with aNogoA mAb or IgG 
control. Oligodendrocytes were stained with MBP antibody (red) and axons were stained with antibody 
directed at neurofilament (NF, green). Myelinated axons are shown by co-staining (yellow). Scale bar, 
50 µm. B, Expression of MBP, Nogo-A, and Tuj-1 in LPC-treated cerebellar slice cultured with different 
concentrations of aNogoA mAb or IgG control. Actin was used as a control for protein loading. C, 
CNPase activity in LPC-treated cerebellar slice. Homogenates prepared from LPC-treated cerebellar 
slice cultured with either aNogoA mAb or IgG control were analyzed in a fluorometric assay. Numbers 
are expressed as percentage average normalized against untreated control. D, Expression of MBP in 
cerebellar slice subjected to indicated treatment conditions. Actin was used as a loading control. The 
data are representative of three independent experiments. *p < 0.05. See page 321 for a full-color 
representation of this figure.
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Effects of amino-Nogo-A and amino-Nogo-A antagonism on OPC differentiation 
and myelination 
To understand the role of amino-Nogo-A in myelination, we investigated its effect in 
differentiation, maturation, and myelination of OPC using a purified OPC culture system. 
The results showed that the addition of soluble amino-Nogo-A, but not Nogo66 (data 
not shown), resulted in a decreased number of MBP-expressing cells (Figure 4A) and a 
reduction in MBP expression in differentiating OPC (Figure 4B), suggesting that amino-
Nogo-A directly inhibits OPC differentiation. The inhibitory effect induced by amino-
Nogo-A was significantly reversed by amino-Nogo-A Ab (Figure 4A and B). To confirm 
the inhibitory effect of amino-Nogo-A on OPC differentiation, the expression of Nogo-A 
was knocked down by specific shNogo-A. Reduction of Nogo-A expression in OPC 
resulted in increased differentiation as evidenced by elevated MBP production (Figure 
4C) as well as from the morphology of mature oligodendrocytes (data not shown). 
To further assess the functional consequence of amino-Nogo-A inhibition on OPC, 
we examined the myelination of established DRG neurons in an OPC/DRG co-culture 
system as measured by MBP immunostaining. Addition of amino-Nogo-A inhibited the 
ability of oligodendrocytes to myelinate DRG neurons, which was abrogated by amino-
Nogo-A Ab but not by control IgG (Figure 4D). Furthermore, exposure of the co-culture 
system to amino-Nogo-A Ab restored the area of myelinated axons to levels comparable 
to those of controls. These results unveiled the novel role of amino-Nogo-A in OPC 
differentiation, maturation, and myelination.
Molecular mechanism underlying the inhibition of OPC differentiation and 
myelination 
To gain further insights into the molecular mechanism and signaling pathways 
underlying the inhibition of OPC differentiation and myelination induced by amino-
Nogo-A, we evaluated multiple signaling pathways that are involved in myelination, 
including Akt, Fyn, αv or β1 integrins, neuregulin, and Wnt4-8. The analyses led to the 
identification of Akt pathway as a critical signaling mechanism in the role of amino-
Nogo-A in myelination. As shown in Figure 5A, amino-Nogo-A-mediated inhibition of 
MBP correlated with a decreased level of phopho-Akt (pAkt), which was reversed by 
the treatment with amino-Nogo-A Ab. The involvement of pAkt in this process was 
further confirmed using a PTEN inhibitor BpvPhen (Figure 5A and 5B) that is known 
to antagonize decreased levels of pAkt by suppressing PTEN catalytic activity and 
impeding PTEN membrane localization33. In the presence of the PTEN inhibitor, there 
was a dose-dependent increase in the pAkt level accompanied by a corresponding 
elevation in MBP (Figure 5B). Thus, the results demonstrated that pAkt was involved 
in amino-Nogo-A mediated inhibition of OPC differentiation, maturation and MBP 
production. Alternately, when PDGF was used to enhance phosphorylation of Akt, the 
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Figure 4. Effect of amino-Nogo-A antagonism in amino-Nogo-A-mediated inhibition of OPC dif-
ferentiation, maturation, and myelination.
A-B, Inhibition of OPC differentiation by amino-Nogo-A (aNogoA). aNogoA at 4 mg/ml was added to 
OPC culture under differentiation condition in the presence or absence of aNogoA mAb for 4 days. 
The resulting OPC culture was analyzed for MBP staining (red, upper images) and the percentage of 
myelin producing oligodendrocytes was quantified by Cellomics (bar graph). The expression level of 
MBP was analyzed by Western blot. Scale bar, 50 µm. C, Reduction in the expression of Nogo-A by 
shRNA through lentivirus infection. OPC were infected with lentivirus containing either shNogo-A or 
control shRNA. The expression of Nogo-A and MBP in mature oligodendrocytes was determined by 
Western blot. D, Effects of aNogoA and aNogoA mAb on OPC and DRG co-culture. aNogoA was added 
to OPC and DRG co-culture in the presence of aNogoA mAb or IgG control. The resulting cultures were 
evaluated for myelination of DRG axons by MBP (red) and NF200 (green) co-staining. Scale bar, 50 
mm. The percentage of myelinated axons was quantified in the lower panel by Cellomics. The data are 
representative of three independent experiments. *p < 0.05. See page 322 for a full-color representation 
of this figure.
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inhibition of pAkt by amino-Nogo-A was reversed in the presence of amino-Nogo-A 
Ab (Figure 5C). Furthermore, purified OPC preparations were subjected to PCR 
array analysis following treatment with amino-Nogo-A in the presence or absence 
of amino-Nogo-A Ab. Expression levels of several genes associated with the Akt 
pathway were altered (data not shown) and their roles in the context of amino-Nogo-A 
signaling are currently under investigation. Collectively, our results suggest that the 
effect of amino-Nogo-A in OPC differentiation and maturation is mediated through 
the Akt pathway.
Figure 5. The role of Akt in amino-Nogo-A-mediated inhibition of OPC differentiation and maturation.
A, aNogoA-mediated inhibition of phosphorylated-Akt (pAkt) and MBP expression in differentiating OPC. 
pAkt, total Akt (tAkt) and MBP levels were determined by Western blot in the presence or absence of 
aNogoA and/or aNogoA mAb. B, Dose-dependent effect of a PTEN inhibitor on MBP and pAkt level in 
the presence of aNogoA. C, Inhibition of PDGF-induced pAkt in aNogoA-treated OPC culture. Actin and 
total Akt were used as loading control in all immunoblot analyses. The data are representative of three 
independent experiments.
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dISCuSSION
Nogo-A is one of the major oligodendrocyte myelin proteins that inhibit growth cones 
and CNS neurite outgrowth via the Rho/Rock pathway34. It is preferentially expressed 
on oligodendrocytes and located at both the outer and the inner adaxonal sheath of 
myelin35. The inhibition of Nogo-A by gene knockout20 or pharmacological agents, such 
as Nogo-A Ab, IN-1, NEP40, and soluble Nogo66 receptor, was shown to promote 
CNS axonal repair and functional recovery in a variety of CNS injury models, including 
rodent spinal cord injury and stroke models36-38. This study is the first demonstration 
indicating that amino-Nogo-A plays a critical role in myelination. We provide compelling 
evidence in vitro and in demyelinating animal models that the role of amino-Nogo-A is 
essential to the rate of myelination or myelin repair under pathological demyelinating 
conditions as amino-Nogo-A antagonism markedly altered the outcome of chemically 
induced or inflammation-induced demyelination in animal models. It is conceivable 
that accumulation of amino-Nogo-A contributes to the decreased rate of myelination 
or myelin repair seen in the CNS pathology in MS2,3. In MS lesions, CNS inflammatory 
insults lead to myelin degradation and the resulting myelin debris contain myelin 
proteins such as amino-Nogo-A. Our findings suggest that amino-Nogo-A present in 
the lesions is likely to suppress oligodendrocyte differentiation and maturation, hence 
affecting myelin repair. This notion is consistent with pathological characteristics of the 
MS lesions where OPC is abundantly present, but their ability to differentiate and repair 
damaged myelin is severely impaired. 
The potential of amino-Nogo-A Ab as a myelin repair therapy for MS is best 
demonstrated by a marked reduction in demyelination in marmoset EAE model that 
closely resembles the human MS pathology21. The myelination effect of amino-Nogo-A 
Ab is specific, as an Ab for myelin associated glycoprotein (MAG) did not exhibit similar 
efficacy in the same marmoset EAE model (data not shown). Such therapy directly 
targeting myelination is novel and urgently needed to complement the immunomodulatory 
treatments that only address the inflammatory component of a complex pathological 
mechanism in MS. In this study, we also addressed the question of whether the 
therapeutic efficacy by amino-Nogo-A Ab was partially attributed to a potential anti-
inflammatory effect of the Ab in marmoset EAE. However, our results do not support this 
possibility, because (a) amino-Nogo-A is not expressed on inflammatory cells, including 
T-cells, B-cells, and macrophages; (b) T-cell reactivity to MOG and their cytokine profile 
that are critical for encephalitogenicity are not altered in EAE induced marmosets treated 
with amino-Nogo-A Ab. Similar findings were reported in a recent study using siRNA 
specific for amino-Nogo-A in rodent EAE39. Furthermore, it is important to note that 
although the Ab is not readily permeable to the blood-brain barrier, it does accumulate 
in sufficient concentrations in CNS following its characteristic pharmacokinetic profile40. 
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There are many examples in literature where CNS-directed Ab is proven to achieve its 
CNS effects or clinical outcome through target engagement in both animal models and 
human trials40,41.
In this study, various forms of the amino-Nogo-A Ab, including the full length Ab, 
bivalent F(ab)2, and monovalent Fab preparations were found equally effective in 
neutralizing LPC-induced reduction of MBP in cerebellar slice culture systems while 
the Ab has no direct effect on purified OPC (data not shown). This suggests that the 
site of action for the Ab may be restricted to exogenous amino-Nogo-A, excluding the 
possibility of an alternative mechanism for amino-Nogo-A Ab to interfere with membrane 
expressed Nogo-A with its putative receptor complex occurring at the OPC membrane 
surface. It is also likely that amino-Nogo-A interacts with its putative Nogo-A receptor on 
a neighbouring OPC. However, this notion needs to be investigated as shRNA-Nogo-A 
knock down leads to the increased expression of MBP, which indicates that either 
surface expressed amino-Nogo-A or intracellular endoplasmic reticulum-expressed 
Nogo-A or both, are inhibitory to OPC differentiation and myelination. The amino-Nogo-
A-mediated myelination effect is specific and is not expected from Nogo66 and NgR 
interactions, as NgR is absent in oligodendrocytes (data not shown). Thus, the two 
distinct domains of Nogo-A may differentially regulate growth cone formation, axon 
growth, and myelination. The amino-Nogo-A-mediated myelination effect is specific and 
is not expected from Nogo66 and NgR interactions, as NgR is absent in oligodendrocytes 
(data not shown). Thus, the two distinct domains of Nogo-A may differentially regulate 
growth cone formation, axon growth, and myelination. 
Another important finding from this study is related to signaling mechanism involved 
in amino-Nogo-A-mediated inhibition of myelination. A variety of signaling pathways 
including Akt, Fyn, αv or β1 integrins, neuregulin, and Wnt4-8,42, were tested in this study to 
identify the molecular mechanism. Only Akt phosphorylation was found to correlate with 
MBP expression and oligodendrocyte maturation. To date, other than amino-Nogo-A, 
modulation of Lingo-1 has been shown to promote myelination in vivo29. However, the 
two inhibitory proteins mediate the effect through different signaling events. In case 
of Lingo-1, RhoA is involved in the inhibition of OPC differentiation and myelination29. 
The mechanism of Lingo-1 modulation via Lingo-1 Ab is complex, as Lingo-1 is not 
only expressed on both neuronal and oligodendrocyte surfaces but itself represents 
part of the NgR/p75/Lingo-1 receptor complex. It is expected that modulation of either 
amino-Nogo-A or Lingo-1 triggers different signal pathways/events. The information 
may provide an important clue in search of a putative receptor for amino-Nogo-A. 
In conclusion, amino-Nogo-A, presented either as degraded fragment from damaged 
myelin (Nogo-A) or as a structural domain of the Nogo-A molecule expressed on 
oligodendrocyte surface, negatively modulates myelination through a ‘trans’ interaction 
with a putative amino-Nogo-A receptor on OPC via the Akt signaling pathway. This newly 
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discovered property of amino-Nogo-A provides a novel explanation for the decreased 
rate of myelination or myelin repair under pathological demyelinating conditions. The 
evidence presented here supports the role of amino-Nogo-A antagonism as a novel 
therapy for MS by promoting CNS myelin repair through increased oligodendrocyte 
differentiation and maturation. 
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SuPPlEMENTAl FIGuRES
Supplemental figure 1. The effect of amino-Nogo-A and amino-Nogo-A antagonism on neurite 
outgrowth.
aNogoA mAb or IgG control at the indicated concentrations was added to CGN culture in the presence 
of soluble aNogoA (A), soluble Nogo66 (B), or myelin (plate-coated) (C) for 72 h. Neurite outgrowth was 
measured by Cellomics and expressed as % of neurite length compared to untreated control. *p < 0.05; 
**p < 0.01. The data are representative of three independent experiments.
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Supplemental figure 2. Amino-Nogo-A expression in cerebellar slice culture.
Cerebellar slice culture was co-stained with aNogoA mAb (green) or antibodies to PDGFRa or MBP 
(red). Scale bar, 20 µm. See page 323 for a full-color representation of this figure.
Proefschrift Yolanda Kap_compleet.indd   231 25-08-2010   21:25:21
Proefschrift Yolanda Kap_compleet.indd   232 25-08-2010   21:25:21
1Department of Immunobiology, Biomedical Primate Research Centre, Rijswijk, 
The Netherlands; 2Department of Immunology, Erasmus Medical Centre, 
Rotterdam, The Netherlands; 3MS Centre ErasMS, Rotterdam, The Netherlands; 
4Image Sciences Institute, University Medical Center Utrecht, Utrecht,  
The Netherlands
Yolanda S. Kap1,2,3, Nikki van Driel1, Erwin Blezer4, Robbert Benner2, Nisar A. 
Khan2, Jon D. Laman2,3, and Bert A. ’t Hart1,2,3
Early treatment with the synthetic hCG-related 
tetrapeptide lQGV does not modulate experimental 
autoimmune encephalomyelitis in marmosets 
4.5
Proefschrift Yolanda Kap_compleet.indd   233 25-08-2010   21:25:21
Proefschrift Yolanda Kap_compleet.indd   234 25-08-2010   21:25:21
 No effect of LQGV on marmoset EAE
235
ABSTRACT
The relapse rate of multiple sclerosis (MS) is decreased during the third trimester 
of pregnancy, but increased in the first three months after delivery. During the third 
trimester, β-core and presumably other fragments derived from the β-subunit of human 
chorionic gonadotropin (hCG) may be present in serum. Synthetic peptides related to the 
hCG β-subunit have remarkable modulatory effects in a broad variety of, mostly acute, 
inflammatory responses. In this study, we investigated whether the synthetic β-hCG-
related tetrapeptide LQGV has modulatory potential in a more chronic inflammatory 
disease using a well-established experimental autoimmune encephalomyelitis (EAE) 
model in common marmosets. EAE was induced in marmosets by immunization with a 
mixture of two synthetic peptides, representing amino acids 34 to 56 and 74 to 96 from 
myelin oligodendrocyte glycoprotein (MOG34-56 and MOG74-96). The peptides were 
emulsified in incomplete Freund’s adjuvant (IFA) and injected into the dorsal skin of five 
male marmosets. LQGV (50 mg/kg) was administered by subcutaneous injection three 
times per week starting two days after immunization to avoid direct interference with the 
immunization procedure. Treatment with LQGV did not have a consistent effect on the 
EAE course in this model, as observed by the clinical scores, lesion load, autoantibody 
levels, or T-cell responses. We conclude that the EAE course in marmosets induced by 
two MOG peptides in IFA is not modulated by LQGV when given three times per week 
at a 50 mg/kg dose.
INTROduCTION
Multiple sclerosis (MS) is a chronic disease characterized by inflammation, 
demyelination, and axonal injury in the central nervous system (CNS). MS manifests itself 
as a relapsing-remitting disease in about 80% of patients. The average age of onset is in 
the third or fourth decade of life, thus often affecting women of childbearing age1. During 
pregnancy, on a population basis, the relapse rate decreases with 70% in the third trimester, 
but increases in 30% of the women in the first three months after delivery compared to 
the pre-pregnancy year2. This increase correlates with the relapse-rate before and during 
early pregnancy2,3. The cause of the reduced relapse rate during pregnancy is unknown, 
but data from animal models suggests a modulatory role of pregnancy hormones, such as 
estradiol4 or estriol5. It has been suggested that during pregnancy the adaptive immune 
response is skewed away from Th1 towards Th26,7, although this hypothesis may need 
revision8. Pregnancy hormones may be used as treatment for MS9. Treatment of MS 
patients with estrogen reduced the number and volume of brain lesions, which correlated 
with a cytokine shift suggesting Th2 skewing10,11.
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During pregnancy, placental syncytiotrophoblasts produce the hormone human 
chorionic gonadotropin (hCG)12. The serum hCG level increases in the first trimester 
and peaks in week 10 of pregnancy, which is followed by a decline during the second 
and third trimester12. This pregnancy hormone is a member of the pituitary glycoprotein 
hormone family and consists of a common α-subunit, which is shared with other members 
of the hormone family, and a unique β-subunit13. During pregnancy loop-2 of β-hCG is 
either nicked or excised. In the latter case β-core is the major metabolic product of hCG, 
which is excreted in the urine12. It has been suggested that besides β-core and other 
metabolic forms of β-hCG also small breakdown products of three to seven amino acids 
might be generated from the β-loop 2 sequence MTRVLQGVLPALPQ14.
Previous work has shown remarkable immunomodulatory effects of β-loop 2-related 
oligopeptides in animal models for a variety of acute inflammatory models15-19. An 
example of the in vivo potency of oligopeptides was the suppression of LPS- or E. 
coli-induced septic shock in mice and non-human primates by one (e.g. LQGV, AQGV) 
or a mixture of three (LQGV, AGQV, VLPALP) β-loop 2-related oligopeptides19. So far, 
AQGV and LQGV were the most promising β-loop 2-related oligopeptides in all models 
tested (Table 1).
These findings led us to investigate the effect of LQGV on experimental autoimmune 
encephalomyelitis (EAE), which is a chronic inflammatory animal model for MS. We 
have used a unique EAE model in the Neotropical primate common marmoset (Callithrix 
jacchus)20. We have previously demonstrated that the core immunopathogenic 
activity in this model is exerted by T-cells specific for amino acid 34 to 56 from myelin 
oligodendrocyte glycoprotein (MOG34-56). These T-cells express the natural killer (NK) 
cell marker CD56, are cytotoxic, and produce IL-17A21,22. These T-cells can be activated 
in vivo by immunization with MOG34-56 in incomplete Freund’s adjuvant (IFA)22. 
Table 2. Overview of monkeys included in this study.
PBS lQGV
Monkey Sexa Ageb Weightc Monkey Sexa Ageb Weightc
M06017 M 21 352 M03148 M 48 319
M05056 M 27 388 M06011 M 20 316
M05082 M 25 393 M06005 M 21 346
M03162 M 47 352 M05045 M 17 433
M06012 M 20 370 M06023 M 20 336
Mean 28.0 371 Mean 25.2 350
S.D. 11.0 19.3 S.D. 12.8 48
a M, Male; F, Female 
b Age in months of the monkeys at the start of the experiment
c Body weight of the monkeys at the start of the experiment
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The aim of this study was to investigate the effect of one of the most potent β-hCG 
derived synthetic tetrapeptides, i.e. the effect of LQGV treatment on EAE induced 
by immunization with MOG34-56 and MOG74-96 in IFA. We have found that LQGV 
displayed no consistent modulatory effect on the clinical score, CNS lesion load, or 
cellular and humoral autoimmune parameters in the treatment regimen chosen.
 
MATERIAlS ANd METHOdS 
Animals
The common marmoset monkeys used in this study were randomly selected from 
the outbred colony kept at the Biomedical Primate Research Centre (Rijswijk, The 
Netherlands) under conventional conditions. Animals were included after a complete 
physical, hematological, and biochemical check-up had been performed. Animals 
included in the study are listed in Table 2. The control animals were shared with another 
experiment aiming at further validation of the IFA model22. During the study, monkeys 
were pair-housed in spacious cages and under intensive veterinary care. The daily diet 
consisted of commercial food pellets for New World monkeys (Special Diet Services, 
Witham, Essex, UK), supplemented with rice, raisins, peanuts, marshmallows, biscuits, 
and fresh fruit. Drinking water was provided ad libitum. According to the Dutch law on 
animal experimentation, all study protocols and experimental procedures have been 
reviewed and approved by the Institute’s Ethics Committee. 
EAE induction
EAE was induced with 100 µg MOG34-56 and 100 µg MOG74-96 (ABC Biotechnology, 
London, UK and Cambridge Research Biochemicals, Cleveland, UK) emulsified in 300 
µl phosphate buffered saline (PBS) and 300 µl IFA (Difco Laboratories, Detroit, MI). 
Antigen-adjuvant emulsions were prepared by gentle stirring the peptide/oil mixture 
at 4°C for at least 1 h. The inoculum was injected at four locations into the dorsal 
skin under ketamine anesthesia (40 mg/kg; Produlab Pharma, Raamsdonkveer, The 
Netherlands). Booster-immunizations were given every four weeks until the monkeys 
developed clinical score 2 (see below). 
Clinical signs were scored daily by two independent observers using a previously 
described semi-quantitative scale23. Briefly, 0 = no clinical signs; 0.5 = apathy, loss of 
appetite, altered walking pattern without ataxia; 1 = lethargy, anorexia, tail paralysis, 
tremor; 2 = ataxia, optic disease; 2.25 = monoparesis; 2.5 = paraparesis, sensory 
loss; 3 = para- or hemiplegia. For ethical reasons monkeys were sacrificed before or 
once complete paralysis of limbs (score ≤ 3.0) was observed, or at the pre-determined 
endpoint of the study (post sensitization day (psd) 162). Body weight measurements 
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of conscious monkeys, which is used as a surrogate disease marker, were performed 
three times per week.
Monkeys selected for necropsy were first deeply sedated by intramuscular ketamin 
anesthesia (40 mg/kg) and subsequently euthanised by infusion of pento-barbital 
sodium (Euthesate; Apharmo, Duiven, The Netherlands).
Treatment regimen
Synthetic LQGV (GL Biochem, Shanghai, China) with a purity of >99% (manufacturer’s 
information) was dissolved in 10 mM PBS (pH 7.4) to a concentration of 50 mg/ml. 
Treatment with LQGV (50 mg/kg body weight) was started two days after immunization 
and repeated three times per week (psd 2, 4, 7, 9, 11, 14, 16, 18, etc). Before each 
administration, LQGV was dissolved freshly. Animals received 1 ml/kg body weight of 
50 mg/ml LQGV subcutaneously in the flank. Control animals received 1 ml/kg body 
weight 10 mM PBS.
Blood sampling 
Venous blood was collected into heparinized vacutainers (Greiner, Sölingen, 
Germany) under ketamin anesthesia (40 mg/kg) every two weeks. After centrifugation 
plasma was collected and stored frozen at -20°C until further analysis. 
At necropsy, the number of red and white blood cells was measured using a Sysmex 
XT-2000iV (Sysmex, Norderstedt, Germany).
Magnetic resonance imaging
Post-mortem magnetic resonance imaging (MRI) was performed as described22. 
Briefly, brain hemispheres were fixed for two weeks in 4% buffered formalin and then 
transferred to PBS containing azide for equilibration purposes24. Post mortem images 
were obtained on a 9.4 T MRI scanner (Varian, Palo Alto, CA). Before scanning, brains 
were submerged in perfluoropolyether (Fomblin) to prevent unwanted susceptibility 
artefacts. White matter lesion load was qualitatively determined and ranged from 0 (no 
lesions) to 10 (complete destruction of white matter).
T-cell responses
T-cell proliferation was determined as described21,22. Briefly, mononuclear cell 
suspensions from blood or secondary lymphoid organs were cultured for 64 h with 
a panel of 23-mer synthetic MOG peptides or recombinant human MOG protein 
(rhMOG). Proliferation was assessed by incorporation of [3H]-thymidine (0.5 µCi/well) 
(PerkinElmer, Boston, MA) during the last 16 h of the culture, which was measured 
using a matrix 9600 β-counter (Packard 9600; Packard Instrument Company, Meriden, 
CT). Results are expressed as the mean stimulation index (SI), which is defined as the 
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counts per minute (cpm) of stimulated cells divided by the cpm of unstimulated cells. SI 
values above 2.0 were considered to be relevant. 
Phenotyping of proliferating cells was performed using CFSE vital dye dilution as 
described21. Briefly, CFSE labeled mononuclear cells were cultured for 7 days with MOG 
peptides. Cells were stained with Alexa Fluor 700-labeled anti-CD3 (BD Biosciences, 
CA), APC-labeled anti-CD4 (Zebra Bioscience, Enschede, The Netherlands), biotinylated 
anti-CD8 (Serotec, Düsseldorf, Germany), streptavidin PerCP (BD Biosciences), and 
PE-Cy7-labeled CD56 (BD Biosciences). Flow cytometric analysis was performed on a 
FACS LSRII flow cytometer using FACSDiva software 5.0 (BD Biosciences).
Supernatants of peripheral blood mononuclear cells (PBMC) or mononuclear cells 
from axillary lymph node (ALN) and spleen were collected after 48 h stimulation with 
MOG peptides. Cytokine levels were determined by ELISA, which was performed 
according to the manufacturers instructions for monkey tumor necrosis factor-α (TNF-α) 
and monkey interferon-γ (IFN-γ) (U-Cytech, Utrecht, The Netherlands) and human 
cross-reactive interleukin-17A (IL-17A) (eBioscience, San Diego, CA). 
Autoantibodies
Anti-MOG antibodies were determined as described22. Briefly, venous blood samples 
were centrifuged and plasma supernatants were collected and stored at -20°C until further 
analysis. Antibody binding to rhMOG or to a panel of overlapping 23-mer MOG peptides 
was determined using ELISA. Bound IgM was detected using alkaline phosphatase-
conjugated goat-anti-monkey IgM (Rockland Immunochemicals, Gilbertsville, PA) and 
bound IgG Ab was detected using alkaline phosphatase-conjugated rabbit-anti-human 
IgG (Abcam, Cambridge, UK). The results of the antibody assays are expressed as fold 
increase of light absorbance at 405 nm compared to the reactivity present in sera of 
non-immunized marmosets.
Table 3. Primer and probe combinations for quantitative PCR.
Gene Forward primer Reverse primer Probe
ABL CAGAGAAGGTCTATGAACTCATGC GGTGGATTTCAGCAAAGGAG GCAGTGGA
CD3 AGGCAAGAGTGTGTGAGAACTG GATGCAGATGTCCACTATGACAA GGAGGTGG
IL-17A CCTCATTGGTGTCACTGCTG TGCAATTCCTGCCTTCACTA GCTGCTGA
IFN-γ GGAGAGAGGAGGGTGACAGA TTGGATGCTCTGGTTGTCTTTA CAGAGCCA
TNF-α GGACGAGCTCTCCAAGGACT GTCACTCGGGATTCGAGAAG GGCCCTGG
IL-4 CTAAAACGGCTGGACAGGAA CCTTCACAGGACAGGAGTTCA CAGCCTGG
IL-6 CCAATCTGGATTCAATGAGGA AACTCCAAAAGACCAGTGGTGA GCCTGCTG
IL-10 GTTGCCTTCAGCAGAGTGAA GCAACCCAGGTAACCCTTAAA TGCTGGAG
IL-1β TGGTCCTAAACAGATGAAGTGC GTAGTGCTGGCGGGAGAGT GACCTGGA
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Quantitative PCR
Spleen and lymph nodes were collected aseptically and a small part was stored 
in RNAlater (Sigma, St. Louis, MO). RNA was isolated using RNeasy minikit (Qiagen, 
Hilden, Germany) and cDNA was synthesized using RevertAid First Strand cDNA 
Synthesis Kit (Fermentas, St. Leon-Rot, Germany) according to the manufacturers 
instructions. Random hexamer primers were used for cDNA synthesis. Expression 
levels of mRNA were determined by quantitative PCR using iTaq supermix with ROX 
and CFX96 Real-Time System (both from Bio-Rad, Hercules, CA). Primer and probes 
used are listed in table 3. Probes were obtained from the Universal Probe Library set 
for human (Roche, Indianapolis, In). Transcript levels were normalized against the 
reference gene abelson (ABL)25.
Statistics
Data are presented as mean ± sem of 5 control and 4 LQGV-treated marmosets. 
Statistical analysis was performed using Prism 5.0b for Mac OS X. Survival was 
analysed using Log-Rank test. Other data was analysed using the Mann-Whitney U 
test. p < 0.05 was considered statistically significant.
RESulTS
Treatment with lQGV has no effect on clinical score
Ten marmosets were immunized with MOG34-56 and MOG74-96 in IFA and boosted 
with the same peptides in IFA at psd 25, 56, 84, and 133. From psd 2 onwards five 
animals were subcutaneously treated with LQGV at 50 mg/kg, which was repeated 
three times per week throughout the study. The other five animals received PBS three 
times per week (Table 2). All five control animals developed neurological deficit (score 
≥ 2). One control animal (M06012) recovered within one week and remained devoid 
of neurological deficit, whereas the other four control animals were sacrificed with 
evident neurological disease (Figure 1A). Three of the five animals treated with LQGV 
developed neurological disease indistinguishable from the control animals and one 
animal (M05045) only developed clinical score 1 (Figure 1A). One of the five animals 
(M06023) of the LQGV group unexpectedly succumbed at psd 34. Post-mortem 
examination revealed a generalized septic process caused by unknown agents. This 
animal was excluded from further analyses. LQGV had no effect on disease-free 
survival (survival until score 2, Figure 1B) nor on survival until sacrifice with overt 
neurological deficit (survival until day of sacrifice with clinical score ≥ 2, Figure 1C). 
These data demonstrate that at this dose and treatment regimen LQGV does not 
ameliorate nor exacerbate EAE.
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Figure 1. lQGV does neither ameliorate nor exacerbate clinical signs of EAE. 
A, The post sensitization day is indicated on the x-axis. Animals were immunized on day zero and 
boosted on the days indicated with the arrows. Shown are the clinical scores of control (left row) and 
LQGV-treated (right row) animals. Dotted lines indicate the percentage of body weight loss compared to 
the day of immunization (left y-axis). Solid lines indicate the clinical score (right y-axis). Cyphers indicate 
the day of sacrifice. LQGV did not change the survival time until score 2 (B) or until the day of sacrifice 
with clinical symptoms ≥ 2 (C).
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Figure 2. white matter lesion load is comparable between control and lQGV-treated animals. 
Shown is a representative brain slice of each animal. Lesion load is scored from 0 (no lesions) to 10 
(complete destruction of white matter) and is indicated under each animal number. 
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No change in CNS lesion load after lQGV treatment
At necropsy, one brain hemisphere was fixed in formalin for two weeks and then 
analysed by post-mortem MRI. T2-weighted images were used to qualify lesion load. 
The images did not show marked differences in lesion load between control and LQGV-
treated animals (Figure 2).
No effect of lQGV on cell numbers in blood
The number of white blood cells was determined before the start of the experiment 
and at necropsy. Before the immunization, all animals had comparable numbers of 
total white blood cells (Range: 2.3 – 8.3 x 109/l), lymphocytes (Range: 1.5 - 4.0 x 109/l), 
monocytes (Range: 0.07 - 0.25 x 109/l), and neutrophils (Range: 0.59 – 4.33 x 109/l). 
At necropsy, one control animal (M05056) showed a profound increase of monocytes 
and neutrophils, but not of lymphocytes. In all other control and LQGV-treated animals 
comparable numbers of white blood cells, lymphocytes, neutrophils, and monocytes 
were observed (Figure 3). These data show that LQGV has no obvious hematological 
effect in this animal model. )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Figure 3. lQGV treatment does not affect the white blood cell numbers during EAE.
The number of total white blood cells, lymphocytes, monocytes, and neutrophils were counted before 
immunization (white bars) and at necropsy (black bars). 
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No effect of lQGV on (auto)immune responses
The effect of LQGV on humoral and cellular immune responses during EAE was 
investigated at the level of autoantibodies, T-cell proliferation, and cytokine production.
Antibodies: Plasma levels of IgM and IgG antibodies against MOG34-56, MOG74-
96, and rhMOG were determined in blood samples collected throughout the study. IgM 
and IgG antibodies against the two immunizing MOG peptides were detected in both 
groups. We observed no IgM against rhMOG and only limited levels of IgG against 
rhMOG. Animals treated with LQGV had similar profiles of IgM and IgG antibodies as 
compared to control animals (Figure 4).
T-cell proliferation: In marmoset peripheral blood only low level proliferation against 
rhMOG and MOG peptides can be measured during EAE studies. Hence, we analysed 
T-cell proliferation only in blood and lymphoid organs collected at necropsy. Of one 
control animal (M05056), no proliferation data were available due to technical failure. 
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Figure 4. All animals produced IgM or IgG in response to the immunizing MOG peptides. 
IgM and IgG levels against MOG34-56, MOG74-96, and rhMOG were measured in plasma obtained 
every two weeks. The post sensitization day is indicated on the x-axis. IgM (two upper rows) and IgG 
(two lower rows) levels are shown as fold increase relative to plasma of non-immunized marmosets. 
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PBMC of two of the four control animals and of one of the four LQGV-treated animals 
proliferated in response to MOG34-56. Splenocytes of all four control animals displayed 
proliferation against MOG34-56 while this was detected in only two of the four LQGV-
treated animals. Splenocytes of three of the four control animals proliferated against 
the other immunizing peptide MOG74-96, in contrast to only one LQGV-treated animal. 
All LQGV-treated animals and three control animals had cells that proliferated against 
the immunizing MOG peptides in their ALN and ILN, which drain the dorsal immunization 
sites. In three of the four control monkeys we observed proliferation against rhMOG in 
the CNS draining CLN, whereas this response was found in only one LQGV-treated 
monkey (Figure 5A).
 The phenotype of proliferating cells in PBMC, spleen, and ALN was assessed 
by the CFSE dye dilution assay. Both CD4 and CD8 cells of the spleen showed a 
somewhat reduced proliferation towards the immunizing MOG peptides, although the 
number of animals analysed was limited. We observed no such difference in PBMC 
or ALN (Figure 5B).
Cytokines: To investigate whether LQGV had an effect on cytokine profiles, PBMC 
or mononuclear cell suspensions from spleen or ALN were cultured with rhMOG or 
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)ROGLQFUHDVH%$ 6,6, 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Figure 5. In vivo lQGV treatment does not affect T-cell proliferation in vitro. 
A, T-cell proliferation at necropsy was determined by the [3H]-thymidine incorporation assay. The 
ranges of the stimulation index are shown in grey-scale. Upper bars, control monkeys; lower bars, 
LQGV-treated monkeys. B, The phenotype of proliferating cells was determined with the CFSE dye 
dilution assay assay. Mononuclear cell suspensions from blood, spleen, and ALN of some animals were 
stimulated with MOG34-56 or MOG74-96. The fold increase is calculated by dividing the percentage 
of dividing CD3+CD4+ or CD3+CD8+ T-cells after stimulation by the percentage of dividing cells without 
stimulation. ALN, axillary lymph node; CLN, cervical lymph node; ILN, inguinal lymph node; hMOG, 
human myelin oligodendrocyte glycoprotein.
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immunizing MOG peptides for 48 h. Since the amount of supernatant and the availability 
of cross-reactive ELISA are limited, protein levels of only IL-17A, IFN-γ, and TNF-α were 
analysed in the supernatant. IFN-γ was hardly detectable, i.e. only PBMC of M06012 
and splenocytes of M06017 produced detectable IFN-γ in response to MOG34-56 (data 
not shown). Similar levels of TNF-α were detected in PBMC and spleen of both groups. 
Mononuclear cells derived from the ALN did not produce TNF-α after stimulation. The 
number of animals with IL-17A secreting cells in the spleen or ALN was lower in the LQGV 
group than in the control group. No differences were observed in PBMC (Figure 6A).
Finally, we assessed mRNA expression levels of CD3, to investigate whether the 
T-cell number had changed, and selected cytokines in spleen and ALN. No significant 
differences in the expression levels between control and LQGV-treated animals were 
observed, although IFN-γ, TNF-α, and IL-4 tended to be increased in the ALN of LQGV-
treated animals (Figure 6B).
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Figure 6. lQGV does not change cytokine levels. 
A, Cytokine production (pg/ml) was determined in supernatant of cells cultured for 48 h with MOG34-56, 
MOG74-96, or rhMOG. Upper bars, control monkeys; lower bars, LQGV-treated monkeys. B, mRNA 
expression levels of CD3 and indicated cytokines in spleen and axillary lymph node (ALN) are shown 
relative to ABL. No RNA could be isolated from the LQGV-treated animal M03148.
Proefschrift Yolanda Kap_compleet.indd   247 25-08-2010   21:25:25
Chapter 4.5
248
Cortisol levels
Corticosteroids have many immunomodulatory effects that may be beneficial in MS 
and are widely used to accelerate MS relapse recovery26-28. Several lines of evidence 
suggest an influence of stress on the occurrence of relapses in MS and EAE. In addition, 
the hypothalamic-pituitary-adrenal axis, which is involved in cortisol production, may be 
disturbed in MS29. Cortisol concentrations are increased during the second and third 
trimester of pregnancy30. 
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Figure 7. lQGV does not elevate cortisol levels in plasma. 
Cortisol levels were determined in plasma every two weeks. Shown are the individual data (A) and 
mean ± sem (B). It is important to note that the average cortisol levels were influenced after psd 50 by 
the death of some animals and the remaining number of animals. Therefore, cortisol levels are shown 
until psd 80 without necropsy samples. The increase in cortisol in animal M06023 may be caused by the 
septic process and therefore M06023 was not included in the mean cortisol levels (B). Cortisol levels 
at necropsy are shown in C. M06012 and M05045 were sacrificed without clinical symptoms of EAE as 
shown in figure 1.
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In order to determine whether LQGV interferes with the cortisol production in this 
model, we analysed cortisol levels in plasma. During the study, analysed until psd 80, no 
differences were observed in cortisol level between control and LQGV-treated animals 
(Figure 7A-B). In the control group, one animal (M05056) had an increase in cortisol at 
the moment it developed clinical score 2. This animal had also the highest cortisol level 
at necropsy (Figure 7C). In the LQGV group one animal (M06023) had higher levels 
of cortisol, but this animal was sacrificed for other reasons than EAE that may have 
induced cortisol production. No obvious difference in cortisol levels between the two 
groups was observed at necropsy (Figure 7C).
dISCuSSION
During the third trimester of pregnancy the relapse rate of MS decreases with 70%2. 
During the same period derivatives from the hCG β-core can be detected in plasma and 
urine12. It has been hypothesized that in this period small breakdown products might 
be generated from the sequence MTRVLQGVLPALPQ, which comprises the loop 2 
of β-hCG. These small breakdown products may be three to seven amino acids long, 
based on preferential cleavage sites14. VLPALP was the first peptide from this sequence 
that was shown to be biologically active in an LPS-induced shock model in mice15. Since 
the reduction of the MS relapse rate and the production of hCG derivates concur in the 
third trimester, we hypothesized that a causal relationship may exist. In this study, we 
have investigated the effect of the four amino acid peptide LQGV in the marmoset EAE 
model, an animal model for MS. We observed that treatment with 50 mg/kg LQGV three 
times per week starting two days after EAE induction had no robust effect on clinical 
signs, pathology, or the immune response. 
Although LQGV did not significantly alter the immune parameters in the marmoset 
EAE model, some changes in the spleen were observed in individual animals. 
Proliferation was reduced in both the CD4 and CD8 T-cell compartment of the spleen. 
IL-17A production in response to MOG stimulation was reduced, although total IL-17A 
mRNA expression was not altered. During necropsy, the spleen of the LQGV-treated 
M03148 appeared dark brown and no leukocytes or RNA could be isolated, suggesting 
that the spleen did not contain viable lymphocytes. The spleen of the LQGV-treated 
M06011 was strongly enlarged and we were able to culture splenocytes of this animal 
for 135 days in standard culture medium without adding exogenous growth factors 
or cytokines. Most of these splenocytes expressed CD20, a B-cell marker (data not 
shown). A speculative interpretation was that LQGV might have suppressed immune 
functions engaged in the control of latent (herpes)viruses, such as the marmoset 
lymphocryptovirus CalHV3. In that case the CD20+ cells could have been immortalized 
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B-cells31. However, our attempts to positively identify an EBV-related virus have failed 
thus far.
Although LQGV neither reduced nor exacerbated the clinical signs or pathology 
in the marmoset EAE model, it induced significant changes in other animal models 
(Table 1). LQGV reduced inflammation and organ damage in a rat hemorrhagic shock 
model16, and a cocktail of three peptides, among which LQGV, reduced pathology in 
a rhesus macaque E. coli induced shock model19. LQGV also increased survival in 
mice after LPS challenge19, renal-ischaemia-reperfusion injury in mice17, and in a low-
grade cecal ligation and puncture (CLP) model in mice (J.W. van den Berg, personal 
communication). LQGV also enhanced the susceptibility to Listeria monocytogenes in 
mice when treatment was started prior to infection, which was associated with decreased 
neutrophil recruitment and increased production of pro-inflammatory cytokines18. 
Why is LQGV effective in these models and not in the marmoset EAE model induced 
by two MOG peptides in IFA? First, EAE in marmosets is a chronic disease that can last 
more than 100 days, whereas all the other models are more acute disease models. The 
chronicity of the model has two consequences, namely the number of LQGV injections 
and the predominance of adaptive over innate immune responses. The average day 
of onset of clinical symptoms in the marmoset EAE model induced by the two MOG 
peptides in IFA is about 70 days. Although CNS pathology may exist earlier, there is 
a profound difference in the experimental time line of this EAE model with the other 
models in which the peptides have been tested. Clinical symptoms and pathology are 
present within one week after disease induction in most other models that are shown in 
Table 1. The only exception is the CLP study in mice that lasted 21 days. We decided 
to chronically treat the marmosets with LQGV, i.e. 3 times per week. This is in contrast 
with the other models in which the total number of injections was limited to 1 to 4. 
The models listed in table 1 are all dominated by innate immune responses, involving 
effector mechanisms of macrophages and neutrophils. Adaptive immune responses can 
play a role, e.g. in L. monocytogenes infection, but not within the time line in which the 
β-hCG-related peptides were tested18. In contrast, in the marmoset EAE model T-cells 
are one of the most important pathogenic cells, whereas the activation of innate antigen 
receptors by the inoculum is not required for the induction of the disease21,22. 
Second, the concentration and dose regimen are different. Marmosets were treated 
subcutaneously with 50 mg/kg three times per week starting 2 days after immunization. 
Treatment was started two days after immunization to prevent interference with the first 
days of immune activation. In all the other models the treatment was started earlier 
(Table 1) and the LQGV was administered intravenously or intraperitoneally. In all 
models 5 mg/kg was given once or twice, except in the L. monocytogenes infection 
model where 50 mg/kg was administered daily during the 3 days of the experiment. 
The subcutaneously route in marmosets was chosen because intraperitoneal injection 
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is not a preferred dosing route in marmosets and intravenous injection three times per 
week for 160 days is causing too much discomfort. Unfortunately, we have no methods 
available to trace LQGV in vivo prohibiting in vivo pharmacokinetic experiments. 
Third, it has not been formally demonstrated that hCG-related oligopeptides pass 
the blood brain barrier (BBB), which in the EAE model induced with IFA may retain its 
impermeability. 
Recent unpublished data by van der Zee et al. (submitted for publication) show 
that LQGV enhances corticosterone levels about six-fold in mice up to at least 24 
h after administration. This correlated with reduced pro-inflammatory immune 
responses. In the marmoset EAE model we did not observe an effect of LQGV on 
cortisol levels. However, we cannot conclude that LQGV is unable to induce cortisol 
in marmosets, because cortisol levels were measured in plasma three days after 
LQGV administration. It is therefore unclear whether LQGV induced elevated levels of 
cortisol within the first 24 h after injection. However, if LQGV indeed enhanced cortisol 
levels in marmosets, the effect of LQGV would have been more profound. Synthetic 
glucocorticoids can imitate the anti-inflammatory effects of cortisol and are amongst 
the most commonly prescribed drugs for autoimmune diseases. Glucocorticoids are 
also prescribed during acute relapses in MS26-28. Methylprednisolone inhibits IFN-γ 
and IL-17A production in mice32. These data suggest that elevated levels of cortisol 
should be able to ameliorate EAE.
In conclusion, LQGV at the tested dosing regimen fails to ameliorate or exacerbate 
clinical signs, lesion load, and immunological parameters of EAE induced by two 
MOG peptides in IFA. It may be that β-hCG-related oligopeptides are able to inhibit 
EAE in marmosets when another dosing regimen is used, such as a cocktail of hCG-
related peptides, administration earlier or later during the disease course, only a few 
injections, or chronic administration via an intravenous infusion pump. However, if the 
mode of immunomodulatory action of β-hCG-related peptides is indeed via cortisol 
induction and mitigation of the innate immune response, we deem it unlikely that other 
treatment regimens or other β-hCG-related peptides can ameliorate T-cell-driven EAE 
in marmosets.
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PREFACE
MS lesions are composed of a multitude of cell types and mediators of the immune 
system. However, their exact and distinct roles in the initiation, progression, or modulation 
of the disease are still unknown. This lack of knowledge hampers the development of 
effective therapies. For more than a decade, EAE in the common marmoset has been 
used as a valid animal model for MS to investigate the pathogenesis. In addition, new 
therapies can be validated in the marmoset EAE model.
At the start of the research described in this thesis in 2006, it had been established 
that MOG is a crucial component of myelin for the progression of EAE in marmosets. In 
addition, it was already demonstrated that sensitization of marmosets against rhMOG 
induces EAE with a 100% disease incidence and that this high incidence mapped to 
the Caja-DRB1*W1201 restricted activation of MOG24-36-specific T-cells1. In contrast 
to immunization with rhMOG, immunization with MOG14-36 in CFA only induced mild 
clinical symptoms with small perivascular infiltrates within the CNS white matter. The 
cause of this clinical and pathological discrepancy remained to be investigated. The 
research described in this thesis aimed at identifying the pathogenic mechanisms 
underlying EAE and MS. In addition, new therapies for MS were validated. 
The main results described in this thesis are summarized in Table 1. The combination 
of exploratory and applied research resulted in new insights into the pathogenic 
mechanisms and in new possible therapy targets (Figure 1). In chapter 3, MOG34-
Table 1. Advances in the marmoset EAE model.
Before 2006 2010 (This thesis)
rhMOG induces EAE with 100% incidence MOG34-56-specific T-cells are associated with fast 
disease progression in the rhMOG/CFA model
rhMOG activates MOG24-36-specific T-cells in  
all marmosets
MOG34-56-specific T-cells are CD4+ or CD8+, 
express CD56, are cytotoxic, and produce IL-17A
Immunization with MOG14-36 induces mild EAE Immunization with MOG34-56 induces full-blown 
EAE
CFA is used for disease induction CFA can be replaced by IFA
White matter lesions in the CNS similar to MS Grey matter lesions are also present and similar 
to MS
Blocking antibodies against IL-12p40  
and CD40 limit EAE
Anti-IL-17A antibody has only a moderate effect 
on EAE onset, but antibody blocking Nogo-A and 
antibody depletion of CD20+ B-cells prevent EAE
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56-specific T-cells were found to play an important pathogenic role in EAE. These 
T-cells can be activated by immunization with MOG34-56 in IFA and express CD56, are 
cytotoxic, and produce IL-17A. In chapter 4, several new therapeutic targets, such as 
IL-17A, CD20, and Nogo-A, were validated. These were evaluated in two different EAE 
models that were developed and validated in this thesis, both using CFA as adjuvant. 
We demonstrated that neutralization of IL-17A had no protective effect on the disease, 
but rather delayed the appearance of clinical signs. By contrast, the striking clinical 
effect of Ab that deplete CD20+ B-cells or block the interaction of Nogo-A with its receptor 
demonstrated that B-cells and Nogo-A are major pathogenic players in the disease.
$SSOLHGUHVHDUFK1HZWKHUDS\GHYHORSPHQW,GHQWLILFDWLRQRIQHZWKHUDS\WDUJHWV6XFFHVVIXOLQWHUYHQWLRQKLJKOLJKWVLPSRUWDQWSDWKRJHQLFPHFKDQLVPV([SORUDWRU\UHVHDUFK3DWKRJHQHVLV&\WRWR[LFLW\%FHOOV 1RJR$ &',/$ ,/$,QWHUYHQWLRQZLWKDPRGHUDWHHIIHFWVKRZVWKDWWKHWDUJHWLVOHVVLPSRUWDQWLQWKHSDWKRJHQHVLV
Figure 1. Results of the research strategy.
During the exploratory research performed in chapter 3, we showed that MOG34-56-specific T-cells 
are associated with EAE. These T-cells are CD56+, are cytotoxic, and produce IL-17A. Therefore, new 
targets for therapy may be CD56, the exocytosis of cytotoxic granules, and IL-17A. Applied research 
described in chapter 4 demonstrated that IL-17A is only moderately involved in the disease, whereas 
CD20+ B-cells and Nogo-A are essential for the disease.
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The induction of EAE in marmosets with a single MOG peptide in IFA without 
microbial ligands raises questions about the activation mechanism of T-cells and how 
the permeabilization of the BBB is effected. Therefore, the underlying mechanisms of 
the IFA model are discussed below. Next, the clinical course and immune response are 
compared between the three used EAE models. In addition, pathogenic mechanisms in 
the periphery and the CNS are discussed as well as future prospects. 
THE MECHANISMS uNdERlYING THE IFA MOdEl
CFA versus IFA
IFA is a water-in-oil emulsion composed of paraffin oil and the surfactant mannide 
mono-oleate. Although IFA prolongs the presence of Ag at the immunization site and 
enhances the uptake of Ag by dendritic cells (DC)2, the mechanisms of action of IFA 
are still unknown. When inactivated mycobacteria are emulsified in IFA it is called 
CFA. The mycobacteria provide the ligands of innate antigen receptors on APC, in 
particular TLR4. Engagement of TLR4 with bacterial antigens relays maturation signals 
to the APC resulting in the induction of co-stimulatory molecules, such as CD40 and 
CD80/86, and pro-inflammatory cytokines, such as IL-12 and IL-23. Previous research 
showed that both CD40 and IL-12/IL-23 are important in the EAE pathogenesis in the 
marmoset models induced with CFA3-6. IFA can be used in human vaccines, where it 
elicits a strong Ab response, although it is nowadays often replaced by other oil-based 
adjuvants7. CFA is the most frequently used adjuvant for formulation of autoantigens to 
induce autoimmune diseases in animals. Immunization with MOG in IFA failed to induce 
EAE in essentially all mouse strains8, but did induce EAE in the DA rat9. Induction of 
full-blown clinical EAE with widespread demyelination in CNS grey and white matter 
with MOG peptide in IFA has also been reported in marmosets (Chapter 3.2). Clearly, 
this new EAE model in the marmoset induced by MOG34-56 in IFA represents a major 
improvement for ethical, practical, and mechanistic reasons. 
IFA and the innate immune response
Although this thesis focuses mainly on the adaptive immune response, the innate 
immune response is also involved in MS10. In EAE, the innate immune response is 
activated by the mycobacteria in CFA as described above. Since IFA does not contain 
mycobacteria, the question raises whether the innate immune response is involved in 
the marmoset EAE model induced by MOG34-56/IFA. 
We have demonstrated that IFA does not activate TLR- or NLR-dependent mechanisms 
in vitro (Chapter 3.2). Also others could not detect NLR-mediated IL-1β production 
after IFA stimulation in vitro11 or in vivo12. The hCG-related oligopeptide LQGV did not 
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modulate EAE induced by MOG34-56+MOG74-96/IFA (Chapter 4.5), whereas LQGV 
impairs the innate immune response in mice after, for example, infection with Listeria 
monocytogenes13. This suggests that the innate immune response may not play a role in 
this particular IFA model. However, as also discussed in chapter 4.5, it is likely that other 
causes underlie the results of the LQGV study, such as the chosen treatment regimen. 
Another explanation may be that LQGV affects mainly the neutrophil compartment13,14, 
whereas neutrophils do not play a role in the marmoset EAE model15. 
Several lines of evidence suggest that IFA can activate the innate immune response. 
IFA increased bacterial resistance in mice16 and induced the expression of various 
cytokines, such as TNF-α and GM-CSF, suggesting that IFA can activate the innate 
immune system12,17. In addition, in chapter 3.2 we demonstrate TNF-α production in 
culture supernatant and the presence of macrophages and complement deposition in 
WM lesions after immunization with MOG34-56/IFA. 
IFA and the APC
DC isolated from IFA-injected mice expressed MHC class II and the co-stimulatory 
molecules CD80, CD86, and CD40 at a low level18. This suggests that IFA does not 
induce DC maturation, which is needed for the activation of naive autoreactive T-cells. 
The addition of M. tuberculosis to IFA induced DC maturation in vitro and in vivo18. 
If non-matured DC serve as APC in the marmoset EAE model, only Ag-experienced 
T-cells may be activated. MOG-specific T-cells are present in the naive repertoire of 
marmosets19, which may have a memory phenotype. Memory T-cells are generated 
after, for example, a viral infection. Amino acids 986 to 993 (WLRSPFSR) from the 
major capsid protein UL86 of CMV and amino acid 963 to 970 (WQRTPFSV) from the 
major capsid protein of HHV-6 show sequence similarity with MOG39-46 (WYRPPFSR). 
This suggests that non-matured DC presenting MOG34-56 can activate CMV- or HHV-
6-specific memory T-cells.
Alternatively, when non-matured DC are not the core APC in the marmoset EAE 
model, which cell type could then have that crucial function? We hypothesize that 
B-cells are the central APC in the MOG34-56/IFA model. Depletion of CD20+ B-cells 
three weeks after immunization of marmosets with rhMOG/CFA significantly reduced 
T-cell proliferation and T-cell activation in secondary lymphoid organs (Chapter 4.2). 
This shows that B-cells can act as APC in the rhMOG/CFA model. In addition, EBV-
transformed marmoset B-cell lines can be used to generate MOG34-56-specific T-cell 
lines in vitro, showing that B-cells are capable of presenting MOG34-56 to T-cells 
(Chapter 3). To investigate whether B-cells are also the APC in the MOG34-56/IFA 
model, the B-cell depletion protocol used in rhMOG/CFA model should be repeated in 
the IFA model.
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IFA and the blood-brain barrier
How do autoreactive T-cells that are activated in the IFA model enter the CNS? 
Both CFA and IFA induce BBB permeability, although CFA is the most potent one20,21. 
In addition, T-cells are able to enter the CNS when the BBB is not permeabilized by 
adjuvants, such as during immune surveillance or after adoptive transfer. Furthermore, 
CCR6+ Th17 cells may enter the BBB via the choroid plexus by interaction with CCL2022 
or Th17 cells induce BBB permeabilization23,24. This suggests that CFA is not necessarily 
required to permeabilize the BBB and that T-cells in the IFA model are also able to enter 
the CNS.
THREE MARMOSET EAE MOdElS
Marmosets were initially immunized with human myelin emulsified in CFA in 
combination with two intravenous doses of heat-inactivated Bordetella pertussis25. 
To identify which myelin epitopes and which autoimmune processes are crucial for 
the induction and progression of EAE, the marmoset EAE model has been stepwise 
refined (Figure 2). This yielded three different EAE models that are induced by 
immunization with rhMOG/CFA, MOG34-56/CFA, or MOG34-56/IFA, respectively. 
These three EAE models display similar clinical signs and overall pathology, but differ 
with respect to the clinical course as well as the humoral and cellular autoreactivity 
profiles.
Clinical course
For comparison of the clinical course, we included 14 marmosets that were 
immunized with rhMOG/CFA (from the control groups of chapter 4.1 and 4.2), 16 
marmosets that were immunized with MOG34-56/CFA (Chapter 3.1 and the control 
group of chapter 4.4), and 5 marmosets that were immunized with MOG34-56/IFA 
(Chapter 3.2). Marmosets immunized with MOG34-56 plus MOG74-96 in IFA (Chapter 
3.2 and 4.5) were not included in the analysis, because this model will not be used in 
the future and was only used as an intermediate refinement step from MOG34-56/CFA 
to MOG34-56/IFA.
The three disease induction protocols all induced a chronic progressive disease 
with similar clinical symptoms, such as ataxia, paresis, and paralysis. However, the 
progression rate to the onset of overt clinical signs (score ≥ 2) and the day of sacrifice 
differs between the three models (Table 2, Figure 3A). The animals immunized with 
rhMOG/CFA (n=14, single immunization) developed clinical score 2 with an average 
time of disease onset of 59 days after immunization (Table 2). In contrast to the single 
immunization with rhMOG/CFA, all animals immunized with MOG34-56 in either CFA or 
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IFA needed at least one booster immunization with MOG34-56 in IFA before developing 
clinical signs. All animals immunized with MOG34-56 in CFA or IFA developed score 2, 
except one MOG34-56/CFA-immunized animal (M02075, chapter 3.1). The average 
time to clinical score 2 was 82 days in MOG34-56/CFA-immunized animals and 69 days 
in MOG34-56/IFA-immunized animals (Table 2). Thus, the time to disease onset was +XPDQP\HOLQ&)$%SHUWXVVLV+XPDQRUPRXVHP\HOLQ&)$02*PRXVHP\HOLQ&)$UK02*&)$02*&)$ 0DLQREVHUYDWLRQ0LQLPDOUHTXLUHPHQWWRLQGXFH($( $FXWHGLVHDVH$FWLYHOHVLRQVDQGGLVUXSWHGD[RQV&KURQLFGLVHDVHDFWLYHDQGLQDFWLYHOHVLRQV&KURQLFGLVHDVHDFWLYHDQGLQDFWLYHOHVLRQV02*VSHFLILFF\WRWR[LFDQG,/$SURGXFLQJ7FHOOV1.&7/$EDJDLQVW02*SUHVHQW$QWLUK02*$ESUHVHQWLQVRPHDQLPDOV02*,)$ &KURQLFGLVHDVHDFWLYHDQGLQDFWLYHOHVLRQV02*VSHFLILFF\WRWR[LFDQG,/$SURGXFLQJ7FHOOV1.&7/$EDJDLQVW02*SUHVHQW1RDQWLUK02*$ESUHVHQW'LVVHFWLRQRIWKHFRUHSDWKRJHQLFSURFHVV 0%3&)$02*&)$ 0LOGFOLQLFDOV\PSWRPV0LOGFOLQLFDOV\PSWRPV0LOGFOLQLFDOV\PSWRPV&KURQLFGLVHDVHDFWLYHDQGLQDFWLYHOHVLRQV02*VSHFLILF7KFHOOV02*VSHFLILFF\WRWR[LFDQG,/$SURGXFLQJ7FHOOV$QWLUK02*$ESUHVHQW
Figure 2. dissection of the core pathogenic process.
EAE was originally induced in marmosets by immunization with human myelin emulsified in CFA and 
an injection of heat-killed Bordetella pertussis. The stepwise elimination of elements from the EAE 
induction protocol has led to a model induced by MOG34-56 emulsified in IFA. During this stepwise 
refinement, it became clear that MOG34-56-specific T-cells play a key pathogenic role. These T-cells 
are cytotoxic, express CD56, and produce IL-17A. Adapted from138.
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significantly shorter in rhMOG/CFA-immunized animals compared with the MOG34-
56/CFA model, but not when compared with the MOG34-56/IFA model (Figure 3A). 
However, the latter experiment comprised five animals. When five animals immunized 
with MOG34-56/IFA of a recently performed, yet unpublished, study were included, 
the disease onset in the rhMOG/CFA model was also significantly earlier than in the 
MOG34-56/IFA model (data not shown). Immunization with MOG34-56 in CFA or IFA 
did not result in marked differences in time to disease onset, neither with nor without the 
five extra animals (Figure 3A). 
In addition to the time to disease onset, the day of sacrifice was compared between 
the three models. Table 2 shows the day that the animals were sacrificed with a clinical 
score of 2 or higher. In the three models, one (rhMOG/CFA and MOG34-56/IFA) or two 
Table 2. Clinical course of three EAE models.
rhMOG/CFA MOG34-56/CFA MOG34-56/IFA
Score 2a Endb Score 2 End Score 2 End
39 53 27 34 43 50
41 55 63 71 59 67
43 46 64 -c 71 79
46 55 68 132 79 -c
46 59 71 91 91 100
48 55 72 85
54 60 72 86
65 85 72 89
66 73 73 78
66 83 73 83
71 78 77 91
71 -c 80 91
78 91 104 110
91 111 146 151
164 166
- -c
59 ± 4d 70 ± 5 82 ± 9e 97 ± 9e 69 ± 8 74 ± 11
a First day after immunization that score 2 was observed
b Time to the day of sacrifice with clinical score ≥ 2
c Sacrificed with clinical score ≤ 2 due to survival until pre-determined end-point
d Mean ± SEM
e  Time to disease onset and time to sacrifice are significantly delayed in the MOG34-56/CFA model 
compared with rhMOG/CFA, see also figure 3
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'LVHDVHIUHHVXUYLYDO 6XUYLYDO
          

2YHUDOO 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Figure 3. Clinical course and cytokine mRNA levels in three marmoset EAE models.
Immunization with rhMOG/CFA, MOG34-56/CFA, and MOG34-56/IFA were compared. A, Demonstrates 
the survival graph until clinical score 2 (left graph) and until the endpoint (right graph). Time to disease 
onset (clinical score 2) and time to sacrifice (with clinical score ≥ 2) is significantly delayed in the MOG34-
56/CFA model compared with the rhMOG/CFA model. B, mRNA expression levels of IL-17A, IFN-γ, IL-7, 
and TNF-α were determined by quantitative PCR in animals immunized with rhMOG/CFA, MOG34-56/
CFA, or MOG34-56/IFA to induce EAE, and in two animals injected with MPTP to induce Parkinson’s like 
disease. The right graph of IFN-γ shows the comparison of rhMOG/CFA and MOG34-56/CFA. Statistical 
differences were analysed by Mann-Whitney U-test and considered significant when p< 0.05 (*).
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(MOG34-56/CFA) animals were sacrificed with a clinical score lower than 2, because 
they survived until the pre-determined end-point of the study. The average day of 
sacrifice with a clinical score 2 or higher was 70, 97, and 74 days after immunization with 
rhMOG/CFA, MOG34-56/CFA, and MOG34-56/IFA, respectively (Table 2). The day of 
sacrifice was significantly earlier in the rhMOG/CFA model compared with the MOG34-
56/CFA model (Figure 3A). The day of sacrifice after immunization with MOG34-56/
IFA did not differ from the other two models, also not when the five animals of the 
unpublished study were included (data not shown).
In conclusion, immunization with rhMOG/CFA leads to a more rapid disease onset 
and day of sacrifice than immunization with MOG34-56/CFA. This may be caused 
by the involvement of autoantibodies and a broader T-cell response in the rhMOG/
CFA model. In addition, the T-cell subsets activated after immunization may influence 
the disease course. There is no obvious difference in the clinical presentation of EAE 
induced with MOG34-56 in CFA or IFA. The overall pathology, such as demyelination 
and inflammation, does also not differ between both MOG peptide models. However, 
lesions should be investigated in further detail to assess whether more subtle differences 
may exist. Adoptive transfer of T-cells stimulated with IL-12p70 or IL-23 both induced 
paralysis, but with distinct cellular composition and cytokine profiles in the lesions26. 
If the MOG34-56/CFA model is more Th1 prone and if the MOG34-56/IFA model is 
more Th17 prone, the lesions in these two models may also show a different cellular 
composition and/or cytokine profile.
The anti-MOG Ab response
The more rapid disease development in the rhMOG/CFA-immunized animals may 
be explained by the involvement of anti-MOG Ab. As shown and discussed in chapter 
3, the Ab response in MOG34-56-immunized animals was mainly directed against the 
immunizing peptide. In about half of the MOG34-56/CFA-immunized animals, we also 
detected Ab binding to rhMOG, but this was not the case in MOG34-56/IFA-immunized 
animals. This indicates a lower capacity of Ag/IFA emulsion to induce anti-MOG Ab. 
This was also shown in guinea pigs, in which serum IgG concentrations increased after 
CFA injection, but remained low after IFA injection20. 
Although deposits of IgM molecules and complement were observed in CNS lesions 
of MOG34-56/CFA- or MOG-34-56/IFA-immunized marmosets, it is unclear whether 
these contributed to lesion formation. It is possible that Ab have passively leaked into 
the CNS, but that they do not have a direct pathogenic role. It has been demonstrated 
that both CFA and IFA can affect the BBB20,21, suggesting that Ab can leak into the CNS 
in all three marmoset EAE models.
 The results obtained in the marmoset EAE models induced with MOG34-56 suggest 
that anti-MOG Ab are not essential for the development of clinical signs and pathology 
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in marmosets. Our results are in line with results obtained in several MOG peptide 
induced mouse EAE models where demyelination can occur in the absence of Ab27-29. 
The conclusion that Ab directed against rhMOG are not essential for lesion formation in 
EAE does not imply that they are irrelevant. It has been well established that anti-MOG 
Ab can amplify demyelination under experimental conditions where demyelination is 
not or only marginally induced. As an example, marmosets immunized with MBP, PLP, 
or a chimeric MBP-PLP protein only developed demyelination when anti-MOG Ab were 
present30,31. 
Anti-MOG T-cell reactivities
Immunization with MOG34-56 in either CFA or IFA induces T-cell responses that 
are mainly directed against MOG34-56 and the overlapping peptide MOG24-46. This 
means that only one or two T-cell specificities are activated after immunization with 
MOG34-56. As shown in chapter 3, immunization with rhMOG/CFA leads to a T-cell 
response directed against several MOG epitopes. In chapter 3, we also demonstrated 
that animals with 1 or 2 anti-MOG specificities have a slower disease onset than animals 
with a broad anti-MOG T-cell response. This suggests that MOG34-56/CFA-immunized 
animals that have 1 or 2 T-cell reactivities are comparable with the slow progressors of 
the rhMOG/CFA model. This may contribute to the slower disease onset in MOG34-56/
CFA-immunized animals. 
The role of Th1 and Th17 cytokines
The cytokine profile of T-cells may also partly contribute to the difference between 
the three EAE models. T-cells isolated from the spleen or lymph nodes of rhMOG/CFA-
immunized animals that were cultured with rhMOG for 48 h secreted IL-17A and IFN-γ 
(Chapter 4.2). In contrast, T-cells isolated from MOG34-56/IFA-immunized animals that 
were cultured for 48 h with MOG34-56 or rhMOG only secreted IL-17A, but no IFN-γ. 
MOG34-56-induced secretion of IFN-γ and IL-17A by T-cells isolated from MOG34-56/
CFA-immunized animals will be determined in future experiments.
In addition to the MOG-induced cytokine protein data, we measured the mRNA 
expression levels of several cytokines in the lymphoid organs. It is important to note 
that these cytokine mRNA expression levels reflect the cytokine production in the whole 
organ and that these responses are not per se produced by MOG-specific T-cells. 
Although the low number of tested samples in all groups makes that data should be 
interpreted with caution, the results are suggestive for different mRNA levels between 
the three EAE models (Figure 3B). 
IL-17A and TNF-α mRNA levels were significantly lower in the spleen, but not in the 
ALN, of MOG34-56/CFA-immunized animals compared with rhMOG/CFA-immunized 
animals. Also, the IFN-γ mRNA level is clearly, albeit not significantly, lower in these 
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animals (p = 0.06). Interestingly, IL-17A, IFN-γ, and TNF-α mRNA levels were higher 
in MOG34-56/IFA-immunized animals compared with the other two groups. Cytokine 
mRNA profiles of healthy animals are not available yet. Therefore, we cannot conclude 
whether the cytokine levels in the IFA group are higher or normal compared with naive 
animals. We have compared the data with the cytokine mRNA expression levels in the 
spleen of two marmosets that did not receive any CFA or IFA injection, but which were 
subcutaneously injected with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to 
induce Parkinson’s like-disease. The mRNA levels of IL-17A, IFN-γ, and TNF-α in the 
spleen of MOG34-56/IFA-immunized animals were comparable with the cytokine mRNA 
levels in the spleen of MPTP-injected animals.
The low mRNA levels of IL-17A and IFN-γ in the CFA models compared to the 
IFA model may be caused by the use of CFA, which is known to change the cellular 
composition of the lymphoid organs. For instance, it has been demonstrated that the 
spleen of rhMOG/CFA-immunized marmosets contains fewer T-cells when clinical 
symptoms are present32. 
The mRNA level of IL-7 is highest in the spleen of the MOG34-56/IFA group and in 
the ALN of the MOG34-56/CFA group (Figure 3B). IL-7 is produced by nonhemopoietic 
stromal cells in multiple organs, such as the thymus and lymphoid organs. IL-7 is required 
for T-cell development and survival33,34 and also acts on B-cells35. IL-7 was recently 
found to be essential for the survival and expansion of Th17 cells36. This suggests that 
the high levels of IL-7 in the spleen of the MOG34-56/IFA group may underlie the high 
levels of IL-17. In addition, IL-7 is involved in the survival of CD56+ NK cells37 and may 
therefore also support the survival of the CD56+ MOG34-56-specific T-cells that were 
found to have a key pathogenic role in the marmoset EAE model. A polymorphism 
in the IL-7 receptor α gene has been identified as a risk factor for MS38 and anti-IL-
7Rα Ab is effective in mouse EAE36. In addition, we show that IL-7 mRNA levels were 
reduced after B-cell depletion, which may be associated with the significant effect of 
B-cell depletion on disease progression (Chapter 4.2). This suggests a pathogenic role 
of IL-7 in EAE and MS. 
Concluding remarks about the three EAE models
In conclusion, the three discussed marmoset EAE models are essentially different 
despite the similar clinical score and overall pathology. To further optimize and refine 
the marmoset EAE model, there are several promising options for future investigation. 
First, the development of GM lesions should be extensively investigated in all three 
models, because these appear to correlate well with clinical progression in MS39-41. 
Second, the marmoset EAE model should be further optimized by immunization with 
rhMOG emulsified in IFA. Predictably, this will induce EAE as MOG34-56-specific 
T-cells are clearly activated by immunization with rhMOG/CFA. When EAE should not 
Proefschrift Yolanda Kap_compleet.indd   266 25-08-2010   21:25:27
General discussion
267
develop in marmosets immunized with rhMOG/IFA, the possibility that rhMOG contains 
epitopes for regulatory T-cells warrants consideration. Immunization with rhMOG/IFA 
may induce autoantibodies similar to the rhMOG/CFA model. Although anti-MOG Ab 
are not essential for the development of EAE in marmosets, this model may better 
reflect the pathogenesis of MS, in which autoantibodies are also present. 
The question remains which model is to be preferred to test a new therapeutic 
compound for MS. We cannot conclude which of these three models best resembles MS, 
because the critical immunopathogenic mechanisms in MS are still unknown. Ideally, 
therapies that were or were not efficient in MS should be tested in all three EAE models 
to investigate which model gives similar results to MS. For example, ustekinumab, an 
anti-IL-12p40 Ab, was very effective in myelin/CFA- and rhMOG/CFA-induced EAE in 
marmosets5,6. In contrast, ustekinumab was essentially ineffective in RRMS42. It would 
be interesting to investigate the effect of ustekinumab in the MOG34-56/IFA model to 
examine whether the results are similar to MS. An example of an effective treatment in 
MS is B-cell depletion by an anti-CD20 Ab. B-cell depletion by an anti-CD20 Ab reduced 
lesion load and relapse rate in RRMS43,44. In the rhMOG/CFA marmoset EAE model, 
B-cell depletion was also effective (Chapter 4.2 and 4.3). To compare whether the 
MOG34-56/IFA model is similar to the rhMOG/CFA model, the B-cell depletion strategy 
should be repeated in the MOG34-56/IFA model. IFN-β is another therapy that should 
be tested in the three marmoset EAE models. It has been shown that IFN-β effectively 
inhibits EAE after adoptive transfer of Th1 cells in mice. In contrast, IFN-β exacerbates 
EAE after adoptive transfer of Th17 cells. In addition, RRMS patients that are non-
responders to IFN-β treatment had elevated serum levels of IL-17F, which is produced 
by Th17 cells45. This suggests that IFN-β is effective in Th1-mediated disease, but not 
in Th17-mediated disease. Treatment of marmosets with IFN-β may demonstrate which 
EAE model is mainly Th1 or Th17 driven. If one of the three marmoset EAE models is 
non-responsive to IFN-β, this model may be used to develop therapies for the IFN-β 
non-responders.
PERIPHERAl IMMuNOPATHOGENIC MECHANISMS
MOG24-36-specific Th1 cells versus MOG34-56-specific cytotoxic T-cells
The normal repertoire of healthy marmosets contains T-cells that are specific for 
several MOG epitopes, mainly to MOG21-40 and MOG31-5019. Both T-cell specificities 
were implicated in the pathogenesis of EAE induced with rhMOG/CFA1 (Chapter 3.1). 
MOG24-36-specific T-cells are activated by APC presenting MOG24-36 via the 
monomorphic MHC class II allele Caja-DRB*W1201, which is expressed in all marmosets 
despite the fact they are outbred1,46,47. MOG24-36-specific T-cells are mainly CD4+1 and 
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express IFN-γ19 suggesting they are Th1 cells. However, some MOG21-40-specific T-cell 
lines isolated from naive marmosets did not produce IFN-γ19. It is unknown whether 
these IFN-γ-, cells produce IL-17A. Therefore, we cannot conclude whether all MOG21-
40-specific T-cells are Th1 and not Th17. Activation of MOG24-36-specific T-cells is not 
enough to induce the full spectrum of clinical symptoms and pathology as immunization 
with MOG14-36/CFA1 or adoptive transfer of MOG21-40-specific T-cells19 induced only 
mild clinical symptoms in marmosets. This suggests that activation of additional T-cell 
specificities is needed for the induction of full-blown disease.
Indeed, T-cells specific for MOG34-56 likely have a pathogenic role in the marmoset 
EAE model. Fast progression of the disease in marmosets immunized with rhMOG/CFA 
is associated with a broadened T-cell reactivity to MOG epitopes, against MOG34-56 
in particular. MOG34-56-specific T-cells are CD4+ or CD8+. In addition, these T-cells 
are cytotoxic and express the NK marker CD56, suggesting that these cells are NK-
CTL (Chapter 3.1). However, these cells also produce IL-17A (Chapter 3.2). These 
T-cells can be activated by immunization with MOG34-56 in CFA or IFA (Chapter 3). 
Whether the MOG34-56-specific T-cells are purely Th1 or Th17 is unclear at this stage. 
In the marmoset IFA model, MOG34-56-specific T-cells produce IL-17A, but no IFN-γ 
(Chapter 3.2). In contrast, two of the three MOG31-50-specific T-cell lines isolated from 
naive non-immunized marmosets produced IFN-γ19. 
In summary, several T-cell subsets likely contribute to the development of marmoset 
EAE, i.e. CD4+ and CD8+ T-cells, Th1 and Th17 cells, as well as MOG24-36 and MOG34-
56-specific T-cells. We would like to hypothesize that after immunization MOG24-36-
specific Th1-cells are activated in all animals and induce inflammation in the CNS, 
whereas MOG34-56-specific cytotoxic T-cells induce demyelination. The inflammation 
induces only mild clinical symptoms, such as altered walking pattern, whereas the 
activity of the MOG34-56-specific cytotoxic T-cells induces the full spectrum of clinical 
signs.
The role of Il-17A
Until a few years ago, only two functional subsets of activated CD4+ T-cells 
were distinguished, namely Th1 and Th2. Since then, additional subsets have been 
discovered, such as Th1748, Th949, and Th2250, named after their signature cytokines. 
MS was initially considered a Th1 driven disease. However, with the discovery of the 
Th17 subset as well as that CD8+ T-cells are more prevalent in MS lesions than CD4+ 
T-cells, this became under debate (extensively reviewed in48,51). It was shown that the 
signature cytokine IL-17A is present in serum, CSF, and CNS of MS patients23,52-55 
and evidence from rodent EAE suggested also involvement of IL-17A (see below and 
Table 3). The activity spectrum of Th17 cells has not been completely elucidated yet. 
Th17 cells may play a role in the defense against extracellular pathogens56. Moreover, 
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Th17 cells are also considered highly pro-inflammatory and may be involved in several 
autoimmune diseases. Th17 cells produce among others IL-17A, IL-17F, IL-21, and 
IL-2256. IL-17 is a family of at least 6 members, but the effect of IL-17A in autoimmunity 
has been investigated in most detail. Besides CD4+ T-cells, IL-17A is also produced by 
CD8+ T-cells57, NK cells58, NKT cells59, and microglia60. IL-17 induces the production of 
cytokines and chemokines, especially neutrophil-attracting chemokines61,62.
By which pathways Th17 cells differentiate and expand has not been completely 
unraveled. These pathways differ between mice and men63. T-cells probably differentiate 
into Th17 cells by a cocktail of TGF-β, IL-6, IL-1β, and TNF-α63,64. Th17 cells can expand 
in the gut65. IL-23 was first considered essential for the differentiation of Th17 cells, but 
now it is suggested to play a role in the expansion or maintenance of already differentiated 
Th17 cells64. IL-23 is a heterodimeric cytokine composed of a p19 and a p40 subunit 
that is shared with IL-12, being the most important cytokine for Th1 induction. 
Many researchers have investigated the role of IL-17A in mouse EAE models 
using different approaches, such as knockout mice66-72, mAb treatment5,6,69,73-75, 
vaccination73,75,76, and adoptive transfer26,69-71,77-79(Table 3). Collectively, these studies 
yielded inconclusive and in part contradictory results. This suggests that the pathogenic 
function of autoreactive Th1 and Th17 cells in EAE and MS is highly complex and 
differs between individual animals or humans. Treatment with anti-IL-17A Ab in the 
rhMOG/CFA marmoset model, starting one day before immunization, caused only a 
modest delay of the disease onset without a marked effect on pathology and immune 
response. This is consistent with anti-IL-17A Ab treatments in mouse EAE models in 
which incidence and maximum score was only reduced 50% and not 100% (Table 3). 
These findings argue against a prominent role of IL-17A in the induction phase of EAE 
in rhMOG/CFA-immunized marmosets (Chapter 4.1). 
That anti-IL-17A Ab did not prevent the development of EAE in marmosets can be 
explained in several ways. First, the pathogenic role of Th17 cells may not be (exclusively) 
mediated by the signature cytokine IL-17A. It has been shown that both Th1 and Th17 
cells can induce EAE after adoptive transfer26,79. Second, neutralization of IL-17A may 
have no beneficial effect on the cytotoxicity of MOG34-56-specific T-cells, which is 
dependent on granule exocytosis as shown in chapter 3.2. This suggests that MOG34-
56-specific T-cells activated by rhMOG/CFA retain their cytotoxic activity and thus the 
ability to induce pathology and thereby clinical signs. Third, EAE induced by CFA may 
not be the appropriate model to test the efficacy of anti-IL-17A Ab treatment, since 
both Th1 and Th17 cells are activated in this model. We have shown that MOG34-56-
specific T-cells activated by immunization with MOG34-56 in IFA produce IL-17A, but no 
IFN-γ. This suggests that the anti-IL-17A Ab may be more effective in the MOG34-56/
IFA model. Which of the three marmoset EAE models is the best representative for MS 
is so far unclear. MS patients that are non-responders to IFN-β treatment have elevated 
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Table 3. Il-17 manipulation in EAE models.
Il-17A essential for EAE induction?
Species EAE 
induction
Transgenic Yes (+) 
No (-)
Maybe 
(-/+)
Remarks Ref.
Mouse: 
C57BL/6
MOG34-56/ 
CFA+PTX
IL-23p19-/- + Resistant to EAE; IL-23 not 
needed for T-cells to cross BBB
68,69,71
IL-12/23p40-/- + Resistant to EAE 66-68
IL-12p35-/- + Susceptible to EAE; IL-23, but 
not IL-12, is essential for EAE
66-68
IL-17-/- -/+ Suppression of EAE; 91% 
incidence with clinical score 2 
(Wt 100%, score 3)
70,72
Overexpression 
of IL-17A
- No change in EAE 72
Species EAE 
induction
mAb treatment
Mouse: SJL
PLP139-151/
CFA
Anti-IL-17A Ab
(day 7)
-/+ Partial protection of EAE; 3/5 
mice with clinical score 2 (5/5 
control score 4)
69
PLP139-151/
CFA+PTX
Anti-IL-17A Ab
(day -1, 6)
-/+ Partial protection of EAE; clinical 
score 1 (control 2) No change in 
CNS inflammation
74
PLP139-151/
CFA
Anti-IL-17A Ab 
(2x/week from 
day 0)
+ EAE prevented in 8/10 mice; 
2/10 mice score 0.5
75
Mouse: 
C57BL/6
MOG34-56/
CFA
Anti-IL-17A Ab 
(day 6, 10, 14)
-/+ EAE score reduced from 2 to 1 73
Marmoset
rhMOG/CFA Anti-IL-17A Ab 
(weekly, from 
day -1)
- Time of onset delayed, but not 
significant
This 
thesis
Mouse: SJL
PLP139-151/
CFA+PTX
Anti-IL-12p40
(day -1, 6)
+ Partial amelioration of EAE; 21 
% incidence with clinical score 1; 
IL-12 or IL-23 needed for EAE 74
Anti-IL-23p19 
Ab (day -1, 6)
+ Prevention of EAE; 8% 
incidence with score 0.3; IL-23 
needed for EAE induction
Marmoset
Myelin/CFA Anti-IL-12p40 
(day 14-86, 
weekly)
+ Prevention of EAE; 1/5 animals 
score 2.5; IL-12 or IL-23 needed 
for EAE
5
rhMOG/CFA Anti-IL-12p40 
(when MRI 
lesions present)
-/+ Time to score 2 delayed 6
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Species EAE 
induction
Vaccination
Mouse: 
C57BL6
MOG34-56/ 
CFA+PTX
IL-17-VLP 
(before EAE 
induction)
-/+ Partial protection against EAE; 
30% incidence with score 1.2 
(control 2.4)
76
IL-17-receptor-
Fc fusion protein 
(after onset 
clinical signs)
-/+ Partial protection of EAE; 0.5 
reduction in clinical scores for a 
few days
73
Mouse: SJL PLP139-151/CFA
IL-17A-OVA 
(before EAE 
induction)
+ Prevention of EAE 75
Adoptive transfer
donor Recipient
MOG-specific lymphocytes 
from MOG35-55/CFA/PTX-
immunized Wt C57BL/6
p40-/- C57BL/6 
+PTX
-/+ EAE severity decreased; 40% 
incidence with score 2.4 (control 
3); IL-12 or IL-23 is essential in 
effector phase of EAE
77
CD4+ T-cells from MOG35-
55/CFA-immunized IL-17-/- 
C57BL/6
Wt C57BL/6 + MOG specific T-cells from IL-
17A-/- mice cannot efficiently 
induce EAE
70
MOG-specific CD4+ T-cells 
from MOG35-55/CFA/PTX-
immunized Wt C57BL/6
p19-/- C57BL/6
p35-/- C57BL/6
p19/p35-/- 
C57BL/6
- Similar to Wt recipient; IL-23 
is not required during effector 
phase of EAE
71
MOG-specific CD4+ T-cells 
from MOG35-55/CFA/PTX- 
immunized p19-/- C57BL/6
Wt C57BL/6 -/+ EAE severity reduced; 100% 
incidence; score 2 instead of 4; 
IL-23 plays a role in induction 
phase
PLP-specific CD4+ 
T-cells from PLP139-151-
immunized SJL, primed 
with IL-23 or IL-12
Wt SJL + Th1 and Th17 both enter CNS; 
Th17 induce clinical signs
69
PLP-specific CD4+ T-cells 
from PLP139-151/IFA 
primed SJL, IL-12p70 or 
IL-23 polarized
Wt SJL + Both Th1 and Th17 induce 
EAE, but using distinct effector 
mechanism
26
MOG-specific lymphocytes 
from MOG35-55/CFA-
immunized Wt C57BL/6 
mice, polarized to Th17 or 
Th1
Wt C57BL/6 -/+ Th17 cells only enter the CNS 
when Th1 cells are present
78
MOG-specific CD4+ T-cells 
from naive 2D2 mice 
polarized to Th1 or Th2
Wt C57BL/6 -/+ Th17 can induce EAE, but with 
very late onset
79
PTX, pertussis toxin
Proefschrift Yolanda Kap_compleet.indd   271 25-08-2010   21:25:28
Chapter 5
272
serum levels of IL-17F, suggesting that Th17 cells dominate in these patients45. This 
may indicate that the MS population exists of different subgroups of patients in which the 
disease is driven by different immune-mediated mechanisms. Therefore, MS patients 
that are non-responders to IFN-β might be responders to anti–IL-17A therapy.
Instead of targeting single cytokines, such as IL-17A, it may be more efficient to 
functionally eliminate Th1 and Th17 cells more upstream during the induction. Mice 
lacking the p40 subunit are resistant to EAE66-68 and treatment of mice or marmosets 
with anti-IL-12p40 prevented or ameliorated EAE5,6,74. This suggests that IL-12p40 
is a promising target for therapy in MS. Unfortunately, treatment of RRMS with the 
same anti-IL-12p40 mAb that was tested in marmosets, known as ustekinumab, did 
not reduce the number of gadolinium enhancing lesions42. Several explanations for 
this failure were suggested, such as suboptimal patient selection, since the patients 
were not in the early phase of the disease, and the inability of ustekinumab to cross 
the BBB42,80,81. Another explanation for the failure of ustekinumab may be that Th17 
cells are pathogenic, but that their induction is not affected by neutralization of IL-
23 by ustekinumab. IL-23 is probably more involved in the maintenance, and not the 
induction of Th17 cells in humans64. The possibility that neutralization of IL-12/IL-23p40 
by ustekinumab prevents the development of Th1 cells only, and not of Th17 cells 
needs consideration. Furthermore, if ustekinumab is able to prevent the development 
of Th1 and Th17, the cytotoxic T-cells are still present. This thesis provides evidence 
that CD4+CD56+ or CD8+CD56+ cytotoxic T-cells contribute to the disease. This explains 
why ustekinumab is effective in the marmoset EAE model induced with CFA, which is 
probably Th1 prone, and not in MS, which may be more dominated by cytotoxic T-cells. 
This should be further investigated in the MOG34-56/IFA model in which Th1 cells are 
less dominant.
The role of B-cells in secondary lymphoid organs 
Treatment of RRMS patients with the CD20+ B-cell depleting Ab rituximab reduced 
the number of gadolinium-enhancing lesions and the number of relapses43,44. However, 
the underlying mechanism is unclear, since total IgG levels were not altered after B-cell 
depletion. This suggests that B-cells have additional functions in the MS pathogenesis 
besides Ab-production.
We investigated the role of B-cells in the pathogenesis of EAE in rhMOG/CFA-
immunized marmosets. Depletion of B-cells by anti-CD20 Ab, starting 21 days after 
immunization, prevented the development of clinical signs (Chapter 4.2). As an 
underlying mechanism we demonstrated that B-cell depletion halts the progressive 
production of anti-MOG IgG. In addition, we found evidence that B-cells may act as 
APC in secondary lymphoid organs. B-cell depletion led to reduced overall and MOG-
induced T-cell proliferation and cytokine production in spleen and lymph nodes. We did 
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not observe a reduced proliferation in PBMC, neither MOG-specific, nor in response to 
the mitogen ConA. This contrasts with the effect on PBMC activation in MS patients that 
were treated with the CD20+ B-cell depleting Ab rituximab. Overall T-cell proliferation 
and the production of IL-17A and IFN-γ were reduced82. MOG-specific T-cell proliferation 
was not tested in the MS clinical trials, probably because the MOG-specific responses 
in PBMC are too low and secondary lymphoid organs are only exceptionally available. 
Our data together with the data obtained from MS patients suggest that B-cells are 
involved in the activation of T-cells in the periphery.
B-cell depletion does not only affect its APC function, but may also interrupt other 
mechanisms. A mechanism that also fits with our results is proposed by Lund and 
Randall83. They propose that effector T-cells and effector B-cells interact with each 
other in a feedforward loop. This leads to the expansion of both subsets. During 
autoimmunity this Ag-driven feedforward loop may not be susceptible to suppression 
by regulatory T-cells or regulatory B-cells. B-cell depletion leads to the interruption 
of the feedforward loop and consequently T-cell activity and pro-inflammatory 
cytokine levels reduce. This favors the generation of regulatory T-cells. The B-cells 
that repopulate likely are regulatory B-cells83. The suggested tolerance or regulatory 
environment that occurs after B-cell depletion is in line with the higher level of IL-
10 in the spleen and axillary lymph node of B-cell depleted marmosets (Chapter 
4.2). Currently, the phenotype of regulatory T-cells and regulatory B-cells is unknown 
in marmosets. Therefore, these subsets cannot be investigated in B-cell depleted 
marmosets.
IMMuNOPATHOGENIC MECHANISMS wITHIN THE CNS
Cytotoxicity of MOG34-56-specific T-cells
MOG34-56-specific cytotoxic T-cells express CD56 (Chapter 3), which is neural 
cell adhesion molecule. CD56 is a transmembrane glycoprotein of the immunoglobulin 
family and is expressed on cells of the CNS, such as neurons and glial cells84-86. In 
addition, CD56 is expressed on NK cells, several T-cell subsets, NKT-cells, and NK-
CTL85,87-89. Expression of CD56 was also observed on T-cells specific for MBP in MS 
patients and healthy controls90,91.
Although CD56 is expressed on cytotoxic T-cells in marmosets, it is unknown 
whether CD56 in marmosets has the same cellular distribution and function as in 
humans. Mouse NK cells do not express the murine equivalent of CD5692. Also in the 
rhesus macaque, an Old World monkey, CD56 is not expressed on NK cells93. However, 
others have demonstrated CD56 expression on CD3- and CD3+ cells in PBMC of rhesus 
macaques94,95. This suggests that a CD56+ T-cell subset similar to marmosets is present 
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in rhesus macaques. Similar to our results, another group also demonstrated CD56 
expression on CD4+ and CD8+ T-cells of marmosets96. 
The expression of clinical EAE in marmosets is associated with the activation 
of MOG34-56-specific CD56+ T-cells. We hypothesize that these T-cells induce 
demyelination via a specific cytotoxic attack on the myelin-forming oligodendrocytes. 
The question remains how they exert their cytotoxic activity. Below four possible 
mechanisms are discussed. 
• MHC class II restricted: The cytolytic activity of MBP-specific CD4+ T-cells isolated 
from MS patients and healthy donors is HLA class II restricted97,98. The MHC restriction 
of MOG34-56-specific T-cells isolated from marmosets has not been tested yet. 
Although MHC class II restricted killing of MHC class II expressing target cells, i.e. 
EBV-transformed B-cell lines, was detected in vitro97,98, it is less likely that this is the 
mechanism of demyelination in vivo. Oligodendrocytes do not express MHC class II 
molecules, neither in active MS lesions99, nor after stimulation with IFN-γ100.
• MHC class Ia restricted: MBP-specific CD8+ cytotoxic T-cells isolated from MS 
patients and healthy donors can induce cytolysis of human oligodendrocytes in a 
HLA-A2 dependent manner101. Human oligodendrocytes express low level HLA class 
I molecules in vitro, which can be enhanced by IFN-γ100,101. However, marmosets 
lack the equivalents of the classical MHC class I molecules of humans, i.e. MHC-A, 
-B, or -C102. Therefore, it is difficult to envisage that marmoset oligodendrocytes are 
killed by MOG34-56-specific T-cells in a MHC class Ia restricted manner. 
• MHC class Ib restricted: The marmoset genome encodes the equivalents of two 
human non-classical MHC class I genes that are also expressed in the CNS, 
i.e. Caja-G and Caja-E103. NK-CTL kill CMV-infected target cells in an MHC-E 
restricted manner88,104-107. To conclude that the MOG34-56-specific killing is MHC-E 
restricted in marmosets, it should be investigated whether the EBV-transformed 
B-cells used for the in vitro cytotoxicity assays express Caja-E. Next, it should be 
tested whether this interaction can be blocked with an anti-MHC-E Ab. In addition, 
the expression of MHC-E on oligodendrocytes in healthy and MS brains should 
be investigated. 
• MHC-independent, CD56 dependent: The lysis of several tumor cell lines by MBP-
specific CD4+CD56+ T-cells depends on CD56 homophilic interaction90. Human 
oligodendrocytes express CD56 and can be lysed by MBP-specific CD4+CD56+ 
T-cells via an MHC-independent, but CD56 dependent mechanism91. This may 
explain the cytotoxicity in marmosets, since CD56 is expressed by EBV-transformed 
marmoset B-cell lines (data not shown), which are used as target cells in the 
cytotoxicity assays.
To summarize, it is unlikely that MOG34-56-specific T-cells exert their cytotoxicity 
in marmosets via classical MHC class Ia or class II, since these are not expressed 
Proefschrift Yolanda Kap_compleet.indd   274 25-08-2010   21:25:28
General discussion
275
on marmoset oligodendrocytes. Although further investigations are needed, the 
most plausible mechanism of MOG34-56-specific cytotoxicity to oligodendrocytes in 
marmosets is via Caja-E.
The role of B-cells
B-cells can be detected in the CNS of MS patients108,109 and in marmoset EAE brains 
(Figure 2 in Chapter 4.3). B-cells may have at least three different roles in the CNS 
of MS patients and in EAE, namely autoantibody production, Ag presentation, and 
modulation of local immune responses via cytokines. It has been well demonstrated 
that Ab against MOG can enhance demyelination and myelin phagocytosis in vitro110,111 
and in vivo30,31,112-114. However, in the MOG34-56/IFA model demyelination occurs in the 
absence of MOG-binding Ab, suggesting that Ab against MOG are not essential for EAE 
induction in marmosets (Chapter 3.2). 
No T-cells were detected in the CNS after B-cell depletion, in contrast to the animals 
of the placebo group (Chapter 4.3). One explanation is that T-cells did not migrate into 
the CNS, because they were not activated in the periphery. Another explanation may be 
that B-cells attract T-cells to the CNS.
B-cell depletion not only prevents the development of WM lesions, but also the 
development of GM lesions (Chapter 4.3). GM lesions contain only a minimal number 
of lymphocytes, low level of complement deposition, and an intact BBB, suggesting that 
inflammation is less prominent in these lesions115-117. How does B-cell depletion then 
prevent the development of grey matter lesions? B-cells are present in the meninges of 
MS brains118. The number of lymphocytes in the meninges does not correlate with the 
percentage of cortical demyelination118. However, B-cells in the meninges produce cytokines 
or chemokines, which may lead to microglia activation in the cortex. Depletion of meningeal 
B-cells by anti-CD20 Ab treatment may reduce microglia activation in the cortex.
The role of Nogo-A
Treatment with anti-Nogo-A Ab in the MOG34-56/CFA model, started one day 
before immunization, effectively prevented clinical symptoms and abrogated pathology. 
Nogo-A binds to its receptor (NgR) expressed on neurons and thereby it inhibits neurite 
outgrowth119,120. The novel finding published in chapter 4.4 is that the reverse signal 
from the binding of an yet unidentified receptor to Nogo-A abrogates demyelination and 
seems to promote remyelination. We hypothesize the role of Nogo-A in MS as follows. In 
non-injured CNS, the interaction of Nogo-A with its receptors prevents axonal sprouting 
and myelination (Figure 4A). In MS lesions, Nogo-A is still present in the remaining 
myelin and in the debris resulting from demyelination. Thus, the locally available Nogo-A 
may still prevent axonal outgrowth and remyelination (Figure 4B). Intervening into the 
two-way signaling between Nogo-A and Nogo-A receptor has a dual effect, removing 
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Figure 4. The role of Nogo-A in remyelination.
Nogo-A is expressed by oligodendrocytes and binds to the Nogo-A receptor (NgR) on axons. Nogo-A 
is also able to inhibit differentiation of oligodendrocyte precursor cells (OPC). In A and B the inhibitory 
signals are indicated with the black arrows. Shown is the situation in a healthy brain (A), in MS (B), 
and after treatment with the mAb against Nogo-A (C). In a healthy situation, Nogo-A prevents ongoing 
axonal sprouting and myelination. In MS lesions, Nogo-A is still present in the remaining myelin, but 
may be also released as a soluble compound upon demyelination and tissue damage. Nogo-A is still 
able to bind to NgR and prevents axonal outgrowth and remyelination. Anti-Nogo-A Ab treatment blocks 
the interaction between Nogo-A and its receptor. Axons and OPC loose the inhibitory signal and axonal 
outgrowth (black arrows) and remyelination is promoted. 
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the block on axonal outgrowth and axon remyelination (Figure 4C). This indicates that 
Nogo-A is a good target for MS therapy, acting as a two-edged sword, preventing axonal 
injury on the one hand and promoting remyelination on the other.
Not only neurons express NgR, but also macrophages121 and B-cells (Figure 5). 
Macrophages express NgR1121, which is a receptor for Nogo-A and other inhibitory 
proteins such as MAG. CD20+ B-cells, which were isolated from a MOG34-56/CFA-
immunized marmoset, express NgR2, but not NgR1. NgR2 mainly binds to MAG and 
not to Nogo-A122. EBV-transformed marmoset B-cell lines express both receptors. The 
percentage of NgR expressing cells is higher in EBV-transformed B-cells compared 
with CD20+ B-cells isolated from blood or lymphoid organs (Figure 5). This suggests 
that EBV-transformed B-cells, but not normal B-cells, can bind Nogo-A in myelin. NgR 
is also a receptor for B lymphocyte stimulator (BLyS), which is indispensable for B-cell 
development. Binding of BLyS to NgR on neurons inhibited neurite outgrowth123. BLyS 
binds to several known receptors on B-cells, such as BLyS receptor 3 and TACI124, 
but it may also bind to NgR on B-cells. The role of NgR expression on, mainly EBV-
transformed, B-cells in the pathogenesis of EAE and MS remains to be investigated.3%0& 6SOHHQ $/1 %FHOOOLQH  1J51J5
Figure 5. The expression of Nogo-A receptor on Cd20+ B-cells.
The expression of Nogo-A receptors (NgR) was analysed by flow cytometry of PBMC, mononuclear 
cells isolated from spleen and axillary lymph node (ALN), and EBV-transformed marmoset B-cell lines. 
NgR1 is a receptor for Nogo-A and other inhibitory proteins. NgR2 mainly binds to MAG and not to 
Nogo-A. Shown is the expression of NgR1 and NgR2 on CD20+ gated cells. CD3+ cells were uniformly 
negative for both NgR1 and NgR2 (data not shown). CD20+ B-cells isolated from PBMC or lymphoid 
organs do not express NgR1 and only a small percentage express NgR2. This suggests that these 
B-cells cannot bind to Nogo-A. In contrast, a large percentage of CD20+ EBV-transformed marmoset 
B-cell lines express NgR1 and NgR2. This suggests that EBV-transformed B-cells can bind to Nogo-A. 
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OuTSTANdING QuESTIONS 
Are MOG34-56-specific T-cells able to induce demyelination?
This thesis demonstrates that MOG34-56-specific T-cells are cytotoxic against 
EBV-transformed B-cell lines that present MOG34-56 in vitro. The question 
remains whether these T-cells are capable of inducing demyelination or killing of 
oligodendrocytes. One way to address this would be adoptive transfer. However, 
creation of MOG34-56-specific T-cell lines on a large scale for adoptive transfer 
remains a major challenge, since these T-cells kill the autologous MOG34-56 
pulsed B-cell lines that are used as APC. As an alternative we plan to investigate 
this in a three-dimensional spheroid culture system, which will be set-up with 
newborn marmoset brains similar to rodent brain spheroids125,126. In this system, 
oligodendrocytes produce myelin and therefore demyelination or oligodendrocyte 
death induced by T-cells can be investigated. In addition, this system can be used to 
investigate the pathogenic role of anti-MOG Ab.
How can the activity of MOG34-56-specific T-cells be inhibited?
The anti-CD52 Ab alemtuzumab127 and the anti-CD25 Ab daclizumab128 inhibit T-cell 
activity in MS. However, these therapies also target other T-cells that are not involved 
in MS. Therefore, targeting the specific activity of MOG34-56-specific T-cells may be a 
better option. 
This thesis demonstrates that MOG34-56-specific T-cells are cytotoxic. Inhibition of 
exocytosis of cytotoxic granules by concanamycin A prevented the cytolytic activity of 
MOG34-56-specific T-cells in vitro (Chapter 3.2). Inhibition of exocytosis of cytotoxic 
granules may prevent cytolysis in vivo. However, this is not an option for therapy, 
because exocytosis of cytotoxic granules is crucial for the anti-viral defense. Inhibition 
of exocytosis may thus lead to viral reactivation or new viral infections.
Although CD56 is a marker of the MOG34-56-specific T-cells, CD56 itself cannot be 
used as a target for therapy. Anti-CD56 Ab did not prevent lysis of tumor cell lines by 
MBP-specific CD4+CD56+ T-cells90. In addition, many other cell types express CD56, 
such as NK cells. CD3-CD56+ NK-cell frequencies are reduced in RRMS compared to 
healthy controls129 and increased after treatment with IFN-β and daclizumab130,131. It is 
suggested that NK cells have a regulatory function in MS132 and these should not be 
inhibited or depleted by an anti-CD56 therapy.
MOG34-56-specific T-cells produce IL-17A. Treatment of marmosets with anti-
IL-17A Ab was not effective in the rhMOG/CFA model, in which both Th1 and Th17 
cells are activated. Before concluding whether IL-17A is essential for the disease or 
not, it should be tested whether neutralization of IL-17A is effective in the MOG34-
56/IFA model. 
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Based on our current knowledge we think that the best therapy to inhibit both 
the cytotoxicity and IL-17A production by MOG34-56-specific T-cells is to prevent 
that these T-cells are activated. We have shown that depletion of B-cells by an anti-
CD20 Ab reduced the proliferation and cytokine production by MOG-specific T-cells. 
This prevented the development of clinical signs and profoundly reduced pathology 
(Chapter 4.2 and 4.3). Therefore, this may be the preferred therapy to inhibit the activity 
of MOG34-56-specific T-cells.
which new developments can optimize in vivo parameters?
The clinico-radiological paradox describes the discrepancy between the clinical 
status and brain WM lesion load in MS133,134. In marmosets, the clinical scores do also 
not correlate very well with the brain WM lesion load. This paradox can be overcome by 
improving the clinical as well as the radiological parameters.
The clinical scoring system used for the research in this thesis was mainly focused on 
motor defects, such as ataxia and paralysis. Before these symptoms appear, changes 
in walking pattern and behavior are observed. However, it is difficult to translate these 
changes into a clinical score, because they are not as obvious as, for example, ataxia. 
A way to measure the first changes in activity is telemetry. For example, an implanted 
transponder that measures the total activity during the day as well as the night may 
show a reduction in activity before other clinical symptoms appear.
It has been suggested that clinical symptoms in MS better correlate with GM 
lesions than with WM lesions. Therefore, GM lesions should be followed in marmosets 
by longitudinal in vivo MRI, after which the correlation with clinical symptoms can be 
investigated.
Will there be a role for the intestinal flora in the pathogenesis?
It has been reported that Th17 cells expand in the lamina propria of the small intestine 
and colon of mice65,135. In addition, a special microflora is required for the differentiation 
of Th17 cells65. This raises the question whether alteration of the microflora by antibiotics 
may prevent EAE. Indeed, treatment of C57BL/6 and SJL mice with oral antibiotics 
reduced the IL-17A production and reduced the clinical score of EAE136. Future 
investigations are warranted to unravel the role of the microbial flora in the intestine of 
humans, among others in relation to the IL-17A production and the clinical symptoms. 
Marmosets are conventionally housed, which means that their microbial flora is more 
closely related to humans than specific pathogen free mice. Therefore, the marmoset 
may be a suitable model to investigate whether the intestinal flora is involved in the 
pathogenesis of EAE and MS. 
A new method has been developed to screen the bacterial composition in the 
intestinal tract by genomic sequencing of faecal samples. This technique can differentiate 
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between healthy individuals and patients with ulcerative colitis or Crohn’s disease137. 
This technique may be used to compare MS patients with healthy controls as well as to 
analyse differences between fast and slow progressors in the marmoset EAE model.
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SuMMARY
Multiple sclerosis (MS) is a chronic disease characterized by inflammation, 
demyelination, and axonal injury in the white and grey matter of the central nervous 
system (CNS). To date, the immunopathogenic mechanisms causing MS are still 
unknown and a therapy to arrest the progressive accumulation of neurological deficits 
is still lacking. Therefore, the aim of this thesis was to investigate the pathogenic 
mechanisms underlying MS as a basis for the development of new therapies. 
The investigation of immunopathogenic mechanisms and the efficacy of new 
therapies benefits from an animal model that approximates MS in its clinical and 
pathological manifestation. Common marmosets are genetically, immunologically, 
and anatomically closely related to humans. The animal model for MS, experimental 
autoimmune encephalomyelitis (EAE), can be induced in marmosets. At the start of 
the research described in this thesis, EAE could be induced in 100% of the marmosets 
from an outbred colony by immunization with myelin or recombinant human myelin 
oligodendrocyte glycoprotein (rhMOG) in complete Freund’s adjuvant (CFA). To 
identify the core pathogenic mechanisms, the marmoset model was refined to the 
minimal requirements for EAE induction. In addition, we used the marmoset model 
to validate pathogenic concepts by the efficacy analysis of several new therapies for 
MS.
Studies in experimental animal models rely on the availability of cross-reactive 
reagents and techniques, such as flow cytometry and immunohistochemistry. A large 
panel of anti-human antibodies that can be used to phenotype marmoset cells with flow 
cytometry is available. However, detailed in situ examination of lymphoid tissue was often 
hampered by the lack of cross-reactive antibodies. In chapter 2, we have investigated 
the cross-reactivity of a selection of anti-human antibodies against lymphoid tissue of 
non-human primates, including the marmoset. Of the 116 monoclonal antibodies tested, 
69 antibodies (60%) were cross-reactive with marmoset spleen or lymph node tissue. 
In previous marmoset EAE experiments, immunization with rhMOG/CFA induced 
a 100% disease incidence with a heterogeneous disease onset. The disease 
heterogeneity seems to be inherent to the outbred nature of the marmoset colony 
from which animals were recruited. The immunopathogenic mechanisms underlying 
this heterogeneity were investigated in chapter 3.1. We have found that fast disease 
progression is associated with a broadened T-cell response against a panel of 23-
mer MOG peptides. The prevalent T-cell response in the fast progressor monkeys 
was directed against MOG34-56 and MOG74-96. MOG35-55 peptide was already 
known as an important epitope for disease induction in rodents. It was therefore not 
surprising that immunization of marmosets with MOG34-56 formulated in CFA led 
to a chronic disease. In this model, we have identified MOG34-56-specific T-cells 
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as major players in the disease. These T-cells have characteristics of natural killer 
cells and cytotoxic T-cells suggesting they are natural killer-cytotoxic T-lymphocytes 
(NK-CTL).
Immunization with MOG74-96 in CFA only induced mild symptoms and pathology. 
However, when these animals were given a single boost with MOG34-56 in incomplete 
Freund’s adjuvant (IFA), neurological deficit as well as profound CNS lesion formation 
was observed. This led us to hypothesize that EAE in marmosets could also be induced 
with only MOG34-56 in IFA. In chapter 3.2, we demonstrated that MOG34-56 in IFA 
induced a chronic disease in marmosets with similar clinical symptoms and pathology as 
in the rhMOG/CFA and MOG34-56/CFA marmoset models. In this model, we identified 
that the MOG34-56-specific T-cells also produce IL-17A. This model induced without 
the use of CFA is a major refinement for ethical, practical, and mechanistic reasons.
Whether IL-17A production by MOG34-56-specific T-cells is indeed essential for 
the disease development was investigated in chapter 4.1. IL-17A was neutralized by 
weekly administration of two doses of anti-IL-17A antibody in the rhMOG/CFA model. 
Treatment with the anti-IL-17A antibody did not prevent the development of clinical 
signs and pathology, although the disease onset was slightly delayed. The treatment 
affected the number of IL-17A producing cells in lymphoid organs, but not in the brain. 
This suggests that IL-17A does not have a major pathogenic role in the induction phase 
of the disease in the chosen EAE model, but may rather play a role in the disease 
progression.
The CD20+ B-cell depleting antibody rituximab is a promising treatment for MS, 
because clinical deterioration is prevented and lesion formation in the brain white matter 
is attenuated. The pathogenic mechanisms targeted by the antibody in MS are still 
unknown. We have therefore investigated the effect of late B-cell depletion with a novel 
anti-CD20 antibody (HuMab 7D8), i.e. well after (21 days) T-cell and B-cell priming and 
clonal expansion, on the immune system and CNS pathology in the marmoset EAE 
model induced by rhMOG in CFA. In chapter 4.2, we demonstrated that B-cells may 
act as antigen presenting cells in the EAE model, since T-cell proliferation and cytokine 
production were significantly reduced in lymphoid organs of B-cell depleted animals. In 
addition, B-cell depletion prevented demyelination and inflammation in brain white and 
grey matter as well as in spinal cord and optic nerve, as shown in chapter 4.3. These 
data underline an important pathogenic role of B-cells in the peripheral activation of 
T-cells and the induction of widespread CNS pathology.
Instead of interfering with the immune response, promotion of (re)myelination and 
neuronal outgrowth are also promising therapy targets. To investigate this, MOG34-
56/CFA-immunized marmosets were treated with a monoclonal antibody against the 
myelin-associated neurite outgrowth inhibitor Nogo-A. In chapter 4.4, we demonstrated 
that anti-Nogo-A antibody abrogates the development of clinical signs and pathology. 
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In addition, we show that Nogo-A is not only a neurite outgrowth inhibitor, but that Nogo-A 
is also involved in the myelination process and the differentiation of oligodendrocyte 
precursor cells. This supports the promise that Nogo-A is a good therapeutic target for 
MS and other demyelinating diseases.
MS relapse rate decreases during pregnancy, especially during the third 
trimester. In this phase of pregnancy, fragments derived from the β-subunit of the 
pregnancy hormone human chorionic gonadotropin (hCG) can be detected in serum 
and urine. Previous studies in rodent and non-human primate models of immune-
mediated inflammatory disease showed that synthetic oligopeptides related to the 
hCG β-subunit have modulatory effects in acute, inflammatory responses. We have 
investigated whether the hCG-related tetrapeptide LQGV has modulatory potential in 
a more chronic inflammatory disease, namely EAE in marmosets. In chapter 4.5, we 
reported that the tested dose and treatment regimen of LQGV had no effect on clinical 
signs, pathology, or the immune response in marmosets immunized with MOG34-56 
and MOG74-96 in IFA.
In conclusion, the studies collectively support the interpretation that the major 
pathogenic immune response is mediated by MOG34-56-specific T-cells, which display 
a unique combination of cytotoxicity and IL-17A production. These T-cells can be 
activated in vivo by immunization with MOG34-56 in IFA, showing that in contrast to 
the generally held dogma, microbial ligands in the adjuvant are not required for their 
activation. In addition, we have shown that anti-IL-17A antibody and LQGV are not 
effective in the marmoset models tested, although both treatments may be effective in 
other EAE marmoset models. Furthermore, B-cell depletion and targeting Nogo-A are 
promising treatments for MS. The improved and refined marmoset EAE model will be 
useful to further dissect the pathogenesis and to validate new therapies for MS.
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Multipele sclerose (MS) is een chronische aandoening die zich kenmerkt door 
ontsteking, demyelinisatie, en schade aan de zenuwcellen in de witte en grijze stof 
van de hersenen en het ruggenmerg. Demyelinisatie wordt mogelijk veroorzaakt 
doordat cellen van het immuunsysteem, zoals macrofagen en T-cellen, zich richten 
tegen de myeline laag om zenuwcellen. De exacte pathogenese, oftewel de oorzaak 
en de ontwikkeling, van MS is nog niet bekend. Tevens is er nog geen medicijn om de 
progressieve voortgang van de ziekte te stoppen. Dit proefschrift beschrijft onderzoek 
dat gedaan is naar de pathogenese van MS en een aantal nieuwe geneesmiddelen die 
zijn getest op hun effectiviteit.
Om onderzoek te kunnen doen naar de pathogenese en het effect van nieuwe 
geneesmiddelen is een diermodel nodig. Dit diermodel moet zo sterk mogelijk lijken 
op MS in het klinische verloop en in de ontwikkeling van de lesies in de hersenen 
en het ruggenmerg. De marmoset, ook wel bekend als de penseelaap, is grotendeels 
vergelijkbaar met de mens op het genetische, immunologische, en anatomische vlak. 
Het diermodel voor MS is experimentele autoimmuun encefalomyelitis (EAE). Voordat 
het onderzoek beschreven in dit proefschrift werd begonnen, was al bekend dat EAE 
geïnduceerd kon worden in marmosets. EAE werd geïnduceerd door immunisatie met 
de recombinante versie van humaan myeline oligodendrocyt glycoproteïne (rhMOG) in 
compleet Freund’s adjuvant (CFA). MOG is één van de eiwitten die aanwezig zijn in de 
myelineschede om zenuwcellen en waartegen een deel van de immuunrespons in MS 
is gericht. CFA is een adjuvant dat er onder andere voor zorgt dat er een langdurige 
afgifte ontstaat van rhMOG op de immunisatie plek. Hierdoor wordt het immuunsysteem 
langdurig geactiveerd door rhMOG. CFA bevat ook geïnactiveerde mycobacteriën 
waardoor het immuunsysteem nog extra geactiveerd wordt. 
Eén van de onderzoeksvragen richtte zich op het vinden van de minimale 
benodigdheden om EAE te induceren. Door de verfijning van het immunisatieprotocol 
is er meer bekend geworden over de minimale benodigdheden voor de inductie van 
EAE. Hierdoor is er ook meer bekend geworden over de pathogenese. Verder is het 
marmoset EAE model gebruikt als preklinisch model om de effectiviteit van nieuwe 
geneesmiddelen te onderzoeken.
Om studies in experimentele (dier)modellen te kunnen uitvoeren zijn kruisreactieve 
reagentia nodig, onder andere voor analyse met flow cytometrie en immunohistochemie. 
Om marmoset cellen te kleuren voor flow cytometrie was al een groot panel van 
anti-humane antistoffen beschikbaar die kruisreageren met marmoset cellen. Het 
onderzoek van lymfoïde organen met immunohistochemie werd nog beperkt doordat 
de kruisreactiviteit van anti-humane antistoffen niet bekend was. In hoofdstuk 2 is de 
kruisreactiviteit getest van een selectie anti-humane antistoffen op lymfoïde weefsel 
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van zes niet-humane primaten, inclusief de marmoset. Van de 116 geteste antistoffen 
waren er 69 (60%) kruisreactief met marmoset weefsel.
Uit eerdere marmoset EAE experimenten was al bekend dat immunisatie met 
rhMOG in CFA klinische symptomen induceert in alle marmosets. De dag dat de 
eerste klinische symptomen zich openbaarden was echter wel verschillend tussen 
de dieren. Deze heterogeniteit wordt veroorzaakt doordat de marmosets genetisch 
verschillend zijn van elkaar, in tegenstelling tot ingeteelde knaagdier stammen die 
ook voor EAE worden gebruikt. Welke immuunresponsen verantwoordelijk zijn voor 
de heterogeniteit in marmosets was nog niet bekend en is onderzocht in hoofdstuk 
3.1. Het blijkt dat dieren die relatief kort na immunisatie symptomen ontwikkelen, een 
brede T-cel respons hebben die gericht is tegen meerdere epitopen van MOG. De 
meest voorkomende T-cel responsen waren gericht tegen het peptide 34 tot en met 56 
van MOG (MOG34-56) en MOG74-96. Het was al bekend dat MOG34-56 belangrijk 
is voor de inductie van EAE in knaagdieren. Ook in marmosets leidt immunisatie met 
MOG34-56 in CFA tot een chronisch ziektebeeld. T-cellen die specifiek reageren op 
MOG34-56 blijken een belangrijke rol te spelen in het marmoset EAE model. Deze 
T-cellen hebben bepaalde kenmerken die zowel overeenkomen met natural killer 
cellen als cytotoxische T-cellen en behoren daarom mogelijk tot de natural killer-
cytotoxische T-lymfocyt populatie (NK-CTL).
Immunisatie van marmosets met MOG74-96 in CFA leidt tot milde klinische 
symptomen en pathologie. Deze dieren ontwikkelen dezelfde klinische symptomen en 
pathologie als dieren die zijn geïmmuniseerd met MOG34-56 in CFA als zij éénmaal 
worden geboost met MOG34-56 in incompleet Freund’s adjuvant (IFA). In tegenstelling 
tot CFA bevat IFA geen bacteriële antigenen, waardoor het immuunsysteem op een 
andere manier wordt geactiveerd. Onze hypothese was dat CFA niet noodzakelijk is 
voor de inductie van EAE en dat MOG34-56 in IFA voldoende is. In hoofdstuk 3.2 
hebben we aangetoond dat immunisatie van marmosets met MOG34-56 in IFA leidt tot 
een chronische ziekte met gelijke klinische symptomen en pathologie als in de rhMOG 
in CFA en MOG34-56 in CFA modellen. In dit model worden dezelfde MOG34-56-
specifieke T-cellen geactiveerd en deze maken tevens IL-17A. Dit model zonder CFA is 
een aanzienlijke verfijning in ethisch, praktisch en conceptueel opzicht.
Om te onderzoeken of de productie van IL-17A door MOG34-56-specifieke 
T-cellen essentieel is voor de ziekte, hebben we in het rhMOG in CFA model IL-17A 
geneutraliseerd door wekelijks te behandelen met twee verschillende concentraties 
van een antistof tegen IL-17A. In hoofdstuk 4.1 laten we zien dat behandeling met dit 
antistof de ontwikkeling van klinische symptomen en pathologie niet kon voorkomen, 
maar dat het wel langer duurde voordat de behandelde dieren ziek werden vergeleken 
met de controle dieren. Na de behandeling was het aantal IL-17A producerende cellen 
veranderd in de lymfoïde organen, maar niet in de hersenen. Dit onderzoek suggereert 
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dat IL-17A geen essentiële rol speelt in de inductie fase van dit model, maar mogelijk 
speelt het wel een rol bij de regulatie van de progressie van de ziekte.
Het verwijderen van CD20+ B-cellen is een veelbelovende behandeling voor 
MS. Het anti-CD20-antistof rituximab verminderde de klinische achteruitgang en de 
ontwikkeling van lesies in de witte stof van de hersenen van mensen met MS. Het 
mechanisme dat ten grondslag ligt aan dit effect is onbekend. Wij hebben het effect 
van B-cel depletie op het immuunsysteem en de pathologie onderzocht. Drie weken 
na immunisatie met rhMOG in CFA, wanneer de T-cel respons in gang is, werden de 
B-cellen verwijderd door wekelijkse behandeling met een nieuw anti-CD20 antistof 
(HuMab 7D8). In hoofdstuk 4.2 laten we zien dat B-cellen mogelijk werken als antigeen 
presenterende cel in het marmoset EAE model. In de behandelde dieren was de deling 
en cytokine productie van T-cellen in lymfoïde organen verminderd vergeleken met 
de niet behandelde dieren. In hoofdstuk 4.3 laten we zien dat het verwijderen van 
B-cellen leidt tot minder demyelinisatie en ontsteking in de witte en grijze stof van de 
hersenen, in het ruggenmerg en de oogzenuw. Deze resultaten tonen aan dat B-cellen 
mogelijk een pathogene rol spelen door de activatie van autoreactieve T-cellen en de 
inductie van de pathologie. 
In plaats van het onderdrukken van de immuunrespons, is het stimuleren van nieuwe 
myeline aanmaak en de uitgroei van zenuwcellen een andere therapeutische strategie. 
Om dit te onderzoeken zijn marmosets geïmmuniseerd met MOG34-56 in CFA en 
wekelijks behandeld met een antistof tegen Nogo-A. Nogo-A is aanwezig in myeline en 
remt de uitgroei van zenuwcellen. In hoofdstuk 4.4 is aangetoond dat een anti-Nogo-A 
antistof de ontwikkeling van klinische symptomen en pathologie remt. Nogo-A blijkt ook 
betrokken bij de aanmaak van myeline en de ontwikkeling van de myeline-producerende 
oligodendrocyten. Een anti-Nogo-A antistof kan dus potentieel een goede therapie zijn 
voor MS en andere ziekten waarin afbraak van myeline plaatsvindt.
Het aantal MS-aanvallen neemt af tijdens zwangerschap en dan met name 
tijdens het derde trimester. In deze fase zijn fragmenten van de β-subunit van het 
zwangerschapshormoon humaan choriongonadotropine (hCG) aanwezig in serum en 
urine. In eerdere studies is aangetoond dat hCG-gerelateerde peptiden, zoals LQGV, 
een acute immuunrespons kunnen moduleren. Het effect van het hCG-gerelateerde 
peptide LQGV op een chronische immuunrespons is onderzocht in het marmoset 
EAE model. Marmosets werden geïmmuniseerd met MOG34-56 en MOG74-96 in IFA 
en drie keer per week behandeld met LQGV. Uit hoofdstuk 4.5 blijkt dat LQGV in 
de geteste dosis en behandelingsregime geen effect heeft op klinische symptomen, 
pathologie of de immuunrespons in marmosets geïmmuniseerd met MOG34-56 en 
MOG74-96 in IFA.
Deze studies verschaffen evidentie dat MOG34-56-specifieke T-cellen een belangrijke 
rol spelen in de pathogenese van EAE en mogelijk ook in MS. Deze T-cellen hebben 
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de unieke combinatie van cytotoxiciteit en IL-17A productie en kunnen geactiveerd 
worden door immunisatie met MOG34-56 in IFA. Dit laat zien dat, in tegenstelling tot 
het algemene dogma, microbiële liganden in het adjuvant niet noodzakelijk zijn voor de 
activatie van deze T-cellen. Tevens hebben we aangetoond dat een anti-IL-17A antistof 
en LQGV niet effectief zijn in de geteste marmoset EAE modellen. B-cel depletie en 
een anti-Nogo-A antistof zijn wel veelbelovende behandelmethoden voor MS. Het 
verbeterde en verfijnde marmoset EAE model zal in de toekomst bijdragen aan verdere 
ontrafeling van de pathogenese en tevens meer gebruikt worden voor de preklinische 
validatie van nieuwe geneesmiddelen.
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ABBREVIATIONS
(m)Ab (monoclonal) antibody
Ag antigen
ALN axillary lymph node
APC antigen presenting cell
BBB blood-brain barrier
B-LCL B-lymphoblastoid cells
BLyS B lymphocyte stimulator
Caja Callithrix jacchus
CD cluster of differentiation
CFA complete Freund’s adjuvant
CFSE carboxyfluorescein diacetate succinimidyl ester
CLN cervical lymph node
CMV cytomegalovirus
CNS central nervous system
cpm counts per minute
CSF cerebrospinal fluid
DC dendritic cell
DTI diffusion tensor imaging
EAE experimental autoimmune encephalomyelitis
EBV Epstein-Barr virus
GM grey matter
HHV human herpesvirus
HIV human immunodeficiency virus
HLA human leukocyte antigen
IFA incomplete Freund’s adjuvant
IFN interferon
Ig immunoglobulin
IL interleukin
ILN inguinal lymph node
LPC lysophosphatidylcholine
MAG myelin associated glycoprotein
MBP myelin basic protein
MHC major histocompatibility complex
MNC mononuclear cell suspension
MOG myelin oligodendrocyte glycoprotein
MRI magnetic resonance imaging
MS multiple sclerosis
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MTR magnetization transfer ratio
NAWM/NAGM normal appearing white/grey matter
NgR Nogo-receptor
NHP non-human primate(s)
NK-CTL natural killer-cytotoxic T lymphocyte
NLR Nodlike receptor
OPC oligodendrocyte glycoprotein
PBMC peripheral blood mononuclear cells
PLP proteolipid protein
PML progressive multifocal leukoencephalopathy
PPMS primary progressive MS
PRMS progressive relapsing MS
psd post sensitization day 
rh recombinant human
ROI region of interest
RRMS relapsing-remitting MS
SI stimulation index
SPMS secondary progressive MS
T1W/T2W T1- or T2-weighted
TCL T-cell line
TCR T-cell receptor
TLR Toll-like receptor
TNF tumor necrosis factor
Th T helper
WM white matter
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Figure 3. Pathology of MS.
A, A staining for proteolipid protein (PLP) shows the demyelinated hypocellular center of a chronic 
active lesion in the white matter of a MS brain (original magnification x50). B, At the rim of the lesion, 
where myelin is phagocytosed by macrophages, axonal transections are visualized by a staining for 
the amyloid precursor protein (original magnification x50). Axonal transections at the rim of the lesion 
in the square are enlarged in C (original magnification x100). D, A PLP staining of the grey matter 
shows a subpial lesion (original magnification x50). Photographs are kindly provided by E.-J. Kooi and 
Dr. J. Geurts (Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands).
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Figure 1. Representative selec-
tion of cross-reactive monoclonal 
antibodies on spleen cryosections 
of rhesus macaque and common 
marmoset.
Spleen sections were stained for 
CD40, HLA-DR, IFN-γ, and IL-17A. 
Controls included isotype control 
and first antibody omission. Bar = 
100 μm.
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Figure 4. diffusion tensor imaging of MOG34-56-induced brain lesions. 
The disruption of the normally restricted orientation (anisotropic) of water diffusion in white matter 
was used as an indirect MRI measure of tissue destruction in formalin-fixed brains. Brains from the 
four MOG34-56-immunized monkeys in experiment 1 (see Table 1) were used for this analysis. A 
tomographic section of the brain of monkey M0167 is depicted as a representative example. A, High 
contrast T2W images were made to visualize hyperintense structural abnormalities. B, The (disturbance 
of) fiber direction within the white matter is visualized with the standard color codes (red, left ==> 
right; blue, superior ==> inferior; green, anterior ==> posterior). C, The ellipsoid representation of fiber 
orientation within a lesion-rich area (white square) shows a round shape in the cortical (C) and lesion (L) 
area whereas these are more unidirectional in the compact white matter. D-F, Mean values of the total 
lesion (grey bars) and white matter (hatched bars) area of four monkeys (M0131, M0167, M0178, and 
M0182) are shown. The depicted quantitative parameters are as follows: 1) the mean of all voxels for T2 
relaxation times (D), which is higher in the lesions than in the NAWM due to increased water content; 2) 
the degree of fractional anisotropy (E), which is decreased due to destruction of compact myelin; and 
3) and the apparent diffusion coefficient (F), which is slightly higher in lesions than in NAWM. Data are 
mean ± SD. * P < 0.05, ** P < 0.001.
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Figure 5. MOG34-56 induces inflammation and demyelination in the CNS. 
A, Luxol fast blue staining (original magnification x23) reveals that in this cross-section of spinal cord 
> 50% of the white matter has been demyelinated (blue line, border with normal white matter) and is 
remyelinating. Magnified views of the rectangle are shown in B and C. B, CNPase staining (original 
magnification x160) confirms demyelination and remyelination. Arrowheads point at oligodendrocyte 
cell bodies in the lesion centre. C, CD3 staining (original magnification x160) shows the presence of T 
lymphocytes in this area. D, Luxol fast blue staining (original magnification x38) indicates the presence 
of demyelinating lesions in the corpus callosum. E, MRP-14 positive macrophages are present in these 
lesions (E, original magnification x99) together with CD3 positive T lymphocytes (F, original magnification 
x200). G, PLP staining (original magnification x310) reveals PLP degradation products in macrophages 
(arrowheads). H, IgM staining (original magnification x290) shows plasma cells and Ig deposition 
on myelin. I, Axonal injury (axonal spheroids) in these white matter lesions is visualized by amyloid 
precursor protein staining (original magnification x275). In addition to spinal cord and brain white matter 
lesions, prominent cortical demyelination is also present. J, PLP staining (original magnification x50) 
reveals subpial demyelination. The meningeal lining is at the upper part of the figure, the blue lining 
marks the border of the demyelinated cortex, and a magnified view of the area inside the rectangle is 
shown in K. K, The area inside the rectangle in J (original magnification x990) in which microglial cells 
with uptake of PLP-positive myelin degradation products can be found. L, These activated microglial 
cells (original magnification x185) also stain positively with MRP-14, being an early activation marker 
of macrophages.
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Figure 7. Pathology of MOG34-56-boosted EAE in MOG74-96-immunized monkeys.
Pathology present in the spinal cord of monkey M03033 is shown in A-C; pathology in the optic tract 
is shown in D-J. A, Staining for luxol fast blue (original magnification x20) reveals demyelinated areas 
(bordered by blue dotted line) in the spinal cord white matter. B, Late active demyelination (original 
magnification x350) is shown by the presence of PLP-positive degradation products in macrophages. 
C, Besides demyelination, inflammation of the lesions is characterized by the presence of CD3+ 
lymphocytes (original magnification x150). D, Luxol fast blue staining (original magnification x45) shows 
large demyelinated lesions (borders indicated by dotted line) in the optic tract. Magnified views of the 
rectangular area are shown in E-J. E, Staining for PLP (original magnification x350) reveals the presence 
of PLP degradation products in macrophages (arrowheads). F, The optic tract lesions contained CD3+ 
lymphocytes (original magnification x150). G, Single macrophages are stained positively for MRP-14 
(original magnification x150). H, A bielschowsky stain for axons (original magnification x150) shows a 
reduced density of axonal fibers in the demyelinated area (D) compared to the surrounding NAWM (N). 
I, Staining for IgM (original magnification x300) and complement C9 (J, original magnification x300) 
shows deposition in the demyelinated areas.
Chapter 3.1
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Figure 4. MOG34-56 in IFA induces demyelination and inflammation in brain and spinal cord. 
Hyperintense white matter areas that were detected in T2-weighted images were analyzed with 
histology and immunohistochemistry. Brain of M05047 (A, D-G) and spinal cord of 9847 (B,C, H-K) 
are shown as representatives. A, Luxol fast blue-Periodic acid-Schiff (LFB-PAS) staining (original 
magnification x4) shows multiple large demyelinating lesions (arrowheads). The lesion in the corpus 
callosum (arrow) is enlarged in figures D-G. B, Subpial demyelination in spinal cord demonstrated with 
LFB-PAS (original magnification x25). The arrow indicates the area enlarged in H-K. C, Multiple large 
focal lesions are also seen in the spinal cord (arrowheads; original magnification x25). D, Enlargement 
of the area indicated with arrow in panel A. LFB-PAS (original magnification x125) staining shows late 
active demyelination and the presence of PAS-positive macrophages. E, Macrophage immunostaining 
using the macrophage marker MRP14 (original magnification x400). F, Immunostaining for myelin PLP 
(original magnification x500) shows macrophages containing phagocytosed PLP positive fragments 
(arrowheads). G, Immunostaining for CD3 (original magnification x200) shows that the lesions contain 
few T -cells. H-K, (original magnification x200) H, Subpial spinal cord area immunostained for MRP14 
shows the presence of macrophages. I, CD3 immunostaining shows some meningeal T lymphocytes. J, 
K, Staining for immunoglobulin (J) reveals deposition in a pattern that overlaps with that of complement 
factor C9neo (K).
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Figure 4. differential expression of Il-17A in the brain and lymphoid organs. 
IL-17A expression was detected by immunohistochemistry. Panel A (original magnification x200) shows 
representative examples of each group for brain, spleen, and axillary (ALN), inguinal (ILN), and cervical 
(CLN) lymph nodes.
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Figure 9. Histological analysis of T-cell and B-cell areas in the spleen and AlN of B-cell depleted 
and control monkeys. 
Shown are representative examples of HE (original magnification x40), CD20 (original magnification 
x100), CD40 (original magnification x100), and CD3 (original magnification x100) staining on spleen (two 
left columns) and ALN (two right columns). The HE staining shows that the overall histology of the spleen 
and ALN was not changed by B-cell depletion. Spleen: The CD20 staining of the control animal shows 
a clearly demarcated B-cell area in the white pulp, which is also CD40+. CD40+ cells are also present 
in the red pulp. The CD3 staining of the white pulp shows the CD3+ T-cell area. In the B-cell depleted 
spleen no CD20+ cells are present. A few CD40+ cells are present, but these morphologically resemble 
follicular dendritic cells or macrophages (insert). The white pulp of the B-cell depleted animal seems to 
consist completely of T-cells. ALN: The ALN of the control animal contains a clearly demarcated CD20+ 
area, which stains also CD40+. CD40+ cells are also observed in the medulla. CD3+ cells are confined to 
the T-cell areas of the cortex. In the ALN of B-cell depleted animals, the B-cell area is hypocellular with a 
few CD20+ and CD40+ cells, but the latter do not have the morphology of B-cells. The number of T-cells 
seems to be increased in the cortex of the ALN of B-cell depleted animals.
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Figure 2. Reduced demyelination and inflammation in the white matter after B-cell depletion. 
A, Luxol fast blue staining for myelin shows demyelination in the brain (original magnification x50), 
spinal cord (original magnification x25), and optic nerve (original magnification x25) of a representative 
control animal (upper panel). The lower panel shows the intact myelin pattern in brain, spinal cord, and 
optic nerve of treated animals. B, T-cells (upper panel) and B-cells (lower panel) were observed in brain 
and spinal cord lesions of control animals, but not in treated animals (original magnification x200).
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Figure 3. B-cell depletion prevents the development of grey matter lesions. 
A, stainings for proteolipid protein and MRP14+ macrophages show a large demyelinated lesion in 
cortical grey matter of a control animal (upper panel). No grey matter demyelination was observed 
in CD20+ B-cell depleted animals (lower panel) (original magnification x500). B, Left hemisphere of a 
control animal is immunostained for PLP. The arrow points to a group of lesions that are depicted in 
the five smaller photographs. The first two photographs show the grey matter lesions in a PLP staining 
(original magnification x25 and x50). MRP14+ staining shows an active lesion (upper lesion) with many 
(recently infiltrated) macrophages and an inactive lesion with macrophages only at the rim of the lesion 
(lower lesion). T-cells and B-cells were present in these lesions (original magnification x400). C shows 
a lesion in the hippocampus (arrow). Demyelination is shown by PLP staining. MRP14+ macrophages, 
T-cells and B-cells were present in this lesion.
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Figure 1. Amelioration of EAE in marmosets by amino-Nogo-A antibody treatment.
A, Individual clinical scores of EAE marmoset treated with amino-Nogo-A antibody (aNogoA mAb) 
and control. Animals (n=5/group) were administered intravenously with a humanized aNogoA mAb or 
control at 30 mg/kg, starting one day before immunization and every week thereafter and monitored 
until post immunization days (p.i.d) 112 and 168. B, Survival analysis in aNogoA mAb treatment and 
control groups. C, Representative spinal cord sections obtained from EAE marmosets analyzed for the 
degree of demyelination by LFB staining and axon integrity by Bielschowsky staining and infiltrating 
mononuclear cells by H&E staining. Scale bar, 600 µm (LFB, upper), 200 µm (LFB, lower), 200 µm 
(H&E) and 50 µm (Bielschowsky). (D) Percentage of demyelination areas in the white matter of spinal 
cord and the brain and the brain. 
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Figure 2. Reduction of demyelination and protection of axons by the treatment of amino-Nogo-A 
antibody in an lPC-induced demyelination model.
A, Area of demyelination by aNogoA mAb treatment in LPC-induced corpus callosum demyelination 
model. Brain samples were collected from mice 3 days after aNogoA mAb treatment or PBS control 
and analyzed for the degree of demyelination by LFB staining. Arrows point to the injection sites or 
needle tracts. Arrowheads indicate the demyelination areas. Scale bar, 500 µm (upper panels) and 200 
µm (bottom panels). Bar graph represents the quantification of the area of demyelination in the corpus 
callosum in relation to the indicated doses of aNogoA mAb. B, Toluidine blue staining of 1 μm corpus 
callosum sections (left) and magnified images of the boxed border areas (right). Scale bars, 2 µm. The 
bar graphs represent the total number of axons and % averages of demyelinated axons from the border 
areas. C, Representative electromicrographs of corpus callosum sections from normal and LPC-injected 
mice treated with aNogoA mAb (2 µg/mouse) or control. Red asterisks denote macrophages. Boxed 
areas are enlarged (bottom). D, Axon sprouting in the lesion area (white asterisks) as demonstrated by 
peripherin staining (green) or neurofilament H (red). *p < 0.05; **p < 0.01.
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Figure 3. Restoration of axon integrity and myelination by amino-Nogo-A antagonism in lPC-
treated cerebellar slice culture.
A, Representative confocal images of LPC-treated cerebellar slice cultured with aNogoA mAb or IgG 
control. Oligodendrocytes were stained with MBP antibody (red) and axons were stained with antibody 
directed at neurofilament (NF, green). Myelinated axons are shown by co-staining (yellow). Scale bar, 
50 µm. B, Expression of MBP, Nogo-A, and Tuj-1 in LPC-treated cerebellar slice cultured with different 
concentrations of aNogoA mAb or IgG control. Actin was used as a control for protein loading. C, 
CNPase activity in LPC-treated cerebellar slice. Homogenates prepared from LPC-treated cerebellar 
slice cultured with either aNogoA mAb or IgG control were analyzed in a fluorometric assay. Numbers 
are expressed as percentage average normalized against untreated control. D, Expression of MBP in 
cerebellar slice subjected to indicated treatment conditions. Actin was used as a loading control. The 
data are representative of three independent experiments. *p < 0.05.
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Figure 4. Effect of amino-Nogo-A antagonism in amino-Nogo-A-mediated inhibition of OPC dif-
ferentiation, maturation, and myelination.
A-B, Inhibition of OPC differentiation by amino-Nogo-A (aNogoA). aNogoA at 4 mg/ml was added to 
OPC culture under differentiation condition in the presence or absence of aNogoA mAb for 4 days. 
The resulting OPC culture was analyzed for MBP staining (red, upper images) and the percentage of 
myelin producing oligodendrocytes was quantified by Cellomics (bar graph). The expression level of 
MBP was analyzed by Western blot. Scale bar, 50 µm. C, Reduction in the expression of Nogo-A by 
shRNA through lentivirus infection. OPC were infected with lentivirus containing either shNogo-A or 
control shRNA. The expression of Nogo-A and MBP in mature oligodendrocytes was determined by 
Western blot. D, Effects of aNogoA and aNogoA mAb on OPC and DRG co-culture. aNogoA was added 
to OPC and DRG co-culture in the presence of aNogoA mAb or IgG control. The resulting cultures were 
evaluated for myelination of DRG axons by MBP (red) and NF200 (green) co-staining. Scale bar, 50 
mm. The percentage of myelinated axons was quantified in the lower panel by Cellomics. The data are 
representative of three independent experiments. *p < 0.05.
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Supplemental figure 2. Amino-Nogo-A expression in cerebellar slice culture.
Cerebellar slice culture was co-stained with aNogoA mAb (green) or antibodies to PDGFRa or MBP 
(red). Scale bar, 20 µm. 
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